Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
31200.0 | 2023-02-01 00:00:00 UTC | Humana (HUM) Q4 Earnings Beat Mark, '23 EPS View Upbeat | ABT | https://www.nasdaq.com/articles/humana-hum-q4-earnings-beat-mark-23-eps-view-upbeat | nan | nan | Humana Inc. HUM reported fourth-quarter 2022 adjusted earnings per share (EPS) of $1.62, beating the Zacks Consensus Estimate by 11% and our estimate of $1.42. The bottom line climbed 30.6% year over year.
The quarterly results benefited on the back of growing premiums coupled with solid segmental performances. However, the upside was partly hurt by an elevated operating expense level.
Revenues of Humana amounted to $22,439 million, which rose 6.6% year over year in the quarter under review and our estimate of $21,977.4 million. The improvement came on the back of membership growth stemming from its individual Medicare Advantage business and state-based contract wins. Improved per-member individual Medicare Advantage premiums also contributed to the quarterly results. Yet, the top line fell short of the consensus mark by a whisker.
Humana Inc. Price, Consensus and EPS Surprise
Humana Inc. price-consensus-eps-surprise-chart | Humana Inc. Quote
Operational Update
Total premiums of Humana grew 7.3% year over year to $21,275 million. The figure outpaced the Zacks Consensus Estimate of $21,181 million and our estimate of $20,680.9 million.
Revenues from services came in at $1,004 million, which dropped 19.9% year over year in the fourth quarter. Investment income of $160 million compared favorably against the prior-year quarter’s investment loss of $34 million.
The benefits expense ratio improved 60 basis points (bps) year over year to 87.3% on account of a decline in patient utilization within HUM’s individual Medicare Advantage business. The operating cost ratio of 15.9% improved 20 bps year over year, thanks to the divestiture of Humana’s 60% ownership stake in Kindred at Home (KAH) Hospice operations in August 2022.
Total operating expenses escalated 6.3% year over year to $22,315 million, higher than our estimate of $21,685.1 million. This was due to an increase in benefits, operating costs, and depreciation and amortization.
Humana reported a net loss of $18 million, wider than the prior-year quarter’s loss of $13 million.
Realignment of Segments
Earlier, HUM had three reportable segments - Retail, Group and Specialty, and Healthcare Services. In December 2022, it redistributed some of its businesses within its earlier segments. The realignment gave rise to two distinct segments: Insurance and CenterWell. The Insurance unit encompasses those businesses that were part of the Retail as well as Group and Specialty segments. Earlier contained within the Healthcare Services unit, the Pharmacy Benefit Manager (PBM) business also forms a part of the newly formed Insurance segment. The second unit named CenterWell comprisees the payor-agnostic healthcare services offerings of Humana that includes pharmacy dispensing services, provider services and home services.
Insurance
The segment recorded revenues of $21,599 million, which advanced 7.3% year over year in the fourth quarter on the back of a growing customer base across its individual Medicare Advantage business and state-based contracts.
Adjusted earnings came in at $53 million in the quarter under review, while a loss of $100 million was reported in the prior-year quarter. The benefits expense ratio improved 100 bps year over year to 87.5%. The operating cost ratio of 12.8% deteriorated 10 bps year over year due to elevated marketing expenses that Humana had incurred in 2022 to provide an impetus to its individual Medicare Advantage growth.
Total medical membership of the segment came in at 17.1 million as of Dec 31, 2022, which inched up 0.1% year over year.
CenterWell
The segment’s revenues of $4,141 million increased 1.4% year over year in the fourth quarter, attributable to higher membership within HUM’s individual Medicare Advantage business, improved pharmacy revenues coupled with growing revenues from its provider business.
Operating income of $263 million tumbled 12% year over year. The segment’s adjusted EBITDA slid 3.6% year over year to $325 million in the quarter under review.
The operating cost ratio of 92.6% deteriorated 90 bps year over year.
Financial Update (as of Dec 31, 2022)
Humana exited the fourth quarter with cash and cash equivalents of $5,061 million, which soared 49.1% from the figure in 2021 end. Total assets of $43,055 million decreased 2.9% from the 2021-end level.
HUM’s long-term debt totaled $9,034 million, down 14.3% from the figure as of Dec 31, 2021. Short-term debt amounted to $2,092 million. Debt to total capitalization improved 170 bps year over year to 42% at the fourth-quarter end.
Total stockholders’ equity of $15,370 million dropped 4.6% from the level in 2021 end.
Net cash used in operating activities amounted to $5,127 million in the fourth quarter, which is way higher than the prior quarter’s figure of $96 million.
Capital Deployment Update
Humana bought back shares worth $1,064 million in the fourth quarter. It had a leftover share repurchase capacity of $1 billion as of Jan 31, 2023. HUM also paid out dividends of $101 million to its shareholders during the quarter under review.
2023 Outlook
This year, HUM anticipates revenues within $102.7-$104.7 billion, the mid-point of which indicates an improvement of 11.6% from the 2022 figure of $92.9 billion.
Adjusted EPS is estimated to be a minimum of $28.00, which suggests minimum growth of 10.9% from the 2022 figure of $25.24.
Revenues from the Insurance segment are projected within $99.5-$101 billion, the mid-point of which indicates a 12.9% rise from the 2022 figure of $88.8 billion. The CenterWell segment’s revenues are forecasted between $18 billion and $18.5 billion, the mid-point of which suggests 5.5% growth from the 2022 figure of $17.3 billion.
Management anticipates individual Medicare Advantage membership to witness a minimum membership growth of 625,000 in 2023, up from the earlier projection of an increase in the range of 325,000-400,000.
Group Medicare Advantage membership is likely to decrease by around 60,000, while the same from the Medicare stand-alone prescription drug plan is estimated to decline by around 800,000 members.
The benefit ratio of the Insurance unit is estimated at 86.3-87.3% in 2023. The consolidated operating cost ratio is expected at 11.6%-12.6%.
Cash flow from operations is forecasted at around $4.5 billion this year, while capital expenditures are projected at $1.2 billion.
2025 Growth Target
Humana remains optimistic to fulfil its target of attaining adjusted earnings of $37 per share within 2025.
Zacks Rank
Humana currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Medical Sector Release
Of the Medical sector players that have reported fourth-quarter results so far, the bottom lines of UnitedHealth Group Incorporated UNH, Elevance Health Inc. ELV and Abbott Laboratories ABT beat the Zacks Consensus Estimate.
UnitedHealth Group reported fourth-quarter 2022 adjusted earnings of $5.34 per share, which beat the Zacks Consensus Estimate of $5.17. The bottom line improved from the $4.48 per share reported a year ago. Revenues of UNH were $82.8 billion in the fourth quarter, which climbed from $73.7 billion a year ago. The top line met the consensus mark. The medical care ratio of UnitedHealth Group improved 20 basis points year over year to 82.8% in the quarter under review.
Elevance Health’s fourth-quarter 2022 earnings of $5.23 per share beat the Zacks Consensus Estimate of $5.20 by 0.6%. Additionally, the bottom line advanced 1.8% year over year. ELV’s operating revenues improved 10.1% year over year to $39,667 million in the quarter under review. The top line missed the consensus mark by a whisker. Medical membership of Elevance Health as of Dec 31, 2022, totaled 47.5 million, which rose 4.8% year over year in the fourth quarter. Premiums of $33,646 million rose 9.4% year over year.
Abott Laboratories reported fourth-quarter 2022 adjusted earnings of $1.03 per share, which exceeded the Zacks Consensus Estimate by 14.4%. The adjusted figure however declined from the prior-year quarter’s levels by 22%. Fourth-quarter worldwide sales of $10.09 billion were down 12% year over year on a reported basis. The top line however exceeded the Zacks Consensus Estimate by 6.4%. ABT reported an adjusted operating profit of $1.80 billion for the quarter under review, down 37.8% year over year. The adjusted operating margin, too, contracted 738 bps to 17.8%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report
Humana Inc. (HUM) : Free Stock Analysis Report
Elevance Health, Inc. (ELV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other Medical Sector Release Of the Medical sector players that have reported fourth-quarter results so far, the bottom lines of UnitedHealth Group Incorporated UNH, Elevance Health Inc. ELV and Abbott Laboratories ABT beat the Zacks Consensus Estimate. ABT reported an adjusted operating profit of $1.80 billion for the quarter under review, down 37.8% year over year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Humana Inc. (HUM) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. | Other Medical Sector Release Of the Medical sector players that have reported fourth-quarter results so far, the bottom lines of UnitedHealth Group Incorporated UNH, Elevance Health Inc. ELV and Abbott Laboratories ABT beat the Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Humana Inc. (HUM) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. ABT reported an adjusted operating profit of $1.80 billion for the quarter under review, down 37.8% year over year. | Other Medical Sector Release Of the Medical sector players that have reported fourth-quarter results so far, the bottom lines of UnitedHealth Group Incorporated UNH, Elevance Health Inc. ELV and Abbott Laboratories ABT beat the Zacks Consensus Estimate. ABT reported an adjusted operating profit of $1.80 billion for the quarter under review, down 37.8% year over year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Humana Inc. (HUM) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. | ABT reported an adjusted operating profit of $1.80 billion for the quarter under review, down 37.8% year over year. Other Medical Sector Release Of the Medical sector players that have reported fourth-quarter results so far, the bottom lines of UnitedHealth Group Incorporated UNH, Elevance Health Inc. ELV and Abbott Laboratories ABT beat the Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Humana Inc. (HUM) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. |
31201.0 | 2023-02-01 00:00:00 UTC | ZBH vs. ABT: Which Stock Is the Better Value Option? | ABT | https://www.nasdaq.com/articles/zbh-vs.-abt%3A-which-stock-is-the-better-value-option | nan | nan | Investors looking for stocks in the Medical - Products sector might want to consider either Zimmer Biomet (ZBH) or Abbott (ABT). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Currently, Zimmer Biomet has a Zacks Rank of #2 (Buy), while Abbott has a Zacks Rank of #3 (Hold). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that ZBH has an improving earnings outlook. But this is only part of the picture for value investors.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
ZBH currently has a forward P/E ratio of 18.29, while ABT has a forward P/E of 25.23. We also note that ZBH has a PEG ratio of 2.39. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. ABT currently has a PEG ratio of 4.96.
Another notable valuation metric for ZBH is its P/B ratio of 2.18. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, ABT has a P/B of 5.37.
These are just a few of the metrics contributing to ZBH's Value grade of B and ABT's Value grade of C.
ZBH stands above ABT thanks to its solid earnings outlook, and based on these valuation figures, we also feel that ZBH is the superior value option right now.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors looking for stocks in the Medical - Products sector might want to consider either Zimmer Biomet (ZBH) or Abbott (ABT). ZBH currently has a forward P/E ratio of 18.29, while ABT has a forward P/E of 25.23. ABT currently has a PEG ratio of 4.96. | Click to get this free report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors looking for stocks in the Medical - Products sector might want to consider either Zimmer Biomet (ZBH) or Abbott (ABT). ZBH currently has a forward P/E ratio of 18.29, while ABT has a forward P/E of 25.23. | These are just a few of the metrics contributing to ZBH's Value grade of B and ABT's Value grade of C. ZBH stands above ABT thanks to its solid earnings outlook, and based on these valuation figures, we also feel that ZBH is the superior value option right now. Click to get this free report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors looking for stocks in the Medical - Products sector might want to consider either Zimmer Biomet (ZBH) or Abbott (ABT). | ABT currently has a PEG ratio of 4.96. These are just a few of the metrics contributing to ZBH's Value grade of B and ABT's Value grade of C. ZBH stands above ABT thanks to its solid earnings outlook, and based on these valuation figures, we also feel that ZBH is the superior value option right now. Investors looking for stocks in the Medical - Products sector might want to consider either Zimmer Biomet (ZBH) or Abbott (ABT). |
31202.0 | 2023-01-31 00:00:00 UTC | Validea Daily Guru Fundamental Report for ABT - 1/31/2023 | ABT | https://www.nasdaq.com/articles/validea-daily-guru-fundamental-report-for-abt-1-31-2023 | nan | nan | Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). | Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. | Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
31203.0 | 2023-01-31 00:00:00 UTC | 5 Top Stocks to Buy Now | ABT | https://www.nasdaq.com/articles/5-top-stocks-to-buy-now | nan | nan | For different reasons, Delta Air Lines (NYSE: DAL), industrial technology company Trimble (NASDAQ: TRMB), infrastructure software company Bentley Systems (NASDAQ: BSY), oil equipment and services company Baker Hughes (NASDAQ: BKR), and industrial giant Siemens (OTC: SIEGY) are all attractive stocks to look at in 2023. Let's briefly examine why they all have something to offer investors.
1. Delta Air Lines
Anyone advocating buying airline stocks in the face of a cyclical slowdown, particularly one led by a slowdown in consumer discretionary spending, usually deserves some questioning. However, the repercussions of the policy decisions made due to the pandemic are still with this economic cycle, which isn't a normal one.
The travel industry is still recovering from the ravages wrought upon it in 2020, and according to Delta's latest earnings presentations, its industry backdrop has never been more constructive. Its advance bookings for the March quarter are ahead of the same period of 2019, and higher-margin corporate travel is coming back.
Delta plans to restore its network to levels comparable with 2019 by the summer and generate $2 billion in free cash flow in 2023, followed by $4 billion in 2024. Put another way, if Delta hits management targets, it will generate a quarter of its $24 billion market cap in free cash flow over the next two years. Of course, Delta is not without risk, and a severe economic slowdown will hurt the indebted airline. Still, if the economy avoids that, Delta will have significant upside potential in 2023.
2. Trimble
This industrial technology company is best known for its positioning hardware used in precise mapping, and for things like fixing precise points on construction and infrastructure projects. However, thanks to the ongoing revolution in digital technology and advanced analytics, it's increasingly moving toward becoming what management describes as an "integrated work process."
This means Trimble is embedding more and more application software in its hardware to link data from customers' operations (a crop farmer in the field, a trucking fleet, or machinery on an infrastructure project) with analytics capability to produce actionable insights. So, for example, the crop farmer can apply insecticide and fertilizer more precisely, the trucking fleet can have routes optimized, and waste and inefficiency can be reduced on an infrastructure project.
The shift to higher-margin software implies margin and cash flow improvement over the long term, and the sell-off in the stock over the last year is creating a buying opportunity in a long-term growth story.
3. Bentley Systems
Sticking with the theme of infrastructure technology stocks, Bentley is a pure-play infrastructure software stock. Its solutions help customers develop digital models, or so-called "digital twins," which are used to design and plan the construction of an infrastructure project. However, the work doesn't stop there. Infrastructure projects (roads, bridges, water and wastewater, etc.) have multi-decade lifespans and require constant maintenance -- something the digital twin can model and simulate to improve servicing.
Considering the vast amounts of information traditionally held separately with myriad contractors and consultants on a major infrastructure project, the ability to collate and fully utilize that data via a digital twin can bring about significant cost savings for infrastructure owners in the planning, construction, and lifecycle of the asset.
4. Baker Hughes
The oil services and equipment company continues to enjoy favorable end-market conditions. After all, with all the talk of recession, the price of oil is still above $80 a barrel at the time of this writing. That's a level conducive to investment in oil equipment and services.
There's a reason to favor Baker Hughes over its peers. Specifically, it has a self-help initiative that could trim $150 million off annual costs. The company is moving from four reporting segments to two and streamlining its operations as it does so.
As an equipment provider, Baker Hughes suffered alongside many other companies in 2022 with component shortages and supply chain inefficiencies. Hopefully, those issues will resolve through 2023, leading to margin expansion. It all points to an opportunity to grow profits significantly in 2023.
5. Siemens
Investors often overlook this German industrial giant, due to concerns over the prospects for the European economy in light of the effect of sanctions imposed on Russia. However, it's worth noting that Siemens generates 29% of its revenue in the Americas and 25% in Asia. It also owns a clutch of businesses positioned in industries containing stocks with significantly higher valuations than Siemens.
The company has a history of generating weak return on invested capital (ROIC) over the last decade, but this is largely a consequence of previous investments in oil & gas and wind energy businesses (now spun-off and part of Siemens Energy). Meanwhile, it's pivoting towards growth industries such as industrial automation, industrial software, and smart infrastructure (see below). Consequently, analysts are forecasting its net income will almost double in the next couple of years (so ROIC should improve notably), and Siemens tends to convert earnings into cash flow at a good rate.
Data by YCharts
In the digital industries segment (3.9 billion euros in profit in 2022), it owns the world's leading automation and industrial software companies, competing with the likes of ABB, Emerson Electric, Rockwell, and PTC. In smart infrastructure (2.2 billion euros), it competes with Honeywell, ABB, and Johnson Controls in providing building management controls and systems and electrification products. Its mobility segment (800 million euros) offers rail infrastructure and competes with Alstom. It also owns 75% of Siemens Healthineers (3.4 billion euros), competing with GE HealthCare (in imaging) and Abbott (diagnostics).
Sporting a 3% dividend yield in the U.S. listing, Siemens represents a value option for income-seeking investors.
10 stocks we like better than Delta Air Lines
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now… and Delta Air Lines wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of January 9, 2023
Lee Samaha has positions in Honeywell International and Siemens Aktiengesellschaft. The Motley Fool has positions in and recommends ABB, Abbott Laboratories, Alstom, and Emerson Electric. The Motley Fool recommends Bentley Systems, Delta Air Lines, PTC, and Trimble. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This means Trimble is embedding more and more application software in its hardware to link data from customers' operations (a crop farmer in the field, a trucking fleet, or machinery on an infrastructure project) with analytics capability to produce actionable insights. The shift to higher-margin software implies margin and cash flow improvement over the long term, and the sell-off in the stock over the last year is creating a buying opportunity in a long-term growth story. Consequently, analysts are forecasting its net income will almost double in the next couple of years (so ROIC should improve notably), and Siemens tends to convert earnings into cash flow at a good rate. | For different reasons, Delta Air Lines (NYSE: DAL), industrial technology company Trimble (NASDAQ: TRMB), infrastructure software company Bentley Systems (NASDAQ: BSY), oil equipment and services company Baker Hughes (NASDAQ: BKR), and industrial giant Siemens (OTC: SIEGY) are all attractive stocks to look at in 2023. Data by YCharts In the digital industries segment (3.9 billion euros in profit in 2022), it owns the world's leading automation and industrial software companies, competing with the likes of ABB, Emerson Electric, Rockwell, and PTC. The Motley Fool recommends Bentley Systems, Delta Air Lines, PTC, and Trimble. | For different reasons, Delta Air Lines (NYSE: DAL), industrial technology company Trimble (NASDAQ: TRMB), infrastructure software company Bentley Systems (NASDAQ: BSY), oil equipment and services company Baker Hughes (NASDAQ: BKR), and industrial giant Siemens (OTC: SIEGY) are all attractive stocks to look at in 2023. Bentley Systems Sticking with the theme of infrastructure technology stocks, Bentley is a pure-play infrastructure software stock. Data by YCharts In the digital industries segment (3.9 billion euros in profit in 2022), it owns the world's leading automation and industrial software companies, competing with the likes of ABB, Emerson Electric, Rockwell, and PTC. | For different reasons, Delta Air Lines (NYSE: DAL), industrial technology company Trimble (NASDAQ: TRMB), infrastructure software company Bentley Systems (NASDAQ: BSY), oil equipment and services company Baker Hughes (NASDAQ: BKR), and industrial giant Siemens (OTC: SIEGY) are all attractive stocks to look at in 2023. Meanwhile, it's pivoting towards growth industries such as industrial automation, industrial software, and smart infrastructure (see below). Its mobility segment (800 million euros) offers rail infrastructure and competes with Alstom. |
31204.0 | 2023-01-31 00:00:00 UTC | U.S. food safety regulator announces shakeup after infant formula crisis | ABT | https://www.nasdaq.com/articles/u.s.-food-safety-regulator-announces-shakeup-after-infant-formula-crisis | nan | nan | By Leah Douglas
Jan 30 (Reuters) - The U.S. Food and Drug Administration (FDA) said on Tuesday it will restructure its food program that was slammed last year for responding too slowly to an outbreak of illness among infants who consumed formula from an Abbott Laboratories production plant.
In response to recommendations made by an outside group following the crisis, the FDA will establish a Human Foods Program led by a deputy commissioner, uniting its Center for Food Safety and Applied Nutrition, food policy office, and certain functions of its regulatory affairs office, agency head Robert M. Califf announced.
The new structure "unifies and elevates the program while removing redundancies, enabling the agency to oversee human food in a more effective and efficient way," Califf said in a statement.
The changes were aligned with several recommendations made last year by the Reagan-Udall Foundation, an organization in part funded by FDA, that assessed how the agency could shore up its food operations.
The report, released in December, found FDA lacked a clear vision for its food program. It recommended consolidating food-related functions under one leader.
Califf requested the report after critics slammed the agency for its response to the infant formula crisis. Ultimately, five infants were sickened and two died after consuming formula from the plant, according to FDA.
The plant's temporary closure led to widespread formula shortages that lasted months. Abbott is facing a criminal investigation by the Justice Department.
Consumer groups cheered Tuesday's announcement.
The new structure "is likely to improve efficiency and benefit the American people," said Peter G. Lurie, president of the Center for Science in the Public Interest and former associate commissioner of FDA from 2014 to 2017.
FDA oversees the vast majority of the U.S. food supply including produce, dairy, infant formula, and food additives. The Department of Agriculture regulates meat, poultry, and egg products.
(Reporting by Leah Douglas; Editing by David Gregorio)
((Leah.Douglas@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The new structure "unifies and elevates the program while removing redundancies, enabling the agency to oversee human food in a more effective and efficient way," Califf said in a statement. The changes were aligned with several recommendations made last year by the Reagan-Udall Foundation, an organization in part funded by FDA, that assessed how the agency could shore up its food operations. The new structure "is likely to improve efficiency and benefit the American people," said Peter G. Lurie, president of the Center for Science in the Public Interest and former associate commissioner of FDA from 2014 to 2017. | By Leah Douglas Jan 30 (Reuters) - The U.S. Food and Drug Administration (FDA) said on Tuesday it will restructure its food program that was slammed last year for responding too slowly to an outbreak of illness among infants who consumed formula from an Abbott Laboratories production plant. In response to recommendations made by an outside group following the crisis, the FDA will establish a Human Foods Program led by a deputy commissioner, uniting its Center for Food Safety and Applied Nutrition, food policy office, and certain functions of its regulatory affairs office, agency head Robert M. Califf announced. Califf requested the report after critics slammed the agency for its response to the infant formula crisis. | By Leah Douglas Jan 30 (Reuters) - The U.S. Food and Drug Administration (FDA) said on Tuesday it will restructure its food program that was slammed last year for responding too slowly to an outbreak of illness among infants who consumed formula from an Abbott Laboratories production plant. In response to recommendations made by an outside group following the crisis, the FDA will establish a Human Foods Program led by a deputy commissioner, uniting its Center for Food Safety and Applied Nutrition, food policy office, and certain functions of its regulatory affairs office, agency head Robert M. Califf announced. FDA oversees the vast majority of the U.S. food supply including produce, dairy, infant formula, and food additives. | In response to recommendations made by an outside group following the crisis, the FDA will establish a Human Foods Program led by a deputy commissioner, uniting its Center for Food Safety and Applied Nutrition, food policy office, and certain functions of its regulatory affairs office, agency head Robert M. Califf announced. The report, released in December, found FDA lacked a clear vision for its food program. Ultimately, five infants were sickened and two died after consuming formula from the plant, according to FDA. |
31205.0 | 2023-01-31 00:00:00 UTC | IWV, MRK, PFE, ABT: ETF Outflow Alert | ABT | https://www.nasdaq.com/articles/iwv-mrk-pfe-abt%3A-etf-outflow-alert | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $313.3 million dollar outflow -- that's a 2.8% decrease week over week (from 48,300,000 to 46,950,000). Among the largest underlying components of IWV, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.7%, Pfizer Inc (Symbol: PFE) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.3%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average:
Looking at the chart above, IWV's low point in its 52 week range is $201.8201 per share, with $268.70 as the 52 week high point — that compares with a last trade of $233.39. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 8%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
Also see:
FFR Videos
Funds Holding ATLS
CF Average Annual Return
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWV, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.7%, Pfizer Inc (Symbol: PFE) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.3%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. | Among the largest underlying components of IWV, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.7%, Pfizer Inc (Symbol: PFE) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.3%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $201.8201 per share, with $268.70 as the 52 week high point — that compares with a last trade of $233.39. Free Report: Top 8%+ Dividends (paid monthly) Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of IWV, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.7%, Pfizer Inc (Symbol: PFE) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $313.3 million dollar outflow -- that's a 2.8% decrease week over week (from 48,300,000 to 46,950,000). For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $201.8201 per share, with $268.70 as the 52 week high point — that compares with a last trade of $233.39. | Among the largest underlying components of IWV, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.7%, Pfizer Inc (Symbol: PFE) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $313.3 million dollar outflow -- that's a 2.8% decrease week over week (from 48,300,000 to 46,950,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. |
31206.0 | 2023-01-28 00:00:00 UTC | Is Abbott Laboratories a Good Dividend Stock to Buy Now? | ABT | https://www.nasdaq.com/articles/is-abbott-laboratories-a-good-dividend-stock-to-buy-now | nan | nan | It's that time of year when Wall Street analysts start adjusting their predictions, and one dividend-paying stock, in particular, is getting a lot of positive attention.
Abbott Laboratories (NYSE: ABT) reported fourth-quarter earnings on Thursday, Jan. 26. Since then, Sanford C. Bernstein, Raymond James, Stifel Nicolaus, and Barclays have all raised their price targets on the healthcare conglomerate. The highest estimate, from Bernstein, implies a 19% gain from its latest closing price.
Is Abbott Laboratories a great dividend stock to buy, as Wall Street price targets would suggest? Let's weigh its weaknesses against its strengths to find out.
The bad news about Abbott Laboratories
Sagging demand for COVID-19 diagnostics and a strengthening dollar caused total sales to contract 12% year over year during the fourth quarter of 2022. A combination of foreign exchange headwinds and more weakness from COVID tests are expected to move the company's bottom line in the wrong direction this year, too.
2021 2022 2023 ESTIMATES
Revenue $43.1 billion $43.7 billion N/A
EPS (GAAP) $3.94 $3.91 $3.05 to $3.25
EPS (adjusted) $5.21 $5.34 $4.30 to $4.50
Data source: Abbott Laboratories. EPS: Earnings per share; GAAP: Generally Accepted Accounting Principles.
If you could receive a relatively high dividend yield, it would be easy to look past the company's contracting profits. Unfortunately, Abbott Laboratories stock offers a 1.8% yield at recent prices. That's only slightly better than the average dividend-paying stock in the benchmark S&P 500 index.
Reasons to buy Abbott Laboratories
If we exclude COVID-related testing revenues and the effects of foreign exchange, Abbott reported 2022 sales that grew by 5.4% year over year.
Viewed on a longer time frame, Abbott's performance is hardly anything to complain about. Management's GAAP EPS estimate for 2023 is miles above what the company was reporting before the pandemic. In fact, the midpoint of the guided range implies earnings growth at an 11.2% annual rate during the four-year period that ends on Dec. 31, 2023.
Abbott doesn't offer a terribly attractive yield at the moment, but the company's long-term investors aren't complaining. This well-diversified conglomerate has raised its payout by 264% over the past decade.
A diverse range of new growth drivers could allow Abbott to make some big dividend bumps in the years ahead. For example, the FDA recently approved Navitor, a minimally invasive transcatheter aortic valve implantation system for folks with severe aortic stenosis where open-heart surgery is too dangerous.
Abbott's next-generation constant glucose monitor (CGM), the FreeStyle Libre 3, earned FDA clearance last May. More than 37 million Americans are living with diabetes, according to the U.S. Centers for Disease Control and Prevention (CDC). Many still monitor their blood sugar with finger sticks and indicator strips, but this outdated method is far from ideal. Soaring demand for a better way to monitor blood sugar pushed U.S. FreeStyle sales up to about $1.1 billion in the fourth quarter.
Abbott doesn't have the U.S. CGM market all to itself, but there are a few reasons we can expect it to maintain a leading share. Last December, the FDA granted clearance to the G7 device from Dexcom (NASDAQ: DXCM) which is Abbott's lead competitor in the space.
The G7 is smaller than Dexcom's previous device, but it's still significantly larger than Abbott's FreeStyle Libre 3 device. With a long lead on a larger CGM from its competitor, diabetes care could continue driving growth at Abbott laboratories for many years to come.
A smart buy now
Declining demand for the COVID-19 tests that drove growth in recent years is a powerful headwind. Luckily, the company runs a well-diversified operation that can overcome the challenge. Investors who buy shares of Abbott now and hold them over the long run have an excellent chance to come out ahead.
10 stocks we like better than Abbott Laboratories
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of January 9, 2023
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends Barclays Plc and DexCom. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (NYSE: ABT) reported fourth-quarter earnings on Thursday, Jan. 26. It's that time of year when Wall Street analysts start adjusting their predictions, and one dividend-paying stock, in particular, is getting a lot of positive attention. A combination of foreign exchange headwinds and more weakness from COVID tests are expected to move the company's bottom line in the wrong direction this year, too. | Abbott Laboratories (NYSE: ABT) reported fourth-quarter earnings on Thursday, Jan. 26. Is Abbott Laboratories a great dividend stock to buy, as Wall Street price targets would suggest? Revenue $43.1 billion $43.7 billion N/A EPS (GAAP) $3.94 $3.91 $3.05 to $3.25 EPS (adjusted) $5.21 $5.34 $4.30 to $4.50 Data source: Abbott Laboratories. | Abbott Laboratories (NYSE: ABT) reported fourth-quarter earnings on Thursday, Jan. 26. Is Abbott Laboratories a great dividend stock to buy, as Wall Street price targets would suggest? Reasons to buy Abbott Laboratories If we exclude COVID-related testing revenues and the effects of foreign exchange, Abbott reported 2022 sales that grew by 5.4% year over year. | Abbott Laboratories (NYSE: ABT) reported fourth-quarter earnings on Thursday, Jan. 26. Unfortunately, Abbott Laboratories stock offers a 1.8% yield at recent prices. Reasons to buy Abbott Laboratories If we exclude COVID-related testing revenues and the effects of foreign exchange, Abbott reported 2022 sales that grew by 5.4% year over year. |
31207.0 | 2023-01-27 00:00:00 UTC | Interesting ABT Put And Call Options For June 2024 | ABT | https://www.nasdaq.com/articles/interesting-abt-put-and-call-options-for-june-2024 | nan | nan | Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the June 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 511 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new June 2024 contracts and identified one put and one call contract of particular interest.
The put contract at the $110.00 strike price has a current bid of $8.90. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $110.00, but will also collect the premium, putting the cost basis of the shares at $101.10 (before broker commissions). To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $110.69/share today.
Because the $110.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 8.09% return on the cash commitment, or 5.78% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $110.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $115.00 strike price has a current bid of $11.40. If an investor was to purchase shares of ABT stock at the current price level of $110.69/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $115.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 14.19% if the stock gets called away at the June 2024 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $115.00 strike highlighted in red:
Considering the fact that the $115.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 10.30% boost of extra return to the investor, or 7.36% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $110.69) to be 26%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of Stocks Analysts Like »
Also see:
Closed End Fund Screener
ICE Options Chain
Top Ten Hedge Funds Holding HAUZ
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $115.00 strike highlighted in red: Considering the fact that the $115.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the June 2024 expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $115.00 strike highlighted in red: Considering the fact that the $115.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the June 2024 expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $115.00 strike highlighted in red: Considering the fact that the $115.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the June 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new June 2024 contracts and identified one put and one call contract of particular interest. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new June 2024 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABT's trailing twelve month trading history, with the $115.00 strike highlighted in red: Considering the fact that the $115.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the June 2024 expiration. |
31208.0 | 2023-01-26 00:00:00 UTC | Abbott's Sales and Earnings Are Sinking: Should Investors Worry? | ABT | https://www.nasdaq.com/articles/abbotts-sales-and-earnings-are-sinking%3A-should-investors-worry | nan | nan | Abbott (NYSE: ABT) reported its full-year and fourth-quarter results for 2022 on Wednesday. As is often the case with companies' updates, there was both good news and bad news.
Our human nature is to usually focus more on the bad than the good. Abbott's bad news definitely jumped out. The healthcare giant's sales fell 12% year over year in Q4. Earnings plunged 48%. Should investors worry about these negative trends?
Behind the declines
While Abbott's sales fell 12% on a reported basis, the year-over-year decline was only 6.1% excluding the impact of foreign exchange. The strong U.S. dollar ranked as a significant headwind for the company, with 58% of its total revenue in the quarter generated in international markets.
Abbott isn't alone in this regard. For example, Johnson & Johnson reported a similar negative impact on its top line due to foreign exchange in its recent Q4 update.
The company's COVID-19 testing business also was a big factor in Abbott's revenue decline. Worldwide COVID-related sales slid to $1.069 billion in Q4 compared to $2.319 billion in the prior-year period. To paraphrase a quote often attributed to the late Sen. Everett Dirksen, a $1.25 billion decline here and a $1.25 billion decline there, and pretty soon you're talking about real money.
Abbott's nutrition segment faced another challenge. Sales fell 11.1% year over year on a reported basis in Q4 due in large part to disruptions in the production of infant formula products at the company's Sturgis, Michigan manufacturing facility.
The expectations game
It's certainly not great for a company's top and bottom lines to worsen. However, investors also have to consider the expectations game played by Wall Street. Bad news can be good news when results exceed expectations.
A year ago, Abbott projected that it would generate adjusted earnings per share of at least $4.70 in full-year 2022. The actual result for the year was adjusted earnings per share of $5.34.
The average analyst's revenue estimate for Q4 was $9.67 billion. Abbott easily topped that estimate with Q4 revenue of $10.1 billion. The consensus Q4 adjusted earnings estimate was $0.92 per share. Abbott delivered adjusted earnings in the quarter of $1.03 per share.
The company also provided full-year 2023 adjusted earnings guidance that was in line with Wall Street expectations. Abbott projects adjusted diluted earnings per share from continuing operations will be between $4.30 and $4.50 this year. The average analyst's estimate is $4.41.
Better days ahead
No one on Wall Street was taken by surprise by any of the issues Abbott faced in Q4. Lower COVID-related sales were fully anticipated. Foreign exchange headwinds are impacting every U.S. company that conducts significant business in international markets. Abbott's manufacturing woes with its infant formula products were widely publicized.
COVID-19 testing revenue is likely to continue to decline. However, Abbott's year-over-year comparisons could improve in future quarters. And there could be reasons for even more optimism on the other fronts.
The U.S. dollar's strength is partially due to aggressive interest rate hikes by the Federal Reserve. The Fed seems likely to moderate any rate increases going forward. Some economists think rate cuts could even be on the way later this year. Abbott also appears to have resolved its manufacturing issues at the Sturgis facility.
Income investors can still count on Abbott. The company's board of directors recently declared its 396th consecutive quarterly dividend. Abbott is a Dividend King with 51 consecutive years of dividend increases.
Innovation stands out as the most important factor behind Abbott's long track record of success. The company remains highly innovative. In October 2022, the Galien Foundation named Freestyle Libre continuous glucose monitoring system the "best medical technology" in the last 50 years. Abbott recently won two key U.S. regulatory approvals for new products.
Should investors worry about Abbott's declining sales and earnings? I don't think so. There should be better days ahead for this healthcare leader. Abbott remains a solid blue-chip stock to buy and hold for the long term.
10 stocks we like better than Abbott Laboratories
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of January 9, 2023
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (NYSE: ABT) reported its full-year and fourth-quarter results for 2022 on Wednesday. The strong U.S. dollar ranked as a significant headwind for the company, with 58% of its total revenue in the quarter generated in international markets. The company also provided full-year 2023 adjusted earnings guidance that was in line with Wall Street expectations. | Abbott (NYSE: ABT) reported its full-year and fourth-quarter results for 2022 on Wednesday. Behind the declines While Abbott's sales fell 12% on a reported basis, the year-over-year decline was only 6.1% excluding the impact of foreign exchange. For example, Johnson & Johnson reported a similar negative impact on its top line due to foreign exchange in its recent Q4 update. | Abbott (NYSE: ABT) reported its full-year and fourth-quarter results for 2022 on Wednesday. A year ago, Abbott projected that it would generate adjusted earnings per share of at least $4.70 in full-year 2022. Abbott projects adjusted diluted earnings per share from continuing operations will be between $4.30 and $4.50 this year. | Abbott (NYSE: ABT) reported its full-year and fourth-quarter results for 2022 on Wednesday. The healthcare giant's sales fell 12% year over year in Q4. Should investors worry about Abbott's declining sales and earnings? |
31209.0 | 2023-01-26 00:00:00 UTC | Two Dividend Kings: Johnson & Johnson or Abbott Laboratories? | ABT | https://www.nasdaq.com/articles/two-dividend-kings%3A-johnson-johnson-or-abbott-laboratories | nan | nan | Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) are 2 of the more attractive Dividend Kings for today’s market. They offer relatively high yields and at least some value while projecting growth in 2023. This is an important factor to note because the outlook for earnings growth is rapidly deteriorating.
A slowdown of inflation or not, interest rates are still on the rise, inflation is still high, and the outlook for earnings has yet to improve. Until then, these 2 Kings are islands of safety, but which one is the best buy today?
Abbott Outperforms Johnson & Johnson in Q4
Abbott Laboratories outperformed JNJ in Q4 and offers a better outlook for revenue, but a very dark cloud is hanging over the company. That cloud is the impact, and fallout from the baby formula recall and shut-down and the worst may be yet to come.
The DOJ has announced an investigation that could result in criminal charges, not to mention the civil litigation already brewing. The takeaway is that Abbott Laboratories' headline results are unfavorable to JNJ’s but, on an adjusted basis, are much better.
So, Abbott Laboratories posted a 12.2% decline in Q4 revenue compared to JNJs -4.4%. Both companies are adjusting for the impact of COVID, however, which puts JNJ at +4.6% compared to Abbotts -1.4%, but when Abbott adjusted for baby formula and divestitures, organic sales are up 7.9%.
Also, Abbott outperformed the consensus estimates by 420 bps, while JNJ underperformed by 80. In regard to earnings, both companies posted 20%+ declines in YOY adjusted earnings, and both beat the consensus estimate, but Abbott outperformed by 1075 bps while JNJ by half the amount.
Guidance is Mixed for JNJ and ABT
The 2023 guidance from JNJ and ABT is a little mixed regarding each other. Both companies are guiding for revenue growth in 2023, but Abbott is looking for about twice the growth at “high single digits”.
The caveat is that impacts from the baby formula recall will cut deeply into the bottom line and produce a sharp contraction in YOY earrings to a level well below the analyst consensus.
The consensus figures may not be comparable, so take them with a grain of salt. The takeaway is that Abbott Laboratories is pulling back from a high on this news, while JNJ shares have already pulled back and are showing signs of support near the long-term uptrend line.
Which Has the Better Yield and Value?
Johnson & Johnson is the superior choice regarding yield and value, but this is a choice between 2 top-paying Dividend Kings. Johnson & Johnson pays about 2.7% compared to Abbott’s 1.8%, and the value is better too. JNJ shares are trading about 16X their 2023 EPS with earnings growth on the table, while ABT shares are trading closer to 22X with earnings under pressure.
Both yields are safe enough, the payout ratios are below 50%, and the balance sheets are healthy, but investors might expect ABT to slow the pace of increases in the coming year to below 10%, while JNJ should be able to maintain its current 6% pace.
The Technical Analysis: Has Abbott Already Broken Trend?
Shares of JNJ made a sharp about-face following its release and appear to be testing support just above an uptrend that has been in place since the pandemic rebound began. However, Abbott appears to have already broken the most comparable uptrend on the chart.
While the Abbott market appears ready to move higher, any upside will likely be capped at $120 or lower until the baby formula issue is in the rearview mirror. Johnson & Johnson shares could move lower and may break the trend, but it does not look like that is in the cards, at least not yet. Until then, tests of support at this level that buyers meet are technical entries into this uptrend.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) are 2 of the more attractive Dividend Kings for today’s market. Guidance is Mixed for JNJ and ABT The 2023 guidance from JNJ and ABT is a little mixed regarding each other. JNJ shares are trading about 16X their 2023 EPS with earnings growth on the table, while ABT shares are trading closer to 22X with earnings under pressure. | Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) are 2 of the more attractive Dividend Kings for today’s market. Guidance is Mixed for JNJ and ABT The 2023 guidance from JNJ and ABT is a little mixed regarding each other. JNJ shares are trading about 16X their 2023 EPS with earnings growth on the table, while ABT shares are trading closer to 22X with earnings under pressure. | Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) are 2 of the more attractive Dividend Kings for today’s market. Guidance is Mixed for JNJ and ABT The 2023 guidance from JNJ and ABT is a little mixed regarding each other. JNJ shares are trading about 16X their 2023 EPS with earnings growth on the table, while ABT shares are trading closer to 22X with earnings under pressure. | Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) are 2 of the more attractive Dividend Kings for today’s market. Guidance is Mixed for JNJ and ABT The 2023 guidance from JNJ and ABT is a little mixed regarding each other. JNJ shares are trading about 16X their 2023 EPS with earnings growth on the table, while ABT shares are trading closer to 22X with earnings under pressure. |
31210.0 | 2023-01-26 00:00:00 UTC | Abbott (ABT) Reports Q4 Earnings: What Key Metrics Have to Say | ABT | https://www.nasdaq.com/articles/abbott-abt-reports-q4-earnings%3A-what-key-metrics-have-to-say | nan | nan | For the quarter ended December 2022, Abbott (ABT) reported revenue of $10.09 billion, down 12% over the same period last year. EPS came in at $1.03, compared to $1.32 in the year-ago quarter.
The reported revenue represents a surprise of +6.47% over the Zacks Consensus Estimate of $9.48 billion. With the consensus EPS estimate being $0.90, the EPS surprise was +14.44%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net sales-Diagnostics-US: $1.70 billion versus the four-analyst average estimate of $1.37 billion. The reported number represents a year-over-year change of -29%.
Net sales-Nutritionals-International: $1.02 billion compared to the $1.04 billion average estimate based on four analysts. The reported number represents a change of -8.3% year over year.
Net sales-Nutritionals-US: $795 million versus $787.80 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -14.3% change.
Net sales-Diagnostics-International: $1.32 billion versus $1.51 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -36.8% change.
Net sales-Nutritionals: $1.82 billion versus $1.85 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -11% change.
Net sales-Established Pharmaceuticals: $1.22 billion compared to the $1.17 billion average estimate based on five analysts. The reported number represents a change of +1.1% year over year.
Net sales-Medical-Abbott diabetes care: $1.27 billion versus $1.15 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +8.5% change.
Net sales-Diagnostics: $2.24 billion versus $2.77 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -50% change.
Net sales-Medical-Vascular- Total: $605 million versus the four-analyst average estimate of $613.96 million. The reported number represents a year-over-year change of -10.8%.
Net sales-Structural Heart-Total: $441 million compared to the $426.62 million average estimate based on four analysts. The reported number represents a change of +5.3% year over year.
Net sales-Heart Failure-Total: $230 million compared to the $228.57 million average estimate based on four analysts. The reported number represents a change of -3.8% year over year.
Net sales-Electrophysiology-Total: $487 million compared to the $483.83 million average estimate based on four analysts. The reported number represents a change of -3.4% year over year.
View all Key Company Metrics for Abbott here>>>
Shares of Abbott have returned +3.7% over the past month versus the Zacks S&P 500 composite's +4.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Free Report: Must-See Energy Stocks for 2023
Record profits at oil companies can mean big gains for you. With soaring demand and elevated prices, oil stocks could be top performers by far in 2023. Zacks has released a special report revealing the 4 oil stocks experts believe will deliver the biggest gains. (You’ll never guess Stock #2!)
Download Oil Market on Fire today, absolutely free.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For the quarter ended December 2022, Abbott (ABT) reported revenue of $10.09 billion, down 12% over the same period last year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. | For the quarter ended December 2022, Abbott (ABT) reported revenue of $10.09 billion, down 12% over the same period last year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The reported revenue represents a surprise of +6.47% over the Zacks Consensus Estimate of $9.48 billion. | For the quarter ended December 2022, Abbott (ABT) reported revenue of $10.09 billion, down 12% over the same period last year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. | For the quarter ended December 2022, Abbott (ABT) reported revenue of $10.09 billion, down 12% over the same period last year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The reported revenue represents a surprise of +6.47% over the Zacks Consensus Estimate of $9.48 billion. |
31211.0 | 2023-01-26 00:00:00 UTC | Abbott Says FDA Oks Proclaim XR Spinal Cord Stimulation System To Treat DPN | ABT | https://www.nasdaq.com/articles/abbott-says-fda-oks-proclaim-xr-spinal-cord-stimulation-system-to-treat-dpn | nan | nan | (RTTNews) - Abbott Laboratories, Inc. (ABT) announced Thursday that the U.S. Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes.
The Proclaim XR SCS system can provide relief to DPN patients in need of alternatives to traditional treatment approaches, such as oral medication. People who receive therapy from the Proclaim XR SCS system will also be able to use Abbott's NeuroSphere Virtual Clinic, a connected care app that allows people to communicate with a physician and receive treatment adjustments remotely.
Roughly 34.2 million Americans, or 10.5% of the U.S. population, have diabetes. Diabetic neuropathy, one of the complications of diabetes, is a type of damage seen predominately in nerves running to the feet.
Currently, there are no disease modifying treatments for DPN, only symptom management and behavioral modifications to mitigate further nerve damage that can result from high blood sugar (glucose) levels
Approved for the treatment of chronic pain in 2019, the Proclaim XR SCS system now offers DPN patients relief from chronic pain by delivering low amounts, or doses, of stimulation.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories, Inc. (ABT) announced Thursday that the U.S. Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes. The Proclaim XR SCS system can provide relief to DPN patients in need of alternatives to traditional treatment approaches, such as oral medication. Currently, there are no disease modifying treatments for DPN, only symptom management and behavioral modifications to mitigate further nerve damage that can result from high blood sugar (glucose) levels Approved for the treatment of chronic pain in 2019, the Proclaim XR SCS system now offers DPN patients relief from chronic pain by delivering low amounts, or doses, of stimulation. | (RTTNews) - Abbott Laboratories, Inc. (ABT) announced Thursday that the U.S. Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes. The Proclaim XR SCS system can provide relief to DPN patients in need of alternatives to traditional treatment approaches, such as oral medication. Currently, there are no disease modifying treatments for DPN, only symptom management and behavioral modifications to mitigate further nerve damage that can result from high blood sugar (glucose) levels Approved for the treatment of chronic pain in 2019, the Proclaim XR SCS system now offers DPN patients relief from chronic pain by delivering low amounts, or doses, of stimulation. | (RTTNews) - Abbott Laboratories, Inc. (ABT) announced Thursday that the U.S. Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes. Currently, there are no disease modifying treatments for DPN, only symptom management and behavioral modifications to mitigate further nerve damage that can result from high blood sugar (glucose) levels Approved for the treatment of chronic pain in 2019, the Proclaim XR SCS system now offers DPN patients relief from chronic pain by delivering low amounts, or doses, of stimulation. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories, Inc. (ABT) announced Thursday that the U.S. Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes. People who receive therapy from the Proclaim XR SCS system will also be able to use Abbott's NeuroSphere Virtual Clinic, a connected care app that allows people to communicate with a physician and receive treatment adjustments remotely. Currently, there are no disease modifying treatments for DPN, only symptom management and behavioral modifications to mitigate further nerve damage that can result from high blood sugar (glucose) levels Approved for the treatment of chronic pain in 2019, the Proclaim XR SCS system now offers DPN patients relief from chronic pain by delivering low amounts, or doses, of stimulation. |
31212.0 | 2023-01-25 00:00:00 UTC | US STOCKS-Wall Street dips as weak corporate guidance fuels recession fears | ABT | https://www.nasdaq.com/articles/us-stocks-wall-street-dips-as-weak-corporate-guidance-fuels-recession-fears | nan | nan | By Stephen Culp
NEW YORK, Jan 25 (Reuters) - Wall Street turned lower on Wednesday as a string of corporate earnings ran the gamut from downbeat to dismal, reviving worries over an economic downturn.
All three major U.S. stock indexes were red, but off session lows. The tech-laden Nasdaq was down the most after Microsoft Corp MSFT.O, the first major technology firm to post quarterly results, offered dour guidance and raised red flags with respect to its megacap peers which have yet to report.
"The slowdown in the economy and in the labor market is starting to materialize," said Oliver Pursche, senior vice president at Wealthspire Advisors, in New York.
"For most of last year, the big concern was inflation and the only way to bring it down is to cool the economy," Pursche added. "We're doing that. It's a natural progression, but it's unnerving to investors."
Fourth-quarter earnings season has shifted into overdrive, with 95 of the companies in the S&P 500 having reported. Of those, 67% have beat consensus estimates, well below the 76% average beat rate over the past four quarters, according to Refintiv.
Analysts now see aggregate S&P 500 earnings dropping 3.0% year-on-year, nearly double the 1.6% drop seen on Jan. 1, per Refinitiv.
The Dow Jones Industrial Average .DJI fell 67.67 points, or 0.2%, to 33,666.29, the S&P 500 .SPX lost 14.05 points, or 0.35%, to 4,002.9 and the Nasdaq Composite .IXIC dropped 74.04 points, or 0.65%, to 11,260.23.
Most of the 11 sectors of the S&P 500 were red, utilities .SPLRCU suffering the largest percentage loss.
Boeing Co's BA.N shares reversed an earlier dip, eking out a 0.8% gain after the plane maker posted widening losses for 2022, but reported its first positive cash flow since 2018 on the strength of commercial airplane deliveries.
Abbott Laboratories ABT.N dropped 2.0%, as weaker-than-expected medical device sales weighed on the stock.
Among gainers, News Corp NWSA.O jumped 5.2% Rupert Murdoch withdrew a proposal to reunite News Corp and Fox Corp.
AT&T Inc T.N also delivered disappointing guidance but its renewed focus on its telecoms business helped boost subscriber numbers, sending its shares up 6.0%.
General Dynamics Corp GD.N beat quarterly expectations, but a weak 2023 forecast helped send the defense contractor's shares sliding 3.2%.
Electric automaker Tesla Inc TSLA.O is among the more closely watched corporate results expected after the closing bell.
Finally, in a post-script to Tuesday's technical glitch which halted the opening auctions for a spate of stocks and prompted a review by the U.S. Securities and Exchange Commission (SEC), the New York Stock Exchange (NYSE) said a manual error resulted in the snafu which caused widespread confusion at the opening bell.
Declining issues outnumbered advancing ones on the NYSE by a 1.28-to-1 ratio; on Nasdaq, a 1.36-to-1 ratio favored decliners.
The S&P 500 posted 6 new 52-week highs and 1 new lows; the Nasdaq Composite recorded 52 new highs and 26 new lows.
(Reporting by Stephen Culp; Additional reporting by Shreyashi Sanyal and Johann M Cherian in Bengaluru; Editing by Aurora Ellis)
((stephen.culp@thomsonreuters.com; 646-223-6076;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT.N dropped 2.0%, as weaker-than-expected medical device sales weighed on the stock. By Stephen Culp NEW YORK, Jan 25 (Reuters) - Wall Street turned lower on Wednesday as a string of corporate earnings ran the gamut from downbeat to dismal, reviving worries over an economic downturn. The tech-laden Nasdaq was down the most after Microsoft Corp MSFT.O, the first major technology firm to post quarterly results, offered dour guidance and raised red flags with respect to its megacap peers which have yet to report. | Abbott Laboratories ABT.N dropped 2.0%, as weaker-than-expected medical device sales weighed on the stock. The Dow Jones Industrial Average .DJI fell 67.67 points, or 0.2%, to 33,666.29, the S&P 500 .SPX lost 14.05 points, or 0.35%, to 4,002.9 and the Nasdaq Composite .IXIC dropped 74.04 points, or 0.65%, to 11,260.23. General Dynamics Corp GD.N beat quarterly expectations, but a weak 2023 forecast helped send the defense contractor's shares sliding 3.2%. | Abbott Laboratories ABT.N dropped 2.0%, as weaker-than-expected medical device sales weighed on the stock. The tech-laden Nasdaq was down the most after Microsoft Corp MSFT.O, the first major technology firm to post quarterly results, offered dour guidance and raised red flags with respect to its megacap peers which have yet to report. Finally, in a post-script to Tuesday's technical glitch which halted the opening auctions for a spate of stocks and prompted a review by the U.S. Securities and Exchange Commission (SEC), the New York Stock Exchange (NYSE) said a manual error resulted in the snafu which caused widespread confusion at the opening bell. | Abbott Laboratories ABT.N dropped 2.0%, as weaker-than-expected medical device sales weighed on the stock. By Stephen Culp NEW YORK, Jan 25 (Reuters) - Wall Street turned lower on Wednesday as a string of corporate earnings ran the gamut from downbeat to dismal, reviving worries over an economic downturn. All three major U.S. stock indexes were red, but off session lows. |
31213.0 | 2023-01-25 00:00:00 UTC | US STOCKS-Wall St falls as Microsoft outlook dents tech stocks, earnings disappoint | ABT | https://www.nasdaq.com/articles/us-stocks-wall-st-falls-as-microsoft-outlook-dents-tech-stocks-earnings-disappoint | nan | nan | By Shreyashi Sanyal and Johann M Cherian
Jan 25 (Reuters) - Wall Street benchmarks dropped on Wednesday as a decline in technology stocks after Microsoft's downbeat forecast and a bleak quarterly report from Boeing fanned fears of a recession.
Shares of Microsoft CorpMSFT.O fell 1.2% after it warned that growth in its lucrative cloud business could stall, while its PC unit continues to struggle.
Amazon.com Inc AMZN.O, Salesforce Inc CRM.N and ServiceNow Inc NOW.N, which have large cloud businesses, fell about 1% each. The S&P 500 technology index .SPLRCT shed 1.3%.
Other major growth stocks, including Apple Inc AAPL.O, Alphabet Inc GOOGL.O and Tesla Inc TSLA.O, also dropped between 0.4% and 3%.
Growth stocks, however, have enjoyed a bounce in January after a battering last year, with investors now focused on earnings reports to assess the impact of the Federal Reserve's rate hikes and to gauge whether the renewed enthusiasm for these stocks will be sustained.
"One of the most resilient sectors in the economy (tech) is starting to feel the softness coming through," said Larry Adam, chief investment officer at Raymond James.
"Microsoft particularly talked about December - and that's another shot across the bow to the Fed that they make sure they do not overtighten and send the economy into a more severe recession than the one we're getting."
An overwhelming majority of traders expect the Federal Reserve to raise interest rates by another 25 basis points in its meeting next week.
They now see the terminal rate peaking at 4.91% in June, even as Fed policymakers have repeatedly backed taking rates above the 5% level. 0#FEDWATCH
Data later in the week is likely to show December personal consumption expenditure index (PCE) fell 0.1% from a 0.1% rise in the prior month. Fourth quarter GDP advance numbers are also awaited.
Dow Jones Industrial Average .DJI constituent, Boeing CoBA.N slipped 1.2% as the planemaker's losses widened in 2022 and it missed fourth-quarter revenue estimates.
At 12:21 p.m. ET, the Dow was down 208.76 points, or 0.62%, at 33,525.20, the S&P 500 .SPX was down 34.45 points, or 0.86%, at 3,982.50, and the Nasdaq Composite .IXIC was down 139.09 points, or 1.23%, at 11,195.19.
Abbott Laboratories ABT.N fell 1.9%, weighed down by lower-than-expected medical device sales in the fourth quarter.
In a bright spot, AT&T Inc T.N jumped 5.4% on higher-than-expected quarterly subscriber additions, while Textron IncTXT.N added 0.9% as its revenue beat estimates.
News CorpNWSA.O jumped 6.1%, leading gains on the S&P 500, after Rupert Murdoch withdrew a proposal to reunite News Corp and Fox Corp.
Meanwhile, the New York Stock Exchange said a manual error triggered a technical issue on Tuesday, preventing the opening auctions in some listed stocks, leading to widespread confusion and attracting a review from the U.S. Securities and Exchange Commission.
Declining issues outnumbered advancers for a 2.20-to-1 ratio on the NYSE and for a 1.92-to-1 ratio on the Nasdaq.
The S&P index recorded two new 52-week highs and one new low, while the Nasdaq recorded 45 new highs and 25 new lows.
(Reporting by Shreyashi Sanyal and Johann M Cherian in Bengaluru; Additional reporting by Medha Singh; Editing by Vinay Dwivedi and Anil D'Silva)
((Shreyashi.Sanyal@thomsonreuters.com; +1 646 223 8780; +91 961 144 3740; Twitter: https://twitter.com/s_shreyashi;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT.N fell 1.9%, weighed down by lower-than-expected medical device sales in the fourth quarter. By Shreyashi Sanyal and Johann M Cherian Jan 25 (Reuters) - Wall Street benchmarks dropped on Wednesday as a decline in technology stocks after Microsoft's downbeat forecast and a bleak quarterly report from Boeing fanned fears of a recession. "One of the most resilient sectors in the economy (tech) is starting to feel the softness coming through," said Larry Adam, chief investment officer at Raymond James. | Abbott Laboratories ABT.N fell 1.9%, weighed down by lower-than-expected medical device sales in the fourth quarter. Amazon.com Inc AMZN.O, Salesforce Inc CRM.N and ServiceNow Inc NOW.N, which have large cloud businesses, fell about 1% each. The S&P index recorded two new 52-week highs and one new low, while the Nasdaq recorded 45 new highs and 25 new lows. | Abbott Laboratories ABT.N fell 1.9%, weighed down by lower-than-expected medical device sales in the fourth quarter. By Shreyashi Sanyal and Johann M Cherian Jan 25 (Reuters) - Wall Street benchmarks dropped on Wednesday as a decline in technology stocks after Microsoft's downbeat forecast and a bleak quarterly report from Boeing fanned fears of a recession. Growth stocks, however, have enjoyed a bounce in January after a battering last year, with investors now focused on earnings reports to assess the impact of the Federal Reserve's rate hikes and to gauge whether the renewed enthusiasm for these stocks will be sustained. | Abbott Laboratories ABT.N fell 1.9%, weighed down by lower-than-expected medical device sales in the fourth quarter. By Shreyashi Sanyal and Johann M Cherian Jan 25 (Reuters) - Wall Street benchmarks dropped on Wednesday as a decline in technology stocks after Microsoft's downbeat forecast and a bleak quarterly report from Boeing fanned fears of a recession. Growth stocks, however, have enjoyed a bounce in January after a battering last year, with investors now focused on earnings reports to assess the impact of the Federal Reserve's rate hikes and to gauge whether the renewed enthusiasm for these stocks will be sustained. |
31214.0 | 2023-01-25 00:00:00 UTC | Health Care Sector Update for 01/25/2023: ISRG,ABT,SNOA | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-01-25-2023%3A-isrgabtsnoa | nan | nan | Health care stocks were drifting lower this afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both sinking 0.2%.
The iShares Biotechnology ETF (IBB) was dropping 0.4%.
In company news, Intuitive Surgical (ISRG) retreated 5.4% after the surgical and diagnostic devices company reported a decline in its adjusted net income for its Q4 ended Dec. 31, falling to $1.23 per share compared with $1.29 per share during the year-ago period and lagging Wall Street expectations for a $1.25 per share non-GAAP profit.
Abbott Laboratories (ABT) fell 1.8% after the pharmaceutical and medical device company reported lower non-GAAP Q4 net income, falling to $1.03 per share during the three months ended Dec. 31 from $1.32 per share during the same quarter in 2021 but still beating the Capital IQ consensus expecting $0.93 per share. Net sales declined 12% year-over-year to $10.09 billion, also exceeding the $9.69 billion Street view.
Sonoma Pharmaceuticals (SNOA) raced more than 52% higher after Wednesday saying the Defense Logistics Agency has approved a distribution and pricing registration agreement for the company's Microcyn wound-care products, clearing the way for Sonoma and its privately held distribution partner, EMC Pharma, to sign supply contracts with agencies throughout the federal government as well as state and local prison systems.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT) fell 1.8% after the pharmaceutical and medical device company reported lower non-GAAP Q4 net income, falling to $1.03 per share during the three months ended Dec. 31 from $1.32 per share during the same quarter in 2021 but still beating the Capital IQ consensus expecting $0.93 per share. In company news, Intuitive Surgical (ISRG) retreated 5.4% after the surgical and diagnostic devices company reported a decline in its adjusted net income for its Q4 ended Dec. 31, falling to $1.23 per share compared with $1.29 per share during the year-ago period and lagging Wall Street expectations for a $1.25 per share non-GAAP profit. Sonoma Pharmaceuticals (SNOA) raced more than 52% higher after Wednesday saying the Defense Logistics Agency has approved a distribution and pricing registration agreement for the company's Microcyn wound-care products, clearing the way for Sonoma and its privately held distribution partner, EMC Pharma, to sign supply contracts with agencies throughout the federal government as well as state and local prison systems. | Abbott Laboratories (ABT) fell 1.8% after the pharmaceutical and medical device company reported lower non-GAAP Q4 net income, falling to $1.03 per share during the three months ended Dec. 31 from $1.32 per share during the same quarter in 2021 but still beating the Capital IQ consensus expecting $0.93 per share. In company news, Intuitive Surgical (ISRG) retreated 5.4% after the surgical and diagnostic devices company reported a decline in its adjusted net income for its Q4 ended Dec. 31, falling to $1.23 per share compared with $1.29 per share during the year-ago period and lagging Wall Street expectations for a $1.25 per share non-GAAP profit. Net sales declined 12% year-over-year to $10.09 billion, also exceeding the $9.69 billion Street view. | Abbott Laboratories (ABT) fell 1.8% after the pharmaceutical and medical device company reported lower non-GAAP Q4 net income, falling to $1.03 per share during the three months ended Dec. 31 from $1.32 per share during the same quarter in 2021 but still beating the Capital IQ consensus expecting $0.93 per share. The iShares Biotechnology ETF (IBB) was dropping 0.4%. In company news, Intuitive Surgical (ISRG) retreated 5.4% after the surgical and diagnostic devices company reported a decline in its adjusted net income for its Q4 ended Dec. 31, falling to $1.23 per share compared with $1.29 per share during the year-ago period and lagging Wall Street expectations for a $1.25 per share non-GAAP profit. | Abbott Laboratories (ABT) fell 1.8% after the pharmaceutical and medical device company reported lower non-GAAP Q4 net income, falling to $1.03 per share during the three months ended Dec. 31 from $1.32 per share during the same quarter in 2021 but still beating the Capital IQ consensus expecting $0.93 per share. Health care stocks were drifting lower this afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both sinking 0.2%. The iShares Biotechnology ETF (IBB) was dropping 0.4%. |
31215.0 | 2023-01-25 00:00:00 UTC | Pre-Markets Edge Lower With Q4 Earnings Underway | ABT | https://www.nasdaq.com/articles/pre-markets-edge-lower-with-q4-earnings-underway | nan | nan | Pre-market futures are sinking into the red this morning, as it appears we’ve finally hit a snag in earnings season in the manner of Microsoft’s (MSFT) fiscal Q2 results, which went from +4% after the release to -3% this morning. Investors have had some time to digest the conference call, and have become near-term negative on the stock.
What we saw in the actual Microsoft report was a notable deceleration in its Azure cloud business. In the conference call, it became understood that this overall slowing has actually picked up pace between December and January. Enterprise software looks to have reached a near-term peak; this is also evident in the large numbers of layoffs coming from software companies of late, Microsoft included.
We also saw a -3600% negative earnings surprise from Boeing (BA) in its Q4 report this morning: the world’s biggest aircraft builder was expected to turn a profit of 5 cents per share in the quarter, but instead produced a -$1.75 per share loss. That said, revenues beat expectations in the quarter by +2.85% to $19.98 billion — and notably ahead of the year-ago’s $14.79 billion. Boeing also reaffirmed its free and operating cash flow for the full year.
Abbott Labs (ABT) put up prominent beats ahead of today’s opening bell, with earnings of $1.03 per share outpacing the 90 cents in the Zacks consensus on revenues of $10.09 billion, for a positive surprise of +6.47%. Yet pre-market forces being what the are this morning, Abbott shares are still down roughly -1.25% — effectively cutting in half the pharma major’s gains thus far year to date.
Dow futures are -280 points at this hour, the Nasdaq is -200 and the S&P 500 -40 points. We do sometimes see turnarounds within the course of the trading day, although today there are no economic reports scheduled that might swing markets in the other direction. After today’s close, we’ll get new earnings results from IBM (IBM), Las Vegas Sands (LVS) and, of course, Tesla (TSLA).
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Boeing Company (BA) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Microsoft Corporation (MSFT) : Free Stock Analysis Report
International Business Machines Corporation (IBM) : Free Stock Analysis Report
Las Vegas Sands Corp. (LVS) : Free Stock Analysis Report
Tesla, Inc. (TSLA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs (ABT) put up prominent beats ahead of today’s opening bell, with earnings of $1.03 per share outpacing the 90 cents in the Zacks consensus on revenues of $10.09 billion, for a positive surprise of +6.47%. Click to get this free report The Boeing Company (BA) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Microsoft Corporation (MSFT) : Free Stock Analysis Report International Business Machines Corporation (IBM) : Free Stock Analysis Report Las Vegas Sands Corp. (LVS) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Yet pre-market forces being what the are this morning, Abbott shares are still down roughly -1.25% — effectively cutting in half the pharma major’s gains thus far year to date. | Click to get this free report The Boeing Company (BA) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Microsoft Corporation (MSFT) : Free Stock Analysis Report International Business Machines Corporation (IBM) : Free Stock Analysis Report Las Vegas Sands Corp. (LVS) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs (ABT) put up prominent beats ahead of today’s opening bell, with earnings of $1.03 per share outpacing the 90 cents in the Zacks consensus on revenues of $10.09 billion, for a positive surprise of +6.47%. We also saw a -3600% negative earnings surprise from Boeing (BA) in its Q4 report this morning: the world’s biggest aircraft builder was expected to turn a profit of 5 cents per share in the quarter, but instead produced a -$1.75 per share loss. | Abbott Labs (ABT) put up prominent beats ahead of today’s opening bell, with earnings of $1.03 per share outpacing the 90 cents in the Zacks consensus on revenues of $10.09 billion, for a positive surprise of +6.47%. Click to get this free report The Boeing Company (BA) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Microsoft Corporation (MSFT) : Free Stock Analysis Report International Business Machines Corporation (IBM) : Free Stock Analysis Report Las Vegas Sands Corp. (LVS) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. We also saw a -3600% negative earnings surprise from Boeing (BA) in its Q4 report this morning: the world’s biggest aircraft builder was expected to turn a profit of 5 cents per share in the quarter, but instead produced a -$1.75 per share loss. | Click to get this free report The Boeing Company (BA) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Microsoft Corporation (MSFT) : Free Stock Analysis Report International Business Machines Corporation (IBM) : Free Stock Analysis Report Las Vegas Sands Corp. (LVS) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs (ABT) put up prominent beats ahead of today’s opening bell, with earnings of $1.03 per share outpacing the 90 cents in the Zacks consensus on revenues of $10.09 billion, for a positive surprise of +6.47%. That said, revenues beat expectations in the quarter by +2.85% to $19.98 billion — and notably ahead of the year-ago’s $14.79 billion. |
31216.0 | 2023-01-25 00:00:00 UTC | S&P 500 closes slightly red as weak corporate guidance fuels recession fears | ABT | https://www.nasdaq.com/articles/sp-500-closes-slightly-red-as-weak-corporate-guidance-fuels-recession-fears | nan | nan | By Stephen Culp
NEW YORK, Jan 25 (Reuters) - The S&P 500 ended lower on Wednesday as a string of corporate earnings ran the gamut from downbeat to dismal, reviving worries over the economic impact of the U.S. Federal Reserve's restrictive policy.
All three major U.S. stock indexes pared their losses throughout the afternoon to close well off session lows.
The tech-laden Nasdaq was weighed down after Microsoft Corp MSFT.O, the first major technology firm to post quarterly results, offered dour guidance and raised red flags with respect to its megacap peers which have yet to report.
"We’ve had up and down days, that indicates an ongoing tug-of-war," said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana. "The dour guidance good news from the standpoint of what the Fed is doing is working."
"That outcome has become the catalyst for the market one way or the other," Carlson added. "Earnings matter but what’s really got the market’s focus is the Fed interest rate/inflation story."
Fourth-quarter earnings season has shifted into overdrive, with 95 of the companies in the S&P 500 having reported. Of those, 67% have beat consensus estimates, well below the 76% average beat rate over the past four quarters, according to Refintiv.
Analysts now see aggregate S&P 500 earnings dropping 3.0% year-on-year, nearly double the 1.6% drop seen on Jan. 1, per Refinitiv.
According to preliminary data, the S&P 500 .SPX lost 0.73 points, or 0.02%, to end at 4,016.22 points, while the Nasdaq Composite .IXIC lost 20.92 points, or 0.20%, to 11,313.35. The Dow Jones Industrial Average .DJI rose 5.67 points, or 0.03%, to 33,742.72.
Boeing Co's BA.N shares reversed an earlier dip, turning positive after the plane maker posted widening losses for 2022, but reported its first positive cash flow since 2018 on the strength of commercial airplane deliveries.
Abbott Laboratories ABT.N dropped as weaker-than-expected medical device sales weighed on the stock.
Among gainers, News Corp NWSA.O jumped after Rupert Murdoch withdrew a proposal to reunite News Corp and Fox Corp.
AT&T Inc T.N also delivered disappointing guidance but its renewed focus on its telecoms business helped boost subscriber numbers, sending its shares higher.
General Dynamics Corp GD.N slid after its weak 2023 forecast overshadowed its earnings beat.
Electric automaker Tesla Inc TSLA.O is expected to post results shortly.
Finally, in a post-script to Tuesday's technical glitch which halted the opening auctions for a spate of stocks and prompted a review by the U.S. Securities and Exchange Commission (SEC), the New York Stock Exchange (NYSE) said a manual error resulted in the snafu which caused widespread confusion at the opening bell.
(Reporting by Stephen Culp; Additional reporting by Shreyashi Sanyal and Johann M Cherian in Bengaluru; Editing by Aurora Ellis)
((stephen.culp@thomsonreuters.com; 646-223-6076;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT.N dropped as weaker-than-expected medical device sales weighed on the stock. By Stephen Culp NEW YORK, Jan 25 (Reuters) - The S&P 500 ended lower on Wednesday as a string of corporate earnings ran the gamut from downbeat to dismal, reviving worries over the economic impact of the U.S. Federal Reserve's restrictive policy. The tech-laden Nasdaq was weighed down after Microsoft Corp MSFT.O, the first major technology firm to post quarterly results, offered dour guidance and raised red flags with respect to its megacap peers which have yet to report. | Abbott Laboratories ABT.N dropped as weaker-than-expected medical device sales weighed on the stock. The tech-laden Nasdaq was weighed down after Microsoft Corp MSFT.O, the first major technology firm to post quarterly results, offered dour guidance and raised red flags with respect to its megacap peers which have yet to report. According to preliminary data, the S&P 500 .SPX lost 0.73 points, or 0.02%, to end at 4,016.22 points, while the Nasdaq Composite .IXIC lost 20.92 points, or 0.20%, to 11,313.35. | Abbott Laboratories ABT.N dropped as weaker-than-expected medical device sales weighed on the stock. The tech-laden Nasdaq was weighed down after Microsoft Corp MSFT.O, the first major technology firm to post quarterly results, offered dour guidance and raised red flags with respect to its megacap peers which have yet to report. Among gainers, News Corp NWSA.O jumped after Rupert Murdoch withdrew a proposal to reunite News Corp and Fox Corp. AT&T Inc T.N also delivered disappointing guidance but its renewed focus on its telecoms business helped boost subscriber numbers, sending its shares higher. | Abbott Laboratories ABT.N dropped as weaker-than-expected medical device sales weighed on the stock. By Stephen Culp NEW YORK, Jan 25 (Reuters) - The S&P 500 ended lower on Wednesday as a string of corporate earnings ran the gamut from downbeat to dismal, reviving worries over the economic impact of the U.S. Federal Reserve's restrictive policy. "The dour guidance good news from the standpoint of what the Fed is doing is working." |
31217.0 | 2023-01-25 00:00:00 UTC | Health Care Sector Update for 01/25/2023: PGEN,ISRG,ABT,SNOA | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-01-25-2023%3A-pgenisrgabtsnoa | nan | nan | Health care stocks were ending little changed this afternoon, with the NYSE Health Care Index climbing 0.1% and the Health Care Select Sector SPDR Fund (XLV) ahead less than 0.1%.
The iShares Biotechnology ETF (IBB) was slipping 0.1%.
In company news, Precigen (PGEN) plunged over 22% after the cellular therapies company overnight priced a $75 million public offering of nearly 42.9 million common shares at $1.75 each, or slightly more than 20% under Tuesday's closing price. Precigen is expecting to use the net proceeds to fund product development, working capital and other general corporate purposes.
Intuitive Surgical (ISRG) retreated 5.5% after the surgical and diagnostic devices company reported a decline in its adjusted net income for its Q4 ended Dec. 31, falling to $1.23 per share compared with $1.29 per share during the year-ago period and lagging Wall Street expectations for a $1.25 per share non-GAAP profit.
Abbott Laboratories (ABT) fell 1.6% after the pharmaceutical and medical device company reported lower non-GAAP Q4 net income, falling to $1.03 per share during the three months ended Dec. 31 from $1.32 per share during the same quarter in 2021 but still beating the Capital IQ consensus expecting $0.93 per share. Net sales declined 12% year-over-year to $10.09 billion, also exceeding the $9.69 billion Street view.
Among gainers, Sonoma Pharmaceuticals (SNOA) raced almost 38% higher after Wednesday, saying the Defense Logistics Agency has approved a distribution and pricing registration agreement for the company's Microcyn wound-care products, clearing the way for Sonoma and its privately held distribution partner, EMC Pharma, to sign supply contracts with agencies throughout the federal government as well as state and local prison systems.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT) fell 1.6% after the pharmaceutical and medical device company reported lower non-GAAP Q4 net income, falling to $1.03 per share during the three months ended Dec. 31 from $1.32 per share during the same quarter in 2021 but still beating the Capital IQ consensus expecting $0.93 per share. In company news, Precigen (PGEN) plunged over 22% after the cellular therapies company overnight priced a $75 million public offering of nearly 42.9 million common shares at $1.75 each, or slightly more than 20% under Tuesday's closing price. Precigen is expecting to use the net proceeds to fund product development, working capital and other general corporate purposes. | Abbott Laboratories (ABT) fell 1.6% after the pharmaceutical and medical device company reported lower non-GAAP Q4 net income, falling to $1.03 per share during the three months ended Dec. 31 from $1.32 per share during the same quarter in 2021 but still beating the Capital IQ consensus expecting $0.93 per share. Intuitive Surgical (ISRG) retreated 5.5% after the surgical and diagnostic devices company reported a decline in its adjusted net income for its Q4 ended Dec. 31, falling to $1.23 per share compared with $1.29 per share during the year-ago period and lagging Wall Street expectations for a $1.25 per share non-GAAP profit. Net sales declined 12% year-over-year to $10.09 billion, also exceeding the $9.69 billion Street view. | Abbott Laboratories (ABT) fell 1.6% after the pharmaceutical and medical device company reported lower non-GAAP Q4 net income, falling to $1.03 per share during the three months ended Dec. 31 from $1.32 per share during the same quarter in 2021 but still beating the Capital IQ consensus expecting $0.93 per share. Intuitive Surgical (ISRG) retreated 5.5% after the surgical and diagnostic devices company reported a decline in its adjusted net income for its Q4 ended Dec. 31, falling to $1.23 per share compared with $1.29 per share during the year-ago period and lagging Wall Street expectations for a $1.25 per share non-GAAP profit. Among gainers, Sonoma Pharmaceuticals (SNOA) raced almost 38% higher after Wednesday, saying the Defense Logistics Agency has approved a distribution and pricing registration agreement for the company's Microcyn wound-care products, clearing the way for Sonoma and its privately held distribution partner, EMC Pharma, to sign supply contracts with agencies throughout the federal government as well as state and local prison systems. | Abbott Laboratories (ABT) fell 1.6% after the pharmaceutical and medical device company reported lower non-GAAP Q4 net income, falling to $1.03 per share during the three months ended Dec. 31 from $1.32 per share during the same quarter in 2021 but still beating the Capital IQ consensus expecting $0.93 per share. Health care stocks were ending little changed this afternoon, with the NYSE Health Care Index climbing 0.1% and the Health Care Select Sector SPDR Fund (XLV) ahead less than 0.1%. The iShares Biotechnology ETF (IBB) was slipping 0.1%. |
31218.0 | 2023-01-25 00:00:00 UTC | Abbott Laboratories (ABT) Q4 2022 Earnings Call Transcript | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-q4-2022-earnings-call-transcript | nan | nan | Image source: The Motley Fool.
Abbott Laboratories (NYSE: ABT)
Q4 2022 Earnings Call
Jan 25, 2023, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning and thank you for standing by. Welcome to Abbott's fourth-quarter 2022earnings conference call All participants will be able to listen only until the question-and-answer portion of this call. [Operator instructions] This call is being recorded by Abbott.
With the exception of any participant's questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It can not be recorded or rebroadcast without Abbott's express written permission. I would now like to introduce Mr. Scott Leinenweber, vice president, investor relations, licensing, and acquisitions.
Scott Leinenweber -- Vice President of Investor Relations, Licensing, and Acquisition
Good morning and thank you for joining us. With me today are Robert Ford, chairman and chief executive officer, and Bob Funck, executive vice president, finance, and chief financial officer. Robert and Bob will provide opening remarks. Following their comments, we'll take your questions.
Before we get started, some statements made today may be forward looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2023. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological, and other factors that may affect Abbott's operations are discussed in item 1A, Risk Factors, to our annual report on Form 10-K for the year ended December 31st, 2021. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments except as required by law.
10 stocks we like better than Abbott Laboratories
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of January 9, 2023
On today's conference call, as in the past, non-GAAP financial measures will be used to help investors understand Abbott's ongoing business performance. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at abbott.com. Note that Abbott has not provided the GAAP financial measure for organic sales growth, excluding COVID testing sales, on a forward-looking basis because the company is unable to predict future changes in foreign exchange rates, which could impact reported sales growth. Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which excludes the impact of foreign exchange.
With that, I will now turn the call over to Robert.
Robert Ford -- Chairman and Chief Executive Officer
Thanks, Scott. Good morning, everyone, and thank you for joining us. Today, I'll discuss our 2022 results as well as our outlook for this year. For the full-year 2022, we achieved ongoing earnings per share of $5.34, which is well above the original EPS guidance we set at the beginning of the year.
As you know, macro business conditions have been highly dynamic and challenging for the last few years, particularly for U.S.-based multinational companies. COVID-19 pandemic played a big role in this, of course. We saw the U.S. dollar strengthened significantly and inflation reached new heights last year.
Supply chains continue to face challenges, and our healthcare customers have been navigating staffing challenges that are negatively impacting certain medical device procedure trends and routine diagnostic testing volumes. As we start the new year, however, while these factors remain headwinds, I'm cautiously optimistic that we're starting to see them peak and, in some cases, ease a bit. Over the past few months, the impact of COVID-19 on society has lessened, and economies around the world are increasingly reopening. In the U.S., the U.S.
dollar weakened a bit, and inflation has eased somewhat. And hospital-based procedures and routine testing trends continue to steadily improve in many areas. As you know, COVID testing has been a big part of our story this past couple of years. And I'm proud of what our team has built: a full suite of tests across several platforms and the intentionality and how we established a leading role in the world's response to the pandemic.
In total, we've delivered nearly 3 billion COVID tests globally since the start of the pandemic. Going forward, we expect COVID-19 to transition to more of an endemic seasonal type of respiratory virus. And with that, COVID testing, while still important, is expected to decline significantly. We expect variants will continue to emerge, and, therefore, our tests will remain an important part of our leading respiratory testing portfolio, along with flu, RSV, and strep, which we offer across multiple testing platforms, including lab-based systems in hospitals, small desktop devices in urgent care centers and physician offices, as well as at-home tests.
As we reflect back on the impact of COVID testing efforts over the last few years, it's clear that our success in this area will have a positive, long-lasting impact for the company. It strengthened our strategic position in diagnostics through the expansion of our installed base of instruments, including ID NOW, our rapid, point-of-care molecular testing platform, and through the opening of new testing channels such as physician offices and at-home testing. It enabled us to increase investments in priority growth areas across the company, including R&D and commercial initiatives, in support of several recent and upcoming new product launches while, at the same time, increasing returns to our shareholders in the forms of dividend growth and share repurchase. And lastly, it further strengthened our overall financial health and balance sheet, which will provide significant strategic flexibility as we look to build and grow the company even further.
I'm proud of the role we played in fighting COVID over the last few years. It reinforced our purpose, had a meaningful impact on society, and enhanced our long-term strategic position going forward. Turning now to our outlook for 2023. As we announced this morning, we forecast ongoing earnings per share of $4.30 to $4.50.
We forecast organic sales growth, excluding COVID testing sales, in the high single digits. And we forecast around $2 billion of COVID testing sales for the full-year 2023. And I'll provide more details on our results by business area before turning the call over to Bob. And I'll start with nutrition where sales declined around 6% in both the fourth quarter and full year as a result of manufacturing disruptions at one of our U.S.
infant formula facilities last year. Production at the facility is up and running. And as we've mentioned previously, our initial supply priority was to the WIC, women, infant, and children federal food assistance program, to ensure underserved participants have access to infant formula. As our manufacturing capacity has continued to recover, we've been able to increase production of our non-WIC brands with a focus on serving the broader infant formula market and building back inventory levels on retail shelves.
Turning to diagnostics where, as expected, sales growth in the fourth quarter was negatively impacted by year-over-year decline in COVID-19 test sales. COVID testing sales were $1.1 billion in the fourth quarter with rapid testing platforms, including BinaxNOW in the U.S. Panbio internationally, and ID NOW globally, compromising approximately 95% of the sales. Excluding COVID testing sales, worldwide diagnostics grew over 11% in the fourth quarter.
Growth in the quarter was led by rapid diagnostics where, excluding COVID-19 tests, sales increased 30% compared to the prior year. As I mentioned earlier, during the pandemic, we significantly expanded the install base of ID NOW and opened new testing channels. This expanded footprint drove strong growth and supported testing needs when flu and other respiratory infections surged late last year. During this past year, we continued the rollout of Alinity, our innovative suite of diagnostic instruments, and expand test menus across our platforms for immunoassay, clinical chemistry, and molecular testing.
Moving to established pharmaceuticals, or EPD, where sales increased 8% in the fourth quarter and over 10% for the full year. EPD continues to perform at a high level, having carved out an attractive growth space in the global pharmaceutical market, specifically, our geographic focus on fast-growing emerging markets with a broad portfolio targeting attractive therapeutic areas. Strong performance in the quarter was led by double-digit growth across several geographies, including India, China, Brazil, and Mexico. And I'll wrap up with medical devices where sales grew 7.5% in the fourth quarter and 8% for the full year.
Growth in both the quarter and full year was led by double-digit growth in electrophysiology, structural heart, and diabetes care in the U.S. Internationally, sales growth was negatively impacted by COVID surges in China during the fourth quarter, as well as lingering supply challenges in a couple of areas. In diabetes care, fourth-quarter sales of FreeStyle Libre, our market-leading continuous glucose monitoring system, grew over 40% in the U.S., and global Libre sales reached $4.3 billion for the full-year 2022. We continue to strengthen our medical device portfolio with numerous pipeline advancements and launches, including recent U.S.
regulatory approvals of Aveir, our highly innovative, leadless pacemakers used to treating people with slow heart rhythms; Eterna, the smallest implantable rechargeable spinal cord stimulation system currently available in the market for the treatment of chronic pain; FreeStyle Libre 3, which provides continuous glucose readings in the world's smallest and most accurate wearable sensor, Libre was recently named the best medical technology of the last 50 years by Galen Foundation; and finally, Navitor, our latest-generation transcatheter aortic heart valve replacement system. So, in summary, 2022 was another highly successful year for Abbott. We're optimistic about the early signs we're seeing of an improving operating environment and excited about the growth opportunities that lie ahead for all of our businesses. And we continue to strengthen our overall strategic position with a steady cadence of innovative technologies that are either in the early stages of launching or expected to launch over the course of this year.
I'll now turn over the call to Bob. Bob.
Bob Funck -- Executive Vice President, Finance, and Chief Financial Officer
Thanks, Robert. As Scott mentioned earlier, please note that all references to sales growth rates, unless otherwise noted, are on an organic basis, which excludes the impact of foreign exchange. Turning to our results. Sales decreased 6.1% on an organic basis in the quarter.
COVID testing-related sales were $1.1 billion in the quarter, which, while stronger than the forecast we provided back in October, reflect a year-over-year decline versus sales in the fourth quarter of the prior year. Excluding both COVID testing-related sales and U.S. infant formula sales that were impacted by manufacturing disruptions last year in our nutrition business, total Abbott sales increased 7.1% on an organic basis in the fourth quarter and 7.4% for the full-year 2022. Foreign exchange had an unfavorable year-over-year impact of 5.9% on fourth-quarter sales, which resulted in a somewhat favorable impact on sales compared to exchange rates at the time of ourearnings callin October as we saw the dollar weakened a bit late last year.
Regarding other aspects of the P&L for the quarter, the adjusted gross margin ratio was 55.6% of sales, which reflects the impact of the nutrition manufacturing disruptions and inflation we've experienced on certain manufacturing and distribution costs across our businesses. Adjusted R&D investment was 6.5% of sales, and adjusted SG&A expense was 28% of sales in the fourth quarter. Turning to our outlook for the full-year 2023. Today, we issued guidance for full-year ongoing earnings per share of $4.30 to $4.50.
For the year, we forecast organic sales growth, excluding the impact of COVID testing-related sales, to be in the high single digits. We forecast COVID testing-related sales around $2 billion with around $750 million forecasted in the first quarter. Based on current rates, we would expect exchange to have an unfavorable impact of approximately 1% on our reported full-year sales, which includes an expected unfavorable impact of approximately 3% on our first-quarter reported sales. We're forecasting adjusted gross margin ratio for the full year of approximately 56% of sales.
Also, for the year, we forecast R&D investment of around $2.5 billion and SG&A investment of around $11 billion, which reflects investments to support several ongoing and upcoming new product launches and strategic growth initiatives. We forecast net interest expense of around $300 million, nonoperating income of around $450 million, and a full-year adjusted tax rate of approximately 14% for the year. As Robert mentioned, the strength and resiliency of our business, particularly since the start of the pandemic, has allowed us to concurrently invest in our strategic priorities, provide strong return to our shareholders, and further strengthen our financial health, which provides a strong base on which to grow the company going forward. With that, we'll now open the call for questions.
Questions & Answers:
Operator
Thank you. At this time, we will conduct the question-and-answer session. [Operator instructions] And our first question will come from Robbie Marcus from J.P. Morgan.
Your line is open.
Robbie Marcus -- JPMorgan Chase and Company -- Analyst
Oh, great. Thanks. Good morning, everyone. Robert, maybe to kick it off, I appreciate the guidance, but there's there's a lot of moving parts through the different business lines with macro involved with a lot of new product launches involved.
Maybe you could just build up how we should be thinking about, you know, how you came up with the guidance range on both the top and bottom lines, given all the moving parts.
Robert Ford -- Chairman and Chief Executive Officer
Sure. I mean, there's obviously a macro environment here that's been complex and you've mentioned it. And as I said in my -- as I said in my remarks, and I think they've gotten significantly better versus where we were in October when -- on our lastearnings call So, I think that we've factored, you know, some of that improvement and some of that stabilization in there.
I mean, I don't necessarily think that we've got too many moving parts here. I mean, obviously, we run a, you know -- the company's got a lot of different, you know, business and business segments. But, I mean, if you look at really the two areas, I would say, Robbie, that kind of have had this effect of -- you know, maybe sometimes distorting the results a little bit is our COVID testing business and the impact of the recall products last year, right? So, you know, from a COVID perspective, in 2022, we actually sold more tests than we sold in 2021. And then, obviously, the impact of recall products, yeah, that was a negative that -- both of those flip next year.
So, if you take those out of the equation, you kind of go back to what we were growing pre-pandemic, right, which was, you know, top-tier, you know, high single digit, 7% to 8% growth. That's what we grew in 2022, again, excluding COVID and the impact of the recall products. And then, if you take that -- you know, that comp out on the recall product side, you know, this year, as as we return to market and, you know, look at the base business, you know, obviously, without the COVID test piece, we're going to be growing, you know, high single digits, probably at a higher, higher end of that pre-pandemic range, probably 8-plus percent. So, I think it starts with with the top line.
And that's probably that -- you know, the number one part of our guidance is obviously making sure that we feel that our top line is taking advantage of all the good parts, all the good product launches, etc. that we have. And from that perspective, I think a lot of what we're doing kind of supports that ongoing -- you know, that ongoing high single-digit growth rate. You know, if you look at our device portfolio, you know, we'll be looking at high single-digit growth rate, low double-digit growth rate, combination of both kind of recovery -- the steady recovery procedures that we're seeing, combined with all these product launches that we've got lined up, you know, that will ultimately have a full-year impact, whether it's Libre 3, Amulet, Aveir, Navitor, CardioMEMS, you know, Eterna on the neuromodulation side, our mapping system in EP, we're going to launch a new ablation catheter.
So, the device portfolio is well set up to be able to drive those high single-digit, low double-digit growth rate. I mean, I think we're going to continue to see strong performance in EPD. I think as the world continues to reopen, those emerging markets continue to be a great opportunity for us. We've strengthened our position in diagnostics throughout these years, and we'll see continued successful rollout of Alinity in our core and molecular diagnostics and then the recovery in infant formula too.
So, I think you put all that in place, our core business, Abbott, that we knew pre-pandemic is actually stronger than we were pre-pandemic with the investments that we made. And I think that's the other part of -- I guess, in the P&L, if you look at what we've been able to do this year is, because of COVID and the investments that we made during COVID in these growth areas, we're able to drive this high single-digit growth across the company with a fairly flat, you know, investment line, whether it's R&D and SG&A. So, really getting the leverage across the businesses. So, I mean, I think it really starts with our top line and the confidence we have in the products we're launching, the pipeline, the positions we have.
And then, you know, COVID, you know, COVID, we forecast about 2 billion next year. And I think that's the right number right now. Obviously, we see kind of society transitioning here. We've got a strong install base.
We've got manufacturing capacity. We haven't factored in any kind of real surge. But if -- you know, if that happens, we do have the capacity to be able to do that. So, I'd say those are some of the moving pieces there.
But fundamentally, we're in a real strong position in terms of our long-term growth opportunities, leading positions in these attractive growth areas, strong pipeline, which I'm sure we'll get into some of them, and a strong balance sheet. So, that's how this has been constructed, and I think that we're in a good position here.
Robbie Marcus -- JPMorgan Chase and Company -- Analyst
Great. Thanks, Robert. Really helpful. Maybe one for Bob.
You know, you're -- you give us the full-year guide and you give some commentary down the P&L, which is really helpful. But how should we be thinking about some of the quarterly cadence here, how FX flows, what is FX on the bottom line, and how did that compare to '22? And any just things we should be thinking about first half or second half on the P&L? Thanks a lot.
Bob Funck -- Executive Vice President, Finance, and Chief Financial Officer
Yeah. So, if you think about the kind of the cadence of our business for 2023, it really starts with the top line and some of the things that Robert kind of talked about. You know, first, we have a lot of new product launch activity, especially in our medical device businesses. You've got, you know, products that either launched last year or will be launching this year.
And I'm sure we'll talk about some of those on the call today. So, you'll see the impact of those launches kind of grow over the course of year, kind of feather into that top line. Secondly, you know, we are seeing a steady improvement in procedure trends in the U.S. and Europe.
And we've been seeing that. And we -- you know, we expect to continue to see kind of a steady improvement there on procedure trends over the course of the year. In our nutrition business, we will see improvement as we continue to continue to supply the market, in particular, the non-WIC segment of the infant formula market in the U.S. And so, we will recover share there.
And so, we'll have the impact of that over the course of the year. For China, Robbie, I'd say, you know, we've assumed to start -- a softer start in Q1, given some of the dynamics there at the start of this year. But we anticipate that will improve over the course of the year. And so, all those changes, all those impacts in the top line that builds over the course of the year, will flow through to earnings.
As Robert talked about, we're going to get leverage in the middle here. And so, you know, for the first quarter, we're -- you know, we think, you know, earnings will be approximately $1. And then, we'll build from there. On your question on foreign exchange, you know, rates have improved a bit recently, but exchange is still a headwind, particularly on earnings.
You know, current rates, as I said in my opening remarks, exchange is approximately 1% headwind on sales. EPS, you know, it's a little bit more than $0.30 headwind for us in 2023. The fall-through impact when currencies move, like we have seen over the last year, is always complex. You know, translation is just a piece of the impact.
And while that has improved from where we were a few months ago, it still remains a headwind. One of the biggest drivers that we're seeing is the impact from our hedging program. We realized pretty significant hedging gains last year that won't repeat this year. And you can really see the impact of those hedging gains on our 2022 results.
Last year, there was a pretty significant exchange headwind on sales, you know, a little over 5%, or $2.1 billion, but a fairly modest impact on earnings. It was less than a dime. And that was really the benefit we realized last year on those hedging gains that won't repeat in 2023. You know, that's not a unique dynamic that we're seeing.
We're seeing that -- we're seeing that from some other multinationals as well.
Robbie Marcus -- JPMorgan Chase and Company -- Analyst
Thanks a lot.
Operator
Thank you. One moment for our next question, please. And our next question will come from Larry Biegelsen from Wells Fargo. Your line is open.
Larry Biegelsen -- Wells Fargo Securities -- Analyst
Good morning. Thanks for taking the question. Robert, I feel compelled to ask about Libre again, just given how important it is. So, maybe I'd love to hear from you, you know, the outlook for 2023, you know.
How should we think about worldwide growth, and it can exceed 20% this year? And can you talk about, you know, international, we've been negatively impacted by the supply issues and the transition to Libre 3 in Germany. When do you expect those issues to be resolved? And, you know, just the growth drivers, you know, like, basal and the vitamin C resolution, you know, what are some of the growth drivers to look forward to this year for Libre? And I had one follow-up. Thank you.
Robert Ford -- Chairman and Chief Executive Officer
Sure, Larry. Well, I think Libre had another great -- a great year, full-year growth of over 21% strong growth, in the U.S., over 42%. And international, you know, kind of grew in this mid-teens number. We were impacted a little bit by back orders, as you said, on the international side.
And I'd say, you know, probably a little bit more on our early generation products. So, kind of Libre 1 was that -- you know, we had a significant improvement in that situation in Q4. I expect, you know, one or two more months of -- you know, until we can completely resolve that, but a significant improvement over there on our international performance. I think one of the key things on the international side is, you know, it was a little bit of this supply chain on chips that we had.
Like I said, it's mostly behind us. The other part of it is, you know, the upgrade cycle, right? And when you go with an accelerated upgrade cycle versus, you know, with Libre 3 that we did from Libre 2 in some of our key markets. And when we went from Libre 1 to Libre 2, we left that upgrade kind of somewhat happened naturally. And that takes, you know, about a year and a half, two years to actually complete.
For Libra 3, we wanted to go more aggressively in some of these markets. So, you know, that takes our sales force away from new demand generation to making sure that we can get the scripts and do all the behind-the-scenes work for those upgrades. So, that's -- I would say that's still ongoing, but I'd call it about 80% to 85% complete. So, then, that allows us, starting now, in 2023 on the international side to start kind of driving new additions here.
So, I'd say I expect a continued growth in the U.S. in terms of, you know, market expansion. You know, basal opportunity, I think, is a great opportunity. And I think it'll start in the U.S., but I think we're seeing that also internationally.
And now that we've got, you know, the supply chain issue largely behind us and, you know, the upgrade cycle, again, largely behind us, we can forecast our demand generation activities on new users. So, I think that that's, you know, one key driver of growth for us. You know, can we see path for a 20 -- another 20% growth in 2023? Yeah, I can. And I think there's a lot of opportunities of growth.
I think one of them that you mentioned being the basal expansion, you know, is a significant opportunity. I think we've been leading the charge over here, Larry, in terms of generating the clinical data that's required to be able to support reimbursement. It'll start, I think, in the U.S., but I don't think it will be a U.S.-only phenomenon. But in the U.S., we'll probably start -- first, you've got about 4 million type 2 basal patients in the U.S.
About a third of them are Medicare. And, you know, even if you assume a reasonable market penetration, you also have to assume, you know, a difference in annual utilization rates versus, you know, a type 1 and an MDI or a pumper. But even if you take all that in consideration, the opportunity, you know, starts with a one -- you know, 1 billion. And it can range, you know, depending on the speed and the uptake of that.
So, I think this is a great growth opportunity. And like I said, I don't think it's a U.S.-only situation. I think this is going to start to expand across the world, given the clinical data that you see with Libre and the impacts that it has. So, I think this is another great opportunity for us.
You know, the vitamin C issue that you asked, you know, we've submitted, you know, our response. You know, we're working with the FDA on this. And, you know, I'm not going to try and forecast that approval. But what I will say is that, you know, as soon as that gets approved, then we'll start to see, you know, the product with a couple quarters connect to AID pump systems.
We have already launched a connected AID system -- AID system in Europe. Initial -- you know, initial results of the receptivity of that product -- of that combined product in Europe is being very favorable. So, I think that's another key growth driver for us in 2023. And then, finally, I would say on the pipeline perspective, I don't think it's a 2023 milestone for sales, but I think it's an important development activity for us is going to be, you know, the running our trial for the combined glucose-ketone sensor with the FDA and generating the data to support a dual sensor.
Because I think, again, as I've mentioned, it seems to be the go-to sensor for pumpers will be this ability to measure glucose and ketones and factoring that into the algorithms. So, that's going to be -- that's obviously having a lot of focus of us, you know, in terms of running that trial. And then, finally, I would say outside of Libre, the Lingo platform is another kind of key growth driver for us. You know, I've talked about, you know, expanding Libre -- the Libre platform outside of diabetes and using this more broadly for a much more broader target.
You know, we have a separate team that's been working on that development, Larry. We will be launching two Lingo products this year. In Europe., I'd say the first one will probably be in the first half of this year and the second one in the second half. So, I've talked about Libre being a $10 billion product by 2028.
You know, that implies a 15%, you know, annual growth rate. We'll do better than that this year. And I think the opportunities we have to be able to drive to that kind of revenue for this product are very real. And I think we've been executing very strongly on all of these areas.
Larry Biegelsen -- Wells Fargo Securities -- Analyst
That's super helpful. Just one brief follow-up. You talked about being excited about the TriClip opportunity at J.P. Morgan.
I think it was just this month. I know, you know, it's limited in what you can say, you know, because you're presenting the TRILUMINATE data at HCC. But how are you thinking about that opportunity relative to mitral? You know, do you still -- and do you still expect to -- you know, do you still expect approval in the U.S. by year-end '23? Thanks for taking the questions.
Robert Ford -- Chairman and Chief Executive Officer
I think it's a great opportunity for us. And, you know, I think that we've shown that we're definitely here, one of the leaders when it comes to, you know, clip-based heart valve repair market. And, you know, do I think it's a -- it could be bigger than mitral? I'm not sure I would go that far yet, but I would say that the uptake of the tricuspid repair market, I think, will be faster than the uptake for the mitral just because I think when mitral was launched it was the first repair system. And now, you have a large group of implanting physicians that, you know, are familiar with the clip technology, are familiar with mapping that clip technology and procedure.
We did make some changes to the delivery device for the clip. It's a little different anatomy, a little bit more challenging to get there with the clip in the tricuspid area. But I think that it's a great opportunity. I mean, I think there's 3 million people today that suffer from tricuspid regurgitation.
There's not a lot of really good options available for treatment, which is why we invested in the trial here in the U.S. to bring product to the trial. Like you said, we're going to be presenting that in a couple of months. And I think it's a great opportunity for us.
We've already seen real nice traction of that in Europe. You know, we launched that in 2021. You know, the team wanted to launch it right in COVID. And, you know, I must say, at the beginning, I was somewhat against that.
But, you know, they proved me wrong and the products done really well in Europe. So, I think this is another great opportunity for us here in the U.S. too. So, you know, we're not, you know, ignoring MitraClip.
It's part of our entire portfolio. And I think the combination of those two products in the implanting physician will be very powerful for Abbott.
Larry Biegelsen -- Wells Fargo Securities -- Analyst
All right. Thanks so much.
Operator
Thank you. One moment for our next question, please. And our next question will come from Josh Jennings from Cowen. Your line is open.
Josh Jennings -- Cowen and Company -- Analyst
Hi. Thanks for taking the questions. Good morning. Robert, I was hoping just to follow up on Larry's question just on Libre, just thinking more kind of in the out-years and this $10 billion target that you've set.
I think maybe -- just I think you outlined everything for 2023 probably holds true for you over the next five years. But just if you could reiterate your confidence, or not, in that $10 billion out-year target. And do you expect consolidation between pump and CGM companies? And maybe it'd be just great to hear strategic rationale of whether a combined pump CGM offering under one roof would be advantageous for either Abbott or another company. And then, the second question is just on the Abbott tour and the launch here in the United States.
And what would represent a win for Abbott from a U.S. share gain perspective? And in what segment is the low-hanging fruit considering the current label? Is it the elderly patients that don't have a long life expectancy that are high risk or even intermediate risk? And how do you expect and have a tour and launch play out and add to the medical device growth in 2023? Thanks for taking the questions.
Robert Ford -- Chairman and Chief Executive Officer
Sure. Well, I mean, I guess on Libre, you know, to your question on, you know, how to get to 10 billion by 2028, I mean, you know, the math will say 15%, right? How do you get to that 15%? I mean, there are real three key areas, and I talked a little bit about them. But, you know, I'd say, first of all, it's to continue to have a dominant share in the heavy insulin user segment. We have that today with the non-pumpers, you know, with the MDI, both in the U.S.
and globally and internationally. So, the real focus there becomes, OK, how do we focus now on the pumpers segment and the connectivity over there? And like I said, I think we'll do that with a little bit of a catch-up of Libre 2 in terms of what is currently offered in the market. But then, to leapfrog that, I think the combined sensor, or glucose-ketone sensor, is ultimately the -- you know, the way we'll play. And we'll see what pump company, you know, is going to want to line up, you know, to be first, you know, on that connectivity, you know, if and once we get that approval because, again, I continue to hear from KOLs the importance of that product for the pumpers segment.
So, the second part is the basal expansion. And, you know, like I said, you can look at the basal population globally, assume a certain penetration rate globally, a certain utilization rate, and that adds a significant amount of growth to that number. And then, the third piece of that is really expanding Libre beyond just diabetes and looking at the Lingo platform. So, the adding up and the execution of those strategies are what ultimately gives us confidence that we can get there and we can sustain that 15% growth rate over the next kind of five years.
Regarding questions on pumps. Listen, I think that it's an important segment. It's one that benefits quite significantly from a combined system. We're now -- you know, we're focusing more aggressively on that.
As it relates to a all in one, you know, I think the market has spoken in terms of -- you know, the pumper's one choice. They want to be able to, you know, choose what is the best sensor-pump combination. And I -- so, I think right now, you know, my view on that is, you know, the consumers have spoken, the market has spoken, the regulator has spoken. They want that interchangeability.
And I think that our focus will be on providing the best sensor for the, you know, pump systems that are out there. So, that's -- I think I got -- I covered your Libre questions. I think you had a question on Navitor. Listen, we're excited about this.
It's a large market. It's a large segment here in the U.S. It's about $3 billion. Our label is about 50% -- sorry, about 50% of the market, because we're only approved right now for the high-risk patients.
But it's got a strength -- it's got a strong clinical profile. I mean, we'll be sharing data at CRT specifically to this. But I mean, we've already released some data on it last year, comparing it to other valve systems. So, I think that, you know, we've been very intentional about, you know, wanting to enter this market and to do it in a way that is sustainable.
Expectations, I mean, I talked a little bit about this. You know, there's obviously two pretty well-entrenched players in the U.S. market. You know, do I think that we can be a leader in, you know, three or four or five years, I think that might be difficult.
But I think that we can come into this market and offer another choice, another opportunity that provides additional benefits or differentiated benefits versus other systems that allow us to pick up share. You know, if I look at where we are in Europe, we launched this in Europe. And, you know, we have high single-digit share in Europe, and we're not in all -- but we're not in all centers. We're in about half of the market.
In the centers that we are implanted and available, you know, our share is in the mid-teens. So, you put that together, we're a high single. But where we're competing, we're in the mid-teens. So, I think this will be a ramp.
I think we've got the sales force in place. We want to roll this out in a way that, you know, allows us to be sustainable in that strategy and be able to be a double-digit share gain over the next couple of years.
Josh Jennings -- Cowen and Company -- Analyst
Appreciate it. Thank you.
Operator
Thank you. One moment for our next question, please. And our next question will come from Joanne Wuensch from Citibank. Your line is open.
Joanne Wuensch -- Citi -- Analyst
Good morning and thank you for taking the questions. I have two. The first one has to do with nutrition, and if you could outline where the company is in terms of the recovery and when do you think it will return to growth. And then, the second question has to do with use of cash, what are your thoughts on it and where you are on share repurchases.
Thank you.
Robert Ford -- Chairman and Chief Executive Officer
Sure. Well, on nutrition, as I said in the opening statements, you know, production at Sturgis is up and running. You know, the team is working around the clock nonstop, very hard. Number one focus here, as I said, was, you know, to serve the customers, get product back on shelves.
We started with WIC. The inventory with -- the inventory levels on our WIC contracts are very good as we entered into Q4. And we then started to focus on our not WIC -- non-WIC brands. And that's -- you know, that's progressed very well in the fourth quarter.
And, you know, as we go into this year, you know, looking very good. So, I would say, if you look at our growth rate, obviously, you've got this year of your comp, you're going to see the growth already in Q1, Joanne, right? Because we were impacted last year in February. But I guess the right way to look at this is, OK, to strip away the comp, strip away, you know, where -- you know, this year-over-year effect of coming back on the market, etc. You know, I expect our business -- you know, our overall nutrition business to be growing at that pre-pandemic level between 4% and 6%.
You know, our market shares in WIC have largely recovered, and we're seeing a nice cadence of recovery in the non-WIC share here in the U.S. So, I think you'll start to see that growth rate already on the print in Q1, obviously, in Q2 and Q3. But, you know, the important thing here is we're looking at our share, and the share recovery is very much in line with -- you know, with our forecast that we've set for the full year. I'd like to see our market share get back to, you know, pre-pandemic levels by the end of the year.
And then, sorry, what was your other question?
Joanne Wuensch -- Citi -- Analyst
Thank you. Use of cash and where you stand on share repurchases. Thank you.
Robert Ford -- Chairman and Chief Executive Officer
Sure. Well, use of cash, you know, I've talked about this. We've taken this balanced approach. I'd say if I were to kind of rank it in terms of use of cash, we're committed to growing a dividend, a strong and growing dividend.
So, that's probably the number one use of cash. We announced that increase of about 9% in our dividend last year. So, that's always priority number one. Number two is, obviously, ensuring that all of these new products that we've got launching are properly resourced in terms of manufacturing and a lot of our capex investments.
On the buybacks, we did -- you know, throughout the first nine months of last year, we had about 3 billion of buybacks. And, you know, I'd say we probably did a little bit of catch-up there, Joanne, in terms of catching up to some of the dilution as we were focusing on getting our leverage down post acquisitions. So, we did a little bit of catch-up there. And I'd say, in terms of buybacks going forward, we'll be contemplating them, and they'll be largely focused on offsetting any kind of dilution that we have this year.
I'd say the other kind of key use here for us this year is going to be debt. We have some debt towers coming up. And, you know, we're not going to be renegotiating those just given interest rates. We want to move those off.
So, that's probably the -- you know, where you see the use of cash.
Joanne Wuensch -- Citi -- Analyst
Thank you.
Robert Ford -- Chairman and Chief Executive Officer
On the M&A side, which I know is always a question, so I'll pre-empt anybody over there who's got that on their list. I've talked about it where -- on several calls. We're interested or actively assessing opportunities, whether it's tucking on up. Clearly, the valuations here have come down somewhat, and I think they need to stabilize a little bit.
But we've cast a -- you know, we cast a pretty wide net. You know, diagnostics devices are the areas where we have most interest. And again, if it's -- it financially makes sense for our shareholders and it fits strategically, then we will -- you know, we've got that strategic flexibility in our balance sheet to do that, you know. And, you know, we're going to be looking at businesses where we can bring value, you know, whether it's -- you know, whether we can accelerate sales, whether we can enhance an R&D program, or enhance its probability of success, you know, a growth area that we can build and have a path to building a position, or even if it's just to augment, you know, our own existing pipeline.
I think when we've taken that approach -- our track record shows that when we've taken that approach, it's largely been very successful for our shareholders.
Joanne Wuensch -- Citi -- Analyst
Thank you.
Operator
Thank you. One moment for our next question, please. And our next question will come from Vijay Kumar from Evercore ISI. Your line is open.
Vijay Kumar -- Evercore ISI -- Analyst
Hey, guys. Thanks for taking my question. And good morning to you, Robert. Maybe my first question on your organic growth assumptions here.
I think I heard 8-plus is a reasonable number for '23. What is that assuming for any impact from China supply chain? Any, you know, VBP impact? If you could just give us some assumptions around those macro factors, that would be helpful.
Robert Ford -- Chairman and Chief Executive Officer
Well, I'll let Bob talk a little bit about some of the, you know, potentially out -- other macro factors. But the ones you've just mentioned here, I mean, China, you know, it's an important market for us, Vijay. It's an important growth market, and it's good that it's moved to a more, you know, kind of reopening play. I think that has not only a big impact for us in China, where we've got a strong position.
I mean, we're not overly reliant. I'd say, you know, it's about less than 5% of our total sales. But nonetheless, it's an important kind of growth market for us. And I think that reopening in China is going to have a real, you know, positive spillover effect in other areas of the world, and I would say predominantly in Asia, Southeast Asia, where we've got strong positions, you know, in our EPD and in our nutrition business and in some device areas, too.
So, I think the overall opening in China is good. You know, like Bob said, there's going to be some choppiness in the first quarter because, you know, we're seeing, you know, a lot of cases, hospitalizations, etc. But I think as that moves -- starts to move down, I think we'll see a pretty strong rebound in our growth prospects over there. So, you know, the VBP that you mentioned, yeah, I mean, that does have an impact.
It's more -- it's more restricted for 2023 in our electrophysiology business. So, we'll feel a little bit of an impact there. But I think that the market, you know, opens up for us, you know, because of the strategy we took on the VBP side. So, I think it's a -- net net, it's going to be positive for us, you know, in the long term here, medium, long term in terms of that being an opportunity for us.
We've seen this, Vijay. I mean, this happened to us -- this happened in the market with stents in 2019 in our vascular business. That business is back to, what I would call, pre-VBP levels, you know, this year. So, there's an impact.
In that case, we didn't necessarily, you know, win some of the contracts. In the case of EP, we did win the contract, so -- or a portion of the contract. So, I'd say macro, yeah, we've got some of these headwinds that we've talked about, FX -- I think Bob already talked about it -- inflation. But all those seem to be, you know, easing off a little bit and the recovery of the procedures and the pipeline and the product launches is a key growth driver for us.
Vijay Kumar -- Evercore ISI -- Analyst
Understood. And, Bob, one for you. On the gross margin here, 56%. That's a step-down year on year.
You know, when I look at pre-pandemic, you know, you guys were at 59%. Is there a simple bridge, Bob, on how much of this has been inflation? You know, you just spoke what hedging impact is. Is that all hitting your gross margin line? And why shouldn't inflationary pressures improve? And when can we start seeing gross margins, you know, creep back up to pre-pandemic levels?
Bob Funck -- Executive Vice President, Finance, and Chief Financial Officer
Yeah. So, you know, the -- as I said in my opening remarks, around 56% for the year, this a modest step-up kind of from where we exited last year. As you would expect, Vijay, in this environment, you know, there's a lot of different dynamics that multinationals are facing. We've got some headwinds.
We talked about those inflationary impacts, how that flows through, including the inventory we built last year that will be sold this year. We talked about currency, where we're going to -- you know, we're not going to see a repeat of those hedging gains that we had in '22. So, that's a head -- you know, it's a bit of a headwind there. On the positive side, I'd say, you know, the recovery we're forecasting in the U.S.
infant nutrition business will contribute positively. And as that recovery occurs over the course of the year, that will have a more positive impact. We also have gross margin improvement programs across all of our businesses that, you know, will help to offset some of those headwinds. And we're taking price where we can, I'd say, in our more consumer-facing businesses.
And then, finally, I'd say, just to kind of from a mix standpoint, as we continue to see an acceleration in our medical device business with some of these new product launches, those are higher gross margins than the overall company, and that will positively contribute to our gross margin. If you -- to your question about kind of where we were pre-pandemic and what we're guiding to this year, kind of I'd say the biggest impact, on a cumulative basis, has really been inflation. And that's really the -- I'd say the big difference here in terms of, you know, where we're guiding right now and where we were pre-pandemic. But as we continue to see an acceleration from a mix standpoint and continue to work at some of our costs, you know, we would expect over time to see that gross margin to continue to improve.
Vijay Kumar -- Evercore ISI -- Analyst
Understood. Thank you, guys.
Operator
Thank you. One moment for our next question, please. And our next question will come from Travis Steed from Bank of America. Your line is open.
Travis Steed -- Bank of America Merrill Lynch -- Analyst
Hi. Good morning and thanks for taking the questions. Just a follow-up to Vijay's question on the inflation piece. Is that still $1 billion baked into the fourth-quarter guidance? So, to make sure I understand what's baked down on the gross margin line.
Then, anything to call out on the 2023 operating margin expansion, some of the moving parts to get the op margin expansion there? it looks like 22% is kind of what's implied by the guide.
Bob Funck -- Executive Vice President, Finance, and Chief Financial Officer
Yeah. So, I'll -- yeah, on the gross on the operating margin, yeah, we're around 22% kind of where we were pre-pandemic. You know, we're getting the high -- you know, the high single-digit growth on the top line kind of in the, you know, excluding the COVID testing. We're getting leverage down to the P&L, which Robert talked about, where we were able to forward invest over the last couple of years.
We're going to get leverage in the expense area, and that gets you to about around 22% of margin. You know, in terms of inflation, you know, we are going to see a carryover impact from last year, still pretty meaningful. But we've been able to mitigate, you know, a good portion of that through both our gross margin improvement programs that we have across our businesses, as well as taking some price where we can.
Travis Steed -- Bank of America Merrill Lynch -- Analyst
OK. That's helpful. A couple of product questions. On EP, I think you mentioned the new EP catheter mapping system and that was new.
Maybe I missed that in the past. And curious how you're thinking about [Inaudible] ablation and the impact on your EP business. And then, the other product question was on Libre. The vitamin C, is that on Libre 2 or Libre 3? So, understanding the pathway to get vitamin C on Libre 3 and the timing there.
Robert Ford -- Chairman and Chief Executive Officer
Sure. On the Libre 3 vit c, I mean, it's going to start off with Libre 2. So, we want to get that done first, and then, we'll progress on to Libre 3. So, focus right now is on Libre 2, and then, we'll move to Libre 3.
On your question on EP, I mean, I think the new catheter that we've launched in Japan and start to launch in Europe toward the end of last year is our TactiFlex, which is really using contact force together with the flexible tip that we had in our flex catheter. So, the feedback we've got on that is really, really positive. So, I think the combination here of, you know, our enhanced new mapping system together with our market-leading mapping catheter and HD Grid, and now bringing TactiFlex, that combination is very powerful. Regarding PFA, you know, it's definitely an area of interest.
We've been investing in it. We've actually -- we actually had two internal programs, had a bake-off, and saw the one that we felt stronger about, taking some of the learnings that we're seeing from the current on -market products. And, you know, there's obviously some trialing that's ongoing right now, but I would say it's a growth opportunity. It's an interesting area.
I think it's still too early to say in terms of, will the market move completely over to this technology or not. I think it's important to have it and, hence, why we're investing in our program and, you know, incorporating into our R&D program all of some of the deficiencies that we've heard from some of the -- you know, the current on-market products are the ones that are being put in development right now. So, important area -- important investment area for us in EP, definitely benefited from kind of, you know, the investments that we made during COVID. And I think it's an important product to have.
Its ability to convert -- you know, I think it'll convert a portion of the market. My sense is cryo was probably the first one. But how much of cryo, you know, still up to see. But definitely an interesting area for investment.
Travis Steed -- Bank of America Merrill Lynch -- Analyst
Great. Thank you.
Scott Leinenweber -- Vice President of Investor Relations, Licensing, and Acquisition
We'll take one more question.
Operator
Thank you. One moment for our next question. And our last question will come from Matt Miksic from Barclays. Your line is open.
Matt Miksic -- Barclays -- Analyst
Hey, thanks for your opinion. I figured maybe just if we could wrap it up with an update on a couple of the pipeline products, the five products, Robert, that you've highlighted in the past, Amulet and CardioMEMS. Maybe if you could just talk a little bit about, you know, where you are with these launches in terms of, you know, size, scale, momentum, and maybe what kinds of catalysts we can look for, and metrics we can see for these two products this year. Thanks.
Robert Ford -- Chairman and Chief Executive Officer
Sure. Well, I mean, I think those five products that I discussed on the last call, you know, we talked about them, you know, exiting at an annual run rate of 500. They actually exited at a run rate of 550. And they grew around, you know, 100%.
So, I expect those five products to kind of have, you know, maybe not 100%, but pretty high growth rate in next -- in this year. Regarding Amulet, listen, I think it's -- like I said, it's a great space. You know, we've been rolling out the product last year, building the sales force. Key focus here is, obviously, ensuring, you know, good implanting technique with the physicians.
We're in about 225 accounts right now. I expect that, you know, in terms of growth catalyst, getting more share of those existing accounts as the physicians become more and more accustomed to using our product and see the benefits of using our product versus other systems, I think that'll be a growth catalyst. And then, expanding, we do want to start to expand more as our sales force has increased, the competency of our sales team has increased, and our clinical team has increased. We feel more confident now to be able to kind of expand to more accounts.
And that's what we'll be focused on. You know, another key catalyst of growth here is, obviously, the trial that we've been investing in, in CATALYST, which is to compare Amulet to novel oral anticoagulant. So, that's another opportunity. It's not one in 2023, but, you know, continuing that enrollment in that trial is an important driver for kind of the long-term growth strategy here of Amulet.
CardioMEMS has done very good. We saw an indication expansion last year in the U.S., seen a nice step up in sales. I think it's a great long-term opportunity. I think it's part of, you know, those five products that are driving a lot of growth, and I'd say probably the next kind of big area.
I mean, we've been investing in sales force and rolling this out. Next big area here is working on that NCD. I think that will remove some of the -- you know, maybe some regional hang-ups in terms of reimbursement. So, the NCD is something that we're going to be working on this year with the -- you know, with the data that we've collected as part of all of our trials.
So, I think they look very strong as part of that group of five products.
Matt Miksic -- Barclays -- Analyst
Just on --
Robert Ford -- Chairman and Chief Executive Officer
Like the -- yeah, to close up the call here, just a few remarks. The operating environment still remains challenging, right? But it's not as challenging as we saw back in Q3 of 2022, in October. There are definitely signs here of stability. There are signs of improvement, whether it's in the macroeconomic side or whether it's specifically in the segments that we are competing in.
And Abbott is well positioned, we're well positioned to both capitalize on this improving environment or to navigate if there's any unforeseen volatility over here. That's what our portfolio has been built for. That's what our balance sheet is set up for, it's set up for these kind of situations and these kind of scenarios. We always knew that pandemic-level testing was not a base case.
We knew that, eventually, this would move down to an endemic-like testing. And we're -- you know, our view here is that in 2023, we will start this process of moving to that. And so, as a result of that, we did do this forward investing into our growth areas, whether it's devices, diagnostics, certain areas in EPD, or nutrition. And that's allowed us to grow at the pre-pandemic level, this high single-digit, top-tier growth without having to make the, you know, opex investment that you would expect to be able to sustain that growth.
So, we're getting that flow-through on the P&L and that leverage on our investments. I do recognize the cost pressures. The company recognizes those cost pressures. We talked about this now, you know, to Vijay's question.
You know, we're going to be working relentlessly on getting our gross margin, you know, back to that pre-pandemic level. And it's a combination of, you know, working at our cost profiles and our GMI programs, but also as we accelerate the growth in our device business, that mix shift contributes to that. So -- and finally, our balance sheet is strong and provides us the strategic flexibility we need to navigate. And we take this balanced approach where we can provide returns to our shareholders while, at the same time, investing for the long term.
So, thank you for being on the call. Overall, I think Abbott is very well positioned as we kind of exit this kind of pandemic state and move into more of an endemic state. I think we're well positioned, and now, it's all about execution.
Scott Leinenweber -- Vice President of Investor Relations, Licensing, and Acquisition
Thank you, operator. And thank you for all of your questions. This now concludes Abbott's conference call. A webcast replay of this call will be available after 11 a.m.
Central Time today on Abbott's investor relations website at abbottinvestor.com. Thank you for joining us today.
Operator
Thank you. This concludes today's conference call. Thank you for your participation. You may now disconnect.
Everyone, have a wonderful day.
Duration: 0 minutes
Call participants:
Scott Leinenweber -- Vice President of Investor Relations, Licensing, and Acquisition
Robert Ford -- Chairman and Chief Executive Officer
Bob Funck -- Executive Vice President, Finance, and Chief Financial Officer
Robbie Marcus -- JPMorgan Chase and Company -- Analyst
Larry Biegelsen -- Wells Fargo Securities -- Analyst
Josh Jennings -- Cowen and Company -- Analyst
Joanne Wuensch -- Citi -- Analyst
Vijay Kumar -- Evercore ISI -- Analyst
Travis Steed -- Bank of America Merrill Lynch -- Analyst
Matt Miksic -- Barclays -- Analyst
More ABT analysis
All earnings call transcripts
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (NYSE: ABT) Q4 2022 Earnings Call Jan 25, 2023, 9:00 a.m. Duration: 0 minutes Call participants: Scott Leinenweber -- Vice President of Investor Relations, Licensing, and Acquisition Robert Ford -- Chairman and Chief Executive Officer Bob Funck -- Executive Vice President, Finance, and Chief Financial Officer Robbie Marcus -- JPMorgan Chase and Company -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Josh Jennings -- Cowen and Company -- Analyst Joanne Wuensch -- Citi -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst Matt Miksic -- Barclays -- Analyst More ABT analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. As our manufacturing capacity has continued to recover, we've been able to increase production of our non-WIC brands with a focus on serving the broader infant formula market and building back inventory levels on retail shelves. | Duration: 0 minutes Call participants: Scott Leinenweber -- Vice President of Investor Relations, Licensing, and Acquisition Robert Ford -- Chairman and Chief Executive Officer Bob Funck -- Executive Vice President, Finance, and Chief Financial Officer Robbie Marcus -- JPMorgan Chase and Company -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Josh Jennings -- Cowen and Company -- Analyst Joanne Wuensch -- Citi -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst Matt Miksic -- Barclays -- Analyst More ABT analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q4 2022 Earnings Call Jan 25, 2023, 9:00 a.m. With me today are Robert Ford, chairman and chief executive officer, and Bob Funck, executive vice president, finance, and chief financial officer. | Duration: 0 minutes Call participants: Scott Leinenweber -- Vice President of Investor Relations, Licensing, and Acquisition Robert Ford -- Chairman and Chief Executive Officer Bob Funck -- Executive Vice President, Finance, and Chief Financial Officer Robbie Marcus -- JPMorgan Chase and Company -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Josh Jennings -- Cowen and Company -- Analyst Joanne Wuensch -- Citi -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst Matt Miksic -- Barclays -- Analyst More ABT analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q4 2022 Earnings Call Jan 25, 2023, 9:00 a.m. Note that Abbott has not provided the GAAP financial measure for organic sales growth, excluding COVID testing sales, on a forward-looking basis because the company is unable to predict future changes in foreign exchange rates, which could impact reported sales growth. | Abbott Laboratories (NYSE: ABT) Q4 2022 Earnings Call Jan 25, 2023, 9:00 a.m. Duration: 0 minutes Call participants: Scott Leinenweber -- Vice President of Investor Relations, Licensing, and Acquisition Robert Ford -- Chairman and Chief Executive Officer Bob Funck -- Executive Vice President, Finance, and Chief Financial Officer Robbie Marcus -- JPMorgan Chase and Company -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Josh Jennings -- Cowen and Company -- Analyst Joanne Wuensch -- Citi -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst Matt Miksic -- Barclays -- Analyst More ABT analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. And so, we'll have the impact of that over the course of the year. |
31219.0 | 2023-01-25 00:00:00 UTC | Why Aurora Cannabis Stock Is Fading Today | ABT | https://www.nasdaq.com/articles/why-aurora-cannabis-stock-is-fading-today | nan | nan | What happened
Shares of Canadian pot giant Aurora Cannabis (NASDAQ: ACB) are under pressure Wednesday morning. Specifically, the pot company's stock was down by a noteworthy 5.4% on elevated volume as of 10:45 a.m. ET Wednesday.
What's causing investors to move to the sidelines today? Most U.S. equities are falling today in response to weaker-than-expected earnings from high-profile companies like Abbott Laboratories, Microsoft, and Intuitive Surgical. The bottom line is that the Federal Reserve's aggressive interest-rate-hike strategy, along with stubbornly high levels of inflation, appear to be having a chilling effect on consumer demand for goods and services.
So what
What's the spillover for global cannabis companies like Aurora? While a fair number of cannabis users do view the plant as an essential medicine, these economic headwinds are having a negative impact on consumers' real buying power. That's bad news for discretionary items like recreational cannabis.
These economic headwinds could deepen a host of fundamental problems already facing companies operating in this emerging industry. Over the past year, for instance, Canadian cannabis companies have battled falling prices, declining profit margins, sizable goodwill impairment charges, a shift in consumer preferences toward higher-potency products, and legal red tape in various forms.
The net result is that nearly all of these companies lost a large chunk of their market capitalization in 2022. Aurora, for instance, shed a staggering 82% of its value last year.
Now what
All that being said, several of these beaten-down cannabis equities were leaking upward to start the year. Aurora's shares, for example, were up by a little over 9% for the year prior to today's pullback.
Can Aurora regain its northward momentum? That's a tough question to answer. Wall Street's latest fair value estimate implies that this marijuana stock could appreciate by an eye-popping 500% from current levels. That kind of notable upside potential might draw in risk-tolerant investors over the balance of the year.
Then again, Aurora is operating in an industry characterized by fierce competition, an unfavorable regulatory environment, high tax burdens, and a vast oversupply of product. So if a global economic slowdown does indeed dampen demand for recreational cannabis, Aurora's stock may have trouble living up to Wall Street's lofty expectations.
Here's The Marijuana Stock You've Been Waiting For
A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.
And make no mistake – it is coming.
Cannabis legalization is sweeping over North America – 19 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.
And one under-the-radar Canadian company is poised to explode from this coming marijuana revolution.
Because a game-changing deal just went down between the Ontario government and this powerhouse company...and you need to hear this story today if you have even considered investing in pot stocks.
Simply click here to get the full story now.
Learn more
George Budwell has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories, Intuitive Surgical, and Microsoft. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The bottom line is that the Federal Reserve's aggressive interest-rate-hike strategy, along with stubbornly high levels of inflation, appear to be having a chilling effect on consumer demand for goods and services. While a fair number of cannabis users do view the plant as an essential medicine, these economic headwinds are having a negative impact on consumers' real buying power. Over the past year, for instance, Canadian cannabis companies have battled falling prices, declining profit margins, sizable goodwill impairment charges, a shift in consumer preferences toward higher-potency products, and legal red tape in various forms. | What happened Shares of Canadian pot giant Aurora Cannabis (NASDAQ: ACB) are under pressure Wednesday morning. Most U.S. equities are falling today in response to weaker-than-expected earnings from high-profile companies like Abbott Laboratories, Microsoft, and Intuitive Surgical. The Motley Fool has positions in and recommends Abbott Laboratories, Intuitive Surgical, and Microsoft. | Over the past year, for instance, Canadian cannabis companies have battled falling prices, declining profit margins, sizable goodwill impairment charges, a shift in consumer preferences toward higher-potency products, and legal red tape in various forms. Here's The Marijuana Stock You've Been Waiting For A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom. Cannabis legalization is sweeping over North America – 19 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018. | So if a global economic slowdown does indeed dampen demand for recreational cannabis, Aurora's stock may have trouble living up to Wall Street's lofty expectations. Because a game-changing deal just went down between the Ontario government and this powerhouse company...and you need to hear this story today if you have even considered investing in pot stocks. The Motley Fool has positions in and recommends Abbott Laboratories, Intuitive Surgical, and Microsoft. |
31220.0 | 2023-01-25 00:00:00 UTC | US STOCKS-Wall St falls as Microsoft forecast hits tech stocks, earnings disappoint | ABT | https://www.nasdaq.com/articles/us-stocks-wall-st-falls-as-microsoft-forecast-hits-tech-stocks-earnings-disappoint | nan | nan | For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.
Microsoft falls on dismal Q3 cloud outlook
Salesforce, Amazon, other cloud-based stocks drop
Tech shares lead sectoral declines on S&P 500
Boeing slides after missing Q4 revenue estimates
Indexes down: Nasdaq 2.0%, S&P 1.2%, Dow 0.7%
Adds details; updates prices to open
By Shreyashi Sanyal and Johann M Cherian
Jan 25 (Reuters) - Wall Street's main indexes dropped on Wednesday, with the Nasdaq down 2% as Microsoft's outlook weighed down technology stocks, while a bleak quarterly report from Boeing added to fears of a recession.
Shares of Microsoft MSFT.O fell 3.9% after it warned that growth in its lucrative cloud business could stall, while its PC unit continued to struggle. The S&P 500 technology index .SPLRCT shed 2.1% to lead declines among the 11 major sector indexes.
Amazon.com Inc AMZN.O, Salesforce Inc CRM.N and ServiceNow Inc NOW.N, which have substantial cloud businesses, fell between 2.5% and 4.5%.
Other major growth stocks, including Apple Inc AAPL.O, Alphabet Inc GOOGL.O and Tesla Inc TSLA.O, also dropped between 1.5% and 3.0%.
Growth stocks, however, have enjoyed a bounce in January after a battering last year, with investors now focused on earnings reports to assess the impact of the Federal Reserve's rate hikes and to gauge whether the renewed enthusiasm for these stocks will be sustained.
"The environment may look attractive because some of these cloud companies, like Salesforce, are down so much, but people are still skeptical because we're heading into weaker economic news," said Robert Pavlik, senior portfolio manager at Dakota Wealth.
"We still have inflation, we still have the Fed raising interest rates, we're seeing companies laying off thousands of peoples ... We're not completely through the cycle yet."
An overwhelming majority of traders expect the Federal Reserve to raise interest rates by another 25 basis points in its meeting next week.
They now see the terminal rate peaking at 4.91% in June, even as Fed policymakers have repeatedly backed taking rates above the 5% level. 0#FEDWATCH
Data later in the week is likely to show December personal consumption expenditure index (PCE) fell 0.1% from a 0.1% rise in the prior month. Fourth quarter GDP advance numbers are also awaited.
Dow Jones Industrial Average .DJI constituent, Boeing CoBA.N slipped 1.3% as the planemaker's losses widened in 2022 and it missed fourth-quarter revenue estimates.
At 10:07 a.m. ET, the Dow was down 227.63 points, or 0.67%, at 33,506.33, the S&P 500 .SPX was down 46.92 points, or 1.17%, at 3,970.03, and the Nasdaq Composite .IXIC was down 220.49 points, or 1.95%, at 11,113.79.
Abbott Laboratories ABT.N fell 0.7%, weighed down by lower-than-expected medical device sales in the fourth quarter.
In a bright spot, AT&T Inc T.N rose 6.2% on higher-than-expected quarterly subscriber additions, while Textron Inc TXT.N added 0.3% as revenue beat estimates, boosted by demand for its private jets.
News CorpNWSA.O jumped 8.0%, leading gains on the S&P 500, after Rupert Murdoch withdrew a proposal to reunite News Corp and Fox Corp.
Declining issues outnumbered advancers for a 3.92-to-1 ratio on the NYSE and for a 2.82-to-1 ratio on the Nasdaq.
The S&P index recorded two new 52-week highs and one new low, while the Nasdaq recorded 29 new highs and 16 new lows.
(Reporting by Shreyashi Sanyal and Johann M Cherian in Bengaluru; Additional reporting by Ankika Biswas; Editing by Vinay Dwivedi and Anil D'Silva)
((Shreyashi.Sanyal@thomsonreuters.com; +1 646 223 8780; +91 961 144 3740; Twitter: https://twitter.com/s_shreyashi;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT.N fell 0.7%, weighed down by lower-than-expected medical device sales in the fourth quarter. Microsoft falls on dismal Q3 cloud outlook Salesforce, Amazon, other cloud-based stocks drop Tech shares lead sectoral declines on S&P 500 Boeing slides after missing Q4 revenue estimates Indexes down: Nasdaq 2.0%, S&P 1.2%, Dow 0.7% Adds details; updates prices to open By Shreyashi Sanyal and Johann M Cherian Jan 25 (Reuters) - Wall Street's main indexes dropped on Wednesday, with the Nasdaq down 2% as Microsoft's outlook weighed down technology stocks, while a bleak quarterly report from Boeing added to fears of a recession. "The environment may look attractive because some of these cloud companies, like Salesforce, are down so much, but people are still skeptical because we're heading into weaker economic news," said Robert Pavlik, senior portfolio manager at Dakota Wealth. | Abbott Laboratories ABT.N fell 0.7%, weighed down by lower-than-expected medical device sales in the fourth quarter. Microsoft falls on dismal Q3 cloud outlook Salesforce, Amazon, other cloud-based stocks drop Tech shares lead sectoral declines on S&P 500 Boeing slides after missing Q4 revenue estimates Indexes down: Nasdaq 2.0%, S&P 1.2%, Dow 0.7% Adds details; updates prices to open By Shreyashi Sanyal and Johann M Cherian Jan 25 (Reuters) - Wall Street's main indexes dropped on Wednesday, with the Nasdaq down 2% as Microsoft's outlook weighed down technology stocks, while a bleak quarterly report from Boeing added to fears of a recession. The S&P 500 technology index .SPLRCT shed 2.1% to lead declines among the 11 major sector indexes. | Abbott Laboratories ABT.N fell 0.7%, weighed down by lower-than-expected medical device sales in the fourth quarter. Microsoft falls on dismal Q3 cloud outlook Salesforce, Amazon, other cloud-based stocks drop Tech shares lead sectoral declines on S&P 500 Boeing slides after missing Q4 revenue estimates Indexes down: Nasdaq 2.0%, S&P 1.2%, Dow 0.7% Adds details; updates prices to open By Shreyashi Sanyal and Johann M Cherian Jan 25 (Reuters) - Wall Street's main indexes dropped on Wednesday, with the Nasdaq down 2% as Microsoft's outlook weighed down technology stocks, while a bleak quarterly report from Boeing added to fears of a recession. Growth stocks, however, have enjoyed a bounce in January after a battering last year, with investors now focused on earnings reports to assess the impact of the Federal Reserve's rate hikes and to gauge whether the renewed enthusiasm for these stocks will be sustained. | Abbott Laboratories ABT.N fell 0.7%, weighed down by lower-than-expected medical device sales in the fourth quarter. Microsoft falls on dismal Q3 cloud outlook Salesforce, Amazon, other cloud-based stocks drop Tech shares lead sectoral declines on S&P 500 Boeing slides after missing Q4 revenue estimates Indexes down: Nasdaq 2.0%, S&P 1.2%, Dow 0.7% Adds details; updates prices to open By Shreyashi Sanyal and Johann M Cherian Jan 25 (Reuters) - Wall Street's main indexes dropped on Wednesday, with the Nasdaq down 2% as Microsoft's outlook weighed down technology stocks, while a bleak quarterly report from Boeing added to fears of a recession. "We still have inflation, we still have the Fed raising interest rates, we're seeing companies laying off thousands of peoples ... We're not completely through the cycle yet." |
31221.0 | 2023-01-25 00:00:00 UTC | Why Abbott Laboratories Stock Got Whacked on Wednesday | ABT | https://www.nasdaq.com/articles/why-abbott-laboratories-stock-got-whacked-on-wednesday | nan | nan | What happened
Wednesday morning, Abbott Laboratories (NYSE: ABT) beat on both the top and bottom lines in its freshly reported fourth quarter of 2022. This, however, was not good enough to send the veteran pharmaceutical company's stock higher, as its price fell by nearly 1.5% on the day.
So what
For the period, Abbott's sales fell by 12% on a year-over-year basis to just shy of $10.1 billion. That slide was chiefly due to a steep decline in sales of COVID-19 testing-related offerings. Yet even removing that from the equation, the veteran healthcare company still would have recorded a sales drop (by 1.4%).
Meanwhile, non-GAAP (adjusted) net income tumbled more violently, falling by 23% to hit just over $1.8 billion ($1.03 per share).
Analysts tracking the stock were fully expecting the drops. In fact, they were counting on Abbott to do worse; on average, those prognosticators estimated the company would book slightly more than $9.6 billion in sales and net a per-share, adjusted profit of only $0.92.
Yet investors were obviously concerned about the tumbles. Reading deeper into the results, they discovered the disquieting fact that only one of the company's four divisions -- and its smallest -- had eked out a sales increase. This is the established pharmaceuticals unit, which posted a not-particularly impressive 1% gain.
Now what
Abbott also proffered adjusted net-income guidance for the entirety of 2023. The company is forecasting that it will earn $4.30 to $4.50 per share for the year. It did not provide any estimate for sales.
10 stocks we like better than Abbott Laboratories
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of January 9, 2023
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Wednesday morning, Abbott Laboratories (NYSE: ABT) beat on both the top and bottom lines in its freshly reported fourth quarter of 2022. In fact, they were counting on Abbott to do worse; on average, those prognosticators estimated the company would book slightly more than $9.6 billion in sales and net a per-share, adjusted profit of only $0.92. Reading deeper into the results, they discovered the disquieting fact that only one of the company's four divisions -- and its smallest -- had eked out a sales increase. | What happened Wednesday morning, Abbott Laboratories (NYSE: ABT) beat on both the top and bottom lines in its freshly reported fourth quarter of 2022. This, however, was not good enough to send the veteran pharmaceutical company's stock higher, as its price fell by nearly 1.5% on the day. So what For the period, Abbott's sales fell by 12% on a year-over-year basis to just shy of $10.1 billion. | What happened Wednesday morning, Abbott Laboratories (NYSE: ABT) beat on both the top and bottom lines in its freshly reported fourth quarter of 2022. In fact, they were counting on Abbott to do worse; on average, those prognosticators estimated the company would book slightly more than $9.6 billion in sales and net a per-share, adjusted profit of only $0.92. 10 stocks we like better than Abbott Laboratories When our award-winning analyst team has a stock tip, it can pay to listen. | What happened Wednesday morning, Abbott Laboratories (NYSE: ABT) beat on both the top and bottom lines in its freshly reported fourth quarter of 2022. In fact, they were counting on Abbott to do worse; on average, those prognosticators estimated the company would book slightly more than $9.6 billion in sales and net a per-share, adjusted profit of only $0.92. 10 stocks we like better than Abbott Laboratories When our award-winning analyst team has a stock tip, it can pay to listen. |
31222.0 | 2023-01-25 00:00:00 UTC | Abbott Issues FY23 Earnings, Sales Growth View - Update | ABT | https://www.nasdaq.com/articles/abbott-issues-fy23-earnings-sales-growth-view-update | nan | nan | (RTTNews) - Abbott Laboratories (ABT), while announcing weak fourth-quarter results, issued fiscal 2023 earnings and sales forecast.
For the year, the company projects earnings per share from continuing operations of $3.05 to $3.25 and adjusted earnings per share from continuing operations of $4.30 to $4.50.
On average, 21 analysts polled by Thomson Reuters expect earnings of $4.4 per share for the year. Analysts' estimates typically exclude special items.
Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of high-single digits and COVID-19 testing-related sales of around $2.0 billion.
In fiscal 2022, the company's reported earnings were $3.91 and adjusted earnings per share were $5.34, on sales growth of 1.3 percent and organic sales growth of 6.4 percent.
Robert Ford, chairman and chief executive officer, said, "We significantly exceeded the EPS guidance we provided at the beginning of last year despite challenging global business conditions. Our R&D pipeline continues to be highly productive with several recent and upcoming new product launches that position us well going forward."
In the fourth quarter, Abbott's profit came in at $1.03 billion, or $0.59 per share, compared to $1.99 billion, or $1.11 per share last year.
Adjusted earnings were $1.81 billion or $1.03 per share for the period. Analysts had expected the company to earn $0.92 per share.
The company's revenue for the quarter fell 12.0 percent to $10.09 billion from $11.47 billion last year.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT), while announcing weak fourth-quarter results, issued fiscal 2023 earnings and sales forecast. On average, 21 analysts polled by Thomson Reuters expect earnings of $4.4 per share for the year. Robert Ford, chairman and chief executive officer, said, "We significantly exceeded the EPS guidance we provided at the beginning of last year despite challenging global business conditions. | (RTTNews) - Abbott Laboratories (ABT), while announcing weak fourth-quarter results, issued fiscal 2023 earnings and sales forecast. For the year, the company projects earnings per share from continuing operations of $3.05 to $3.25 and adjusted earnings per share from continuing operations of $4.30 to $4.50. Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of high-single digits and COVID-19 testing-related sales of around $2.0 billion. | (RTTNews) - Abbott Laboratories (ABT), while announcing weak fourth-quarter results, issued fiscal 2023 earnings and sales forecast. For the year, the company projects earnings per share from continuing operations of $3.05 to $3.25 and adjusted earnings per share from continuing operations of $4.30 to $4.50. In fiscal 2022, the company's reported earnings were $3.91 and adjusted earnings per share were $5.34, on sales growth of 1.3 percent and organic sales growth of 6.4 percent. | (RTTNews) - Abbott Laboratories (ABT), while announcing weak fourth-quarter results, issued fiscal 2023 earnings and sales forecast. For the year, the company projects earnings per share from continuing operations of $3.05 to $3.25 and adjusted earnings per share from continuing operations of $4.30 to $4.50. In fiscal 2022, the company's reported earnings were $3.91 and adjusted earnings per share were $5.34, on sales growth of 1.3 percent and organic sales growth of 6.4 percent. |
31223.0 | 2023-01-25 00:00:00 UTC | Abbott Laboratories Q4 22 Earnings Conference Call At 9:00 AM ET | ABT | https://www.nasdaq.com/articles/abbott-laboratories-q4-22-earnings-conference-call-at-9%3A00-am-et | nan | nan | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Jan. 25, 2023, to discuss Q4 22 earnings results.
To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Jan. 25, 2023, to discuss Q4 22 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Jan. 25, 2023, to discuss Q4 22 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Jan. 25, 2023, to discuss Q4 22 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Jan. 25, 2023, to discuss Q4 22 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
31224.0 | 2023-01-25 00:00:00 UTC | Abbott Laboratories Q4 Profit Decreases, but beats estimates | ABT | https://www.nasdaq.com/articles/abbott-laboratories-q4-profit-decreases-but-beats-estimates | nan | nan | (RTTNews) - Abbott Laboratories (ABT) revealed a profit for fourth quarter that decreased from the same period last year but beat the Street estimates.
The company's bottom line came in at $1.03 billion, or $0.59 per share. This compares with $1.99 billion, or $1.11 per share, in last year's fourth quarter.
Excluding items, Abbott Laboratories reported adjusted earnings of $1.81 billion or $1.03 per share for the period.
Analysts on average had expected the company to earn $0.92 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter fell 12.0% to $10.09 billion from $11.47 billion last year.
Abbott Laboratories earnings at a glance (GAAP) :
-Earnings (Q4): $1.03 Bln. vs. $1.99 Bln. last year. -EPS (Q4): $0.59 vs. $1.11 last year. -Analyst Estimates: $0.92 -Revenue (Q4): $10.09 Bln vs. $11.47 Bln last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) revealed a profit for fourth quarter that decreased from the same period last year but beat the Street estimates. Excluding items, Abbott Laboratories reported adjusted earnings of $1.81 billion or $1.03 per share for the period. Analysts on average had expected the company to earn $0.92 per share, according to figures compiled by Thomson Reuters. | (RTTNews) - Abbott Laboratories (ABT) revealed a profit for fourth quarter that decreased from the same period last year but beat the Street estimates. Excluding items, Abbott Laboratories reported adjusted earnings of $1.81 billion or $1.03 per share for the period. Abbott Laboratories earnings at a glance (GAAP) : -Earnings (Q4): $1.03 Bln. | (RTTNews) - Abbott Laboratories (ABT) revealed a profit for fourth quarter that decreased from the same period last year but beat the Street estimates. The company's revenue for the quarter fell 12.0% to $10.09 billion from $11.47 billion last year. -Analyst Estimates: $0.92 -Revenue (Q4): $10.09 Bln vs. $11.47 Bln last year. | (RTTNews) - Abbott Laboratories (ABT) revealed a profit for fourth quarter that decreased from the same period last year but beat the Street estimates. This compares with $1.99 billion, or $1.11 per share, in last year's fourth quarter. Excluding items, Abbott Laboratories reported adjusted earnings of $1.81 billion or $1.03 per share for the period. |
31225.0 | 2023-01-25 00:00:00 UTC | Pre-Markets Sink on Quarterly Earnings Ruminations | ABT | https://www.nasdaq.com/articles/pre-markets-sink-on-quarterly-earnings-ruminations | nan | nan | Wednesday, January 25th, 2023
Pre-market futures are sinking into the red this morning, as it appears we’ve finally hit a snag in earnings season in the manner of Microsoft’s MSFT fiscal Q2 results, which went from +4% after the release to -3% this morning. Investors have had some time to digest the conference call, and have become near-term negative on the stock.
What we saw in the actual Microsoft report was a notable deceleration in its Azure cloud business. In the conference call, it became understood that this overall slowing has actually picked up pace between December and January. Enterprise software looks to have reached a near-term peak; this is also evident in the large numbers of layoffs coming from software companies of late, Microsoft included.
We also saw a -3600% negative earnings surprise from Boeing BA in its Q4 report this morning: the world’s biggest aircraft builder was expected to turn a profit of 5 cents per share in the quarter, but instead produced a -$1.75 per share loss. That said, revenues beat expectations in the quarter by +2.85% to $19.98 billion — and notably ahead of the year-ago’s $14.79 billion. Boeing also reaffirmed its free and operating cash flow for the full year. For more on BA’s earnings, click here.
Abbott Labs ABT put up prominent beats ahead of today’s opening bell, with earnings of $1.03 per share outpacing the 90 cents in the Zacks consensus on revenues of $10.09 billion, for a positive surprise of +6.47%. Yet pre-market forces being what the are this morning, Abbott shares are still down roughly -1.25% — effectively cutting in half the pharma major’s gains thus far year to date. For more on ABT’s earnings, click here.
Dow futures are -280 points at this hour, the Nasdaq is -200 and the S&P 500 -40 points. We do sometimes see turnarounds within the course of the trading day, although today there are no economic reports scheduled that might swing markets in the other direction. After today’s close, we’ll get new earnings results from IBM IBM, Las Vegas Sands LVS and, of course, Tesla TSLA.
Questions or comments about this article and/or its author? Click here>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Boeing Company (BA) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Microsoft Corporation (MSFT) : Free Stock Analysis Report
International Business Machines Corporation (IBM) : Free Stock Analysis Report
Las Vegas Sands Corp. (LVS) : Free Stock Analysis Report
Tesla, Inc. (TSLA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ABT put up prominent beats ahead of today’s opening bell, with earnings of $1.03 per share outpacing the 90 cents in the Zacks consensus on revenues of $10.09 billion, for a positive surprise of +6.47%. For more on ABT’s earnings, click here. Click to get this free report The Boeing Company (BA) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Microsoft Corporation (MSFT) : Free Stock Analysis Report International Business Machines Corporation (IBM) : Free Stock Analysis Report Las Vegas Sands Corp. (LVS) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report The Boeing Company (BA) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Microsoft Corporation (MSFT) : Free Stock Analysis Report International Business Machines Corporation (IBM) : Free Stock Analysis Report Las Vegas Sands Corp. (LVS) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT put up prominent beats ahead of today’s opening bell, with earnings of $1.03 per share outpacing the 90 cents in the Zacks consensus on revenues of $10.09 billion, for a positive surprise of +6.47%. For more on ABT’s earnings, click here. | Abbott Labs ABT put up prominent beats ahead of today’s opening bell, with earnings of $1.03 per share outpacing the 90 cents in the Zacks consensus on revenues of $10.09 billion, for a positive surprise of +6.47%. Click to get this free report The Boeing Company (BA) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Microsoft Corporation (MSFT) : Free Stock Analysis Report International Business Machines Corporation (IBM) : Free Stock Analysis Report Las Vegas Sands Corp. (LVS) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. For more on ABT’s earnings, click here. | Click to get this free report The Boeing Company (BA) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Microsoft Corporation (MSFT) : Free Stock Analysis Report International Business Machines Corporation (IBM) : Free Stock Analysis Report Las Vegas Sands Corp. (LVS) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT put up prominent beats ahead of today’s opening bell, with earnings of $1.03 per share outpacing the 90 cents in the Zacks consensus on revenues of $10.09 billion, for a positive surprise of +6.47%. For more on ABT’s earnings, click here. |
31226.0 | 2023-01-25 00:00:00 UTC | Abbott (ABT) Q4 Earnings and Revenues Top Estimates | ABT | https://www.nasdaq.com/articles/abbott-abt-q4-earnings-and-revenues-top-estimates | nan | nan | Abbott (ABT) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $0.90 per share. This compares to earnings of $1.32 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 14.44%. A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $0.91 per share when it actually produced earnings of $1.15, delivering a surprise of 26.37%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $10.09 billion for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 6.47%. This compares to year-ago revenues of $11.47 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Abbott shares have added about 2.5% since the beginning of the year versus the S&P 500's gain of 4.6%.
What's Next for Abbott?
While Abbott has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Abbott: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1 on $9.44 billion in revenues for the coming quarter and $4.39 on $39.23 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the top 43% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, SurModics (SRDX), has yet to report results for the quarter ended December 2022.
This drug delivery technology company is expected to post quarterly loss of $0.64 per share in its upcoming report, which represents a year-over-year change of -392.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
SurModics' revenues are expected to be $24.19 million, up 5.2% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Surmodics, Inc. (SRDX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $0.90 per share. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report To read this article on Zacks.com click here. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $0.90 per share. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $10.09 billion for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 6.47%. | Abbott (ABT) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $0.90 per share. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $10.09 billion for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 6.47%. | Abbott (ABT) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $0.90 per share. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report To read this article on Zacks.com click here. The company has topped consensus revenue estimates four times over the last four quarters. |
31227.0 | 2023-01-25 00:00:00 UTC | US STOCKS-Wall St eyes lower open as weak earnings updates dent sentiment | ABT | https://www.nasdaq.com/articles/us-stocks-wall-st-eyes-lower-open-as-weak-earnings-updates-dent-sentiment | nan | nan | By Shreyashi Sanyal and Johann M Cherian
Jan 25 (Reuters) - Wall Street's main indexes were set to open lower on Wednesday as downbeat quarterly updates from Microsoft and Boeing added to fears of a recession.
Shares of the software giant MSFT.O fell 2.7% in premarket trading after it warned that growth in its lucrative cloud business could stall, while its PC unit continued to struggle.
Amazon.com Inc AMZN.O, Salesforce Inc CRM.N and ServiceNow Inc NOW.N, which have substantial cloud businesses, fell between 1.3% and 3.0%.
Other large growth stocks, including Apple Inc AAPL.O, Alphabet Inc GOOGL.Oand Tesla Inc TSLA.O, also dropped between 0.7% and 1.5%.
Growth stocks, however, have enjoyed a bounce in January after a battering last year, with investors now focused on earnings reports to assess the impact of the Federal Reserve's rate hikes and to gauge whether the renewed enthusiasm for such stocks will be sustained.
The S&P 500 Growth index .IGX has added over 4% in the month, reclaiming more than half of its losses from December.
"The environment may look attractive because some of these cloud companies, like Salesforce, are down so much, but people are still skeptical because we're heading into weaker economic news," said Robert Pavlik, senior portfolio manager at Dakota Wealth.
"We still have inflation, we still have the Fed raising interest rates, we're seeing companies laying off thousands of peoples ... We're not completely through the cycle yet."
Dow constituent, Boeing CoBA.N slipped 2.4% as the planemaker's losses widened in 2022 and it fell short of fourth-quarter revenue expectations.
AT&T Inc T.N rose 1.7% on reporting higher-than-expected quarterly subscriber additions, while Textron Inc TXT.Nadded 3% as the Cessna jet maker reported better-than-expected revenue, boosted by demand for its private jets.
Abbott Laboratories ABT.Nslid over 1.5% weighed down by lower-than-expected medical device sales in the fourth quarter as COVID-19 lockdown restrictions in China and supply chain issues hit its international operations.
News CorpNWSA.Oadded 5% after Rupert Murdoch withdrew a proposal to reunite News Corp and Fox Corp.
(Reporting by Shreyashi Sanyal and Johann M Cherian in Bengaluru; Additional reporting by Ankika Biswas; Editing by Vinay Dwivedi and Anil D'Silva)
((Shreyashi.Sanyal@thomsonreuters.com; +1 646 223 8780; +91 961 144 3740; Twitter: https://twitter.com/s_shreyashi;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT.Nslid over 1.5% weighed down by lower-than-expected medical device sales in the fourth quarter as COVID-19 lockdown restrictions in China and supply chain issues hit its international operations. By Shreyashi Sanyal and Johann M Cherian Jan 25 (Reuters) - Wall Street's main indexes were set to open lower on Wednesday as downbeat quarterly updates from Microsoft and Boeing added to fears of a recession. "The environment may look attractive because some of these cloud companies, like Salesforce, are down so much, but people are still skeptical because we're heading into weaker economic news," said Robert Pavlik, senior portfolio manager at Dakota Wealth. | Abbott Laboratories ABT.Nslid over 1.5% weighed down by lower-than-expected medical device sales in the fourth quarter as COVID-19 lockdown restrictions in China and supply chain issues hit its international operations. By Shreyashi Sanyal and Johann M Cherian Jan 25 (Reuters) - Wall Street's main indexes were set to open lower on Wednesday as downbeat quarterly updates from Microsoft and Boeing added to fears of a recession. Amazon.com Inc AMZN.O, Salesforce Inc CRM.N and ServiceNow Inc NOW.N, which have substantial cloud businesses, fell between 1.3% and 3.0%. | Abbott Laboratories ABT.Nslid over 1.5% weighed down by lower-than-expected medical device sales in the fourth quarter as COVID-19 lockdown restrictions in China and supply chain issues hit its international operations. Shares of the software giant MSFT.O fell 2.7% in premarket trading after it warned that growth in its lucrative cloud business could stall, while its PC unit continued to struggle. Growth stocks, however, have enjoyed a bounce in January after a battering last year, with investors now focused on earnings reports to assess the impact of the Federal Reserve's rate hikes and to gauge whether the renewed enthusiasm for such stocks will be sustained. | Abbott Laboratories ABT.Nslid over 1.5% weighed down by lower-than-expected medical device sales in the fourth quarter as COVID-19 lockdown restrictions in China and supply chain issues hit its international operations. By Shreyashi Sanyal and Johann M Cherian Jan 25 (Reuters) - Wall Street's main indexes were set to open lower on Wednesday as downbeat quarterly updates from Microsoft and Boeing added to fears of a recession. Amazon.com Inc AMZN.O, Salesforce Inc CRM.N and ServiceNow Inc NOW.N, which have substantial cloud businesses, fell between 1.3% and 3.0%. |
31228.0 | 2023-01-25 00:00:00 UTC | Health Care Sector Update for 01/25/2023: AUPH, ISRG, ABT, XLV, IBB | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-01-25-2023%3A-auph-isrg-abt-xlv-ibb | nan | nan | Health care stocks were mixed premarket Wednesday. The Health Care Select Sector SPDR Fund (XLV) was slipping by 0.62% and the iShares Biotechnology ETF (IBB) was recently inactive.
Aurinia Pharmaceuticals (AUPH) rose by nearly 8% after saying the US Patent and Trademark Office issued a notice of allowance for its patent application covering a treatment for lupus nephritis.
Intuitive Surgical (ISRG) fell by nearly 9% after it reported Q4 non-GAAP diluted earnings of $1.23 a share, down from $1.29 a year earlier. Analysts polled by Capital IQ expected $1.25.
Abbott Laboratories (ABT) was more than 2% lower after it reported Q4 adjusted earnings of $1.03 per diluted share, down from $1.32 a year earlier. Analysts polled by Capital IQ expected $0.93.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT) was more than 2% lower after it reported Q4 adjusted earnings of $1.03 per diluted share, down from $1.32 a year earlier. The Health Care Select Sector SPDR Fund (XLV) was slipping by 0.62% and the iShares Biotechnology ETF (IBB) was recently inactive. Intuitive Surgical (ISRG) fell by nearly 9% after it reported Q4 non-GAAP diluted earnings of $1.23 a share, down from $1.29 a year earlier. | Abbott Laboratories (ABT) was more than 2% lower after it reported Q4 adjusted earnings of $1.03 per diluted share, down from $1.32 a year earlier. Intuitive Surgical (ISRG) fell by nearly 9% after it reported Q4 non-GAAP diluted earnings of $1.23 a share, down from $1.29 a year earlier. Analysts polled by Capital IQ expected $1.25. | Abbott Laboratories (ABT) was more than 2% lower after it reported Q4 adjusted earnings of $1.03 per diluted share, down from $1.32 a year earlier. The Health Care Select Sector SPDR Fund (XLV) was slipping by 0.62% and the iShares Biotechnology ETF (IBB) was recently inactive. Intuitive Surgical (ISRG) fell by nearly 9% after it reported Q4 non-GAAP diluted earnings of $1.23 a share, down from $1.29 a year earlier. | Abbott Laboratories (ABT) was more than 2% lower after it reported Q4 adjusted earnings of $1.03 per diluted share, down from $1.32 a year earlier. Health care stocks were mixed premarket Wednesday. The Health Care Select Sector SPDR Fund (XLV) was slipping by 0.62% and the iShares Biotechnology ETF (IBB) was recently inactive. |
31229.0 | 2023-01-24 00:00:00 UTC | Pre-Market Earnings Report for January 25, 2023 : ASML, ABT, NEE, T, BA, ELV, ADP, PGR, USB, FCX, GD, NSC | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-for-january-25-2023-%3A-asml-abt-nee-t-ba-elv-adp-pgr-usb-fcx-gd | nan | nan | The following companies are expected to report earnings prior to market open on 01/25/2023. Visit our Earnings Calendar for a full list of expected earnings releases.
ASML Holding N.V. (ASML)is reporting for the quarter ending December 31, 2022. The capital goods company's consensus earnings per share forecast from the 3 analysts that follow the stock is $4.62. This value represents a 7.78% decrease compared to the same quarter last year. In the past year ASML and beat the expectations the other three quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ASML is 46.21 vs. an industry ratio of 23.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Abbott Laboratories (ABT)is reporting for the quarter ending December 31, 2022. The medical products company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.90. This value represents a 31.82% decrease compared to the same quarter last year. In the past year ABT has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 27.78%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABT is 21.88 vs. an industry ratio of 9.70, implying that they will have a higher earnings growth than their competitors in the same industry.
NextEra Energy, Inc. (NEE)is reporting for the quarter ending December 31, 2022. The electric power utilities company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.49. This value represents a 19.51% increase compared to the same quarter last year. In the past year NEE has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 7.59%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for NEE is 28.61 vs. an industry ratio of 6.90, implying that they will have a higher earnings growth than their competitors in the same industry.
AT&T Inc. (T)is reporting for the quarter ending December 31, 2022. The wireless (national) company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.58. This value represents a 25.64% decrease compared to the same quarter last year. T missed the consensus earnings per share in the 1st calendar quarter of 2022 by -1.28%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for T is 7.23 vs. an industry ratio of 28.40.
Boeing Company (BA)is reporting for the quarter ending December 31, 2022. The aerospace and defense company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.30. This value represents a 103.90% increase compared to the same quarter last year. Zacks Investment Research reports that the 2022 Price to Earnings ratio for BA is -23.65 vs. an industry ratio of 4.40.
Elevance Health, Inc. (ELV)is reporting for the quarter ending December 31, 2022. The medical services company's consensus earnings per share forecast from the 17 analysts that follow the stock is $5.21. This value represents a 1.36% increase compared to the same quarter last year. In the past year ELV has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 6.06%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ELV is 16.47 vs. an industry ratio of -5.40, implying that they will have a higher earnings growth than their competitors in the same industry.
Automatic Data Processing, Inc. (ADP)is reporting for the quarter ending December 31, 2022. The outsourcing company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.94. This value represents a 17.58% increase compared to the same quarter last year. In the past year ADP has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 4.49%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ADP is 29.67 vs. an industry ratio of 16.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Progressive Corporation (PGR)is reporting for the quarter ending December 31, 2022. The insurance (property & casualty) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.49. This value represents a 41.90% increase compared to the same quarter last year. Zacks Investment Research reports that the 2022 Price to Earnings ratio for PGR is 31.39 vs. an industry ratio of 2.70, implying that they will have a higher earnings growth than their competitors in the same industry.
U.S. Bancorp (USB)is reporting for the quarter ending December 31, 2022. The bank company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.11. This value represents a 3.74% increase compared to the same quarter last year. USB missed the consensus earnings per share in the 4th calendar quarter of 2021 by -3.6%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for USB is 10.96 vs. an industry ratio of 9.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Freeport-McMoran, Inc. (FCX)is reporting for the quarter ending December 31, 2022. The mining company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.40. This value represents a 58.33% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2022 Price to Earnings ratio for FCX is 19.54 vs. an industry ratio of -0.80, implying that they will have a higher earnings growth than their competitors in the same industry.
General Dynamics Corporation (GD)is reporting for the quarter ending December 31, 2022. The aerospace and defense company's consensus earnings per share forecast from the 7 analysts that follow the stock is $3.53. This value represents a 4.13% increase compared to the same quarter last year. In the past year GD has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 3.16%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for GD is 19.15 vs. an industry ratio of 4.40, implying that they will have a higher earnings growth than their competitors in the same industry.
Norfolk Southern Corporation (NSC)is reporting for the quarter ending December 31, 2022. The transportation (rail) company's consensus earnings per share forecast from the 8 analysts that follow the stock is $3.41. This value represents a 9.29% increase compared to the same quarter last year. In the past year NSC has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 12.64%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for NSC is 18.54 vs. an industry ratio of 22.20.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT)is reporting for the quarter ending December 31, 2022. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABT is 21.88 vs. an industry ratio of 9.70, implying that they will have a higher earnings growth than their competitors in the same industry. | Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABT is 21.88 vs. an industry ratio of 9.70, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories (ABT)is reporting for the quarter ending December 31, 2022. In the past year ABT has beat the expectations every quarter. | Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABT is 21.88 vs. an industry ratio of 9.70, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories (ABT)is reporting for the quarter ending December 31, 2022. In the past year ABT has beat the expectations every quarter. | Abbott Laboratories (ABT)is reporting for the quarter ending December 31, 2022. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABT is 21.88 vs. an industry ratio of 9.70, implying that they will have a higher earnings growth than their competitors in the same industry. |
31230.0 | 2023-01-24 00:00:00 UTC | Noteworthy Tuesday Option Activity: ACI, JOE, ABT | ABT | https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-aci-joe-abt | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Albertsons Companies Inc (Symbol: ACI), where a total of 10,632 contracts have traded so far, representing approximately 1.1 million underlying shares. That amounts to about 44.5% of ACI's average daily trading volume over the past month of 2.4 million shares. Especially high volume was seen for the $21 strike call option expiring February 17, 2023, with 10,194 contracts trading so far today, representing approximately 1.0 million underlying shares of ACI. Below is a chart showing ACI's trailing twelve month trading history, with the $21 strike highlighted in orange:
St. Joe Co. (Symbol: JOE) saw options trading volume of 765 contracts, representing approximately 76,500 underlying shares or approximately 44.2% of JOE's average daily trading volume over the past month, of 173,110 shares. Especially high volume was seen for the $41 strike put option expiring March 17, 2023, with 472 contracts trading so far today, representing approximately 47,200 underlying shares of JOE. Below is a chart showing JOE's trailing twelve month trading history, with the $41 strike highlighted in orange:
And Abbott Laboratories (Symbol: ABT) options are showing a volume of 19,547 contracts thus far today. That number of contracts represents approximately 2.0 million underlying shares, working out to a sizeable 42.7% of ABT's average daily trading volume over the past month, of 4.6 million shares. Especially high volume was seen for the $105 strike put option expiring February 17, 2023, with 2,908 contracts trading so far today, representing approximately 290,800 underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $105 strike highlighted in orange:
For the various different available expirations for ACI options, JOE options, or ABT options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
Also see:
Global Payments Average Annual Return
Top Ten Hedge Funds Holding TFI
ASH Dividend History
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $105 strike put option expiring February 17, 2023, with 2,908 contracts trading so far today, representing approximately 290,800 underlying shares of ABT. Below is a chart showing JOE's trailing twelve month trading history, with the $41 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) options are showing a volume of 19,547 contracts thus far today. That number of contracts represents approximately 2.0 million underlying shares, working out to a sizeable 42.7% of ABT's average daily trading volume over the past month, of 4.6 million shares. | Below is a chart showing JOE's trailing twelve month trading history, with the $41 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) options are showing a volume of 19,547 contracts thus far today. That number of contracts represents approximately 2.0 million underlying shares, working out to a sizeable 42.7% of ABT's average daily trading volume over the past month, of 4.6 million shares. Especially high volume was seen for the $105 strike put option expiring February 17, 2023, with 2,908 contracts trading so far today, representing approximately 290,800 underlying shares of ABT. | Below is a chart showing JOE's trailing twelve month trading history, with the $41 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) options are showing a volume of 19,547 contracts thus far today. That number of contracts represents approximately 2.0 million underlying shares, working out to a sizeable 42.7% of ABT's average daily trading volume over the past month, of 4.6 million shares. Especially high volume was seen for the $105 strike put option expiring February 17, 2023, with 2,908 contracts trading so far today, representing approximately 290,800 underlying shares of ABT. | Below is a chart showing ABT's trailing twelve month trading history, with the $105 strike highlighted in orange: For the various different available expirations for ACI options, JOE options, or ABT options, visit StockOptionsChannel.com. Below is a chart showing JOE's trailing twelve month trading history, with the $41 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) options are showing a volume of 19,547 contracts thus far today. That number of contracts represents approximately 2.0 million underlying shares, working out to a sizeable 42.7% of ABT's average daily trading volume over the past month, of 4.6 million shares. |
31231.0 | 2023-01-24 00:00:00 UTC | Will Abbott Stock Rise After Its Q4 Results? | ABT | https://www.nasdaq.com/articles/will-abbott-stock-rise-after-its-q4-results-0 | nan | nan | Abbott (NYSE: ABT) is scheduled to report its Q4 2022 results on Wednesday, January 25. We expect the company to post revenue and earnings slightly above the street expectations. However, supply chain disruptions, forex headwinds, and a decline in Covid-19-related demand will likely weigh on the company’s overall performance. Although we expect Abbott to post upbeat results in Q4, our forecast indicates that ABT stock is appropriately priced, as discussed below. Our interactive dashboard analysis of Abbott Earnings Preview has additional details.
(1) Revenues expected to be slightly above the consensus estimates
Trefis estimates Abbott’s Q4 2022 revenues to be around $9.7 billion, reflecting a 16% y-o-y decline and slightly above the consensus estimate of $9.6 billion.
The revenue decline can primarily be attributed to lower demand for Covid-19 testing and forex headwinds.
For perspective, Abbott expects total Covid-19 related sales of $500 million in Q4, compared to $2.3 billion in the prior-year quarter.
Looking at Q3, the company reported total revenue of $10.4 billion, down 4.7% y-o-y, due to lower sales for Medical Devices, Nutrition, and Diagnostics businesses.
Our dashboard on Abbott Revenues offers more details on the company’s segments.
(2) EPS likely to be above the consensus estimates
Abbott’s Q4 2022 adjusted earnings per share (EPS) is expected to be $0.99 per Trefis analysis, comfortably above the $0.91 consensus estimate.
Abbott’s adjusted net income of $2.0 billion in Q3 2022 reflected a 19% fall from its $2.5 billion figure in the prior-year quarter. This can be attributed to lower revenues and nearly a 300 bps gross margin contraction due to higher costs.
For the full-year 2023, we expect the adjusted EPS to be lower at $4.60, compared to $5.24 in 2021 and an estimated $5.30 in 2022. This can be attributed to an anticipated decline in Covid-19-related sales.
(3) ABT stock looks fairly valued
We estimate Abbott’s Valuation to be around $118 per share, about 3% above the current market price of $114.
At its current levels, ABT stock is trading at a forward P/E multiple of 25x based on our EPS estimate of $4.60 for 2023, compared to the last three-year average of 24x, implying that ABT stock is fully valued.
If the company reports upbeat Q4 results and provides a 2023 outlook better than the street estimates, the P/E multiple will likely be revised upward, resulting in higher levels for ABT stock.
While ABT stock looks appropriately priced, it is helpful to see how Abbott’s Peers fare on metrics that matter. You will find other valuable comparisons for companies across industries at Peer Comparisons.
Furthermore, the Covid-19 crisis has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised at how counter-intuitive the stock valuation is for Cintas vs. Merck.
With inflation rising and the Fed raising interest rates, among other factors, ABT stock has fallen 8% in the last twelve months. Can it drop more? See how low Abbott stock can go by comparing its decline in previous market crashes. Here is a performance summary of all stocks in previous market crashes.
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
Returns Jan 2023
MTD [1] 2023
YTD [1] 2017-23
Total [2]
ABT Return 4% 4% 197%
S&P 500 Return 5% 5% 80%
Trefis Multi-Strategy Portfolio 10% 10% 245%
[1] Month-to-date and year-to-date as of 1/24/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although we expect Abbott to post upbeat results in Q4, our forecast indicates that ABT stock is appropriately priced, as discussed below. With inflation rising and the Fed raising interest rates, among other factors, ABT stock has fallen 8% in the last twelve months. Abbott (NYSE: ABT) is scheduled to report its Q4 2022 results on Wednesday, January 25. | Abbott (NYSE: ABT) is scheduled to report its Q4 2022 results on Wednesday, January 25. Although we expect Abbott to post upbeat results in Q4, our forecast indicates that ABT stock is appropriately priced, as discussed below. (3) ABT stock looks fairly valued We estimate Abbott’s Valuation to be around $118 per share, about 3% above the current market price of $114. | At its current levels, ABT stock is trading at a forward P/E multiple of 25x based on our EPS estimate of $4.60 for 2023, compared to the last three-year average of 24x, implying that ABT stock is fully valued. Total [2] ABT Return 4% 4% 197% S&P 500 Return 5% 5% 80% Trefis Multi-Strategy Portfolio 10% 10% 245% [1] Month-to-date and year-to-date as of 1/24/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott (NYSE: ABT) is scheduled to report its Q4 2022 results on Wednesday, January 25. | (3) ABT stock looks fairly valued We estimate Abbott’s Valuation to be around $118 per share, about 3% above the current market price of $114. Total [2] ABT Return 4% 4% 197% S&P 500 Return 5% 5% 80% Trefis Multi-Strategy Portfolio 10% 10% 245% [1] Month-to-date and year-to-date as of 1/24/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott (NYSE: ABT) is scheduled to report its Q4 2022 results on Wednesday, January 25. |
31232.0 | 2023-01-23 00:00:00 UTC | Want Safe and Growing Passive Income? Buy These 2 Dividend Kings In 2023 | ABT | https://www.nasdaq.com/articles/want-safe-and-growing-passive-income-buy-these-2-dividend-kings-in-2023 | nan | nan | There are few guarantees in life. But investing in quality dividend-paying stocks will just have to do for income investors.
An efficient way to measure quality among dividend stocks is by how many consecutive years the payout has been raised. With at least 50 consecutive years of dividend growth, Dividend Kings are the crème de la crème. Fifty-plus consecutive years means that Dividend Kings raised their dividends paid to shareholders through numerous recessions, stock market crashes, global pandemics, and military conflicts. Here are two Dividend Kings that are growing steadily and are reasonably valued to consider buying for 2023 and beyond.
Image source: Getty Images.
1. Johnson & Johnson: The lengthiest dividend growth streak in all of healthcare
Johnson & Johnson (NYSE: JNJ) is a company that needs no introduction, but here's one anyway: With corporate roots dating back to the late 19th century and over 140,000 employees throughout the world, J&J is a world-class business. In fact, its $445 billion market capitalization makes J&J the largest pharmaceutical company on the planet.
Thirteen of the company's medicines and its COVID-19 vaccine are each expected to report more than $1 billion in annual sales when J&J reports full-year 2022 earnings results on Jan. 24. As one of the most successful companies in history, the drugmaker couldn't really be blamed if it were to get complacent.
But with 107 projects in differing stages of clinical development as of Oct. 18, J&J isn't doing that at all. This is why analysts expect mid-single-digit annual earnings growth from the company over the next five years. The company should also benefit from a once-in-a-decade opportunity later this year when J&J spins off one of its slower-growing segments. The main company will focus on developing new medical devices and pharmaceuticals and it will retain the J&J name. The other will focus on consumer health goods like over-the-counter medicines and brands like Band-Aid and it will be called Kenvue.
The spinoff and the encouraging growth forecast, coupled with a dividend payout ratio that will clock in at approximately 44% in 2022, bodes well for future dividend growth. That should allow J&J to build on its 60-year dividend growth streak -- the most established streak in the entire healthcare sector -- moving forward. Income investors will also be pleased to learn that the stock's 2.7% dividend yield is considerably higher than the S&P 500 index's average 1.7% yield.
And to top it all off, shares of J&J can be snatched up at a forward price-to-earnings (P/E) ratio of 16.4. This is slightly below the S&P 500 healthcare sector average forward P/E ratio of 17.2, which makes J&J a buy for dividend growth investors.
2. Abbott Laboratories: An outstanding healthcare business
Like J&J, Abbott Laboratories (NYSE: ABT) is a company that is well-known around the world, with market-leading positions in numerous areas of healthcare. Abbott's most prominent products include the continuous glucose monitor FreeStyle Libre, the nutritional shake Ensure, and the BinaxNOW COVID-19 rapid test.
The company's 130-plus years in business helped it to foster a culture of innovation. Because of this factor, analysts anticipate that Abbott's earnings will compound at 8.3% annually over the next five years.
Yield-hungry investors will prize the stock's market-topping 1.8% dividend yield. Investors can also rest assured that the dividend is sustainable, since it is projected that Abbott's dividend payout ratio will be just 36% in 2022. This should provide the company with the flexibility to extend its dividend growth streak well past the current mark of 50 years.
The cherry on top is that the market doesn't seem to be giving Abbott the respect that it deserves. The stock is trading at a forward P/E ratio of 25.3, which is a tad lower than the medical devices industry average forward P/E ratio of 25.5. If anything, a Dividend King like Abbott is arguably worthy of at least some premium over its peers. That's what makes it such a compelling buy for investors seeking rising dividend income.
10 stocks we like better than Johnson & Johnson
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of January 9, 2023
Kody Kester has positions in Abbott Laboratories and Johnson & Johnson. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories: An outstanding healthcare business Like J&J, Abbott Laboratories (NYSE: ABT) is a company that is well-known around the world, with market-leading positions in numerous areas of healthcare. This is slightly below the S&P 500 healthcare sector average forward P/E ratio of 17.2, which makes J&J a buy for dividend growth investors. Abbott's most prominent products include the continuous glucose monitor FreeStyle Libre, the nutritional shake Ensure, and the BinaxNOW COVID-19 rapid test. | Abbott Laboratories: An outstanding healthcare business Like J&J, Abbott Laboratories (NYSE: ABT) is a company that is well-known around the world, with market-leading positions in numerous areas of healthcare. Johnson & Johnson: The lengthiest dividend growth streak in all of healthcare Johnson & Johnson (NYSE: JNJ) is a company that needs no introduction, but here's one anyway: With corporate roots dating back to the late 19th century and over 140,000 employees throughout the world, J&J is a world-class business. This is slightly below the S&P 500 healthcare sector average forward P/E ratio of 17.2, which makes J&J a buy for dividend growth investors. | Abbott Laboratories: An outstanding healthcare business Like J&J, Abbott Laboratories (NYSE: ABT) is a company that is well-known around the world, with market-leading positions in numerous areas of healthcare. Fifty-plus consecutive years means that Dividend Kings raised their dividends paid to shareholders through numerous recessions, stock market crashes, global pandemics, and military conflicts. Johnson & Johnson: The lengthiest dividend growth streak in all of healthcare Johnson & Johnson (NYSE: JNJ) is a company that needs no introduction, but here's one anyway: With corporate roots dating back to the late 19th century and over 140,000 employees throughout the world, J&J is a world-class business. | Abbott Laboratories: An outstanding healthcare business Like J&J, Abbott Laboratories (NYSE: ABT) is a company that is well-known around the world, with market-leading positions in numerous areas of healthcare. With at least 50 consecutive years of dividend growth, Dividend Kings are the crème de la crème. The main company will focus on developing new medical devices and pharmaceuticals and it will retain the J&J name. |
31233.0 | 2023-01-23 00:00:00 UTC | Noteworthy ETF Inflows: VONV, PFE, VZ, ABT | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-vonv-pfe-vz-abt | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Russell 1000 Value ETF (Symbol: VONV) where we have detected an approximate $356.1 million dollar inflow -- that's a 5.4% increase week over week in outstanding units (from 97,102,615 to 102,302,615). Among the largest underlying components of VONV, in trading today Pfizer Inc (Symbol: PFE) is up about 0.3%, Verizon Communications Inc (Symbol: VZ) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is up by about 0.9%. For a complete list of holdings, visit the VONV Holdings page » The chart below shows the one year price performance of VONV, versus its 200 day moving average:
Looking at the chart above, VONV's low point in its 52 week range is $58.8266 per share, with $74.4595 as the 52 week high point — that compares with a last trade of $68.90. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
Also see:
GSE Videos
EEB Historical Stock Prices
CNP Dividend History
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VONV, in trading today Pfizer Inc (Symbol: PFE) is up about 0.3%, Verizon Communications Inc (Symbol: VZ) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is up by about 0.9%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. | Among the largest underlying components of VONV, in trading today Pfizer Inc (Symbol: PFE) is up about 0.3%, Verizon Communications Inc (Symbol: VZ) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is up by about 0.9%. For a complete list of holdings, visit the VONV Holdings page » The chart below shows the one year price performance of VONV, versus its 200 day moving average: Looking at the chart above, VONV's low point in its 52 week range is $58.8266 per share, with $74.4595 as the 52 week high point — that compares with a last trade of $68.90. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». | Among the largest underlying components of VONV, in trading today Pfizer Inc (Symbol: PFE) is up about 0.3%, Verizon Communications Inc (Symbol: VZ) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is up by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Russell 1000 Value ETF (Symbol: VONV) where we have detected an approximate $356.1 million dollar inflow -- that's a 5.4% increase week over week in outstanding units (from 97,102,615 to 102,302,615). For a complete list of holdings, visit the VONV Holdings page » The chart below shows the one year price performance of VONV, versus its 200 day moving average: Looking at the chart above, VONV's low point in its 52 week range is $58.8266 per share, with $74.4595 as the 52 week high point — that compares with a last trade of $68.90. | Among the largest underlying components of VONV, in trading today Pfizer Inc (Symbol: PFE) is up about 0.3%, Verizon Communications Inc (Symbol: VZ) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is up by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Russell 1000 Value ETF (Symbol: VONV) where we have detected an approximate $356.1 million dollar inflow -- that's a 5.4% increase week over week in outstanding units (from 97,102,615 to 102,302,615). For a complete list of holdings, visit the VONV Holdings page » The chart below shows the one year price performance of VONV, versus its 200 day moving average: Looking at the chart above, VONV's low point in its 52 week range is $58.8266 per share, with $74.4595 as the 52 week high point — that compares with a last trade of $68.90. |
31234.0 | 2023-01-23 00:00:00 UTC | Abbott's (ABT) New FDA Approval to Improve Patient Outcome | ABT | https://www.nasdaq.com/articles/abbotts-abt-new-fda-approval-to-improve-patient-outcome | nan | nan | Abbott Laboratories ABT recently announced the receipt of the FDA’s approval for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. The Navitor TAVI system, the latest addition to the company's comprehensive transcatheter structural heart portfolio, is expected to offer less-invasive treatment options for some of the most common and serious heart diseases.
The latest regulatory clearance is expected to significantly boost Abbott’s structural heart business of the broader Medical Devices segment.
Significance of the Approval
Aortic stenosis, which occurs when the aortic valve's opening narrows, restricts blood flow to the body. If left untreated, it can lead to heart failure and death. For patients with severe aortic stenosis who are at high or extreme surgical risk due to the potential complications stemming from age, frailty, or having multiple other diseases or conditions, physicians may now opt for a minimally-invasive procedure using TAVI therapies, such as the Navitor system.
Navitor’s unique fabric cuff (NaviSeal) is expected to reduce or eliminate the backflow of blood around the valve frame, known as the paravalvular leak. Additionally, the new device is the only self-expanding TAVI system with leaflets within the native valve. This design is expected to aid in improving access to coronary arteries to facilitate future procedures for treating coronary artery disease.
The Navitor device is implanted using Abbott's FlexNav delivery system, which features a slim design to accommodate different patient anatomies and small vessels for stable, predictable and accurate valve delivery and placement.
Per Abbott's management, Navitor is the first TAVI system that is expected to offer optimal hemodynamics (blood flow) in all valve sizes while preserving options for lifetime disease management. This is an important consideration for physicians and patients when selecting a TAVI solution, and receiving this approval will likely improve patients’ lives.
Industry Prospects
Per a report by Allied Market Research, the global TAVI market was valued at $4,559 million in 2020 and is anticipated to reach $16,937 million by 2030 at a CAGR of 14%. Factors like the increase in the prevalence of aortic stenosis, rise in demand for various TAVI procedures and rise in the elderly population are likely to drive the market.
Given the market potential, the latest regulatory clearance is expected to significantly strengthen Abbott's global structural heart business.
Notable Developments in Medical Devices
Last month, Abbott announced that its FreeStyle Libre 3 sensor is now compatible with the mylife Loop solution from partners, Ypsomed and CamDiab, thus creating a smart, automated process to deliver insulin based on real-time glucose data. This automated insulin delivery system solution is now available in Germany and will be available in additional European countries beginning in 2023.
The same month, Abbott announced the receipt of the FDA’s approval of its Eterna spinal cord stimulation system. It is the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain.
In October 2022, Abbott announced its third-quarter 2022 results, where it registered a robust uptick in its total worldwide sales on an organic basis, benefiting from robust organic sales growth across the company’s core Established Pharmaceuticals and Medical Devices segments. The U.S. Medical Devices sales also improved in the third quarter, led by strong double-digit growth in Electrophysiology, Structural Heart and Diabetes Care.
Price Performance
Shares of the company have lost 8.9% in the past year compared with the industry’s 37.5% decline and the S&P 500's 11.1% fall.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Abbott carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. AMN, Cardinal Health, Inc. CAH and Merit Medical Systems, Inc. MMSI.
AMN Healthcare, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 3.3%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 10.9%.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare has lost 0.8% compared with the industry’s 22.3% decline in the past year.
Cardinal Health, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11.7%. CAH’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average beat being 3%.
Cardinal Health has gained 49.2% against the industry’s 1.9% decline over the past year.
Merit Medical, flaunting a Zacks Rank #1 at present, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average beat being 25.4%.
Merit Medical has gained 22.2% against the industry’s 1.9% decline over the past year.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Cardinal Health, Inc. (CAH) : Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT recently announced the receipt of the FDA’s approval for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report To read this article on Zacks.com click here. For patients with severe aortic stenosis who are at high or extreme surgical risk due to the potential complications stemming from age, frailty, or having multiple other diseases or conditions, physicians may now opt for a minimally-invasive procedure using TAVI therapies, such as the Navitor system. | Abbott Laboratories ABT recently announced the receipt of the FDA’s approval for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. AMN, Cardinal Health, Inc. CAH and Merit Medical Systems, Inc. MMSI. | Abbott Laboratories ABT recently announced the receipt of the FDA’s approval for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research Zacks Rank & Key Picks Currently, Abbott carries a Zacks Rank #3 (Hold). | Abbott Laboratories ABT recently announced the receipt of the FDA’s approval for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report To read this article on Zacks.com click here. The Navitor TAVI system, the latest addition to the company's comprehensive transcatheter structural heart portfolio, is expected to offer less-invasive treatment options for some of the most common and serious heart diseases. |
31235.0 | 2023-01-21 00:00:00 UTC | Abbott Reportedly Under Criminal Probe Over Baby Formula | ABT | https://www.nasdaq.com/articles/abbott-reportedly-under-criminal-probe-over-baby-formula | nan | nan | (RTTNews) - Abbott Laboratories' (ABT) Michigan infant-formula plant faces a criminal investigation by the Justice Department over its baby formula, the Wall Street Journal reported, citing people familiar with the matter.
Attorneys with the Justice Department's consumer-protection branch are conducting the criminal investigation, the WSJ report said, citing people familiar with the matter.
The branch, which has criminal as well as civil authority, was involved last year in a settlement with Abbott that allowed its Sturgis plant to resume operations after Food and Drug Administration inspectors found a potentially deadly bacteria there.
"The DOJ has informed us of its investigation, and we're cooperating fully," an Abbott spokesman said. The DOJ did not immediately respond to a request for comment.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories' (ABT) Michigan infant-formula plant faces a criminal investigation by the Justice Department over its baby formula, the Wall Street Journal reported, citing people familiar with the matter. Attorneys with the Justice Department's consumer-protection branch are conducting the criminal investigation, the WSJ report said, citing people familiar with the matter. The branch, which has criminal as well as civil authority, was involved last year in a settlement with Abbott that allowed its Sturgis plant to resume operations after Food and Drug Administration inspectors found a potentially deadly bacteria there. | (RTTNews) - Abbott Laboratories' (ABT) Michigan infant-formula plant faces a criminal investigation by the Justice Department over its baby formula, the Wall Street Journal reported, citing people familiar with the matter. Attorneys with the Justice Department's consumer-protection branch are conducting the criminal investigation, the WSJ report said, citing people familiar with the matter. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories' (ABT) Michigan infant-formula plant faces a criminal investigation by the Justice Department over its baby formula, the Wall Street Journal reported, citing people familiar with the matter. Attorneys with the Justice Department's consumer-protection branch are conducting the criminal investigation, the WSJ report said, citing people familiar with the matter. The branch, which has criminal as well as civil authority, was involved last year in a settlement with Abbott that allowed its Sturgis plant to resume operations after Food and Drug Administration inspectors found a potentially deadly bacteria there. | (RTTNews) - Abbott Laboratories' (ABT) Michigan infant-formula plant faces a criminal investigation by the Justice Department over its baby formula, the Wall Street Journal reported, citing people familiar with the matter. Attorneys with the Justice Department's consumer-protection branch are conducting the criminal investigation, the WSJ report said, citing people familiar with the matter. The branch, which has criminal as well as civil authority, was involved last year in a settlement with Abbott that allowed its Sturgis plant to resume operations after Food and Drug Administration inspectors found a potentially deadly bacteria there. |
31236.0 | 2023-01-20 00:00:00 UTC | Abbott faces U.S. criminal probe over baby formula -WSJ | ABT | https://www.nasdaq.com/articles/abbott-faces-u.s.-criminal-probe-over-baby-formula-wsj | nan | nan | Adds Abbott's response
Jan 20 (Reuters) - Abbott Laboratories' ABT.N Michigan plant, which was at the center of the U.S. baby formula shortage last year, is being investigated by the Justice Department, the Wall Street Journal reported on Friday.
Attorneys with the Justice Department's consumer-protection branch are conducting the criminal investigation, the report said, citing people familiar with the matter.
"DOJ has informed us of its investigation and we're cooperating fully," an Abbott spokesman told Reuters.
In February 2022, Abbott, the biggest U.S. supplier of baby formula, recalled Similac and other infant formula products produced at the Michigan facility after reports of bacterial infections in babies who had consumed products made there.
The shutdown of the plant and subsequent product recalls exacerbated a baby formula shortage in the United States that began due to pandemic-induced supply chain issues.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Himani Sarkar)
((mrinalika.roy@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds Abbott's response Jan 20 (Reuters) - Abbott Laboratories' ABT.N Michigan plant, which was at the center of the U.S. baby formula shortage last year, is being investigated by the Justice Department, the Wall Street Journal reported on Friday. Attorneys with the Justice Department's consumer-protection branch are conducting the criminal investigation, the report said, citing people familiar with the matter. "DOJ has informed us of its investigation and we're cooperating fully," an Abbott spokesman told Reuters. | Adds Abbott's response Jan 20 (Reuters) - Abbott Laboratories' ABT.N Michigan plant, which was at the center of the U.S. baby formula shortage last year, is being investigated by the Justice Department, the Wall Street Journal reported on Friday. In February 2022, Abbott, the biggest U.S. supplier of baby formula, recalled Similac and other infant formula products produced at the Michigan facility after reports of bacterial infections in babies who had consumed products made there. The shutdown of the plant and subsequent product recalls exacerbated a baby formula shortage in the United States that began due to pandemic-induced supply chain issues. | Adds Abbott's response Jan 20 (Reuters) - Abbott Laboratories' ABT.N Michigan plant, which was at the center of the U.S. baby formula shortage last year, is being investigated by the Justice Department, the Wall Street Journal reported on Friday. In February 2022, Abbott, the biggest U.S. supplier of baby formula, recalled Similac and other infant formula products produced at the Michigan facility after reports of bacterial infections in babies who had consumed products made there. (Reporting by Mrinalika Roy in Bengaluru; Editing by Himani Sarkar) ((mrinalika.roy@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds Abbott's response Jan 20 (Reuters) - Abbott Laboratories' ABT.N Michigan plant, which was at the center of the U.S. baby formula shortage last year, is being investigated by the Justice Department, the Wall Street Journal reported on Friday. Attorneys with the Justice Department's consumer-protection branch are conducting the criminal investigation, the report said, citing people familiar with the matter. "DOJ has informed us of its investigation and we're cooperating fully," an Abbott spokesman told Reuters. |
31237.0 | 2023-01-20 00:00:00 UTC | Validea Daily Guru Fundamental Report for ABT - 1/20/2023 | ABT | https://www.nasdaq.com/articles/validea-daily-guru-fundamental-report-for-abt-1-20-2023 | nan | nan | Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). | Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. | Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
31238.0 | 2023-01-20 00:00:00 UTC | Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings | ABT | https://www.nasdaq.com/articles/want-better-returns-dont-ignore-these-2-medical-stocks-set-to-beat-earnings-2 | nan | nan | Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the metrics and results to consider, earnings is one of the most important.
Life and the stock market are both about expectations, and rising above what is expected is often rewarded, while falling short can come with negative consequences. Investors might want to try to capture stronger returns by finding positive earnings surprises.
Hunting for 'earnings whispers' or companies poised to beat their quarterly earnings estimates is a somewhat common practice. But that doesn't make it easy. One way that has been proven to work is by using the Zacks Earnings ESP tool.
The Zacks Earnings ESP, Explained
The Zacks Earnings ESP, or Expected Surprise Prediction, aims to find earnings surprises by focusing on the most recent analyst revisions. The basic premise is that if an analyst reevaluates their earnings estimate ahead of an earnings release, it means they likely have new information that could possibly be more accurate.
The core of the ESP model is comparing the Most Accurate Estimate to the Zacks Consensus Estimate, where the resulting percentage difference between the two equals the Expected Surprise Prediction. The Zacks Rank is also factored into the ESP metric to better help find companies that appear poised to top their next bottom-line consensus estimate, which will hopefully help lift the stock price.
When we join a positive earnings ESP with a Zacks Rank #3 (Hold) or stronger, stocks posted a positive bottom-line surprise 70% of the time. Plus, this system saw investors produce roughly 28% annual returns on average, according to our 10 year backtest.
Most stocks, about 60%, fall into the #3 (Hold) category, and they are expected to perform in-line with the broader market. Stocks with a #2 (Buy) and #1 (Strong Buy) rating, or the top 15% and top 5% of stocks, respectively, should outperform the market, with Strong Buy stocks outperforming more than any other rank.
Should You Consider Abbott?
The last thing we will do today, now that we have a grasp on the ESP and how powerful of a tool it can be, is to quickly look at a qualifying stock. Abbott (ABT) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at $0.92 a share five days away from its upcoming earnings release on January 25, 2023.
By taking the percentage difference between the $0.92 Most Accurate Estimate and the $0.90 Zacks Consensus Estimate, Abbott has an Earnings ESP of +2.6%. Investors should also know that ABT is one of a large group of stocks with positive ESPs. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
ABT is just one of a large group of Medical stocks with a positive ESP figure. Humana (HUM) is another qualifying stock you may want to consider.
Slated to report earnings on February 1, 2023, Humana holds a #3 (Hold) ranking on the Zacks Rank, and it's Most Accurate Estimate is $1.47 a share 12 days from its next quarterly update.
Humana's Earnings ESP figure currently stands at +0.04% after taking the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $1.46.
ABT and HUM's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report.
Find Stocks to Buy or Sell Before They're Reported
Use the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Humana Inc. (HUM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT and HUM's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report. Abbott (ABT) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at $0.92 a share five days away from its upcoming earnings release on January 25, 2023. Investors should also know that ABT is one of a large group of stocks with positive ESPs. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Humana Inc. (HUM) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at $0.92 a share five days away from its upcoming earnings release on January 25, 2023. Investors should also know that ABT is one of a large group of stocks with positive ESPs. | Abbott (ABT) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at $0.92 a share five days away from its upcoming earnings release on January 25, 2023. Investors should also know that ABT is one of a large group of stocks with positive ESPs. ABT is just one of a large group of Medical stocks with a positive ESP figure. | ABT and HUM's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report. Abbott (ABT) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at $0.92 a share five days away from its upcoming earnings release on January 25, 2023. Investors should also know that ABT is one of a large group of stocks with positive ESPs. |
31239.0 | 2023-01-20 00:00:00 UTC | Will Intuitive Surgical Stock Rise Post Q4? | ABT | https://www.nasdaq.com/articles/will-intuitive-surgical-stock-rise-post-q4 | nan | nan | Intuitive Surgical (NASDAQ: ISRG) is scheduled to report its Q4 2022 results on Tuesday, January 24. We expect Intuitive Surgical to report revenue and earnings above the street estimates, driven by a rise in total procedures volume. However, inflationary headwinds may weigh on the company’s net margins. Although we believe the company will navigate well during the quarter, we find the stock to be fully valued, as discussed below. Our interactive dashboard analysis on Intuitive Surgical Earnings Preview has additional details.
(1) Revenues expected to align with the consensus estimates
Trefis estimates Intuitive Surgical’s Q4 2022 revenues to be around $1.7 billion, aligning with the $1.7 billion consensus estimate.
The overall procedure volume continued to see double-digit growth, rising 18% in Q4, per the company’s preliminary results released last week.
Looking at Q3 2022, the company saw its sales rise 11% (y-o-y) to $1.6 billion. This can be attributed to a higher demand for consumables. The overall procedure volume grew 20% during the quarter.
Our dashboard on Intuitive Surgical Revenues has more details on the company’s segments.
(2) EPS likely to be slightly above the consensus estimates
Intuitive Surgical’s Q4 2022 adjusted earnings per share (EPS) is expected to be $1.33 per Trefis analysis, slightly above the $1.25 consensus estimate.
The company’s adjusted net income of $429 million in Q3 2022 reflected a 1.4% fall from its $435 million figure in the prior-year quarter, as the 11% sales growth was more than offset by nearly 350 bps drop in net margins. This can primarily be attributed to higher logistics costs and increased component pricing.
With the rising inflation, the costs may remain high for the company in the near term.
For the full-year 2023, we expect the adjusted EPS to be higher at $5.52 compared to $4.96 in 2021, and an estimated $4.79 in 2022.
(3) ISRG stock is undervalued
We estimate Intuitive Surgical’s Valuation to be around $243 per share, which is 6% below the current market price of $259.
At its current levels, ISRG stock is trading at 47x forward adjusted earnings, aligning with its last three-year average, implying the stock is fully valued.
Investors have assigned a high trading multiple for ISRG stock, given the substantial revenue and earnings growth over the past years.
Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year
While ISRG stock looks appropriately priced, it is helpful to see how Intuitive Surgical’s Peers fare on metrics that matter. You will find other valuable comparisons for companies across industries at Peer Comparisons.
Furthermore, the Covid-19 crisis has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised at how counter-intuitive the stock valuation is for Abbott vs. Amerco.
With inflation rising and the Fed raising interest rates, among other factors, ISRG stock has plunged 13% in the last twelve months. Can it drop more? See how low Intuitive Surgical stock can go by comparing its decline in previous market crashes. Here is a performance summary of all stocks in previous market crashes.
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
Returns Jan 2023
MTD [1] 2023
YTD [1] 2017-23
Total [2]
ISRG Return -2% -2% 269%
S&P 500 Return 4% 4% 79%
Trefis Multi-Strategy Portfolio 8% 8% 241%
[1] Month-to-date and year-to-date as of 1/17/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We expect Intuitive Surgical to report revenue and earnings above the street estimates, driven by a rise in total procedures volume. Investors have assigned a high trading multiple for ISRG stock, given the substantial revenue and earnings growth over the past years. With inflation rising and the Fed raising interest rates, among other factors, ISRG stock has plunged 13% in the last twelve months. | We expect Intuitive Surgical to report revenue and earnings above the street estimates, driven by a rise in total procedures volume. (1) Revenues expected to align with the consensus estimates Trefis estimates Intuitive Surgical’s Q4 2022 revenues to be around $1.7 billion, aligning with the $1.7 billion consensus estimate. (2) EPS likely to be slightly above the consensus estimates Intuitive Surgical’s Q4 2022 adjusted earnings per share (EPS) is expected to be $1.33 per Trefis analysis, slightly above the $1.25 consensus estimate. | (1) Revenues expected to align with the consensus estimates Trefis estimates Intuitive Surgical’s Q4 2022 revenues to be around $1.7 billion, aligning with the $1.7 billion consensus estimate. Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year While ISRG stock looks appropriately priced, it is helpful to see how Intuitive Surgical’s Peers fare on metrics that matter. Total [2] ISRG Return -2% -2% 269% S&P 500 Return 4% 4% 79% Trefis Multi-Strategy Portfolio 8% 8% 241% [1] Month-to-date and year-to-date as of 1/17/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We expect Intuitive Surgical to report revenue and earnings above the street estimates, driven by a rise in total procedures volume. (3) ISRG stock is undervalued We estimate Intuitive Surgical’s Valuation to be around $243 per share, which is 6% below the current market price of $259. Total [2] ISRG Return -2% -2% 269% S&P 500 Return 4% 4% 79% Trefis Multi-Strategy Portfolio 8% 8% 241% [1] Month-to-date and year-to-date as of 1/17/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
31240.0 | 2023-01-20 00:00:00 UTC | Why Abbott (ABT) is Poised to Beat Earnings Estimates Again | ABT | https://www.nasdaq.com/articles/why-abbott-abt-is-poised-to-beat-earnings-estimates-again | nan | nan | Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry.
This maker of infant formula, medical devices and drugs has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 28.78%.
For the last reported quarter, Abbott came out with earnings of $1.15 per share versus the Zacks Consensus Estimate of $0.91 per share, representing a surprise of 26.37%. For the previous quarter, the company was expected to post earnings of $1.09 per share and it actually produced earnings of $1.43 per share, delivering a surprise of 31.19%.
Price and EPS Surprise
With this earnings history in mind, recent estimates have been moving higher for Abbott. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Abbott currently has an Earnings ESP of +2.60%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on January 25, 2023.
Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.
Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. This maker of infant formula, medical devices and drugs has an established record of topping earnings estimates, especially when looking at the previous two reports. | It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank. | It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank. | It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. For the last reported quarter, Abbott came out with earnings of $1.15 per share versus the Zacks Consensus Estimate of $0.91 per share, representing a surprise of 26.37%. |
31241.0 | 2023-01-19 00:00:00 UTC | 3 Top Passive-Income Stocks to Own in 2023 | ABT | https://www.nasdaq.com/articles/3-top-passive-income-stocks-to-own-in-2023 | nan | nan | Times have been tough for investors over the past year. The three major indexes hit bear territory -- and some of the world's strongest stocks sank.
But here are two pieces of good news. First, these difficult periods don't last forever. And second, there's a way to cushion your portfolio from the shock. And by this, I mean investing in dividend stocks.
These players will offer you passive income that's much appreciated during bad times -- and this income is a plus during good times, too. Whether the market downturn continues this year or the market recovers and thrives, you won't regret owning the following three stocks during 2023 and beyond.
1. Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) has lifted its dividend for more than 50 consecutive years. That puts it on the list of Dividend Kings.
What does this track record mean for you? It means you can probably count on continued dividend growth. That's because J&J has shown that rewarding shareholders is an important part of its strategy.
The pharmaceutical giant pays an annual dividend of $4.52 per share. The dividend yield is 2.61%, well above the average of 2.15% according to NYU's Stern Business School. So, even if stocks in your portfolio decline, you'll still benefit from recurrent income from J&J.
J&J also offers a track record of earnings growth -- and this could be getting even better. I'll explain. This year, J&J is spinning off its consumer health business into a separate entity. That means it will focus on its two higher-growth businesses: pharmaceuticals and medtech. This should boost earnings moving forward. And that could translate into share performance over time.
2. Abbott Laboratories
Abbott Laboratories (NYSE: ABT) also has increased its dividend for more than 50 years. The company recently lifted its quarterly payment by 8.5%. Abbott said the move represents its "long-standing commitment to sustainable growth and shareholder returns."
The healthcare company pays an annual dividend of $2.04. That's at a dividend yield of 1.83%. And Abbott's growth in free cash flow shows it has what it takes to continue rewarding shareholders.
ABT Free Cash Flow data by YCharts
Like J&J, Abbott offers you another big reason to invest. And that's its earnings strength over time and potential to keep that going. Abbott has four businesses: medical devices, diagnostics, established pharmaceuticals, and nutrition.
This offers a big advantage. If one business faces a challenge, the others can compensate. We've seen that as sales in the nutrition business fell in the first nine months of last year due to a product recall -- but sales in the other units climbed.
So, moving forward, you can benefit from Abbott more than one way. You can count on passive income growth and earnings growth over time. And Abbott shares are likely to climb over the long term too.
3. Target
Target (NYSE: TGT) is another stock on the Dividend King list. The retailer today pays an annual dividend of $4.32 at a yield of 2.70%.
In the third-quarterearnings call Target said it aims "to support our dividend and build on our 50-year record of annual dividend increases." Target paid nearly $500 million in dividends in the quarter. That's a 13% increase from the year-earlier period. All of this means there's reason to be confident about passive income growth into the future.
Target shares slipped last year as investors shied away from companies sensitive to the economy.
The company faced higher costs, and its shoppers began looking more and more for bargains. That weighed on Target's operating margin.
Still, Target managed to grow comparable revenue -- in fact, it climbed for the 22nd consecutive quarter. It gained market share across all of its merchandise categories. And the company said it was launching a plan to maximize efficiency. That could save as much as $3 billion in the coming three years.
So, an investment in Target now represents access to passive income growth right away -- and an opportunity to benefit from Target's bright growth prospects down the road.
10 stocks we like better than Johnson & Johnson
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of January 9, 2023
Adria Cimino has positions in Target. The Motley Fool has positions in and recommends Abbott Laboratories and Target. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT Free Cash Flow data by YCharts Like J&J, Abbott offers you another big reason to invest. Abbott Laboratories Abbott Laboratories (NYSE: ABT) also has increased its dividend for more than 50 years. The three major indexes hit bear territory -- and some of the world's strongest stocks sank. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) also has increased its dividend for more than 50 years. ABT Free Cash Flow data by YCharts Like J&J, Abbott offers you another big reason to invest. Johnson & Johnson Johnson & Johnson (NYSE: JNJ) has lifted its dividend for more than 50 consecutive years. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) also has increased its dividend for more than 50 years. ABT Free Cash Flow data by YCharts Like J&J, Abbott offers you another big reason to invest. Johnson & Johnson Johnson & Johnson (NYSE: JNJ) has lifted its dividend for more than 50 consecutive years. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) also has increased its dividend for more than 50 years. ABT Free Cash Flow data by YCharts Like J&J, Abbott offers you another big reason to invest. These players will offer you passive income that's much appreciated during bad times -- and this income is a plus during good times, too. |
31242.0 | 2023-01-19 00:00:00 UTC | See Which Of The Latest 13F Filers Holds Abbott Laboratories | ABT | https://www.nasdaq.com/articles/see-which-of-the-latest-13f-filers-holds-abbott-laboratories-3 | nan | nan | At Holdings Channel, we have reviewed the latest batch of the 25 most recent 13F filings for the 12/31/2022 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 15 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed, it is important to point out that 13F filings do not tell the whole story, because these funds are only required to disclose their long positions with the SEC, but are not required to disclose their short positions. A fund making a bearish bet against a stock by shorting calls, for example, might also be long some amount of stock as they trade around their overall bearish position. This long component could show up in a 13F filing and everyone might assume the fund is bullish, but this tells only part of the story because the bearish/short side of the position is not seen.
Having given that caveat, we believe that looking at groups of 13F filings can be revealing, especially when comparing one holding period to another. Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers:
FUND NEW POSITION? CHANGE IN SHARE COUNT CHANGE IN MARKET VALUE ($ IN 1000'S)
KFG Wealth Management LLC NEW +3,361 +$369
Oak Harbor Wealth Partners LLC Existing UNCH +$374
Prentice Wealth Management LLC Existing +269 +$76
Opus Capital Group LLC Existing -145 +$31
One Plus One Wealth Management LLC Existing UNCH +$52
Bassett Hargrove Investment Counsel LLC Existing UNCH +$31
Cardinal Strategic Wealth Guidance Existing UNCH +$39
Tandem Capital Management Corp ADV Existing -104 +$484
Beaumont Asset Management L.L.C. Existing UNCH +$40
Calton & Associates Inc. Existing +561 +$92
Mckinley Capital Management LLC Delaware Existing -61,757 -$5,191
Winthrop Advisory Group LLC Existing -11 +$29
Wesbanco Bank Inc. Existing +81,424 +$9,514
J.P. Marvel Investment Advisors LLC Existing UNCH +$919
Mcdonald Partners LLC Existing +156 +$205
Aggregate Change: +23,754 +$7,064
In terms of shares owned, we count 4 of the above funds having increased existing ABT positions from 09/30/2022 to 12/31/2022, with 4 having decreased their positions and 1 new position.
Looking beyond these particular funds in this one batch of most recent filers, we tallied up the ABT share count in the aggregate among all of the funds which held ABT at the 12/31/2022 reporting period (out of the 515 we looked at in total). We then compared that number to the sum total of ABT shares those same funds held back at the 09/30/2022 period, to see how the aggregate share count held by hedge funds has moved for ABT. We found that between these two periods, funds increased their holdings by 550,066 shares in the aggregate, from 12,329,995 up to 12,880,061 for a share count increase of approximately 4.46%. The overall top three funds holding ABT on 12/31/2022 were:
» FUND SHARES OF ABT HELD
1. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST 2,080,000
2. Bartlett & Co. LLC 1,034,630
3. Ardevora Asset Management LLP 884,291
4-10 Find out the full Top 10 Hedge Funds Holding ABT »
We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like Abbott Laboratories (Symbol: ABT).
10 S&P 500 Components Hedge Funds Are Buying »
Also see:
ENDP Stock Predictions
NI YTD Return
GBR Split History
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At Holdings Channel, we have reviewed the latest batch of the 25 most recent 13F filings for the 12/31/2022 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 15 of these funds. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like Abbott Laboratories (Symbol: ABT). Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers: | At Holdings Channel, we have reviewed the latest batch of the 25 most recent 13F filings for the 12/31/2022 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 15 of these funds. Existing +81,424 +$9,514 J.P. Marvel Investment Advisors LLC Existing UNCH +$919 Mcdonald Partners LLC Existing +156 +$205 Aggregate Change: +23,754 +$7,064 In terms of shares owned, we count 4 of the above funds having increased existing ABT positions from 09/30/2022 to 12/31/2022, with 4 having decreased their positions and 1 new position. Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers: | Existing +81,424 +$9,514 J.P. Marvel Investment Advisors LLC Existing UNCH +$919 Mcdonald Partners LLC Existing +156 +$205 Aggregate Change: +23,754 +$7,064 In terms of shares owned, we count 4 of the above funds having increased existing ABT positions from 09/30/2022 to 12/31/2022, with 4 having decreased their positions and 1 new position. Ardevora Asset Management LLP 884,291 4-10 Find out the full Top 10 Hedge Funds Holding ABT » We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. At Holdings Channel, we have reviewed the latest batch of the 25 most recent 13F filings for the 12/31/2022 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 15 of these funds. | Existing +81,424 +$9,514 J.P. Marvel Investment Advisors LLC Existing UNCH +$919 Mcdonald Partners LLC Existing +156 +$205 Aggregate Change: +23,754 +$7,064 In terms of shares owned, we count 4 of the above funds having increased existing ABT positions from 09/30/2022 to 12/31/2022, with 4 having decreased their positions and 1 new position. Ardevora Asset Management LLP 884,291 4-10 Find out the full Top 10 Hedge Funds Holding ABT » We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. At Holdings Channel, we have reviewed the latest batch of the 25 most recent 13F filings for the 12/31/2022 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 15 of these funds. |
31243.0 | 2023-01-19 00:00:00 UTC | Should You Invest in the iShares U.S. Medical Devices ETF (IHI)? | ABT | https://www.nasdaq.com/articles/should-you-invest-in-the-ishares-u.s.-medical-devices-etf-ihi-4 | nan | nan | The iShares U.S. Medical Devices ETF (IHI) was launched on 05/01/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Medical Devices segment of the equity market.
Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs, transparency, flexibility, and tax efficiency; these kind of funds are also excellent vehicles for long term investors.
Sector ETFs are also funds of convenience, offering many ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Medical Devices is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 5, placing it in top 31%.
Index Details
The fund is sponsored by Blackrock. It has amassed assets over $6.27 billion, making it one of the largest ETFs attempting to match the performance of the Healthcare - Medical Devices segment of the equity market. IHI seeks to match the performance of the Dow Jones U.S. Select Medical Equipment Index before fees and expenses.
The Dow Jones U.S. Select Medical Equipment Index measures the performance of the medical equipment sector of the U.S. equity market.
Costs
Cost is an important factor in selecting the right ETF, and cheaper funds can significantly outperform their more expensive counterparts if all other fundamentals are the same.
Annual operating expenses for this ETF are 0.39%, making it one of the cheaper products in the space.
It has a 12-month trailing dividend yield of 0.44%.
Sector Exposure and Top Holdings
Even though ETFs offer diversified exposure that minimizes single stock risk, investors should also look at the actual holdings inside the fund. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.
This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio.
Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 17.47% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT).
The top 10 holdings account for about 64.37% of total assets under management.
Performance and Risk
The ETF has added roughly 2.23% and is down about -10.47% so far this year and in the past one year (as of 01/19/2023), respectively. IHI has traded between $47.07 and $62.20 during this last 52-week period.
The ETF has a beta of 0.86 and standard deviation of 25.89% for the trailing three-year period, making it a medium risk choice in the space. With about 69 holdings, it effectively diversifies company-specific risk.
Alternatives
IShares U.S. Medical Devices ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, IHI is a reasonable option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.
First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the SPDR S&P Health Care Equipment ETF (XHE) tracks S&P Health Care Equipment Select Industry Index. First Trust Indxx Medical Devices ETF has $2 million in assets, SPDR S&P Health Care Equipment ETF has $394.17 million. MDEV has an expense ratio of 0.70% and XHE charges 0.35%.
Bottom Line
To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week.
Get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
iShares U.S. Medical Devices ETF (IHI): ETF Research Reports
Abbott Laboratories (ABT) : Free Stock Analysis Report
Medtronic PLC (MDT) : Free Stock Analysis Report
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports
First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 17.47% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT). Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. It has amassed assets over $6.27 billion, making it one of the largest ETFs attempting to match the performance of the Healthcare - Medical Devices segment of the equity market. | Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 17.47% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT). First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the SPDR S&P Health Care Equipment ETF (XHE) tracks S&P Health Care Equipment Select Industry Index. | Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 17.47% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT). First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the SPDR S&P Health Care Equipment ETF (XHE) tracks S&P Health Care Equipment Select Industry Index. | Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 17.47% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT). Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. The iShares U.S. Medical Devices ETF (IHI) was launched on 05/01/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Medical Devices segment of the equity market. |
31244.0 | 2023-01-18 00:00:00 UTC | Top Analyst Reports for Pfizer, Abbott Laboratories & Union Pacific | ABT | https://www.nasdaq.com/articles/top-analyst-reports-for-pfizer-abbott-laboratories-union-pacific | nan | nan | Wednesday, January 18, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Abbott Laboratories (ABT) and Union Pacific Corporation (UNP). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Pfizer have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-13.9% vs. +14.6%), with the absence of credible growth drivers beyond the company's Covid offerings as the primary drag. Other issues like currency headwinds and pricing pressures are some of the other concerns.
Estimates have gone down slightly ahead of Q4 earnings. Pfizer has a mixed record of earnings surprises in the recent quarters. However, Pfizer boasts a diversified portfolio of innovative drugs and vaccines, including Ibrance and Prevnar.
Its COVID-19 vaccine and oral antiviral pill for COVID-19, Paxlovid have become a key contributor to the top line. Pfizer boasts a sustainable pipeline with multiple late-stage programs that can drive growth.
(You can read the full research report on Pfizer here >>>)
Abbott Laboratories shares have declined -10.1% over the past year against the Zacks Medical - Products industry’s decline of -38.4%. The company’s sales were negatively impacted by COVID-19 testing-related sales decline and a manufacturing stoppage initiated in February of certain infant nutrition formula products manufactured at Abbott's Sturgis, MI, facility.
However, excluding these negative factors, total worldwide sales increased 6% on an organic basis, benefitting from robust sales growth across the company’s core Established Pharmaceuticals and Medical Devices segments.
Meanwhile, the Diabetes Care business continued to benefit from the growing sales of its flagship CGM system, FreeStyle Libre. The raised 2022 guidance buoys optimism.
(You can read the full research report on Abbott Laboratories here >>>)
Shares of Union Pacific have underperformed the Zacks Transportation - Rail industry over the past year (-10.5% vs. -5.2%). The company is facing escalation in fuel costs as oil prices move north is worrisome. This phenomenon induced a 22% rise in the operating expenses in the first nine months of 2022. Fuel costs surged 78% in the period. The same is likely to have been high in the December quarter as well. Detailed results will be out on Jan 24.
However, Union Pacific's efforts to reward its shareholders even in the current uncertain scenario please us. The company hiked dividend twice in 2021. In May 2022, UNP further upped its quarterly dividend by 10%. The railroad operator is also active on the buyback front.
Management expects share repurchases in 2022 to bearound $6.5 billion. UNP's strong free cash flow generating ability supports its shareholder-friendly activities. The uptick in overall volumes as labor woes ease is an added positive.
(You can read the full research report on Union Pacific here >>>)
Other noteworthy reports we are featuring today include The Goldman Sachs Group, Inc. (GS), Citigroup Inc. (C) and Intuitive Surgical, Inc. (ISRG).
Director of Research
Sheraz Mian
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Pfizer (PFE) Growth Drivers Beyond COVID Products a Concern
Abbott (ABT) Rides on Diabetes Business amid Forex Woes
Union Pacific's (UNP) Dividends Support, Fuel Costs Hurt
Featured Reports
Goldman (GS) Rides on Strong Consumer Banking Growth
Per the Zacks analyst, Goldman benefits from robust consumer banking business, robust client engagement, and a decent investment banking backlog.
Citigroup (C) Rides on Strong Institutional Clients Revenues
Per the Zacks analyst, Citigroup is benefiting from solid revenue performance from Institutional Clients. Its focus on institutional franchises and improve long-term profitability is positive.
Intuitive Surgical's (ISRG) da Vinci System Helps Offset Risks
Per the Zacks analyst, growing adoption of Intuitive Surgical's da Vinci system is driving its revenues as well as helping offsetting risks like COVID-19 resurgences and rising costs.
General Mills (GIS) Gains From Focus on Accelerate Strategy
Per the Zacks analyst, General Mills is gaining from its Accelerate strategy, as part of which it is competing efficiently via brand building, investing in saving initiatives and reshaping portfolio.
Rising Gold Prices to Aid Franco-Nevada (FNV), Costs Ail
Per the Zacks analyst, a debt-free balance sheet, the recent pickup in gold prices and cost management efforts will drive Franco-Nevada despite the impact of high costs.
Solid Demand For Live Events Aid Live Nation (LYV), Costs High
Per the Zacks analyst, Live Nation is likely to benefit from pent-up demand for live events, Ticketmaster systems and sponsorship business. However, inflationary pressures is a concern.
Low Breakeven Costs to Aid Marathon Oil's (MRO) Cash Flows
The Zacks analyst believes that Marathon's extremely low oil price breakeven costs of just $35 a barrel should generate meaningful free cash flows and improve future profitability.
New Upgrades
Investments, Clean Energy Initiatives to Bolster ConEd (ED)
Per the Zacks analyst, solid investments will aid Consolidated Edison's (ConEd) infrastructural development. Further, its initiatives to add more clean energy to its grid must benefit ConEd.
Capri Holdings' (CPRI) Digital Endeavors to Aid Top Line
Per the Zacks analyst Capri Holdings has been deploying resources to expand product offering and upgrade distribution infrastructure. This along with cost containment and focus on e-commerce bode well
Higher Rates, Loans, Buyout to Aid Washington Federal (WAFD)
Per the Zacks analyst, higher interest rates, steady loan demand, strategic acquisition of Luther Burbank, and a robust balance sheet and liquidity position will support Washington Federal's top line.
New Downgrades
High Debt Load & Stiff Competition to Hurt Generac (GNRC)
Per the Zacks analyst, Generac's performance is being affected by a leveraged balance sheet and supply chain constraints. Also, stiff competition a major concern.
Increased Cat Loss & Elevated Debt Level Hurt Allstate (ALL)
Per the Zacks analyst, exposure to catastrophic events continues to dent underwriting profitability. Rising debts remain a concern as it leads to escalated interest expenses.
Capital Market Volatility to Hamper Bank of America (BAC)
Per the Zacks analyst, Bank of America's over dependence on trading revenues for fee income is a woe. The volatile nature of the capital markets makes us apprehensive as it might hurt fee revenues.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report
Citigroup Inc. (C) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Union Pacific Corporation (UNP) : Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Abbott Laboratories (ABT) and Union Pacific Corporation (UNP). If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Pfizer (PFE) Growth Drivers Beyond COVID Products a Concern Abbott (ABT) Rides on Diabetes Business amid Forex Woes Union Pacific's (UNP) Dividends Support, Fuel Costs Hurt Featured Reports Goldman (GS) Rides on Strong Consumer Banking Growth Per the Zacks analyst, Goldman benefits from robust consumer banking business, robust client engagement, and a decent investment banking backlog. Click to get this free report The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report Citigroup Inc. (C) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Union Pacific Corporation (UNP) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report To read this article on Zacks.com click here. | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Pfizer (PFE) Growth Drivers Beyond COVID Products a Concern Abbott (ABT) Rides on Diabetes Business amid Forex Woes Union Pacific's (UNP) Dividends Support, Fuel Costs Hurt Featured Reports Goldman (GS) Rides on Strong Consumer Banking Growth Per the Zacks analyst, Goldman benefits from robust consumer banking business, robust client engagement, and a decent investment banking backlog. Click to get this free report The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report Citigroup Inc. (C) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Union Pacific Corporation (UNP) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report To read this article on Zacks.com click here. Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Abbott Laboratories (ABT) and Union Pacific Corporation (UNP). | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Pfizer (PFE) Growth Drivers Beyond COVID Products a Concern Abbott (ABT) Rides on Diabetes Business amid Forex Woes Union Pacific's (UNP) Dividends Support, Fuel Costs Hurt Featured Reports Goldman (GS) Rides on Strong Consumer Banking Growth Per the Zacks analyst, Goldman benefits from robust consumer banking business, robust client engagement, and a decent investment banking backlog. Click to get this free report The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report Citigroup Inc. (C) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Union Pacific Corporation (UNP) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report To read this article on Zacks.com click here. Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Abbott Laboratories (ABT) and Union Pacific Corporation (UNP). | Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Abbott Laboratories (ABT) and Union Pacific Corporation (UNP). If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Pfizer (PFE) Growth Drivers Beyond COVID Products a Concern Abbott (ABT) Rides on Diabetes Business amid Forex Woes Union Pacific's (UNP) Dividends Support, Fuel Costs Hurt Featured Reports Goldman (GS) Rides on Strong Consumer Banking Growth Per the Zacks analyst, Goldman benefits from robust consumer banking business, robust client engagement, and a decent investment banking backlog. Click to get this free report The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report Citigroup Inc. (C) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Union Pacific Corporation (UNP) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report To read this article on Zacks.com click here. |
31245.0 | 2023-01-18 00:00:00 UTC | Analysts Estimate Abbott (ABT) to Report a Decline in Earnings: What to Look Out for | ABT | https://www.nasdaq.com/articles/analysts-estimate-abbott-abt-to-report-a-decline-in-earnings%3A-what-to-look-out-for-0 | nan | nan | Wall Street expects a year-over-year decline in earnings on lower revenues when Abbott (ABT) reports results for the quarter ended December 2022. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on January 25. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on theearnings call it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus Estimate
This maker of infant formula, medical devices and drugs is expected to post quarterly earnings of $0.90 per share in its upcoming report, which represents a year-over-year change of -31.8%.
Revenues are expected to be $9.48 billion, down 17.4% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0.53% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Abbott?
For Abbott, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.19%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that Abbott will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Abbott would post earnings of $0.91 per share when it actually produced earnings of $1.15, delivering a surprise of +26.37%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Abbott doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Wall Street expects a year-over-year decline in earnings on lower revenues when Abbott (ABT) reports results for the quarter ended December 2022. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. | Wall Street expects a year-over-year decline in earnings on lower revenues when Abbott (ABT) reports results for the quarter ended December 2022. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. | Wall Street expects a year-over-year decline in earnings on lower revenues when Abbott (ABT) reports results for the quarter ended December 2022. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. | Wall Street expects a year-over-year decline in earnings on lower revenues when Abbott (ABT) reports results for the quarter ended December 2022. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on January 25. |
31246.0 | 2023-01-17 00:00:00 UTC | What's in Store for Abbott Laboratories (ABT) in Q4 Earnings? | ABT | https://www.nasdaq.com/articles/whats-in-store-for-abbott-laboratories-abt-in-q4-earnings | nan | nan | Abbott Laboratories ABT is slated to report fourth-quarter 2022 results on Jan 25, before market open.
In the last reported quarter, the company delivered an earnings surprise of 26.37%. Over the trailing four quarters, its earnings exceeded the Zacks Consensus Estimate on all the occasions, the average beat being 21.78%.
Let's see how things have shaped up prior to this announcement.
Factors at Play
Stubborn inflationary pressure, record strengthening of the U.S. dollar and supply chain issues in certain areas of business, most notably, in Electrophysiology are expected to have adversely impacted Abbott’s overall fourth-quarter performance. Going by the industry-wide trend so far, logistical challenges and increasing unit cost might have weighed on corporate profitability of the company. Not just this, the existing healthcare staffing challenges and diminishing demand for COVID-testing products may also have weighed on the company through the Q4 months. The lockdown issues in limited geographies, including China where the company has extensive base, are expected to have also impacted business during the fourth quarter.
On a positive note, within Established Pharmaceuticals Division (EPD), the company has been witnessing visible signs of a rebound, reflecting sequential improvement based on its stable business model. New product launches across key markets have been majorly boosting the EPD business in recent months. The fourth-quarter performance is likely to have been driven by growing customer demand for core therapeutic lines, including cardiometabolic, respiratory and central nervous system/pain management.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories price-eps-surprise | Abbott Laboratories Quote
In Diagnostics, we expect the company to report a year-over-year decline in COVID test sales due to lower demand for laboratory-based tests. However, the company might have registered growth in rapid tests, which include BinaxNOW, Panbio and ID NOW, in Q4. According to the company, with the emergence of new viruses that escape immunity, rapid tests have become the best tool to help slow and prevent transmission.
Excluding COVID testing revenues, sales of routine diagnostic tests are expected to have improved in Q4 on the continuous rollout of Alinity, Abbott’s suite of diagnostic instruments, as well as expanding menus across the company’s testing platforms of immunoassay, clinical chemistry and molecular testing.
Abbott’s other consumer-facing businesses, which include diabetes care, have been catching up, backed by new product instructions. In the United States, the company initiated the full launch of Libre 3, which automatically delivers minute glucose readings with accuracy, courtesy of the world’s smallest and thinnest wearable sensor. This is likely to have majorly contributed to the company's fourth-quarter performance. In this regard, we note that Abbott has been in the limelight for developments in its flagship, sensor-based continuous glucose monitoring system, widely known as the FreeStyle Libre System.
However, internationally, sales growth is expected to have been impacted by a couple of transitory items, including supply constraints on Libre 1 in certain emerging markets. Further, a strategic choice that the company made in Germany to rapidly transition its large existing user base to the latest generation Libre 3 system might have temporarily reduced Abbott’s focus on new user additions during the fourth quarter in this region.
Within Nutrition, total worldwide Nutrition and Pediatric Nutrition sales are expected to have declined in Q4, thanks to the voluntary recall and manufacturing shutdown of certain infant formula products being manufactured at one of Abbott's U.S. plants since last February. These include the company’s market-leading Similac and Elecare.
Though the company announced an update on the resumption of production at the Sturgis, MI facility, starting with the specialty formula EleCare and metabolic formulas, business recovery might take some more time. Per the last update, the company, in September, began production of several Similac products. Although Similac sales are expected to have been similar in the fourth-quarter months, a full-fledged business rebound might take longer.
Estimates
For fourth-quarter 2022, the Zacks Consensus Estimate for total revenues of $9.48 billion indicates a 17.4% decline from the prior-year comparable quarter’s reported figure. The consensus mark for earnings is pegged at 90 cents, suggesting a 31.8% decline year on year.
Earnings Whispers
Per our proven model, a stock with the combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a higher chance of beating estimates. However, that is not the case here as you can see:
Earnings ESP: Abbott has an Earnings ESP of -0.19%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: It currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter.
Cardinal Health CAH has an Earnings ESP of +5.75% and a Zacks Rank of #2. The company will release fourth-quarter 2022 results on Feb 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cardinal Health has a long-term expected earnings growth rate of 11.7%. Cardinal Health’s earnings yield of 6.87% compares favorably with the industry’s 4.34%.
Hologic HOLX has an Earnings ESP of +3.13% and a Zacks Rank of #2. Hologic is scheduled to release first-quarter fiscal 2023 results on Feb 1.
Hologic’s long-term historical earnings growth rate is estimated at 23.4%. Hologic’s earnings yield of 4.35% compares favorably with the industry’s -6.74%.
Laboratory Corporation of America Holdings or LabCorp LH currently has an Earnings ESP of +2.67% and a Zacks Rank of #2. LabCorp is expected to release fourth-quarter 2022 results soon.
LabCorp’s long-term historical earnings growth rate is estimated at 26.1%. LabCorp’s earnings yield of 7.02% compares favorably with the industry’s 4.34%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation
Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.
>>Yes, I Want to Help Protect My Portfolio During the Recession
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report
Cardinal Health, Inc. (CAH) : Free Stock Analysis Report
Hologic, Inc. (HOLX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT is slated to report fourth-quarter 2022 results on Jan 25, before market open. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report To read this article on Zacks.com click here. Factors at Play Stubborn inflationary pressure, record strengthening of the U.S. dollar and supply chain issues in certain areas of business, most notably, in Electrophysiology are expected to have adversely impacted Abbott’s overall fourth-quarter performance. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is slated to report fourth-quarter 2022 results on Jan 25, before market open. Abbott Laboratories Price and EPS Surprise Abbott Laboratories price-eps-surprise | Abbott Laboratories Quote In Diagnostics, we expect the company to report a year-over-year decline in COVID test sales due to lower demand for laboratory-based tests. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is slated to report fourth-quarter 2022 results on Jan 25, before market open. Abbott Laboratories Price and EPS Surprise Abbott Laboratories price-eps-surprise | Abbott Laboratories Quote In Diagnostics, we expect the company to report a year-over-year decline in COVID test sales due to lower demand for laboratory-based tests. | Abbott Laboratories ABT is slated to report fourth-quarter 2022 results on Jan 25, before market open. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report To read this article on Zacks.com click here. In the last reported quarter, the company delivered an earnings surprise of 26.37%. |
31247.0 | 2023-01-17 00:00:00 UTC | Abbott Says FDA Oks Navitor TAVI System To Treat Severe Aortic Stenosis | ABT | https://www.nasdaq.com/articles/abbott-says-fda-oks-navitor-tavi-system-to-treat-severe-aortic-stenosis | nan | nan | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved the company's latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery.
The Navitor TAVI system is the latest addition to the company's comprehensive transcatheter structural heart portfolio that offers less invasive treatment options to physicians and patients for some of the most common and serious heart diseases.
Aortic stenosis occurs when the aortic valve's opening narrows, restricting blood flow to the body. Left untreated, it can lead to heart failure and death.
Navitor features a unique fabric cuff (NaviSeal) to reduce or eliminate the backflow of blood around the valve frame known as paravalvular leak (PVL). Additionally, the new device is the only self-expanding TAVI system with leaflets within the native valve.
The Navitor device is implanted using Abbott's FlexNav delivery system, which features a slim design to accommodate different patient anatomies and small vessels for stable, predictable and accurate valve delivery and placement.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved the company's latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. Navitor features a unique fabric cuff (NaviSeal) to reduce or eliminate the backflow of blood around the valve frame known as paravalvular leak (PVL). The Navitor device is implanted using Abbott's FlexNav delivery system, which features a slim design to accommodate different patient anatomies and small vessels for stable, predictable and accurate valve delivery and placement. | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved the company's latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. The Navitor TAVI system is the latest addition to the company's comprehensive transcatheter structural heart portfolio that offers less invasive treatment options to physicians and patients for some of the most common and serious heart diseases. The Navitor device is implanted using Abbott's FlexNav delivery system, which features a slim design to accommodate different patient anatomies and small vessels for stable, predictable and accurate valve delivery and placement. | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved the company's latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. The Navitor TAVI system is the latest addition to the company's comprehensive transcatheter structural heart portfolio that offers less invasive treatment options to physicians and patients for some of the most common and serious heart diseases. The Navitor device is implanted using Abbott's FlexNav delivery system, which features a slim design to accommodate different patient anatomies and small vessels for stable, predictable and accurate valve delivery and placement. | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved the company's latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. The Navitor TAVI system is the latest addition to the company's comprehensive transcatheter structural heart portfolio that offers less invasive treatment options to physicians and patients for some of the most common and serious heart diseases. Aortic stenosis occurs when the aortic valve's opening narrows, restricting blood flow to the body. |
31248.0 | 2023-01-15 00:00:00 UTC | Validea's Top Ten Healthcare Stocks Based On Peter Lynch - 1/15/2023 | ABT | https://www.nasdaq.com/articles/valideas-top-ten-healthcare-stocks-based-on-peter-lynch-1-15-2023 | nan | nan | The following are the top rated Healthcare stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
EMERGENT BIOSOLUTIONS INC (EBS) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Emergent BioSolutions, Inc. is a life sciences company focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats (PHTs). The Company is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. It provides solutions for PHTs through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. It offers TEMBEXA (brincidofovir) an antiviral for the treatment of smallpox in all age groups, including adults, and for patients who have difficulty swallowing.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of EMERGENT BIOSOLUTIONS INC
EBS Guru Analysis
EBS Fundamental Analysis
LABORATORY CORP. OF AMERICA HOLDINGS (LH) is a large-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on Peter Lynch is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Laboratory Corporation of America Holdings is a global life sciences company. The Company provides information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make decisions. Its segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). The Dx segment is an independent clinical laboratory business. It offers a menu of frequently requested and specialty diagnostic tests through an integrated network of primary and specialty laboratories across the United States. In addition to diagnostic testing along with occupational and wellness testing for employers and forensic DNA analysis, Dx segment also offers a range of other testing services. The DD segment is a contract research organizations (CRO) business that provides end-to-end drug development services. The DD segment provides these services predominantly to pharmaceutical, biotechnology and medical device companies across the world. It serves clients in more than 100 countries.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of LABORATORY CORP. OF AMERICA HOLDINGS
LH Guru Analysis
LH Fundamental Analysis
NOVARTIS AG (ADR) (NVS) is a large-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of NOVARTIS AG (ADR)
NVS Guru Analysis
NVS Fundamental Analysis
REGENERON PHARMACEUTICALS INC (REGN) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of REGENERON PHARMACEUTICALS INC
REGN Guru Analysis
REGN Fundamental Analysis
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
CORCEPT THERAPEUTICS INCORPORATED (CORT) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Corcept Therapeutics Incorporated is a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. It has marketed Korlym (mifepristone) for the treatment of patients suffering from Cushing's syndrome. The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Its cortisol activity can be modulated by a drug that competes with cortisol as it attempts to bind to the glucocorticoid receptor (GR). The Company's ingredient, mifepristone, reduces the binding of excess cortisol to GR. Its compounds bind to GR but not the progesterone, estrogen, or androgen receptors.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of CORCEPT THERAPEUTICS INCORPORATED
CORT Guru Analysis
CORT Fundamental Analysis
DUPONT DE NEMOURS INC (DD) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: DuPont de Nemours, Inc. provides technology-based materials and solutions. The Company's segments include Electronics & Industrial and Water & Protection. Its Electronics & Industrial segment is a global supplier of differentiated materials and systems for a range of consumer electronics, including mobile devices, television monitors, personal computers, and electronics used in a variety of industries. The segment is a provider of materials and solutions for the fabrication and packaging of semiconductors and integrated circuits. It also provides solutions for thermal management and electromagnetic shielding as well as metallization processes for metal finishing, decorative, and industrial applications. The Company's Water & Protection segment is a provider of engineered products and integrated systems for a range of industries, including, worker safety, water purification and separation, transportation, energy, medical packaging, and building materials.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of DUPONT DE NEMOURS INC
DD Guru Analysis
DD Fundamental Analysis
QUEST DIAGNOSTICS INC (DGX) is a large-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through the DIS segment, which provides diagnostic information services to a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers, accountable care organizations (ACOs) and direct contract entities (DCEs). It is also engaged in two business operations, Diagnostic Information Services, which develops and delivers diagnostic information services that provide insights to a range of customers, and the Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services primarily are provided under the Quest Diagnostics brand. The Company is also engaged in providing outreach laboratory services business.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of QUEST DIAGNOSTICS INC
DGX Guru Analysis
DGX Fundamental Analysis
FUJIFILM HOLDINGS CORP. (ADR) (FUJIY) is a large-cap value stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: FUJIFILM Holdings Corporation is a Japan-based holding company engaged in the business related to photography, medical care & printing & liquid crystal display materials and copying machines. The Company operates in three business segments. Imaging Solutions segment develops, manufactures and sells color films, digital cameras, color paper services for photographic prints, instant printing equipment and optical devices mainly for general consumers. Healthcare & Materials Solutions segment provides medical system equipment, cosmetics and supplements, pharmaceutical products, biopharmaceutical manufacturing development contract, regenerative medicine products, chemical products, graphic system equipment, inkjet equipment, display materials, recording media and electronic materials for commercial use. Document Solutions segment provides digital multi-functional peripherals, publishing systems, document management software and related solution services mainly for commercial use.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of FUJIFILM HOLDINGS CORP. (ADR)
FUJIY Guru Analysis
FUJIY Fundamental Analysis
MERCK & CO INC (MRK) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of MERCK & CO INC
MRK Guru Analysis
MRK Fundamental Analysis
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of REGENERON PHARMACEUTICALS INC REGN Guru Analysis REGN Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis CORCEPT THERAPEUTICS INCORPORATED (CORT) is a mid-cap growth stock in the Biotechnology & Drugs industry. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. | Detailed Analysis of REGENERON PHARMACEUTICALS INC REGN Guru Analysis REGN Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis CORCEPT THERAPEUTICS INCORPORATED (CORT) is a mid-cap growth stock in the Biotechnology & Drugs industry. Detailed Analysis of NOVARTIS AG (ADR) NVS Guru Analysis NVS Fundamental Analysis REGENERON PHARMACEUTICALS INC (REGN) is a large-cap growth stock in the Biotechnology & Drugs industry. | Detailed Analysis of REGENERON PHARMACEUTICALS INC REGN Guru Analysis REGN Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis CORCEPT THERAPEUTICS INCORPORATED (CORT) is a mid-cap growth stock in the Biotechnology & Drugs industry. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. | Detailed Analysis of REGENERON PHARMACEUTICALS INC REGN Guru Analysis REGN Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis CORCEPT THERAPEUTICS INCORPORATED (CORT) is a mid-cap growth stock in the Biotechnology & Drugs industry. It is also engaged in two business operations, Diagnostic Information Services, which develops and delivers diagnostic information services that provide insights to a range of customers, and the Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers and its healthcare information technology businesses, which offers solutions for healthcare providers. |
31249.0 | 2023-01-15 00:00:00 UTC | Validea's Top Ten Healthcare Stocks Based On John Neff - 1/15/2023 | ABT | https://www.nasdaq.com/articles/valideas-top-ten-healthcare-stocks-based-on-john-neff-1-15-2023 | nan | nan | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
CIGNA CORP (CI) is a large-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Cigna Corporation is a health services company that offers medical, dental insurance and related products and services. The Company's segments include Evernorth and Cigna Healthcare. Evernorth segment includes a range of coordinated and point solution health services and capabilities, as well as those from partners across the healthcare system, in pharmacy solutions, benefits management solutions, care delivery and care management solutions and intelligence solutions. Cigna Healthcare consists of its U.S. Commercial, U.S. Government and International Health operating segments, which provide a range of medical and coordinated solutions to clients and customers to support whole-person health needs. The U.S. Commercial products and services include medical, pharmacy, behavioral health, dental, vision, health advocacy programs and other products and services for insured and self-insured customers. International Health solutions include health care coverage in its international markets.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of CIGNA CORP
CI Guru Analysis
CI Fundamental Analysis
ENSIGN GROUP INC (ENSG) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: The Ensign Group, Inc. is a holding company, which provides skilled nursing, senior living, and rehabilitative services, as well as other ancillary businesses (including mobile diagnostics and medical transportation) through its subsidiaries. The Company operates through two segments: skilled services and real estate. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The real estate segment primarily comprised of properties owned by the Company and leased to skilled nursing and senior living operations, including its own operating subsidiaries and third-party operators, and are subject to triple-net long-term leases. It offers skilled nursing, senior living and rehabilitative care services through approximately 268 skilled nursing and senior living facilities. Its real estate portfolio includes approximately 107 owned real estate properties located in Arizona, California, Colorado, Idaho, and Nebraska, among others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of ENSIGN GROUP INC
ENSG Guru Analysis
ENSG Fundamental Analysis
PFIZER INC. (PFE) is a large-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on John Neff is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: FAIL
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of PFIZER INC.
PFE Guru Analysis
PFE Fundamental Analysis
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on John Neff is 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Major Drugs industry. The rating according to our strategy based on John Neff is 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AmerisourceBergen Corporation is a global pharmaceutical sourcing and distribution services company. The Company's U.S. Healthcare Solutions segment distributes an offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. This segment consists of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty. The Company also focuses on specialty services and a global platform of pharma manufacturer services capabilities.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of AMERISOURCEBERGEN CORP.
ABC Guru Analysis
ABC Fundamental Analysis
DAVITA INC (DVA) is a mid-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: DaVita Inc. is a healthcare provider. The Company provides kidney care services in the United States. The Company's operations are comprised of its U.S. dialysis and related lab services business (U.S. dialysis business), its U.S. ancillary services and strategic initiatives, its international operations (ancillary services), and corporate administrative support. The U.S. dialysis business treats patients with chronic kidney failure, and end-stage kidney disease (ESKD). The Company provides dialysis and administrative services and related laboratory services. Its services include outpatient hemodialysis services, hospital inpatient hemodialysis services, and home-based dialysis services. The ancillary services consist of integrated kidney care services, physician services supporting integrated kidney care and kidney care initiatives outside of dialysis, clinical research programs, and transplant software business as well as international operations.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: FAIL
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of DAVITA INC
DVA Guru Analysis
DVA Fundamental Analysis
EMBECTA CORP (EMBC) is a small-cap value stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on John Neff is 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Embecta Corp. is a global medical device company. The Company is focused on providing solutions to people living with diabetes. The Company's portfolio of products include a variety of pen needles, syringes and safety devices, which are complemented by its digital applications designed to assist people with managing their diabetes. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with insulin pens and are used to inject insulin or other diabetes medications. The Company also sells sterile, single-use insulin syringes, safety pen needles, which include resin injection-molded shields on both ends of the cannula that automatically help prevent needlestick exposure and injury during injection and disposal. Its products are used in retail and acute care hospitals, clinics and other institutional channels, healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of EMBECTA CORP
EMBC Guru Analysis
EMBC Fundamental Analysis
ZOETIS INC (ZTS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on John Neff is 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. It commercializes products across eight core species: dogs, cats and horses and cattle, swine, poultry, fish and sheep and within product categories, such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. It operates through two segments: the United States and International. Within each of these operating segments, it offers a product portfolio for both companion animal and livestock customers, including Alfaxan. The Company market its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America, and its products are sold in more than 100 countries.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: PASS
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: FAIL
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of ZOETIS INC
ZTS Guru Analysis
ZTS Fundamental Analysis
MEDIFAST INC (MED) is a small-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on John Neff is 58% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Medifast, Inc. sells a variety of weight loss, weight management and healthy living products all based on its own formulas under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. The Company's product line includes approximately 95 consumable options, including, but not limited to, bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes and soups. The Company's nutritional products are formulated with ingredients. The processing, formulation, packaging, labeling and advertising of the Company's products are subject to regulation by one or more federal agencies, including the Food and Drug Administration (FDA), the Federal Trade Commission (the FTC), the Consumer Product Safety Commission, the United States Department of Agriculture and the United States Environmental Protection Agency.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: FAIL
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: FAIL
EPS PERSISTENCE: FAIL
Detailed Analysis of MEDIFAST INC
MED Guru Analysis
MED Fundamental Analysis
ACADIA HEALTHCARE COMPANY INC (ACHC) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 42% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services across the United States. It is focused on acquiring and developing behavioral healthcare facilities. It is engaged in developing and operating inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States and Puerto Rico. Its facilities that offer acute care services provide evaluation and crisis stabilization of patients with severe psychiatric diagnoses through a medical delivery model that incorporates structured and intensive medical and behavioral therapies with 24-hour monitoring by a psychiatrist, psychiatric trained nurses, therapists and direct care staff. Its specialty treatment facilities include residential recovery facilities, eating disorder facilities and comprehensive treatment centers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: FAIL
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of ACADIA HEALTHCARE COMPANY INC
ACHC Guru Analysis
ACHC Fundamental Analysis
John Neff Portfolio
About John Neff: While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. He was mild-mannered and low-key, and the same might be said of the Windsor Fund that he managed for more than three decades. In fact, Neff himself described the fund as "relatively prosaic, dull, [and] conservative." There was nothing dull about his results, however. From 1964 to 1995, Neff guided Windsor to a 13.7 percent average annual return, easily outpacing the S&P 500's 10.6 percent return during that time. That 3.1 percentage point difference is huge over time -- a $10,000 investment in Windsor (with dividends reinvested) at the start of Neff's tenure would have ended up as more than $564,000 by the time he retired, more than twice what the same investment in the S&P would have yielded (about $233,000). Considering the length of his tenure, that track record may be the best ever for a manager of such a large fund.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of PFIZER INC. PFE Guru Analysis PFE Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Major Drugs industry. The Company's portfolio of products include a variety of pen needles, syringes and safety devices, which are complemented by its digital applications designed to assist people with managing their diabetes. | Detailed Analysis of PFIZER INC. PFE Guru Analysis PFE Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Major Drugs industry. The Company's U.S. Healthcare Solutions segment distributes an offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. | Detailed Analysis of PFIZER INC. PFE Guru Analysis PFE Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Major Drugs industry. Company Description: Cigna Corporation is a health services company that offers medical, dental insurance and related products and services. | Detailed Analysis of PFIZER INC. PFE Guru Analysis PFE Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Major Drugs industry. Company Description: Cigna Corporation is a health services company that offers medical, dental insurance and related products and services. |
31250.0 | 2023-01-13 00:00:00 UTC | Friday Sector Leaders: Healthcare, Services | ABT | https://www.nasdaq.com/articles/friday-sector-leaders%3A-healthcare-services | nan | nan | The best performing sector as of midday Friday is the Healthcare sector, up 0.4%. Within the sector, Illumina Inc (Symbol: ILMN) and Abbott Laboratories (Symbol: ABT) are two large stocks leading the way, showing a gain of 2.8% and 1.7%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.2% on the day, and down 0.21% year-to-date. Illumina Inc, meanwhile, is down 0.85% year-to-date, and Abbott Laboratories is up 3.78% year-to-date. Combined, ILMN and ABT make up approximately 4.4% of the underlying holdings of XLV.
The next best performing sector is the Services sector, higher by 0.2%. Among large Services stocks, Expedia Group Inc (Symbol: EXPE) and Amazon.com Inc (Symbol: AMZN) are the most notable, showing a gain of 3.7% and 2.8%, respectively. One ETF closely tracking Services stocks is the iShares U.S. Consumer Services ETF (IYC), which is up 0.2% in midday trading, and up 8.10% on a year-to-date basis. Expedia Group Inc, meanwhile, is up 21.84% year-to-date, and Amazon.com Inc is up 14.16% year-to-date. Combined, EXPE and AMZN make up approximately 11.9% of the underlying holdings of IYC.
Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom:
Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Friday. As you can see, three sectors are up on the day, while three sectors are down.
SECTOR % CHANGE
Healthcare +0.4%
Services +0.2%
Materials +0.1%
Consumer Products 0.0%
Financial -0.0%
Energy 0.0%
Technology & Communications -0.1%
Industrial -0.3%
Utilities -0.5%
25 Dividend Giants Widely Held By ETFs »
Also see:
ONCR market cap history
MINN Videos
JACK Stock Predictions
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Combined, ILMN and ABT make up approximately 4.4% of the underlying holdings of XLV. Within the sector, Illumina Inc (Symbol: ILMN) and Abbott Laboratories (Symbol: ABT) are two large stocks leading the way, showing a gain of 2.8% and 1.7%, respectively. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Friday. | Within the sector, Illumina Inc (Symbol: ILMN) and Abbott Laboratories (Symbol: ABT) are two large stocks leading the way, showing a gain of 2.8% and 1.7%, respectively. Combined, ILMN and ABT make up approximately 4.4% of the underlying holdings of XLV. Among large Services stocks, Expedia Group Inc (Symbol: EXPE) and Amazon.com Inc (Symbol: AMZN) are the most notable, showing a gain of 3.7% and 2.8%, respectively. | Within the sector, Illumina Inc (Symbol: ILMN) and Abbott Laboratories (Symbol: ABT) are two large stocks leading the way, showing a gain of 2.8% and 1.7%, respectively. Combined, ILMN and ABT make up approximately 4.4% of the underlying holdings of XLV. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.2% on the day, and down 0.21% year-to-date. | Within the sector, Illumina Inc (Symbol: ILMN) and Abbott Laboratories (Symbol: ABT) are two large stocks leading the way, showing a gain of 2.8% and 1.7%, respectively. Combined, ILMN and ABT make up approximately 4.4% of the underlying holdings of XLV. The best performing sector as of midday Friday is the Healthcare sector, up 0.4%. |
31251.0 | 2023-01-12 00:00:00 UTC | Abbott (ABT) Stock Sinks As Market Gains: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-stock-sinks-as-market-gains%3A-what-you-should-know-1 | nan | nan | In the latest trading session, Abbott (ABT) closed at $111.36, marking a -1.58% move from the previous day. This change lagged the S&P 500's daily gain of 0.34%. Meanwhile, the Dow gained 0.64%, and the Nasdaq, a tech-heavy index, added 8.98%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had gained 1.7% over the past month. This has outpaced the Medical sector's loss of 0.28% and the S&P 500's gain of 1% in that time.
Wall Street will be looking for positivity from Abbott as it approaches its next earnings report date. This is expected to be January 25, 2023. The company is expected to report EPS of $0.90, down 31.82% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $9.48 billion, down 17.36% from the year-ago period.
Investors might also notice recent changes to analyst estimates for Abbott. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.16% lower. Abbott is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Abbott has a Forward P/E ratio of 25.79 right now. This represents a premium compared to its industry's average Forward P/E of 23.14.
Investors should also note that ABT has a PEG ratio of 5.07 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products was holding an average PEG ratio of 2.3 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 157, which puts it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the latest trading session, Abbott (ABT) closed at $111.36, marking a -1.58% move from the previous day. Investors should also note that ABT has a PEG ratio of 5.07 right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. In the latest trading session, Abbott (ABT) closed at $111.36, marking a -1.58% move from the previous day. Investors should also note that ABT has a PEG ratio of 5.07 right now. | In the latest trading session, Abbott (ABT) closed at $111.36, marking a -1.58% move from the previous day. Investors should also note that ABT has a PEG ratio of 5.07 right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | In the latest trading session, Abbott (ABT) closed at $111.36, marking a -1.58% move from the previous day. Investors should also note that ABT has a PEG ratio of 5.07 right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. |
31252.0 | 2023-01-12 00:00:00 UTC | Should You Buy This Promising New Healthcare Stock? | ABT | https://www.nasdaq.com/articles/should-you-buy-this-promising-new-healthcare-stock | nan | nan | GE Healthcare Technologies (NASDAQ: GEHC) is the newest big healthcare stock to hit the markets. Officially separated from General Electric, it began trading independently on Jan. 4. As a leaner, isolated business, it's a lot easier for healthcare investors to buy shares of GE's healthcare business now without having to own a piece of the whole conglomerate. Here's a closer look at the business and whether you should consider investing in it out of the gate.
The business is big and diverse
GE Healthcare makes many types of products and devices for the healthcare industry. It groups them under four operating segments: imaging, ultrasound, patient care solutions (PCS), and pharmaceutical diagnostics. The most important segment is the imaging business, with GE Healthcare estimating that the industry was worth $44 billion in 2021. PCS was a distant second, worth $18 billion.
In addition to making a broad range of products, the company also has locations all over the world. The majority of the revenue it generates comes from outside of the U.S. and Canada.
Source: GE Healthcare Investor Day presentation.
GE Healthcare can give investors some valuable diversification, making it not unlike other big medical device makers in the industry, including Medtronic, Johnson & Johnson, and Abbott Laboratories.
Sales growth is a bit underwhelming
Through the first three-quarters of 2022, GE Healthcare has generated $13.4 billion in revenue, which isn't a whole lot higher than the $13 billion it posted for the same period in 2021.
Image source: GE Healthcare Investor Day presentation.
In 2021, the company's sales totaled $17.6 billion and rose by 2.5%. And the year before that, the growth was just 3.2%. The company hinted that it could be looking at ways to grow its business via acquisitions, with CEO Peter Arduini telling Reuters, "I think I'd be disappointed if we didn't do some deals this year." And GE Healthcare's imaging division has already gotten off to a fast start, announcing on Monday (Jan. 9) plans to acquire French company Imactis, which has a navigation system for computed tomography (CT) that improves workflow and procedural accuracy.
No dividend for now
At least initially, it doesn't appear there will be any dividend from GE Healthcare. The company is carrying a relatively high debt load of more than $15 billion (including pension liabilities), which may be a priority to bring down before it considers making recurring dividend payments to investors. That's a significant amount, given that the company's market cap is around $28 billion.
Many established healthcare companies do pay dividends, and particularly for one that isn't generating much in the way of growth, that could come as a disappointment. But it may be too early to know for sure as the company says it will evaluate whether or not to pay a dividend in the future.
It's too early to invest in GE Healthcare
With single-digit growth, a high debt load, and potentially no dividend for the foreseeable future, there's not much of a reason to buy shares of GE Healthcare today. As a newly independent company, investors are better off taking a wait-and-see approach and evaluating the business' plan for growth. At this stage, it may simply be too early to stake out a position in the business. There's no incentive just yet to buy shares of GE Healthcare instead of other healthcare stocks that may offer more growth potential.
10 stocks we like better than Ge HealthCare Technologies
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Ge HealthCare Technologies wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of January 9, 2023
David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company hinted that it could be looking at ways to grow its business via acquisitions, with CEO Peter Arduini telling Reuters, "I think I'd be disappointed if we didn't do some deals this year." And GE Healthcare's imaging division has already gotten off to a fast start, announcing on Monday (Jan. 9) plans to acquire French company Imactis, which has a navigation system for computed tomography (CT) that improves workflow and procedural accuracy. The company is carrying a relatively high debt load of more than $15 billion (including pension liabilities), which may be a priority to bring down before it considers making recurring dividend payments to investors. | Source: GE Healthcare Investor Day presentation. Image source: GE Healthcare Investor Day presentation. It's too early to invest in GE Healthcare With single-digit growth, a high debt load, and potentially no dividend for the foreseeable future, there's not much of a reason to buy shares of GE Healthcare today. | As a leaner, isolated business, it's a lot easier for healthcare investors to buy shares of GE's healthcare business now without having to own a piece of the whole conglomerate. It's too early to invest in GE Healthcare With single-digit growth, a high debt load, and potentially no dividend for the foreseeable future, there's not much of a reason to buy shares of GE Healthcare today. There's no incentive just yet to buy shares of GE Healthcare instead of other healthcare stocks that may offer more growth potential. | As a leaner, isolated business, it's a lot easier for healthcare investors to buy shares of GE's healthcare business now without having to own a piece of the whole conglomerate. Many established healthcare companies do pay dividends, and particularly for one that isn't generating much in the way of growth, that could come as a disappointment. * They just revealed what they believe are the ten best stocks for investors to buy right now... and Ge HealthCare Technologies wasn't one of them! |
31253.0 | 2023-01-11 00:00:00 UTC | Validea Daily Guru Fundamental Report for ABT - 1/11/2023 | ABT | https://www.nasdaq.com/articles/validea-daily-guru-fundamental-report-for-abt-1-11-2023 | nan | nan | Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). | Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. | Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
31254.0 | 2023-01-11 00:00:00 UTC | 3 Supercharged Dividend Stocks to Buy If There's a Stock Market Sell-Off | ABT | https://www.nasdaq.com/articles/3-supercharged-dividend-stocks-to-buy-if-theres-a-stock-market-sell-off-4 | nan | nan | Choosing solid dividend stocks can be tricky. Buying a stock with a really high dividend yield is tempting, but many stocks with high dividends got that way because their share prices have plummeted. Often there's a genuine reason for declining shares, such as declining revenue or earnings.
Many stocks with high yields also have high dividend payout ratios, meaning a company devotes much of its earnings to those dividends. That can out a dividend at risk of being cut, which can lead to a double whammy for investors. A dividend cut negates the advantages of buying a high-dividend stock and is usually accompanied by share price erosion as disgruntled investors sell the stock.
So, in looking for three healthcare stocks with supercharged dividends to buy in a market sell-off, it makes sense to look for companies that are strong enough to handle a down market while protecting their dividends -- companies such as Bristol-Myers Squibb (NYSE: BMY), AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE).
All three pharmaceutical companies have dividend yields of more than 3%, yet they have dividend payout ratios below 50%. On top of that, all three stocks are trading below 24 times earnings.
Bristol-Myers Squibb's pipeline is popping
Bristol-Myers's quarterly dividend works out to a yield of 3.2%. The company raised its quarterly dividend by 5.6% this year to $0.57, the 13th consecutive year it has boosted its dividend. Its payout ratio of 36% leaves plenty of room for continued growth.
Bristol's stock rose more than 10% over the past 12 months, while the S&P 500 average is down more than 17% in that period, which shows the company's strength in a down year. Over the past 10 years, Bristol has increased quarterly revenue by 193%.
Through nine months, the company reported revenue of $34.8 billion, up just 1% over the same period a year earlier. However, the company is seeing continued growth in revenue from blood thinner Eliquis (up 12% through nine months) and cancer drug Opdivo (up 9%), plus new therapies that are breaking through, as the company's pipeline includes 51 compounds.
New product portfolio revenue increased to $553 million in the quarter, up 61%, year over year, thanks to the increased sales from Abecma, used to treat refractory multiple myeloma; Opdualag, used to treat advanced melanoma; and Reblozyl, used to treat anemia in patients with the genetic blood disorder beta thalassemia.
AbbVie continues to grow
AbbVie is another company that easily shrugged off the share declines that affected other stocks in 2022, and it's up more than 19% during the past year.
In the first nine month of 2022, the company had revenue of $33.56 billion, up 6.2% over 2021. Over the past 10 years, it has increased quarterly revenue by 242%.
The pharmaceutical company raised its quarterly dividend by 5% this year to $1.48 per share, equal to a yield of 3.6%. Counting this year and the time it spent as part of Abbott Laboratories, AbbVie has raised its quarterly dividend in 51 consecutive years. Since it split off from Abbott in 2013, AbbVie has raised its dividend by 270%. Even so, it has kept its payout ratio below 50%, and it's currently at 44%.
AbbVie has 12 drugs that are expected to bring in more than $1 billion this year in revenue, led by blockbuster Humira, which is forecast to generate at least $20 billion in sales. The company has a huge portfolio of immunology and oncology therapies, including two, Rinvoq and Skyrizi, which are expected to have $7.5 billion in sales this year and more than $15 billion in annual sales by 2025. As they continue to add label expansions, these drugs will make up for Humira's declining sales due to its patent loss this year.
Pfizer is ready to reload
Pfizer raised its quarterly dividend by 2.5% this year to $0.41, representing a yield of about 3.3%. The company has boosted its dividend for 14 consecutive years. The payout ratio is only 38%, leaving plenty of room for continued dividend increases.
Pfizer said in its third-quarter report that it expects revenue this year of between $99.5 billion and $102 billion, compared to $81.3 billion last year. It also projects annual earnings per share (EPS) of between $6.40 and $6.50, compared to $3.99 in EPS last year.
Despite an attractive dividend and solid financials, the stock is down about 13% during the past year. Investors are wary because the company is looking at a potential losses of $17 billion in revenue from 2025 to 2030, thanks to various patent expirations.
However, like AbbVie, it has an active pipeline that should more than replace those losses. The company, as of December, said it anticipates 19 therapy launches over the next 18 months, and according to Chief Commercial Officer Angela Hwang, those therapies have the potential to generate $20 billion in annual revenue over time.
10 stocks we like better than Bristol-Myers Squibb
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Bristol-Myers Squibb wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of January 9, 2023
Jim Halley has positions in AbbVie and Pfizer. The Motley Fool has positions in and recommends Abbott Laboratories, Bristol-Myers Squibb, and Pfizer. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Bristol's stock rose more than 10% over the past 12 months, while the S&P 500 average is down more than 17% in that period, which shows the company's strength in a down year. As they continue to add label expansions, these drugs will make up for Humira's declining sales due to its patent loss this year. The Motley Fool has positions in and recommends Abbott Laboratories, Bristol-Myers Squibb, and Pfizer. | So, in looking for three healthcare stocks with supercharged dividends to buy in a market sell-off, it makes sense to look for companies that are strong enough to handle a down market while protecting their dividends -- companies such as Bristol-Myers Squibb (NYSE: BMY), AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). Counting this year and the time it spent as part of Abbott Laboratories, AbbVie has raised its quarterly dividend in 51 consecutive years. The payout ratio is only 38%, leaving plenty of room for continued dividend increases. | Many stocks with high yields also have high dividend payout ratios, meaning a company devotes much of its earnings to those dividends. So, in looking for three healthcare stocks with supercharged dividends to buy in a market sell-off, it makes sense to look for companies that are strong enough to handle a down market while protecting their dividends -- companies such as Bristol-Myers Squibb (NYSE: BMY), AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). The company raised its quarterly dividend by 5.6% this year to $0.57, the 13th consecutive year it has boosted its dividend. | AbbVie continues to grow AbbVie is another company that easily shrugged off the share declines that affected other stocks in 2022, and it's up more than 19% during the past year. Over the past 10 years, it has increased quarterly revenue by 242%. The Motley Fool has positions in and recommends Abbott Laboratories, Bristol-Myers Squibb, and Pfizer. |
31255.0 | 2023-01-10 00:00:00 UTC | Abbott Laboratories To Present At J.P. Morgan Healthcare Conference; Webcast At 12:00 PM ET | ABT | https://www.nasdaq.com/articles/abbott-laboratories-to-present-at-j.p.-morgan-healthcare-conference-webcast-at-12%3A00-pm-et | nan | nan | (RTTNews) - Abbott Laboratories (ABT) will present at the 41st Annual J.P. Morgan Healthcare Conference.
The event is scheduled to begin at 12:00 PM ET on Jan. 10, 2023.
To access the live webcast, log on to http://www.abbottinvestor.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will present at the 41st Annual J.P. Morgan Healthcare Conference. The event is scheduled to begin at 12:00 PM ET on Jan. 10, 2023. To access the live webcast, log on to http://www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will present at the 41st Annual J.P. Morgan Healthcare Conference. The event is scheduled to begin at 12:00 PM ET on Jan. 10, 2023. To access the live webcast, log on to http://www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will present at the 41st Annual J.P. Morgan Healthcare Conference. The event is scheduled to begin at 12:00 PM ET on Jan. 10, 2023. To access the live webcast, log on to http://www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will present at the 41st Annual J.P. Morgan Healthcare Conference. The event is scheduled to begin at 12:00 PM ET on Jan. 10, 2023. To access the live webcast, log on to http://www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
31256.0 | 2023-01-09 00:00:00 UTC | Abbott's (ABT) New Launch to Boost Blood Donation Experience | ABT | https://www.nasdaq.com/articles/abbotts-abt-new-launch-to-boost-blood-donation-experience | nan | nan | Abbott Laboratories ABT recently unveiled an advanced new mixed reality experience for use during blood donation along with Blood Centers of America. Currently, the experience is being piloted on a limited basis at select Blood Centers of America locations nationwide.
As part of the effort to launch this new technology, Abbott and Blood Centers of America are asking people to pledge to donate blood now and sign up to be notified when the mixed reality experience becomes available in their local area.
The latest development is expected to fortify Abbott’s Medical Device business.
More on Mixed Reality
The mixed reality technology is an immersive digital experience intended to enhance the blood donation process, attract new donors and motivate a younger generation to give blood. It was designed based on research that natural settings are the most favored environment as donors give blood.
The mixed reality experience enables blood donation professionals to safely conduct the donation and interact with donors at every step of the process. During the donation, donors' eyes are always visible to ensure constant monitoring and assessment. Participants wear lightweight mixed reality headsets to enter a digital world but remain fully aware of their surroundings, ensuring a seamless, convenient and safe donation.
The mixed reality journey utilizes Microsoft HoloLens 2 — the world's first self-contained holographic computer, enabling hands-free interaction with three-dimensional digital objects and a library of applications.
Benefits of Mixed Reality Experience
Per Abbott’s management, mixed reality experience tends to tackle the global challenge of sustaining a reliable blood supply. Not only is it an immersive and exclusive use of mixed reality controlled completely through eye tracking, but it is highly technology-enabled and creative way to enhance the donation experience and make it more alluring for people to participate.
Image Source: Zacks Investment Research
It is worth mentioning that as the need for blood is constant, companies are looking for creative new ways to cultivate the next generation of blood donors and find younger people interested in giving. By attracting people who have never donated before or may be apprehensive, the mixed reality experience is a tremendous way to get those interested in participating as it adds a fun, interactive element to donation and it's easy and convenient for blood centers to use.
Industry Prospects
Per a report by GlobeNewsWire, the demand for global Blood Transfusion Market size & share was valued at nearly $4.1 billion in 2021 and is anticipated to reach over $6.1 billion by 2028 at a CAGR of 6.90%.
Recent Developments
In December 2022, Abbott announced that its FreeStyle Libre 3 sensor integrated with the mylife Loop solution — building a smart, automated process to deliver insulin based on real-time glucose data. This automated insulin delivery system (AID) solution is now available in Germany and will be accessible in other European countries starting in 2023.
In the same month, Abbott received FDA approval for its Eterna spinal cord stimulation (SCS) system for treating chronic pain. The Eterna SCS system is the smallest implantable, rechargeable system that is currently available on the market for this indication.
Price Performance
Shares of the company have lost 17% in a year compared with the industry’s fall of 40.9%.
Zacks Rank and Key Pick
Abbott currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. AMN, Boston Scientific Corporation BSX and Merit Medical Systems, Inc. MMSI.
AMN Healthcare, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 3.3%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 10.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare has lost 10.6% compared with the industry’s 30.3% decline in the past year.
Boston Scientific, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.3%. BSX’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average beat being 1.9%.
Boston Scientific has gained 6.8% against the industry’s 42.6% decline in the past year.
Merit Medical, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average beat being 25.4%.
Merit Medical has gained 13.7% against the industry’s 8.7% decline in the past year.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT recently unveiled an advanced new mixed reality experience for use during blood donation along with Blood Centers of America. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report To read this article on Zacks.com click here. Participants wear lightweight mixed reality headsets to enter a digital world but remain fully aware of their surroundings, ensuring a seamless, convenient and safe donation. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT recently unveiled an advanced new mixed reality experience for use during blood donation along with Blood Centers of America. More on Mixed Reality The mixed reality technology is an immersive digital experience intended to enhance the blood donation process, attract new donors and motivate a younger generation to give blood. | Abbott Laboratories ABT recently unveiled an advanced new mixed reality experience for use during blood donation along with Blood Centers of America. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report To read this article on Zacks.com click here. More on Mixed Reality The mixed reality technology is an immersive digital experience intended to enhance the blood donation process, attract new donors and motivate a younger generation to give blood. | Abbott Laboratories ABT recently unveiled an advanced new mixed reality experience for use during blood donation along with Blood Centers of America. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report To read this article on Zacks.com click here. More on Mixed Reality The mixed reality technology is an immersive digital experience intended to enhance the blood donation process, attract new donors and motivate a younger generation to give blood. |
31257.0 | 2023-01-09 00:00:00 UTC | 3 Reliable Dividend Stocks You Can Buy With $600 | ABT | https://www.nasdaq.com/articles/3-reliable-dividend-stocks-you-can-buy-with-%24600 | nan | nan | How would you like to have a portfolio of income-generating stocks that pay you a steadily growing wage? Contrary to popular belief, you don't need to be rich to get started.
To show just how accessible building wealth through dividend stock investing can be, I've pulled out three names that everyday investors can rely on to make regular dividend payments that rise year after year. Just $600 is more than enough to buy multiple shares of all three.
Image source: Getty Images.
There are heaps of dividend-paying stocks out there that you could choose from, but they won't be able to fuel your retirement dreams if they can't maintain and raise their payouts over time. Read on to see why these three rise to the top.
Medtronic
Medtronic (NYSE: MDT) is the world's largest manufacturer of medical devices. You can't open your eyes in a modern hospital room without seeing at least a handful of its products. It's also one of the most reliable dividend growth stocks you could ask for. The company's raised its payout for 45 consecutive years.
Despite being a giant company with more than $30 billion in annual sales, Medtronic has raised its payout by 8% annually over the past five years. At this pace, the 3.4% yield that the stock offers at the moment will double in about nine years.
Many of Medtronic's high-margin products, like heart replacement valves, require multiple in-person doctor visits before patients go under the knife. With fewer pandemic-related hurdles to cross, Medtronic's payout growth rate could return to double digits.
Medtronic leverages thousands of customer relationships that it's built over the years to ensure the strongest possible launch for innovative new devices. For example, the company's robotic-assisted surgery system, called Hugo, began performing urologic procedures in Europe last year.
Abbott Laboratories
Abbott Laboratories (NYSE: ABT) is a healthcare conglomerate with a collection of businesses that include medical devices. It also has such a strong nutrition business that the temporary closure of one of its plants in Michigan last year led to a national baby formula shortage.
At recent prices, the stock offers a 1.8% dividend yield that investors can rely on to continue growing. A winning combination of well-positioned healthcare businesses has allowed Abbott to raise its payout for 50 consecutive years.
Abbott's present dividend yield isn't too inspiring at the moment, but it's growing fast. The company raised its payout by 82% over the past five years despite challenges to its medical device segment that are similar to those Medtronic experienced.
Last May, the FDA cleared Abbott's next-generation constant blood glucose monitor (CGM) for diabetic patients called FreesSyle Libre 3. At the size of two stacked pennies, this is the smallest CGM on the market. With less pandemic disruption and a product that healthcare plan sponsors don't want their diabetic members to live without, it looks as if Abbott's best days are ahead.
CVS Health
Shares of CVS Health (NYSE: CVS) pay a dividend that has grown 169% over the past decade. This rapid pace is even more impressive when you consider the company held its payout steady for a few years to help pay for a transformative merger with Aetna in 2018. At the moment, the stock offers a 2.6% yield.
Aetna's a major U.S. health insurer that collects insurance premiums from around 35 million people. With more than 1,100 private medical clinics and 9,000 pharmacies, CVS Health has a lot of opportunities to provide the various health benefits it also gets paid to manage.
Pharmaceutical companies get a lot of attention, but savvy healthcare investors know that primary care was responsible for a much larger portion of the roughly $4.3 trillion Americans spent on healthcare in 2021. To realize an enormous opportunity for business synergies, CVS Health agreed to acquire Signify Health for around $8 billion last September.
CVS Health expects to close the Signify Health acquisition in the first half of 2022. Once it does, Signify's network of more than 10,000 clinicians throughout all 50 states could help this company's bottom line soar at its fastest pace to date.
10 stocks we like better than Medtronic
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Medtronic wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2022
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a healthcare conglomerate with a collection of businesses that include medical devices. Many of Medtronic's high-margin products, like heart replacement valves, require multiple in-person doctor visits before patients go under the knife. Last May, the FDA cleared Abbott's next-generation constant blood glucose monitor (CGM) for diabetic patients called FreesSyle Libre 3. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a healthcare conglomerate with a collection of businesses that include medical devices. CVS Health Shares of CVS Health (NYSE: CVS) pay a dividend that has grown 169% over the past decade. The Motley Fool recommends CVS Health. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a healthcare conglomerate with a collection of businesses that include medical devices. To show just how accessible building wealth through dividend stock investing can be, I've pulled out three names that everyday investors can rely on to make regular dividend payments that rise year after year. CVS Health Shares of CVS Health (NYSE: CVS) pay a dividend that has grown 169% over the past decade. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a healthcare conglomerate with a collection of businesses that include medical devices. The company's raised its payout for 45 consecutive years. At this pace, the 3.4% yield that the stock offers at the moment will double in about nine years. |
31258.0 | 2023-01-09 00:00:00 UTC | This Robotic Products Company Is A Better Pick Over Medtronic Stock | ABT | https://www.nasdaq.com/articles/this-robotic-products-company-is-a-better-pick-over-medtronic-stock | nan | nan | We believe Intuitive Surgical stock (NASDAQ: ISRG) is currently a better pick than Medtronic stock (NYSE: MDT), given its better prospects. Although Medtronic is trading at a comparatively lower valuation of 3.4x trailing revenues vs. 15.4x for Intuitive Surgical, this gap in the valuation is justified mainly given the latter’s superior revenue growth and lower financial risk, as discussed below.
If we look at stock returns, both MDT and ISRG fell over 21% over the last year, aligning with the 20% fall in the broader S&P 500 index. There is more to the comparison, and in the sections below, we discuss why we believe ISRG stock will offer better returns than MDT stock in the next three years. We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis Medtronic vs. Intuitive Surgical: Which Stock Is A Better Bet? Parts of the analysis are summarized below.
1. Intuitive Surgical’s Revenue Growth Is Better
Intuitive Surgical’s revenue growth of 11.3% over the last twelve months is much better than -1.7% for Medtronic.
Even if we look at a longer time frame, Intuitive Surgical has fared better, with its sales rising at an average annual rate of 16.2% to $5.7 billion in 2021, compared to $3.7 billion in 2018, while Medtronic saw its revenue rise at an average annual rate of just 1.3% to $31.7 billion in fiscal 2022 (Medtronic’s fiscal ends in April), compared to $30.0 billion in 2018.
Medtronic’s sales were hurt during the pandemic due to the postponement of elective surgeries. The rise of new Covid-19 variants, including Delta and Omicron, impacted demand recovery.
However, the company saw a rebound in sales over the last year or so, aided by higher procedure volume. The company also benefits from its new products, including the Micra AV pacemaker and Abre venous self-expanding stent system for Deep Venous disease.
Its Medical Surgical segment sales are adversely impacted due to a continued decline in ventilator demand. Furthermore, forex headwinds have also weighed on the overall top-line growth in recent quarters.
For Intuitive Surgical, revenue growth over the recent past has been driven by a rebound in procedure volume, which was adversely impacted in the initial phases of the pandemic due to the shelter-in-place restrictions. The company continues to expand its installed base, which results in the growth of recurring revenues, such as consumables.
Our Medtronic Revenue Comparison and Intuitive Surgical Revenue Comparison dashboards provide more insight into the companies’ sales.
Looking forward, Intuitive Surgical’s revenue is expected to grow faster than Medtronic’s over the next three years. The table below summarizes our revenue expectations for the two companies over the next three years. It points to a CAGR of 1.6% for Medtronic, compared to a 13.7% CAGR for Intuitive Surgical, based on Trefis Machine Learning analysis.
Note that we have different methodologies for companies that are negatively impacted by Covid and those that are not impacted or positively impacted by Covid while forecasting future revenues. For companies negatively affected by Covid, we consider the quarterly revenue recovery trajectory to forecast recovery to the pre-Covid revenue run rate. Beyond the recovery point, we apply the average annual growth observed three years before Covid to simulate a return to normal conditions. For companies registering positive revenue growth during Covid, we consider yearly average growth before Covid with a certain weight to growth during Covid and the last twelve months.
2. Medtronic Is More Profitable, But It Comes With Higher Risk
Medtronic’s operating margin of 21.2% over the last twelve-month period is marginally better than 20.5% for Intuitive Surgical.
This compares with 25.2% and 30.7% figures seen in 2019, before the pandemic, respectively.
Intuitive Surgical’s free cash flow margin of 24.7% is also better than 23.0% for Medtronic.
Our Medtronic Operating Income Comparison and Intuitive Surgical Operating Income dashboards have more details.
Looking at financial risk, Intuitive Surgical fares better. Its 0.5% debt as a percentage of equity is much lower than 21.6% for Medtronic, while its 61.7% cash as a percentage of assets is higher than 9.9% for the latter, implying that Intuitive Surgical has a better debt position and more cash cushion.
3. The Net of It All
We see that Intuitive Surgical has demonstrated better revenue growth, has a better debt position, and has more cash cushion. On the other hand, Medtronic is more profitable and is available at a comparatively lower valuation.
Looking at prospects, using P/S as a base, due to high fluctuations in P/E and P/EBIT, we believe Intuitive Surgical is currently the better choice of the two.
The table below summarizes our revenue and return expectations for Medtronic and Intuitive Surgical over the next three years and points to an expected return of 15% for Medtronic over this period vs. a 46% expected return for Intuitive Surgical, based on Trefis Machine Learning analysis – Medtronic vs. Intuitive Surgical – which also provides more details on how we arrive at these numbers.
While ISRG stock looks like a better pick over MDT stock, it is helpful to see how Medtronic’s Peers fare on metrics that matter. You will find other valuable comparisons for companies across industries at Peer Comparisons.
Furthermore, the Covid-19 crisis has created many pricing discontinuities, which can offer attractive trading opportunities. For example, you’ll be surprised at how counter-intuitive the stock valuation is for UnitedHealth Group vs. Pool Corporation.
Given the higher inflation and the Fed raising interest rates, among other factors, MDT stock fell over 20% last year. Can it drop more from here? See how low Medtronic stock can go by comparing its decline in previous market crashes. Here is a performance summary of all stocks in previous market crashes.
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
Returns Jan 2023
MTD [1] 2023
YTD [1] 2017-23
Total [2]
MDT Return 4% 4% 14%
ISRG Return 2% 2% 283%
S&P 500 Return 0% 0% 72%
Trefis Multi-Strategy Portfolio 2% 2% 221%
[1] Month-to-date and year-to-date as of 1/5/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis Medtronic vs. Intuitive Surgical: Which Stock Is A Better Bet? For Intuitive Surgical, revenue growth over the recent past has been driven by a rebound in procedure volume, which was adversely impacted in the initial phases of the pandemic due to the shelter-in-place restrictions. Beyond the recovery point, we apply the average annual growth observed three years before Covid to simulate a return to normal conditions. | Even if we look at a longer time frame, Intuitive Surgical has fared better, with its sales rising at an average annual rate of 16.2% to $5.7 billion in 2021, compared to $3.7 billion in 2018, while Medtronic saw its revenue rise at an average annual rate of just 1.3% to $31.7 billion in fiscal 2022 (Medtronic’s fiscal ends in April), compared to $30.0 billion in 2018. Our Medtronic Operating Income Comparison and Intuitive Surgical Operating Income dashboards have more details. The table below summarizes our revenue and return expectations for Medtronic and Intuitive Surgical over the next three years and points to an expected return of 15% for Medtronic over this period vs. a 46% expected return for Intuitive Surgical, based on Trefis Machine Learning analysis – Medtronic vs. Intuitive Surgical – which also provides more details on how we arrive at these numbers. | Intuitive Surgical’s Revenue Growth Is Better Intuitive Surgical’s revenue growth of 11.3% over the last twelve months is much better than -1.7% for Medtronic. Even if we look at a longer time frame, Intuitive Surgical has fared better, with its sales rising at an average annual rate of 16.2% to $5.7 billion in 2021, compared to $3.7 billion in 2018, while Medtronic saw its revenue rise at an average annual rate of just 1.3% to $31.7 billion in fiscal 2022 (Medtronic’s fiscal ends in April), compared to $30.0 billion in 2018. The table below summarizes our revenue and return expectations for Medtronic and Intuitive Surgical over the next three years and points to an expected return of 15% for Medtronic over this period vs. a 46% expected return for Intuitive Surgical, based on Trefis Machine Learning analysis – Medtronic vs. Intuitive Surgical – which also provides more details on how we arrive at these numbers. | There is more to the comparison, and in the sections below, we discuss why we believe ISRG stock will offer better returns than MDT stock in the next three years. Intuitive Surgical’s Revenue Growth Is Better Intuitive Surgical’s revenue growth of 11.3% over the last twelve months is much better than -1.7% for Medtronic. The table below summarizes our revenue and return expectations for Medtronic and Intuitive Surgical over the next three years and points to an expected return of 15% for Medtronic over this period vs. a 46% expected return for Intuitive Surgical, based on Trefis Machine Learning analysis – Medtronic vs. Intuitive Surgical – which also provides more details on how we arrive at these numbers. |
31259.0 | 2023-01-06 00:00:00 UTC | Abbott (ABT) Gains But Lags Market: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-gains-but-lags-market%3A-what-you-should-know-11 | nan | nan | Abbott (ABT) closed at $112.33 in the latest trading session, marking a +1.38% move from the prior day. This move lagged the S&P 500's daily gain of 2.28%. Elsewhere, the Dow gained 2.13%, while the tech-heavy Nasdaq added 5.02%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had gained 3.63% in the past month. In that same time, the Medical sector gained 0.62%, while the S&P 500 lost 4.61%.
Wall Street will be looking for positivity from Abbott as it approaches its next earnings report date. This is expected to be January 25, 2023. On that day, Abbott is projected to report earnings of $0.90 per share, which would represent a year-over-year decline of 31.82%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.47 billion, down 17.41% from the year-ago period.
It is also important to note the recent changes to analyst estimates for Abbott. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Abbott currently has a Zacks Rank of #3 (Hold).
Looking at its valuation, Abbott is holding a Forward P/E ratio of 25.22. This valuation marks a premium compared to its industry's average Forward P/E of 20.91.
It is also worth noting that ABT currently has a PEG ratio of 4.95. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry currently had an average PEG ratio of 2.28 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 152, putting it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed at $112.33 in the latest trading session, marking a +1.38% move from the prior day. It is also worth noting that ABT currently has a PEG ratio of 4.95. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) closed at $112.33 in the latest trading session, marking a +1.38% move from the prior day. It is also worth noting that ABT currently has a PEG ratio of 4.95. | Abbott (ABT) closed at $112.33 in the latest trading session, marking a +1.38% move from the prior day. It is also worth noting that ABT currently has a PEG ratio of 4.95. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Abbott (ABT) closed at $112.33 in the latest trading session, marking a +1.38% move from the prior day. It is also worth noting that ABT currently has a PEG ratio of 4.95. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. |
31260.0 | 2023-01-05 00:00:00 UTC | 2 Best Healthcare Stocks to Buy Right Now | ABT | https://www.nasdaq.com/articles/2-best-healthcare-stocks-to-buy-right-now-0 | nan | nan | Picking stocks that can thrive in just about any economic environment is often a major contributing factor to an investor's success. And it doesn't have to be complicated: Investors need to just focus on buying stocks that operate in sectors of the economy that are of utmost importance.
Healthcare is a sector that tends to do well no matter what's going on in the world. That is because patients rely on the goods and services provided by healthcare companies at all times. Here are two quality stocks that could build meaningful wealth for investors over the long haul and are currently intriguing buys.
Image source: Getty Images.
1. Humana: A leading managed care company
Health insurance is a necessity for most people. And with more than 22.3 million members for its medical, dental, and vision insurance products as of Sept. 30, Humana (NYSE: HUM) is a well-established provider.
Health insurance is arguably one of the very best industries in which to be a leader. As an aging population develops more chronic medical conditions, the health insurance industry is expected to grow as well. The market research firm Fortune Business Insights projects that the global health insurance market will compound at 5.5% annually from $2.1 trillion in 2021 to $3 trillion by 2028.
Thanks to Humana's growing Medicare Advantage customer base, analysts anticipate the company will generate 14.7% annual non-GAAP (adjusted) diluted earnings per share (EPS) through the next five years. For context, this is meaningfully higher than the healthcare plans industry average of 12.5%.
The company's 0.6% dividend yield is well below the S&P 500 index's 1.7% yield. And with the dividend payout ratio standing at a very modest 12%, Humana should have no issues delivering 15%-plus annual dividend growth over the next five to 10 years.
The stock's forward price-to-earnings (P/E) ratio of 18.3 is only slightly more than the healthcare plans industry average of 16.6. This makes Humana a no-brainer buy for dividend growth investors.
2. Abbott Laboratories: A healthcare giant
Abbott Laboratories' (NYSE: ABT) $192 billion market capitalization makes it one of the biggest makers of medical devices and other healthcare products in the world. Notably, the company has a diagnostics segment that notably sells the COVID-19 rapid test called BinaxNOW, a nutrition segment that sells nutritional shakes and baby formula, and an off-patent pharmaceutical segment. This provides Abbott with diverse revenue streams that can rise in just about any environment.
The outlook for its medical devices business looks promising. This is because Precedence Research predicts that the global medical devices industry will increase 5.5% each year from $550 billion in 2021 to $850 billion by 2030. That's one reason why analysts believe that Abbott will produce 8.3% annual adjusted diluted EPS growth over the next five years.
The stock's 1.9% dividend yield slightly tops the S&P 500 index's yield. Since Abbott's dividend payout ratio clocks in at just 36%, there should be room for additional dividend growth. This is why I would be surprised if there weren't many more dividend raises like the most recent 8.5% in the company's future.
Topping it off, Abbott's forward P/E ratio of 24.9 is in line with the average for the medical devices industry. That's a decent valuation for a world-class business such as Abbott, which makes it a solid buy for dividend growth investors.
10 stocks we like better than Humana
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Humana wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2022
Kody Kester has positions in Abbott Laboratories. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories: A healthcare giant Abbott Laboratories' (NYSE: ABT) $192 billion market capitalization makes it one of the biggest makers of medical devices and other healthcare products in the world. And it doesn't have to be complicated: Investors need to just focus on buying stocks that operate in sectors of the economy that are of utmost importance. And with more than 22.3 million members for its medical, dental, and vision insurance products as of Sept. 30, Humana (NYSE: HUM) is a well-established provider. | Abbott Laboratories: A healthcare giant Abbott Laboratories' (NYSE: ABT) $192 billion market capitalization makes it one of the biggest makers of medical devices and other healthcare products in the world. That's one reason why analysts believe that Abbott will produce 8.3% annual adjusted diluted EPS growth over the next five years. The stock's 1.9% dividend yield slightly tops the S&P 500 index's yield. | Abbott Laboratories: A healthcare giant Abbott Laboratories' (NYSE: ABT) $192 billion market capitalization makes it one of the biggest makers of medical devices and other healthcare products in the world. And with the dividend payout ratio standing at a very modest 12%, Humana should have no issues delivering 15%-plus annual dividend growth over the next five to 10 years. See the 10 stocks *Stock Advisor returns as of December 1, 2022 Kody Kester has positions in Abbott Laboratories. | Abbott Laboratories: A healthcare giant Abbott Laboratories' (NYSE: ABT) $192 billion market capitalization makes it one of the biggest makers of medical devices and other healthcare products in the world. Topping it off, Abbott's forward P/E ratio of 24.9 is in line with the average for the medical devices industry. That's right -- they think these 10 stocks are even better buys. |
31261.0 | 2023-01-05 00:00:00 UTC | Noteworthy ETF Outflows: XLV, MRK, ABT, DHR | ABT | https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-xlv-mrk-abt-dhr | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $129.0 million dollar outflow -- that's a 0.3% decrease week over week (from 310,220,000 to 309,270,000). Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is trading flat, and Danaher Corp (Symbol: DHR) is lower by about 3.9%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $143.42 as the 52 week high point — that compares with a last trade of $134.56. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
Also see:
TGH shares outstanding history
BLUE shares outstanding history
Top Ten Hedge Funds Holding TCHI
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is trading flat, and Danaher Corp (Symbol: DHR) is lower by about 3.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $129.0 million dollar outflow -- that's a 0.3% decrease week over week (from 310,220,000 to 309,270,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is trading flat, and Danaher Corp (Symbol: DHR) is lower by about 3.9%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $143.42 as the 52 week high point — that compares with a last trade of $134.56. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is trading flat, and Danaher Corp (Symbol: DHR) is lower by about 3.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $129.0 million dollar outflow -- that's a 0.3% decrease week over week (from 310,220,000 to 309,270,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $143.42 as the 52 week high point — that compares with a last trade of $134.56. | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is trading flat, and Danaher Corp (Symbol: DHR) is lower by about 3.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $129.0 million dollar outflow -- that's a 0.3% decrease week over week (from 310,220,000 to 309,270,000). Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. |
31262.0 | 2023-01-03 00:00:00 UTC | Beat the Dow Jones With This Unstoppable Dividend Stock | ABT | https://www.nasdaq.com/articles/beat-the-dow-jones-with-this-unstoppable-dividend-stock-10 | nan | nan | The iconic Dow Jones needs no introduction to those fully immersed in the investing world. It is composed of 30 leading companies in the U.S. and stands as one of the country's oldest and most popular stock market indexes. Like other major U.S. indexes, it has delivered solid returns over the long run, so perhaps investing in an exchange-traded fund that tracks the Dow Jones isn't a bad idea.
However, some companies are more than capable of providing even better returns. Pharma giant AbbVie (NYSE: ABBV) falls in that category. Here is why.
This patent cliff won't sink AbbVie's prospects
Since splitting off from Abbott Laboratories in 2013, AbbVie has comfortably beaten the Dow Jones.
But the company's key asset in this period is now under threat. AbbVie's immunology drug Humira -- its top-selling product and one of the most successful drugs in history -- could start facing generic competition in the U.S. in 2023. Humira's sales have been declining in international markets since 2018 when it lost patent exclusivity in Europe.
But AbbVie was able to keep its revenue associated with the medicine afloat thanks to the U.S. market. Now, Humira's sales might drop off a cliff when generics enter that market. What will happen to AbbVie's top line? Thankfully, it shouldn't be the end of the world. Drugmakers often plan well in advance when they know they will face important patent cliffs, and that's what AbbVie did.
First, the company's blockbuster 2020 acquisition of Allergan helped expand its lineup with products like Vraylar -- which recently earned a label expansion as an adjunctive treatment for depression -- and Allergan's Botox franchise. These products should help offset Humira's declining sales. Second, AbbVie earned approvals for new key products.
Most notably, it expanded its immunology lineup with Skyrizi and Rinvoq, two medicines that have earned approvals across many of Humira's indications and have grown their sales at a rapid clip. AbbVie won't stop there. The company has plenty of pipeline programs that will help it strengthen its lineup down the line. In October 2022, it submitted epcoritamab, a potential cancer medicine, for approval in the U.S. and Europe.
In May 2022, the company submitted an application for ABBV-951 to the U.S. Food and Drug Administration for approval. ABBV-951 is the subcutaneous version of AbbVie's oral combo medicine, carbidopa/levodopa, which treats Parkinson's disease. AbbVie boasts dozens of other programs, including brand-new clinical compounds in various stages of development.
The company's track record and pipeline strongly suggest that losing patent exclusivity for Humira in the U.S. won't be a death sentence.
AbbVie's strong dividend record
In the third quarter, AbbVie reported revenue growth of 3.3% year over year to $14.8 billion, while its adjusted earnings per share came in at $3.66, 29.3% higher than the year-ago period. It seems very plausible that AbbVie's revenue and earnings growth rates will drop once it starts facing generic competition from Humira, at least momentarily. But that's unlikely to affect the company's dividend.
AbbVie is part of the club of Dividend Kings; it has raised its payouts for 50 consecutive years when considering the time it spent under the banner of Abbott Laboratories. With a cash payout ratio of almost 45%, the company's cash balance more than covers its dividends, leaving plenty of room for payout increases even if revenue and earnings drop for a few quarters.
AbbVie raised its dividends throughout the pandemic period and the subsequent economic troubles to the tune of 25% in the past three years. It currently boasts a yield of 3.66%, well above the average S&P 500 dividend yield of 1.82%. AbbVie's dividend track record is impeccable.
A solid forever stock
After a down 2022, the iconic Dow Jones may recover in 2023, although there is no guarantee that it will. AbbVie, on the other hand, had a solid showing in 2022. Given the upcoming issues related to Humira, investors could sell off the stock in the short term, but the company has all the tools needed to be successful over the long run.
AbbVie's solid business should lead to more approvals, a broader revenue base, stronger top-line and bottom-line growth, and consistent dividend increases. Whatever happens to the pharma company in 2023, AbbVie has an excellent chance of outperforming the Dow Jones in the next five years and beyond.
10 stocks we like better than AbbVie
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2022
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abb and Abbott Laboratories. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Like other major U.S. indexes, it has delivered solid returns over the long run, so perhaps investing in an exchange-traded fund that tracks the Dow Jones isn't a bad idea. Most notably, it expanded its immunology lineup with Skyrizi and Rinvoq, two medicines that have earned approvals across many of Humira's indications and have grown their sales at a rapid clip. Given the upcoming issues related to Humira, investors could sell off the stock in the short term, but the company has all the tools needed to be successful over the long run. | The company's track record and pipeline strongly suggest that losing patent exclusivity for Humira in the U.S. won't be a death sentence. AbbVie's strong dividend record In the third quarter, AbbVie reported revenue growth of 3.3% year over year to $14.8 billion, while its adjusted earnings per share came in at $3.66, 29.3% higher than the year-ago period. It seems very plausible that AbbVie's revenue and earnings growth rates will drop once it starts facing generic competition from Humira, at least momentarily. | This patent cliff won't sink AbbVie's prospects Since splitting off from Abbott Laboratories in 2013, AbbVie has comfortably beaten the Dow Jones. AbbVie's strong dividend record In the third quarter, AbbVie reported revenue growth of 3.3% year over year to $14.8 billion, while its adjusted earnings per share came in at $3.66, 29.3% higher than the year-ago period. Whatever happens to the pharma company in 2023, AbbVie has an excellent chance of outperforming the Dow Jones in the next five years and beyond. | This patent cliff won't sink AbbVie's prospects Since splitting off from Abbott Laboratories in 2013, AbbVie has comfortably beaten the Dow Jones. But AbbVie was able to keep its revenue associated with the medicine afloat thanks to the U.S. market. Second, AbbVie earned approvals for new key products. |
31263.0 | 2022-12-30 00:00:00 UTC | What Tech Investors Can Expect to See at CES 2023 | ABT | https://www.nasdaq.com/articles/what-tech-investors-can-expect-to-see-at-ces-2023 | nan | nan | T
he year 2022 has been a difficult one for investors as they’ve had to contend with a variety of evolving landscapes, such as the Russia-Ukraine war, inflation, rising interest rates, concerns of a global economic contraction and ongoing supply chain issues. As we prepare to shut the door and walk into 2023, several of those concerns remain in play.
Despite recent Purchasing Manager’s Index (PMI) data published by S&P Global and the Institute for Supply Management pointing to an economic contraction, consensus earnings expectations for the S&P 500 still point to year-over-year growth ahead for 2022. Next week brings a bevy of economic data that should bring more answers on the pace of the economy and prospects for earnings season.
The new year will also bring CES 2023, the largest trade show, and this will likely be a huge focus for tech investors during January 5 to 8.
What is CES?
CES, formerly known as the Consumer Electronics Show, is an annual trade show organized by the Consumer Technology Association, a trade association that represents more than 1,500 consumer technology companies. Held early January, CES is a showcase of forthcoming technologies and applications that expand the digital lifestyle.
This includes a bevy of new TVs, PCs, smartphones, wearables and other connected devices targeted for in-store shelves and digital shopping later in the year, usually in time for the year-end holiday shopping season. This bonanza of new product announcements is usually accompanied by a barrage of press releases laying out the new capabilities of these devices, but some companies also hold investor and product briefings during the event. And there is no shortage of stories written about the event and what is announced there – more than 177,000 related stories were produced during CES 2022.
While many will focus on these new offerings, others will also pay close attention to the various keynotes given during the trade show. With chips and technologies seeping into more aspects of our daily lives, the kinds of companies participating in CES’s keynotes have expanded in the last few years to include technology companies such as IBM (IBM), AMD (AMD), Nvidia (NVDA) and Samsung (SSNLF) but also General Motors (GM), Verizon (VZ), Abbott Labs (ABT) and Unilever (UL).
With listed topics ranging from 5G, artificial intelligence, augmented and virtual reality, digital health, food technology, robotics and drones as well as smart cities, vehicle technologies and the metaverse, the array of companies giving keynotes continues to expand. A look at the keynote speaker list for CES 2023 sees AMD returning joined by BMW (BMWYY), John Deere (DE), Delta Air Lines (DAL), Netflix (NFLX), Instacart, Riot Games, Stellantis (STLA), United Healthcare (UNH) and Teladoc (TDOC). Featured exhibitors include Amazon (AMZN), Google (GOOGL), LG, Microsoft (MSFT) and Sony (SONY), and investors can find the full list at the CES 2023 Exhibitor Directory here.
How will CES 2023 be different?
While we expect the keynotes to touch on forthcoming disruptions like how the underlying technology will further improve productivity and the quality of our lives, there could be a more sober tone at this year's CES. Recently, memory and computer storage chip company Micron (MU) reported its latest quarterly earnings where it served up the latest warning for the chip sector that has been plagued by supply chain woes and bloated inventories.
Micron commented the industry is “experiencing the most severe imbalance between supply and demand” in the last 13 years and expects its customer inventory to return to relatively healthy levels by mid-calendar 2023. The current market environment, however, has Micron thinking industry profitability will remain challenged through calendar 2023, likely due to inventory reduction efforts that will hit margins and bottom-line results.
One area that Micron called out is the PC market, as it now sees unit volumes for 2022 falling in the high-teens percentage and with low-to mid-single-digit declines to follow in 2023. Calendar 2022 smartphone unit volume is expected to decline 10% year-over-year versus compared to Micron’s prior high single-digit percentage decline forecast and the company sees calendar year 2023 smartphone unit volume being flattish to up slightly on a year-over-year basis.
Despite all the talk in recent quarters over semiconductor shortages, those expected declines are poised to free up semiconductor capacity, which explains why Micron cut its 2023 and 2024 capital spending for new semiconductor capital equipment. Micron now sees its 2023 capex budget between $7-7.5 billion, 40% lower than in 2022 and down from its earlier forecast of $8 billion. While the company didn’t share any particular figure for 2024, it did say it is “now significantly reducing our fiscal 2024 capex from earlier plans to align with the supply-demand environment.”
As companies close their books for the December quarter, assess the state of their end markets and take stock of upcoming economic data and what Fed monetary policy means for interest rates, there is a growing probability that earnings expectations for the coming year will be revised lower. This could lead to a round of earnings pre-announcements alongside the expected flurry of headlines that accompanies CES. While this could lead to further downside in stocks as the December quarter season unfolds, investors may have the opportunity to buy quality companies at better prices. That’s a 2023 shopping list worth building as we move into the new year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With chips and technologies seeping into more aspects of our daily lives, the kinds of companies participating in CES’s keynotes have expanded in the last few years to include technology companies such as IBM (IBM), AMD (AMD), Nvidia (NVDA) and Samsung (SSNLF) but also General Motors (GM), Verizon (VZ), Abbott Labs (ABT) and Unilever (UL). he year 2022 has been a difficult one for investors as they’ve had to contend with a variety of evolving landscapes, such as the Russia-Ukraine war, inflation, rising interest rates, concerns of a global economic contraction and ongoing supply chain issues. A look at the keynote speaker list for CES 2023 sees AMD returning joined by BMW (BMWYY), John Deere (DE), Delta Air Lines (DAL), Netflix (NFLX), Instacart, Riot Games, Stellantis (STLA), United Healthcare (UNH) and Teladoc (TDOC). | With chips and technologies seeping into more aspects of our daily lives, the kinds of companies participating in CES’s keynotes have expanded in the last few years to include technology companies such as IBM (IBM), AMD (AMD), Nvidia (NVDA) and Samsung (SSNLF) but also General Motors (GM), Verizon (VZ), Abbott Labs (ABT) and Unilever (UL). he year 2022 has been a difficult one for investors as they’ve had to contend with a variety of evolving landscapes, such as the Russia-Ukraine war, inflation, rising interest rates, concerns of a global economic contraction and ongoing supply chain issues. Calendar 2022 smartphone unit volume is expected to decline 10% year-over-year versus compared to Micron’s prior high single-digit percentage decline forecast and the company sees calendar year 2023 smartphone unit volume being flattish to up slightly on a year-over-year basis. | With chips and technologies seeping into more aspects of our daily lives, the kinds of companies participating in CES’s keynotes have expanded in the last few years to include technology companies such as IBM (IBM), AMD (AMD), Nvidia (NVDA) and Samsung (SSNLF) but also General Motors (GM), Verizon (VZ), Abbott Labs (ABT) and Unilever (UL). Calendar 2022 smartphone unit volume is expected to decline 10% year-over-year versus compared to Micron’s prior high single-digit percentage decline forecast and the company sees calendar year 2023 smartphone unit volume being flattish to up slightly on a year-over-year basis. While the company didn’t share any particular figure for 2024, it did say it is “now significantly reducing our fiscal 2024 capex from earlier plans to align with the supply-demand environment.” As companies close their books for the December quarter, assess the state of their end markets and take stock of upcoming economic data and what Fed monetary policy means for interest rates, there is a growing probability that earnings expectations for the coming year will be revised lower. | With chips and technologies seeping into more aspects of our daily lives, the kinds of companies participating in CES’s keynotes have expanded in the last few years to include technology companies such as IBM (IBM), AMD (AMD), Nvidia (NVDA) and Samsung (SSNLF) but also General Motors (GM), Verizon (VZ), Abbott Labs (ABT) and Unilever (UL). The new year will also bring CES 2023, the largest trade show, and this will likely be a huge focus for tech investors during January 5 to 8. What is CES? |
31264.0 | 2022-12-28 00:00:00 UTC | iShares MSCI World ETF Experiences Big Inflow | ABT | https://www.nasdaq.com/articles/ishares-msci-world-etf-experiences-big-inflow-0 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI World ETF (Symbol: URTH) where we have detected an approximate $174.7 million dollar inflow -- that's a 7.4% increase week over week in outstanding units (from 21,500,000 to 23,100,000). Among the largest underlying components of URTH, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.6%, Danaher Corp (Symbol: DHR) is up about 1.1%, and NextEra Energy Inc (Symbol: NEE) is lower by about 0.4%. For a complete list of holdings, visit the URTH Holdings page » The chart below shows the one year price performance of URTH, versus its 200 day moving average:
Looking at the chart above, URTH's low point in its 52 week range is $97.44 per share, with $136.69 as the 52 week high point — that compares with a last trade of $108.89. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 8%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
Also see:
Funds Holding PHK
TLRY Videos
MSEX Insider Buying
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of URTH, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.6%, Danaher Corp (Symbol: DHR) is up about 1.1%, and NextEra Energy Inc (Symbol: NEE) is lower by about 0.4%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. | Among the largest underlying components of URTH, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.6%, Danaher Corp (Symbol: DHR) is up about 1.1%, and NextEra Energy Inc (Symbol: NEE) is lower by about 0.4%. For a complete list of holdings, visit the URTH Holdings page » The chart below shows the one year price performance of URTH, versus its 200 day moving average: Looking at the chart above, URTH's low point in its 52 week range is $97.44 per share, with $136.69 as the 52 week high point — that compares with a last trade of $108.89. Free Report: Top 8%+ Dividends (paid monthly) Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of URTH, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.6%, Danaher Corp (Symbol: DHR) is up about 1.1%, and NextEra Energy Inc (Symbol: NEE) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI World ETF (Symbol: URTH) where we have detected an approximate $174.7 million dollar inflow -- that's a 7.4% increase week over week in outstanding units (from 21,500,000 to 23,100,000). For a complete list of holdings, visit the URTH Holdings page » The chart below shows the one year price performance of URTH, versus its 200 day moving average: Looking at the chart above, URTH's low point in its 52 week range is $97.44 per share, with $136.69 as the 52 week high point — that compares with a last trade of $108.89. | Among the largest underlying components of URTH, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.6%, Danaher Corp (Symbol: DHR) is up about 1.1%, and NextEra Energy Inc (Symbol: NEE) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI World ETF (Symbol: URTH) where we have detected an approximate $174.7 million dollar inflow -- that's a 7.4% increase week over week in outstanding units (from 21,500,000 to 23,100,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. |
31265.0 | 2022-12-28 00:00:00 UTC | Baby formula imports to face tariffs again in 2023 - WSJ | ABT | https://www.nasdaq.com/articles/baby-formula-imports-to-face-tariffs-again-in-2023-wsj-0 | nan | nan | Adds details, background
Dec 28 (Reuters) - Imported baby formula would be subject to tariffs again in the new year after the expiration of exemptions implemented amid a nationwide shortage, the Wall Street Journal reported on Wednesday.
The shortage that began due to pandemic-induced supply chain issues worsened in February when Abbott Laboratories ABT.N, the biggest U.S. supplier, recalled some products and closed a manufacturing plant after reports of bacterial infections.
In response, U.S. health regulators relaxed import policies and President Joe Biden invoked the Cold War-era Defense Production Act to shore up supplies.
The country has since shipped in millions of cans of emergency supplies from companies such as Nestle SA NESN.S and Reckitt Benckiser RKT.L.
According to the WSJ report, a White House spokesman said the tariff waivers doubled the number of manufacturers selling baby formula in the United States.
The White House did not immediately respond to a Reuters request for comment.
Congress made the tariff waivers temporary as part of a deal to pass the measures quickly, the report said, citing people familiar with the matter.
In August, two big U.S. retailers Walmart Inc WMT.N and Target Corp TGT.Nsaid supplies of baby formula were improving. Still, Target had purchase restrictions on baby formula products both at its stores and online.
However, Reckitt in early December said it expects the U.S. infant formula shortage to "persist" until spring. It is the maker of what is now the biggest brand in the market, Enfamil.
According to data firm IRI, in-stock rates at U.S. stores have continued to improve and are close to pre-recall levels at 86% now compared with 88%–90% before the recall.
(Reporting by Ananya Mariam Rajesh in Bengaluru)
((AnanyaMariam.Rajesh@thomsonreuters.com ; Twitter: https://twitter.com/AnanyaMariam;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The shortage that began due to pandemic-induced supply chain issues worsened in February when Abbott Laboratories ABT.N, the biggest U.S. supplier, recalled some products and closed a manufacturing plant after reports of bacterial infections. Adds details, background Dec 28 (Reuters) - Imported baby formula would be subject to tariffs again in the new year after the expiration of exemptions implemented amid a nationwide shortage, the Wall Street Journal reported on Wednesday. In response, U.S. health regulators relaxed import policies and President Joe Biden invoked the Cold War-era Defense Production Act to shore up supplies. | The shortage that began due to pandemic-induced supply chain issues worsened in February when Abbott Laboratories ABT.N, the biggest U.S. supplier, recalled some products and closed a manufacturing plant after reports of bacterial infections. Adds details, background Dec 28 (Reuters) - Imported baby formula would be subject to tariffs again in the new year after the expiration of exemptions implemented amid a nationwide shortage, the Wall Street Journal reported on Wednesday. In August, two big U.S. retailers Walmart Inc WMT.N and Target Corp TGT.Nsaid supplies of baby formula were improving. | The shortage that began due to pandemic-induced supply chain issues worsened in February when Abbott Laboratories ABT.N, the biggest U.S. supplier, recalled some products and closed a manufacturing plant after reports of bacterial infections. Adds details, background Dec 28 (Reuters) - Imported baby formula would be subject to tariffs again in the new year after the expiration of exemptions implemented amid a nationwide shortage, the Wall Street Journal reported on Wednesday. According to the WSJ report, a White House spokesman said the tariff waivers doubled the number of manufacturers selling baby formula in the United States. | The shortage that began due to pandemic-induced supply chain issues worsened in February when Abbott Laboratories ABT.N, the biggest U.S. supplier, recalled some products and closed a manufacturing plant after reports of bacterial infections. Adds details, background Dec 28 (Reuters) - Imported baby formula would be subject to tariffs again in the new year after the expiration of exemptions implemented amid a nationwide shortage, the Wall Street Journal reported on Wednesday. According to the WSJ report, a White House spokesman said the tariff waivers doubled the number of manufacturers selling baby formula in the United States. |
31266.0 | 2022-12-28 00:00:00 UTC | Baby formula imports to face tariffs again in 2023 - WSJ | ABT | https://www.nasdaq.com/articles/baby-formula-imports-to-face-tariffs-again-in-2023-wsj | nan | nan | Dec 28 (Reuters) - Imported baby formula would be subject to tariffs again in the new year, after the expiration of exemptions implemented amid a nationwide shortage, the Wall Street Journal reported on Wednesday.
The shortage that began due to pandemic-induced supply chain issues worsened in February when Abbott Laboratories ABT.N, the biggest U.S. supplier, recalled some products and closed a manufacturing plant after reports of bacterial infections.
In response, U.S. health regulators relaxed import policies and shipped in millions of cans of emergency supplies from companies such as Nestle SA NESN.S and Reckitt Benckiser RKT.L.
According to the WSJ report, a White House spokesman said the tariff waivers doubled the number of manufacturers selling baby formula in the United States.
Congress made the tariff waivers temporary as part of a deal to pass the measures quickly, the report said, citing people familiar with the matter.
(Reporting by Ananya Mariam Rajesh in Bengaluru)
((AnanyaMariam.Rajesh@thomsonreuters.com ; Twitter: https://twitter.com/AnanyaMariam;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The shortage that began due to pandemic-induced supply chain issues worsened in February when Abbott Laboratories ABT.N, the biggest U.S. supplier, recalled some products and closed a manufacturing plant after reports of bacterial infections. Dec 28 (Reuters) - Imported baby formula would be subject to tariffs again in the new year, after the expiration of exemptions implemented amid a nationwide shortage, the Wall Street Journal reported on Wednesday. In response, U.S. health regulators relaxed import policies and shipped in millions of cans of emergency supplies from companies such as Nestle SA NESN.S and Reckitt Benckiser RKT.L. | The shortage that began due to pandemic-induced supply chain issues worsened in February when Abbott Laboratories ABT.N, the biggest U.S. supplier, recalled some products and closed a manufacturing plant after reports of bacterial infections. Dec 28 (Reuters) - Imported baby formula would be subject to tariffs again in the new year, after the expiration of exemptions implemented amid a nationwide shortage, the Wall Street Journal reported on Wednesday. According to the WSJ report, a White House spokesman said the tariff waivers doubled the number of manufacturers selling baby formula in the United States. | The shortage that began due to pandemic-induced supply chain issues worsened in February when Abbott Laboratories ABT.N, the biggest U.S. supplier, recalled some products and closed a manufacturing plant after reports of bacterial infections. Dec 28 (Reuters) - Imported baby formula would be subject to tariffs again in the new year, after the expiration of exemptions implemented amid a nationwide shortage, the Wall Street Journal reported on Wednesday. According to the WSJ report, a White House spokesman said the tariff waivers doubled the number of manufacturers selling baby formula in the United States. | The shortage that began due to pandemic-induced supply chain issues worsened in February when Abbott Laboratories ABT.N, the biggest U.S. supplier, recalled some products and closed a manufacturing plant after reports of bacterial infections. Dec 28 (Reuters) - Imported baby formula would be subject to tariffs again in the new year, after the expiration of exemptions implemented amid a nationwide shortage, the Wall Street Journal reported on Wednesday. In response, U.S. health regulators relaxed import policies and shipped in millions of cans of emergency supplies from companies such as Nestle SA NESN.S and Reckitt Benckiser RKT.L. |
31267.0 | 2022-12-28 00:00:00 UTC | Abbott (ABT) to Upgrade PHCs Across India With New Pact | ABT | https://www.nasdaq.com/articles/abbott-abt-to-upgrade-phcs-across-india-with-new-pact | nan | nan | Abbott Laboratories ABT recently partnered with Americares India Foundation to upgrade 75 Primary Health Centres (PHCs) to Health and Wellness Centres (HWCs) across nine States in India. These centers are essential to support the government's Ayushman Bharat initiative and will advance access to healthcare, optimize required resources and help reduce the burden on healthcare facilities at the secondary and tertiary levels.
For investors’ note, Americares India is a health-focused relief and development organization. It helps people affected by poverty or disasters with life-changing health programs, medicines and medical supplies.
The recent development is likely to fortify Abbott's commitment to advance its global sustainability priority of innovating for access and affordability in health.
More on the HWC Program
The HWC program is supported by Abbott funding of nearly $2.4 million and will benefit more than 2.5 million people from under-resourced communities annually. The program has three core objectives — to upgrade local PHCs to HWCs, boost capacity building for healthcare workers and enhance community awareness around noncommunicable diseases and infectious diseases.
As part of its first phase, Abbott and Americares have upgraded 16 PHCs across Maharashtra, Goa, Himachal Pradesh and Chhattisgarh, serving more than 500,000 people. Both companies plan to upgrade the remaining 59 PHCs across the four mentioned states along with Karnataka, Tamil Nadu, Odisha, Madhya Pradesh and Jharkhand by early 2024.
Image Source: Zacks Investment Research
The program will offer vital medical instruments, including ECG machines and equipment for maternal, neonatal, respiratory and eye care, and fortify key infrastructure and water, sanitation and hygiene interventions.
Benefits of the HWC Program
The HWC program is likely to expand ABT’s customer base across India. Moreover, in line with its 2030 Global Sustainability Plan, the company aims to extend affordable access to healthcare by offering advanced, decentralized models of care that augment prevention and early diagnosis, providing quality treatment and care.
Moreover, by upgrading PHCs, Abbott also aims to advance community-wide health-seeking behaviors like early diagnosis and treatment, alongside lifestyle measures, by enhancing awareness around key communicable and infectious diseases and providing access to quality healthcare infrastructure.
Industry Prospects
Per a report by imarc, the Indian health and wellness market is expected to exhibit a CAGR of 5.45% during the 2022-2027 period, propelled by the rising health consciousness among individuals. Considering the market potential, Abbott’s latest move is well-thought-of.
Recent Developments
This month, Abbott announced that its FreeStyle Libre 3 sensor integrated with the mylife Loop solution, building a smart, automated process to deliver insulin based on real-time glucose data. This automated insulin delivery system solution is now available in Germany and will be accessible in other European countries, starting in 2023.
Also, this month, Abbott received the FDA approval for its Eterna spinal cord stimulation (SCS) system for treating chronic pain. The Eterna SCS system is the smallest implantable, rechargeable system that is currently available in the market for this indication.
Price Performance
Shares of Abbott have declined 23.1% in a year compared with the industry’s fall of 44.9%.
Zacks Rank & Key Picks
Currently, Abbott carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space that investors can consider are ShockWave Medical, Inc. SWAV, Orthofix Medical Inc. OFIX and Merit Medical System MMSI.
ShockWave Medical, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 33.1% for 2023. The company’s earnings surpassed estimates in all the trailing four quarters, the average beat being 180.1%.
ShockWave Medical has outperformed its industry in the past year. SWAV has risen 35% against the industry’s 32.6% fall in the past year.
Orthofix Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter 2022 adjusted EPS of 13 cents, which beat the Zacks Consensus Estimate by a stupendous 550%. Revenues of $114 million outpaced the consensus mark by 2.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Orthofix Medical has an estimated next-year growth rate of 58.97%. OFIX’s earnings surpassed estimates in the trailing three quarters and missed in one, the average being 129.1%.
Merit Medical, currently carrying a Zacks Rank of 2, reported a third-quarter 2022 adjusted EPS of 64 cents, which beat the Zacks Consensus Estimate by 20.8%. Revenues of $287.2 million outpaced the consensus mark by 5.2%.
Merit Medical has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average being 25.4%.
Zacks Top 10 Stocks for 2023
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2023? From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500’s +287.4%.
Now our Director of Research is combing through 4,000 companies covered by the Zacks Rank to handpick the best 10 tickers to buy and hold. Don’t miss your chance to get in on these stocks when they’re released on January 3.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT recently partnered with Americares India Foundation to upgrade 75 Primary Health Centres (PHCs) to Health and Wellness Centres (HWCs) across nine States in India. Benefits of the HWC Program The HWC program is likely to expand ABT’s customer base across India. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. | Abbott Laboratories ABT recently partnered with Americares India Foundation to upgrade 75 Primary Health Centres (PHCs) to Health and Wellness Centres (HWCs) across nine States in India. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Benefits of the HWC Program The HWC program is likely to expand ABT’s customer base across India. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT recently partnered with Americares India Foundation to upgrade 75 Primary Health Centres (PHCs) to Health and Wellness Centres (HWCs) across nine States in India. Benefits of the HWC Program The HWC program is likely to expand ABT’s customer base across India. | Abbott Laboratories ABT recently partnered with Americares India Foundation to upgrade 75 Primary Health Centres (PHCs) to Health and Wellness Centres (HWCs) across nine States in India. Benefits of the HWC Program The HWC program is likely to expand ABT’s customer base across India. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. |
31268.0 | 2022-12-28 00:00:00 UTC | Will Baxter Stock Rebound After A 9% Fall In A Month? | ABT | https://www.nasdaq.com/articles/will-baxter-stock-rebound-after-a-9-fall-in-a-month | nan | nan | Baxter stock (NYSE: BAX) has seen a fall of 9% in a month, while it’s down 42% this year. This compares with -5% and -20% returns for the broader S&P500 index over the same periods, respectively. The broader markets have been falling of late on positive economic data, which implies that the Fed may have to continue to increase interest rates, likely resulting in a recession in 2023. Baxter also faces risks from a recession, primarily a decline in hospital spending that could weigh on its sales growth.
But now that BAX stock has seen a 9% fall in a month, will it continue its downward trajectory, or is a rise imminent? Going by historical performance, there is a higher chance of an increase in BAX stock over the next month. BAX stock has seen a move of -9% or more 111 times in the last ten years. Of those, 63 resulted in BAX stock rising over the subsequent one-month period (twenty-one trading days). This historical pattern reflects 63 out of 111, or a 57% chance of a rise in BAX stock over the coming month. See our analysis on Baxter Stock Chance of Rise for more details.
Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using the last ten years’ data
After moving -1.2% or more over five days, the stock rose on 57% of the occasions in the next five days.
After moving -4.7% or more over ten days, the stock rose on 67% of the occasions in the next ten days.
After moving -9.4% or more over a twenty-one-day period, the stock rose on 57% of the occasions in the next twenty-one days.
This pattern suggests a higher chance of a rise in BAX stock over the next five, ten, and twenty-one days.
Baxter (BAX) Stock Return (Recent) Comparison With Peers And S&P500
Five-Day Return: CAH highest at 2.5%; BAX lowest at -1.2%
Ten-Day Return: EW highest at 2.7%; BAX lowest at -4.7%
Twenty-One Days Return: BDX highest at 7.6%; BAX lowest at -9.4%
While BAX stock looks like it can see higher levels, it is helpful to see how Baxter’s Peers fare on metrics that matter. You will find other valuable comparisons for companies across industries at Peer Comparisons.
Furthermore, the Covid-19 crisis has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised at how counter-intuitive the stock valuation is for Phibro Animal Health vs. Tri Pointe Homes.
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
Returns Dec 2022
MTD [1] 2022
YTD [1] 2017-22
Total [2]
BAX Return -11% -42% 13%
S&P 500 Return -6% -20% 71%
Trefis Multi-Strategy Portfolio -6% -23% 212%
[1] Month-to-date and year-to-date as of 12/23/2022
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The broader markets have been falling of late on positive economic data, which implies that the Fed may have to continue to increase interest rates, likely resulting in a recession in 2023. Baxter also faces risks from a recession, primarily a decline in hospital spending that could weigh on its sales growth. For example, you’ll be surprised at how counter-intuitive the stock valuation is for Phibro Animal Health vs. Tri Pointe Homes. | Of those, 63 resulted in BAX stock rising over the subsequent one-month period (twenty-one trading days). Baxter (BAX) Stock Return (Recent) Comparison With Peers And S&P500 Five-Day Return: CAH highest at 2.5%; BAX lowest at -1.2% Ten-Day Return: EW highest at 2.7%; BAX lowest at -4.7% Twenty-One Days Return: BDX highest at 7.6%; BAX lowest at -9.4% While BAX stock looks like it can see higher levels, it is helpful to see how Baxter’s Peers fare on metrics that matter. Total [2] BAX Return -11% -42% 13% S&P 500 Return -6% -20% 71% Trefis Multi-Strategy Portfolio -6% -23% 212% [1] Month-to-date and year-to-date as of 12/23/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This pattern suggests a higher chance of a rise in BAX stock over the next five, ten, and twenty-one days. Baxter (BAX) Stock Return (Recent) Comparison With Peers And S&P500 Five-Day Return: CAH highest at 2.5%; BAX lowest at -1.2% Ten-Day Return: EW highest at 2.7%; BAX lowest at -4.7% Twenty-One Days Return: BDX highest at 7.6%; BAX lowest at -9.4% While BAX stock looks like it can see higher levels, it is helpful to see how Baxter’s Peers fare on metrics that matter. Total [2] BAX Return -11% -42% 13% S&P 500 Return -6% -20% 71% Trefis Multi-Strategy Portfolio -6% -23% 212% [1] Month-to-date and year-to-date as of 12/23/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of those, 63 resulted in BAX stock rising over the subsequent one-month period (twenty-one trading days). This pattern suggests a higher chance of a rise in BAX stock over the next five, ten, and twenty-one days. Baxter (BAX) Stock Return (Recent) Comparison With Peers And S&P500 Five-Day Return: CAH highest at 2.5%; BAX lowest at -1.2% Ten-Day Return: EW highest at 2.7%; BAX lowest at -4.7% Twenty-One Days Return: BDX highest at 7.6%; BAX lowest at -9.4% While BAX stock looks like it can see higher levels, it is helpful to see how Baxter’s Peers fare on metrics that matter. |
31269.0 | 2022-12-27 00:00:00 UTC | Abbott (ABT) Gains As Market Dips: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-gains-as-market-dips%3A-what-you-should-know-6 | nan | nan | Abbott (ABT) closed at $108.57 in the latest trading session, marking a +0.36% move from the prior day. This move outpaced the S&P 500's daily loss of 0.41%. Meanwhile, the Dow gained 0.11%, and the Nasdaq, a tech-heavy index, lost 6.67%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had gained 2.65% over the past month. This has outpaced the Medical sector's gain of 0.95% and the S&P 500's loss of 4.4% in that time.
Wall Street will be looking for positivity from Abbott as it approaches its next earnings report date. In that report, analysts expect Abbott to post earnings of $0.90 per share. This would mark a year-over-year decline of 31.82%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.47 billion, down 17.41% from the year-ago period.
ABT's full-year Zacks Consensus Estimates are calling for earnings of $5.21 per share and revenue of $43.03 billion. These results would represent year-over-year changes of 0% and -0.1%, respectively.
Investors should also note any recent changes to analyst estimates for Abbott. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Abbott currently has a Zacks Rank of #3 (Hold).
Digging into valuation, Abbott currently has a Forward P/E ratio of 20.77. This valuation marks a premium compared to its industry's average Forward P/E of 19.42.
Also, we should mention that ABT has a PEG ratio of 4.08. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ABT's industry had an average PEG ratio of 2.23 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 184, which puts it in the bottom 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.8% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed at $108.57 in the latest trading session, marking a +0.36% move from the prior day. ABT's full-year Zacks Consensus Estimates are calling for earnings of $5.21 per share and revenue of $43.03 billion. Also, we should mention that ABT has a PEG ratio of 4.08. | Abbott (ABT) closed at $108.57 in the latest trading session, marking a +0.36% move from the prior day. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. ABT's full-year Zacks Consensus Estimates are calling for earnings of $5.21 per share and revenue of $43.03 billion. | Abbott (ABT) closed at $108.57 in the latest trading session, marking a +0.36% move from the prior day. ABT's full-year Zacks Consensus Estimates are calling for earnings of $5.21 per share and revenue of $43.03 billion. Also, we should mention that ABT has a PEG ratio of 4.08. | Abbott (ABT) closed at $108.57 in the latest trading session, marking a +0.36% move from the prior day. ABT's full-year Zacks Consensus Estimates are calling for earnings of $5.21 per share and revenue of $43.03 billion. Also, we should mention that ABT has a PEG ratio of 4.08. |
31270.0 | 2022-12-27 00:00:00 UTC | Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know | ABT | https://www.nasdaq.com/articles/investors-heavily-search-abbott-laboratories-abt%3A-here-is-what-you-need-to-know-0 | nan | nan | Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this maker of infant formula, medical devices and drugs have returned +2.7% over the past month versus the Zacks S&P 500 composite's -4.4% change. The Zacks Medical - Products industry, to which Abbott belongs, has gained 0.6% over this period. Now the key question is: Where could the stock be headed in the near term?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Abbott is expected to post earnings of $0.90 per share for the current quarter, representing a year-over-year change of -31.8%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.
For the current fiscal year, the consensus earnings estimate of $5.21 points to no change from the prior year. Over the last 30 days, this estimate has remained unchanged.
For the next fiscal year, the consensus earnings estimate of $4.39 indicates a change of -15.6% from what Abbott is expected to report a year ago. Over the past month, the estimate has changed -0.2%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Abbott is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Abbott, the consensus sales estimate of $9.47 billion for the current quarter points to a year-over-year change of -17.4%. The $43.03 billion and $39.29 billion estimates for the current and next fiscal years indicate changes of -0.1% and -8.7%, respectively.
Last Reported Results and Surprise History
Abbott reported revenues of $10.41 billion in the last reported quarter, representing a year-over-year change of -4.7%. EPS of $1.15 for the same period compares with $1.40 a year ago.
Compared to the Zacks Consensus Estimate of $9.58 billion, the reported revenues represent a surprise of +8.67%. The EPS surprise was +26.37%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
Valuation
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Abbott is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom Line
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Abbott. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.8% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Shares of this maker of infant formula, medical devices and drugs have returned +2.7% over the past month versus the Zacks S&P 500 composite's -4.4% change. | Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Last Reported Results and Surprise History Abbott reported revenues of $10.41 billion in the last reported quarter, representing a year-over-year change of -4.7%. | Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. | Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. When earnings estimates for a company go up, the fair value for its stock goes up as well. |
31271.0 | 2022-12-24 00:00:00 UTC | 2 Healthcare Stocks You Can Buy and Hold for the Next Decade | ABT | https://www.nasdaq.com/articles/2-healthcare-stocks-you-can-buy-and-hold-for-the-next-decade-6 | nan | nan | It's a scary time to be an investor, with the markets languishing and the threat of additional interest rate hikes next year weighing on stock prices. In this environment, it is important to control risk and one way to do that is by investing in quality healthcare companies with consistent, sustainable dividends.
Cardinal Health (NYSE: CAH) and AbbVie (NYSE: ABBV) offer dependable revenue growth with above-average dividends. These are the type of value companies investors turn to in tough times and they are likely to be among the first stocks to bounce back when the economy improves.
Cardinal is in the middle of everything
Cardinal Health's stock is up more than 60% over the past year. The drug and laboratory products distributor operates in two segments: pharmaceutical and medical. In the first quarter of fiscal 2023, it reported revenue of $49.6 billion, up 13% year over year, with income from operations of $137 million, down 67% over the same period in 2022, and earnings per share (EPS) of $0.40, down 57% year over year. The pharmaceutical segment is the one fueling growth, bringing in $46 billion of the company's first-quarter revenue, up 15% year over year. Medical saw revenue fall by 9% to $3.8 billion, with lower product and distribution sales.
The company's bottom line was hurt by supply chain issues and inflation because many of its contracts are long-term, limiting how fast the company can raise prices. New CEO Jason Hollar, however, is focusing on raising prices.
Cardinal is also looking at improving its medical segment sales. In November, the company, in a collaborative effort with Medically Home, launched a supply chain network and last-mile fulfillment solution Velocare. The point is to deliver hospital-level care at home for patients, bringing critical products and services to patients within an hour or two, saving money, and bringing more efficient care.
What I like about Cardinal is it doesn't have the expenses that pharmaceutical and medical device makers do in developing and making drugs and medical devices. It carves out its own profits from being the middleman. With inflation rising so fast this past year that put a short-term strain on the company, but it is built for long-term success with less risk than most healthcare companies.
Cardinal also offers an above-average quarterly dividend, which it raised by 1% last year to $0.4957 per share, the 36th consecutive year the company has increased its dividend. Its current yield is roughly 2.5%.
CAH Revenue (Annual) data by YCharts
AbbVie is prepared for its next phase
AbbVie has proven its doubters wrong for so long that they're even joining the shareholder ranks. Over the past year, the pharmaceutical stock is up more than 20%.
The looming patent cliff for Humira has made AbbVie a better company. The immunology blockbuster's sales will likely decline beginning in 2023 when it faces biosimilar competition in the U.S. for the first time. CEO Richard Gonzalez said he expects sales for Humira to drop 45% by 2024. The anti-tumor necrosis factor therapy has long been the standard of care for inflammatory diseases such as rheumatoid arthritis and Crohn's disease.
However, AbbVie already has two drugs that are lining up to replace the $20 billion in revenue that Humira earned last year: Skyrizi and Rinvoq. Just as Humira did, the two biologics are steadily adding approvals. Skyrizi gained its third Food and Drug Administration (FDA) approval this summer, to treat moderate to severe Crohn's disease, and it also picked up that approval this fall in Europe. Rinvoq already has approvals to treat active ankylosing spondylitis (a type of arthritis along the spine), Crohn's disease, ulcerative colitis, atopic dermatitis, rheumatoid arthritis, and psoriatic arthritis.
AbbVie said last year that the two drugs should deliver $15 billion in annual revenue by 2025. They're well on the way as they combined to bring in $5.3 billion in the first nine months of this year, with Skyrizi's sales up 75.6% year over year and Rinvoq's up 54.5% in that same period.
Thanks in no small part to a big research and development budget fueled by Humira profits, the company has a huge pipeline, particularly in oncology, with 26 molecules currently in trials. Another drug with huge potential is Vraylar, which earned its fourth indication this month by the FDA, as an add-on therapy for major depressive disorder. An estimated 21 million adults in the United States had at least one major depressive episode in 2020, according to data from the Substance Abuse and Mental Health Services Administration. The drug was already approved to treat schizophrenia, manic or mixed episodes from bipolar I disorder, and depressive episodes associated with bipolar I disorder.
The company is raising its dividend by 5% next quarter to $1.48 per share, offering a yield of around 3.7%, more than double the average S&P 500 dividend of 1.82%. AbbVie, because it spent years as part of Abbott Laboratories, is a Dividend King that is on schedule to raise its dividend for the 51st straight year. The one downside to AbbVie stock is the pain of knowing you could have gotten a lower share price a few months ago, but that annoyance ends when you consider the company's potential for growth.
10 stocks we like better than Cardinal Health
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Cardinal Health wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2022
Jim Halley has positions in AbbVie. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Thanks in no small part to a big research and development budget fueled by Humira profits, the company has a huge pipeline, particularly in oncology, with 26 molecules currently in trials. An estimated 21 million adults in the United States had at least one major depressive episode in 2020, according to data from the Substance Abuse and Mental Health Services Administration. The one downside to AbbVie stock is the pain of knowing you could have gotten a lower share price a few months ago, but that annoyance ends when you consider the company's potential for growth. | Cardinal Health (NYSE: CAH) and AbbVie (NYSE: ABBV) offer dependable revenue growth with above-average dividends. The pharmaceutical segment is the one fueling growth, bringing in $46 billion of the company's first-quarter revenue, up 15% year over year. Cardinal also offers an above-average quarterly dividend, which it raised by 1% last year to $0.4957 per share, the 36th consecutive year the company has increased its dividend. | In the first quarter of fiscal 2023, it reported revenue of $49.6 billion, up 13% year over year, with income from operations of $137 million, down 67% over the same period in 2022, and earnings per share (EPS) of $0.40, down 57% year over year. Cardinal also offers an above-average quarterly dividend, which it raised by 1% last year to $0.4957 per share, the 36th consecutive year the company has increased its dividend. They're well on the way as they combined to bring in $5.3 billion in the first nine months of this year, with Skyrizi's sales up 75.6% year over year and Rinvoq's up 54.5% in that same period. | The pharmaceutical segment is the one fueling growth, bringing in $46 billion of the company's first-quarter revenue, up 15% year over year. Over the past year, the pharmaceutical stock is up more than 20%. Skyrizi gained its third Food and Drug Administration (FDA) approval this summer, to treat moderate to severe Crohn's disease, and it also picked up that approval this fall in Europe. |
31272.0 | 2022-12-24 00:00:00 UTC | 3 Stocks on Santa's Nice List to Buy Before 2023 | ABT | https://www.nasdaq.com/articles/3-stocks-on-santas-nice-list-to-buy-before-2023 | nan | nan | Santa's known for making lists and checking them twice, and that's a great idea if you're an investor. It's important to create a watch list and survey those stocks for potential buying opportunities.
Of course, we don't know if Santa is an investor. But if he were, he probably would put a certain kind of stock on his "nice" list. Santa would favor stocks that keep on giving over time -- such as those with dividend growth.
Understanding as he is, Santa would scoop up shares that have declined this year -- if the companies demonstrated earnings strength that could power future growth. Let's check out three Santa-style stocks to buy before 2023.
1. Home Depot
Home Depot (NYSE: HD) falls into the category of companies with shares that have dropped -- even as earnings advanced. The world's biggest home-improvement retailer is heading for a 24% loss this year.
This has left Home Depot trading for about 18 times forward earnings estimates. That's down from more than 24 earlier in the year.
At the earlier level, Home Depot was a buy. At today's level, it's a steal.
The company has continued to grow revenue and profit, even in today's tough environment. In the most recent quarter, all of the company's 19 U.S. regions posted positive comparable-sales growth. And 11 of the 14 merchandising categories reported positive comparable-sales growth, too.
Return on invested capital (ROIC) has dipped somewhat this year but has remained high over time. This indicates the company is benefiting from its investments.
HD Return on Invested Capital data by YCharts.
Importantly, Home Depot's two customer types -- the do-it-yourselfer and the professional -- remain healthy. The pro customer is a particularly good guide for what may happen in the future. Their backlogs offer us clues about project volume. And pros are telling Home Depot backlogs are strong.
All of this makes Home Depot a great buy now -- and one that could deliver big over the long term.
2. Abbott Laboratories
Abbott Laboratories (NYSE: ABT) is a stock that will keep on giving. The healthcare company is a Dividend King and has raised its dividend for at least 50 consecutive years.
Why is this good for you if you're only investing in Abbott as of now? It shows dividend growth is important to the company, so it's likely it will continue to boost its dividend over time. And the company's earnings growth indicates it can afford to do that.
Abbott has grown revenue, profit, and free cash flow over time.
ABT Free Cash Flow data by YCharts.
In the most recent quarter, Abbott reported sales of more than $10 billion and raised its earnings-per-share guidance for the year. The company has four business units: diagnostics, medical devices, established pharmaceuticals, and nutrition. Three of them have increased sales over the first nine months of the year.
The advantage of having four distinct businesses is that when one of them sees a decline in sales, the other units may compensate. For instance, a baby formula recall weighed on the nutrition business this year. But regulatory approvals in the medical-devices unit helped that business to compensate.
Abbott shares have declined 24% this year. That leaves them trading at about 20 times forward earnings estimates, a reasonable valuation for a company offering passive income and earnings growth over time.
3. Tesla
Tesla (NASDAQ: TSLA) is heading for a 60% decrease this year. Why have investors turned their backs on the electric-vehicle (EV) giant? They've worried about the impact of today's tough economy on the company. After all, higher interest rates are increasing costs, and currency-exchange rates are weighing on the value of sales.
These problems won't disappear overnight, but it's important to take a long-term view when investing in stocks. That means looking at a time frame of at least five years. And from this angle, the Tesla story still looks bright.
Even in today's difficult environment, Tesla has managed to report record revenue, operating profit, and free cash flow. The company is ramping up operations at two huge new factories and has grown vehicle deliveries in the double digits.
Tesla also remains the leader in both the regular U.S. EV market and the luxury market.
All of these factors are reasons to be confident about Tesla's prospects over time, especially considering the stock's current valuation. It's trading at 33 times forward earnings estimates, down from more than 80 earlier this year. Considering Tesla's leadership and future potential, the stock is a steal right now.
10 stocks we like better than Home Depot
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Home Depot wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2022
Adria Cimino has positions in Home Depot and Tesla. The Motley Fool has positions in and recommends Abbott Laboratories, Home Depot, and Tesla. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a stock that will keep on giving. ABT Free Cash Flow data by YCharts. Understanding as he is, Santa would scoop up shares that have declined this year -- if the companies demonstrated earnings strength that could power future growth. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a stock that will keep on giving. ABT Free Cash Flow data by YCharts. Abbott has grown revenue, profit, and free cash flow over time. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a stock that will keep on giving. ABT Free Cash Flow data by YCharts. Home Depot Home Depot (NYSE: HD) falls into the category of companies with shares that have dropped -- even as earnings advanced. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a stock that will keep on giving. ABT Free Cash Flow data by YCharts. At the earlier level, Home Depot was a buy. |
31273.0 | 2022-12-22 00:00:00 UTC | FOCUS-U.S. baby formula shortage leads to boom in advertisements | ABT | https://www.nasdaq.com/articles/focus-u.s.-baby-formula-shortage-leads-to-boom-in-advertisements | nan | nan | By Jessica DiNapoli
NEW YORK, Dec 22 (Reuters) - It's not your imagination if you feel like you're seeing more ads for baby formula than ever before.
Formula makers have stepped up marketing campaigns to grab a bigger piece of the lucrative, $5.6 billion formula market, after a severe shortage earlier this year shook consumer confidence, said Allen Sayler, an industry consultant.
The months-long closure of Abbott Laboratories' ABT.N formula plant in Michigan, after complaints of bacterial infections in infants, eroded the Similac maker's market share. Other brands had a chance to step in due to relaxed government rules, frantic parents looking for formula and retailers like Walmart WMT.N seeking alternatives, Sayler said.
“A high level of uncertainty on supply created business opportunities that did not exist before,” Sayler said, adding that formula makers are attracted to the United States because birth rates are higher than Europe, China and Japan and many U.S. moms return to work outside the home.
Profit margins have also grown, according to a report from industry research firm IBISWorld.
The number of viewers of TV and streaming ads for formula skyrocketed to roughly 562 million this year, up from just 200,000 last year, according to data from media measurement firm ISpotTV. Some ads came from new brands the U.S. government approved to ease the shortage. Others came from already approved brands stepping up marketing.
French dairy producer Danone SA DANO.PA made an exception to its internal policy against advertising formula due to the U.S. shortage, a spokesperson said.
The World Health Organization (WHO) asks that governments and companies ban advertising of baby formula to guard against predatory marketing practices and encourage breastfeeding, which it recommends as the healthier choice. The United States never enacted legislation enforcing the WHO advertising ban.
To be sure, breastfeeding is not always possible and formula is an essential food.
Danone ran the biggest of the formula campaigns this year for its Aptamil brand, recently allowed by regulators on U.S. shelves, ISpotTV found.
Danone spent roughly $2.1 million to air commercials on NBC, the Hallmark channel and ION, according to ISpotTV. The ads tout that Aptamil is Europe’s No.1 formula, and “now we’re here for you.” The ads are still airing on streaming services, and the campaign has boosted awareness of Aptamil, an executive said.
Danone's aim with the commercials is to "accelerate education" as "we're still seeing bare shelves across the country," the spokesperson said.
An average of roughly 77% of infant formula was in stock in December across major U.S. retailers, up from 51% in June, according to e-commerce analytics firm Dataweave.
An executive from Reckitt Benckiser Group Plc RKT.L, which makes Enfamil, recently told Reuters he expects the formula shortage will persist until the spring.
Three million viewers spotted Enfamil's streaming and local TV ads for its Gentlease formula this year, according to ISpotTV. A fraction of that figure saw Enfamil ads in 2021.
ISpotTV does not track spending on streaming and local TV campaigns.
A Reckitt spokesperson said that online videos have been part of its "media mix" for several years and that its expansion into streaming platforms is part of the company's strategy.
The U.K.-based company has a policy prohibiting advertising formula in countries with high child mortality and malnutrition rates. The policy "acknowledges the importance and supports the aim and principles" of the WHO Code.
The last significant U.S. TV advertising campaign for formula was in 2017, when Enfamil ran commercials for its formula for toddlers over 1 year old, according to ISpotTV.
Brands have also targeted .
U.S.-based formula company Bobbie, which saw its sales soar in the shortage, ran an ad featuring supermodel Ashley Graham on ABC's "Bachelor in Paradise" last month, attracting 5 million views, ISpotTV found.
ISpotTV pegged the cost of the ad at $71,000 but a Bobbie spokeswoman said it was less without sharing the exact figure.
In the commercial, Graham talks about overcoming the stigma of bottle-feeding. Bobbie's strategy for advertising is to "show up" for parents, who deserve to learn about formula in the same way they would for any other product, said CEO Laura Modi.
"The...approach to stop all formula companies from advertising has swung the pendulum in another direction where formula is within the same category as cigarettes," Modi said. "This fuels guilt and prevents new, next-generation companies from establishing their own, ethical approach."
EXCLUSIVE -Reckitt expects U.S. infant formula shortage until spring
FOCUS-How infant formula makers are saturating mothers' social media
(Reporting by Jessica DiNapoli in New York; additional reporting by Richa Naidu in London; Editing by Lisa Shumaker)
((Jessica.DiNapoli@thomsonreuters.com; 845-591-4428;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The months-long closure of Abbott Laboratories' ABT.N formula plant in Michigan, after complaints of bacterial infections in infants, eroded the Similac maker's market share. “A high level of uncertainty on supply created business opportunities that did not exist before,” Sayler said, adding that formula makers are attracted to the United States because birth rates are higher than Europe, China and Japan and many U.S. moms return to work outside the home. The World Health Organization (WHO) asks that governments and companies ban advertising of baby formula to guard against predatory marketing practices and encourage breastfeeding, which it recommends as the healthier choice. | The months-long closure of Abbott Laboratories' ABT.N formula plant in Michigan, after complaints of bacterial infections in infants, eroded the Similac maker's market share. Three million viewers spotted Enfamil's streaming and local TV ads for its Gentlease formula this year, according to ISpotTV. U.S.-based formula company Bobbie, which saw its sales soar in the shortage, ran an ad featuring supermodel Ashley Graham on ABC's "Bachelor in Paradise" last month, attracting 5 million views, ISpotTV found. | The months-long closure of Abbott Laboratories' ABT.N formula plant in Michigan, after complaints of bacterial infections in infants, eroded the Similac maker's market share. Formula makers have stepped up marketing campaigns to grab a bigger piece of the lucrative, $5.6 billion formula market, after a severe shortage earlier this year shook consumer confidence, said Allen Sayler, an industry consultant. The last significant U.S. TV advertising campaign for formula was in 2017, when Enfamil ran commercials for its formula for toddlers over 1 year old, according to ISpotTV. | The months-long closure of Abbott Laboratories' ABT.N formula plant in Michigan, after complaints of bacterial infections in infants, eroded the Similac maker's market share. The number of viewers of TV and streaming ads for formula skyrocketed to roughly 562 million this year, up from just 200,000 last year, according to data from media measurement firm ISpotTV. Danone ran the biggest of the formula campaigns this year for its Aptamil brand, recently allowed by regulators on U.S. shelves, ISpotTV found. |
31274.0 | 2022-12-22 00:00:00 UTC | Abbott's (ABT) FreeStyle Libre 3 Integrates With AID System | ABT | https://www.nasdaq.com/articles/abbotts-abt-freestyle-libre-3-integrates-with-aid-system | nan | nan | Abbott Laboratories ABT recently announced that its FreeStyle Libre 3 sensor integrated with the mylife Loop solution — building a smart, automated process to deliver insulin based on real-time glucose data. This automated insulin delivery system (AID) solution is now available in Germany and will be accessible in other European countries starting in 2023.
It is worth mentioning that the mylife Loop solution is the first automated insulin delivery system in the world to work with Abbott's FreeStyle Libre 3 sensor.
With the latest development, Abbott is expected to bolster its diabetes care segment.
More on the News
Abbott’s FreeStyle Libre portfolio is already supporting to better 4.5 million diabetes patients’ lives globally. Advanced diabetes technologies, such as AID systems, are intended to aid people living with diabetes by improving their glucose control and minimizing the burden of daily diabetes management.
For investors’ note, the hybrid closed-loop system mylife Loop combines technology from two partners, Ypsomed and CamDiab. CamDiab's algorithm automatically adjusts insulin dosage on Ypsomed's insulin pump, while the mylife YpsoPump is based on accurate, real-time glucose information from FreeStyle Libre 3 sensor.
Furthermore, Abbott is working to make the FreeStyle Libre platform interoperable with other leading insulin delivery systems in addition to associating with Ypsomed and CamDiab. At present, the mylife Loop AID solution is not available in the United States.
Significance of the Integration
By Integrating CamDiab's CamAPS FX mobile app and Ypsomed's mylife YpsoPump with accurate, real-time data from Abbott's FreeStyle Libre 3 sensor, the connected solution continuously tracks a person's glucose levels, adjusts and delivers the coorect amount of insulin at the right time, reduces diabetes complications and helps diabetes patients reach better treatment targets.
Image Source: Zacks Investment Research
Per Abbott’s management, partnering with diabetes and digital health technology providers like Ypsomed and CamDiab will help the company to provide new advanced solutions that make diabetes care more simple.
Industry Prospects
Per a report published in Allied Market research, the global continuous glucose monitoring systems’ market size is expected to see a CAGR of 22% by 2027. Factors, including a surge in the geriatric population and the increasing prevalence of diabetes, are expected to fuel market growth.
Recent Developments
During the third quarter, Abbott diabetes business achieved organic sales growth of 12.9% in the third quarter of 2022, led by strong growth in FreeStyle Libre. In the quarter, sales of FreeStyle Libre exceeded $1 billion. Abbott’s user base expanded to approximately 4.5 million users globally. In the United States, where sales grew more than 40%, the company initiated the full launch of Libre 3. This latest device can automatically deliver up-to-the-minute glucose readings with more accuracy in the world’s smallest and thinnest wearable sensor.
In September 2022, Abbott presented new data from the Real World Evidence of FreeStyle Libre (RELIEF) study at the 58th Annual European Association for the Study of Diabetes (EASD) meeting. According to the latest findings, Type 2 diabetes patients receiving once-daily (basal) insulin therapy experienced a significantly lower rate of hospitalizations from acute diabetes events (ADEs) when using the FreeStyle Libre, a continuous glucose monitoring system (CGM).
Price Performance
Shares of the company have lost 22.3% in a year compared with the industry’s fall of 45%.
Zacks Rank and Key Picks
Currently, Abbott carries a Zacks Rank #3 (Hold).
Few other better-ranked stocks in the broader medical space that investors can consider are ShockWave Medical, Inc. SWAV, Orthofix Medical Inc. OFIX and Merit Medical System MMSI.
ShockWave Medical, sporting a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 33.1% for 2023. The company’s earnings surpassed estimates in all the trailing four quarters, the average beat being 180.1%.
ShockWave Medical has outperformed its industry in the past year. SWAV has gained 35% against the industry’s 32.6% fall in the past year.
Orthofix Medical, currently carrying a Zacks Rank #1 (Strong Buy), reported third-quarter 2022 adjusted EPS of 13 cents, which beat the Zacks Consensus Estimate by a stupendous 550%. Revenues of $114 million outpaced the consensus mark by 2.7%.
Orthofix Medical has an estimated next-year growth rate of 58.97%. MMSI’s earnings surpassed estimates in the trailing three quarters and missed in one, the average being 129.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Merit Medical, currently carrying a Zacks Rank of 2, reported third-quarter 2022 adjusted EPS of 64 cents, which beat the Zacks Consensus Estimate by 20.8%. Revenues of $287.2 million outpaced the consensus mark by 5.2%.
Merit Medical has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average being 25.4%.
Zacks Top 10 Stocks for 2023
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2023? From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500’s +287.4%.
Now our Director of Research is combing through 4,000 companies covered by the Zacks Rank to handpick the best 10 tickers to buy and hold. Don’t miss your chance to get in on these stocks when they’re released on January 3.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT recently announced that its FreeStyle Libre 3 sensor integrated with the mylife Loop solution — building a smart, automated process to deliver insulin based on real-time glucose data. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. It is worth mentioning that the mylife Loop solution is the first automated insulin delivery system in the world to work with Abbott's FreeStyle Libre 3 sensor. | Abbott Laboratories ABT recently announced that its FreeStyle Libre 3 sensor integrated with the mylife Loop solution — building a smart, automated process to deliver insulin based on real-time glucose data. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Orthofix Medical, currently carrying a Zacks Rank #1 (Strong Buy), reported third-quarter 2022 adjusted EPS of 13 cents, which beat the Zacks Consensus Estimate by a stupendous 550%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT recently announced that its FreeStyle Libre 3 sensor integrated with the mylife Loop solution — building a smart, automated process to deliver insulin based on real-time glucose data. Significance of the Integration By Integrating CamDiab's CamAPS FX mobile app and Ypsomed's mylife YpsoPump with accurate, real-time data from Abbott's FreeStyle Libre 3 sensor, the connected solution continuously tracks a person's glucose levels, adjusts and delivers the coorect amount of insulin at the right time, reduces diabetes complications and helps diabetes patients reach better treatment targets. | Abbott Laboratories ABT recently announced that its FreeStyle Libre 3 sensor integrated with the mylife Loop solution — building a smart, automated process to deliver insulin based on real-time glucose data. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. More on the News Abbott’s FreeStyle Libre portfolio is already supporting to better 4.5 million diabetes patients’ lives globally. |
31275.0 | 2022-12-22 00:00:00 UTC | 2 Beaten-Down Growth Stocks Set to Rebound in 2023 | ABT | https://www.nasdaq.com/articles/2-beaten-down-growth-stocks-set-to-rebound-in-2023 | nan | nan | This year's bear market crushed many companies that otherwise have solid businesses and excellent prospects.
Take, for instance, medical device giants Intuitive Surgical (NASDAQ: ISRG) and Abbott Laboratories (NYSE: ABT). Neither has escaped the sell-off, and both are lagging the market this year. But there are excellent reasons to think they could recover as early as next year, and even if they don't, patient investors will want to take the opportunity to buy their shares at a discount and hold them for a while.
Let's look closer at what makes these companies such excellent options.
1. Intuitive Surgical
Despite a terrible performance this year, Intuitive Surgical seems to be recovering -- that is, if its performance in the past three months is any indication. One key reason why the maker of the da Vinci robotic surgical system is on the rebound is that it continues to deliver decent financial results despite the challenging economic environment.
Intuitive Surgical's revenue increased by about 11% year over year in the third quarter to $1.56 billion, while its adjusted earnings per share (EPS) remained flat at $1.19. There is another reason why Intuitive Surgical is on a solid run. In October, it announced a $1 billion share repurchase program. Stock buybacks can impact a company's stock in several ways. First, having fewer shares on the market can boost a company's stock price.
Second, it shows the confidence that management -- which has an up-close view of the business -- has in the company's prospects. That's a good sign in the eyes of investors, who often respond by bidding up a company's shares. Intuitive Surgical could carry this momentum into the new year.
Another piece of good news for the company is that supply chain issues, which have disrupted its placement of da Vinci systems, seem to be easing. That could contribute to the sale of more of its crown jewel next year. Beyond these dynamics that could impact Intuitive Surgical in the next 12 months, the healthcare giant is well-positioned for long-term growth.
Robotic-assisted surgery confers important benefits such as shorter hospital stays, less scarring, less bleeding, and faster recovery. The company has an installed base of 7,364 da Vinci systems worldwide -- and growing. The company's revenue will expand as there are more procedures performed with its system, which will increase the demand for instruments and accessories it sells.
Procedure growth will also likely occur due to long-term trends such as the world's aging population. People will need medical services in their older days. Further, Intuitive Surgical's da Vinci system costs between $500,000 and $2.5 million, not to mention countless hours of training to master. The company benefits from high switching costs as a result, a solid competitive edge.
In short, the company has what it needs to consistently deliver robust financial results and stock market returns for a long time.
2. Abbott Laboratories
Abbott Laboratories is a medical device specialist with a diversified business. Some of its operations have encountered headwinds this year, including a recall of its baby formula products. The healthcare giant's financial results also haven't been spectacular. Total sales decreased by 4.7% year over year in the third quarter to $10.4 billion.
The company's adjusted earnings per share came in at $1.15 for the quarter, down from the $1.40 reported in the year-ago period. How can Abbott rebound next year? First, note that many of the company problems are temporary. Its sales decline in the third quarter was partly due to unfavorable currency exchange fluctuations. Putting that aside, the company's total revenue climbed by 1.3% year over year.
That's still not that impressive, but it's a lot better than its reported sales drop. Then there is the impact the recall of its baby formula had on its top line -- and on its public image. The company initially stopped producing baby formula at some of its facilities due to these dynamics, but it resumed production during the third quarter.
Then there are year-over-year comparisons in Abbott's diagnostics business. It reported stronger sales of coronavirus tests last year. In 2023, the company could still lose ground in this area as the pandemic (hopefully) continues to fade. But the impact of COVID-related sales will also weigh less on the company overall as its medical device business continues to grow thanks partly to new launches.
Abbott Laboratories expects various new products to aid its progress, including its FreeStyle Libre 3, a continuous glucose monitoring (CGM) system that helps diabetes patients keep their blood glucose levels in check. The company recently started the full rollout of the FreeStyle Libre 3 in the U.S. Abbott's FreeStyle Libre devices already have an installed base of about 4.5 million users worldwide.
It is arguably one of the most promising growth drivers for Abbott Laboratories. But the company is also making progress in other areas, including within its structural heart business. Abbott's stock market performance hasn't been that much worse than that of the broader market this year. And with a booming medical device business and troubles related to its baby formula in the rearview mirror, it should have a stronger showing in 2023.
See beyond next year
There can be no guarantee that Abbott Laboratories and Intuitive Surgical will manage to turn things around in 2023. A recession could hit, or either corporation could face company-specific issues that will sink their share prices. But these two healthcare giants are leaders in their respective fields and boast plenty of growth left. That's why investors should consider adding both to their portfolios regardless of what happens in 2023.
10 stocks we like better than Intuitive Surgical
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Intuitive Surgical wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2022
Prosper Junior Bakiny has positions in Intuitive Surgical. The Motley Fool has positions in and recommends Abbott Laboratories and Intuitive Surgical. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Take, for instance, medical device giants Intuitive Surgical (NASDAQ: ISRG) and Abbott Laboratories (NYSE: ABT). But there are excellent reasons to think they could recover as early as next year, and even if they don't, patient investors will want to take the opportunity to buy their shares at a discount and hold them for a while. One key reason why the maker of the da Vinci robotic surgical system is on the rebound is that it continues to deliver decent financial results despite the challenging economic environment. | Take, for instance, medical device giants Intuitive Surgical (NASDAQ: ISRG) and Abbott Laboratories (NYSE: ABT). Intuitive Surgical's revenue increased by about 11% year over year in the third quarter to $1.56 billion, while its adjusted earnings per share (EPS) remained flat at $1.19. The company recently started the full rollout of the FreeStyle Libre 3 in the U.S. Abbott's FreeStyle Libre devices already have an installed base of about 4.5 million users worldwide. | Take, for instance, medical device giants Intuitive Surgical (NASDAQ: ISRG) and Abbott Laboratories (NYSE: ABT). Intuitive Surgical Despite a terrible performance this year, Intuitive Surgical seems to be recovering -- that is, if its performance in the past three months is any indication. Intuitive Surgical's revenue increased by about 11% year over year in the third quarter to $1.56 billion, while its adjusted earnings per share (EPS) remained flat at $1.19. | Take, for instance, medical device giants Intuitive Surgical (NASDAQ: ISRG) and Abbott Laboratories (NYSE: ABT). First, having fewer shares on the market can boost a company's stock price. Beyond these dynamics that could impact Intuitive Surgical in the next 12 months, the healthcare giant is well-positioned for long-term growth. |
31276.0 | 2022-12-22 00:00:00 UTC | Is A Rise Imminent For Guardant Health Stock After A 38% Fall In A Month? | ABT | https://www.nasdaq.com/articles/is-a-rise-imminent-for-guardant-health-stock-after-a-38-fall-in-a-month | nan | nan | Guardant Health stock (NASDAQ: GH), a healthcare company that offers non-invasive cancer diagnosis tests, has seen a fall of 38% in a month, while it’s down 70% this year. This compares with -4% and -20% returns for the broader S&P500 index over the same periods, respectively. This recent underperformance can primarily be attributed to underwhelming results from a study of its test for detecting colorectal cancer (CRC). The test showed 83% sensitivity in detecting individuals with CRC, slightly lower than 92% sensitivity for a rival’s stool-based DNA test. The lower sensitivity rate of Guardant didn’t sit well with the investors, evident from the sharp stock decline for GH. However, the stock price correction appears to be overdone, in our view. The 83% sensitivity rate is good and exceeds the performance criteria set by the Centers for Medicare & Medicaid Services for reimbursement, as reported by the company. The company will likely submit its premarket approval submission to the FDA in the next few months.
But now that GH stock has seen a significant 38% fall in a month, will it continue its downward trajectory, or is a rise imminent? Going by historical performance, there is a very high chance of an increase in GH stock over the next month. GH stock has seen a move of -38% or more 15 times in the last four years. Of those, all 15 resulted in GH stock rising over the subsequent one-month period (twenty-one trading days). This historical pattern reflects a very high 15 out of 15, or more than a 90% chance of a rise in GH stock over the coming month. See our analysis on Guardant Health Stock Chance of Rise for more details.
Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using the last seven years’ data
After moving -34% or more over five days, the stock rose on 67% of the occasions in the next five days.
After moving -42% or more over ten days, the stock rose on 86% of the occasions in the next ten days.
After moving -38% or more over a twenty-one-day period, the stock rose on 100% of the occasions in the next twenty-one days.
This pattern suggests a higher chance of a rise in GH stock over the next five, ten, and twenty-one days.
The Covid-19 crisis has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised at how counter-intuitive the stock valuation is for Phibro Animal Health vs. Paramount Global.
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
Returns Dec 2022
MTD [1] 2022
YTD [1] 2017-22
Total [2]
GH Return -42% -70% -20%
S&P 500 Return -6% -20% 71%
Trefis Multi-Strategy Portfolio -7% -23% 209%
[1] Month-to-date and year-to-date as of 12/20/2022
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Guardant Health stock (NASDAQ: GH), a healthcare company that offers non-invasive cancer diagnosis tests, has seen a fall of 38% in a month, while it’s down 70% this year. The lower sensitivity rate of Guardant didn’t sit well with the investors, evident from the sharp stock decline for GH. The 83% sensitivity rate is good and exceeds the performance criteria set by the Centers for Medicare & Medicaid Services for reimbursement, as reported by the company. | Guardant Health stock (NASDAQ: GH), a healthcare company that offers non-invasive cancer diagnosis tests, has seen a fall of 38% in a month, while it’s down 70% this year. See our analysis on Guardant Health Stock Chance of Rise for more details. Total [2] GH Return -42% -70% -20% S&P 500 Return -6% -20% 71% Trefis Multi-Strategy Portfolio -7% -23% 209% [1] Month-to-date and year-to-date as of 12/20/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Guardant Health stock (NASDAQ: GH), a healthcare company that offers non-invasive cancer diagnosis tests, has seen a fall of 38% in a month, while it’s down 70% this year. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using the last seven years’ data After moving -34% or more over five days, the stock rose on 67% of the occasions in the next five days. Total [2] GH Return -42% -70% -20% S&P 500 Return -6% -20% 71% Trefis Multi-Strategy Portfolio -7% -23% 209% [1] Month-to-date and year-to-date as of 12/20/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Guardant Health stock (NASDAQ: GH), a healthcare company that offers non-invasive cancer diagnosis tests, has seen a fall of 38% in a month, while it’s down 70% this year. Of those, all 15 resulted in GH stock rising over the subsequent one-month period (twenty-one trading days). Total [2] GH Return -42% -70% -20% S&P 500 Return -6% -20% 71% Trefis Multi-Strategy Portfolio -7% -23% 209% [1] Month-to-date and year-to-date as of 12/20/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
31277.0 | 2022-12-21 00:00:00 UTC | Abbott : FreeStyle Libre 3 Integrated With Automated Insulin Delivery System Mylife Loop In Germany | ABT | https://www.nasdaq.com/articles/abbott-%3A-freestyle-libre-3-integrated-with-automated-insulin-delivery-system-mylife-loop | nan | nan | (RTTNews) - Abbott (ABT) announced that its FreeStyle Libre 3 sensor is now compatible with the mylife Loop solution from partners, Ypsomed and CamDiab, creating a smart, automated process to deliver insulin based on real-time glucose data.
The company noted that the automated insulin delivery system (AID) solution is now available in Germany and will be available in additional European countries beginning in 2023. But the AID solution is currently not available in the United States.
Integrating CamDiab's CamAPS FX mobile app and Ypsomed's mylifeTM YpsoPump with accurate, real-time data from Abbott's FreeStyle Libre 3 sensor, the connected solution continuously monitors a person's glucose levels, and automatically adjusts and delivers the right amount of insulin at the right time, removing the guesswork of insulin dosing and helping people with diabetes reach better treatment targets.
In addition to partnering with Ypsomed and CamDiab, Abbott said it is working to make the FreeStyle Libre platform interoperable with other leading insulin delivery systems.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) announced that its FreeStyle Libre 3 sensor is now compatible with the mylife Loop solution from partners, Ypsomed and CamDiab, creating a smart, automated process to deliver insulin based on real-time glucose data. Integrating CamDiab's CamAPS FX mobile app and Ypsomed's mylifeTM YpsoPump with accurate, real-time data from Abbott's FreeStyle Libre 3 sensor, the connected solution continuously monitors a person's glucose levels, and automatically adjusts and delivers the right amount of insulin at the right time, removing the guesswork of insulin dosing and helping people with diabetes reach better treatment targets. In addition to partnering with Ypsomed and CamDiab, Abbott said it is working to make the FreeStyle Libre platform interoperable with other leading insulin delivery systems. | (RTTNews) - Abbott (ABT) announced that its FreeStyle Libre 3 sensor is now compatible with the mylife Loop solution from partners, Ypsomed and CamDiab, creating a smart, automated process to deliver insulin based on real-time glucose data. The company noted that the automated insulin delivery system (AID) solution is now available in Germany and will be available in additional European countries beginning in 2023. Integrating CamDiab's CamAPS FX mobile app and Ypsomed's mylifeTM YpsoPump with accurate, real-time data from Abbott's FreeStyle Libre 3 sensor, the connected solution continuously monitors a person's glucose levels, and automatically adjusts and delivers the right amount of insulin at the right time, removing the guesswork of insulin dosing and helping people with diabetes reach better treatment targets. | (RTTNews) - Abbott (ABT) announced that its FreeStyle Libre 3 sensor is now compatible with the mylife Loop solution from partners, Ypsomed and CamDiab, creating a smart, automated process to deliver insulin based on real-time glucose data. Integrating CamDiab's CamAPS FX mobile app and Ypsomed's mylifeTM YpsoPump with accurate, real-time data from Abbott's FreeStyle Libre 3 sensor, the connected solution continuously monitors a person's glucose levels, and automatically adjusts and delivers the right amount of insulin at the right time, removing the guesswork of insulin dosing and helping people with diabetes reach better treatment targets. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) announced that its FreeStyle Libre 3 sensor is now compatible with the mylife Loop solution from partners, Ypsomed and CamDiab, creating a smart, automated process to deliver insulin based on real-time glucose data. But the AID solution is currently not available in the United States. In addition to partnering with Ypsomed and CamDiab, Abbott said it is working to make the FreeStyle Libre platform interoperable with other leading insulin delivery systems. |
31278.0 | 2022-12-20 00:00:00 UTC | What Stocks To Buy Today? 3 Dividend Aristocrats To Watch | ABT | https://www.nasdaq.com/articles/what-stocks-to-buy-today-3-dividend-aristocrats-to-watch | nan | nan | Dividend Aristocrats are stocks that have consistently increased their dividends for 25 consecutive years or more. These stocks are often considered a good choice for long-term investors seeking a reliable source of income. In this article, we’ll explore what dividend aristocrats are and provide an overview of three dividend aristocrats that you may want to watch in the stock market today.
First, let’s define what dividends are and how they work. Dividends are payments made by a company to its shareholders out of its profits or reserves. These payments are typically made in cash. However, they can also pay in the form of additional shares of stock or other assets. Companies may choose to pay dividends for a variety of reasons, such as to reward shareholders for their investment or to distribute excess cash that the company is not using for other purposes.
Dividend aristocrats are stocks that have consistently raised their dividends for 25 straight years or longer. These companies are known for their strong financial performance, stability, and ability to consistently generate profits. With that being said, let’s take a look at three dividend aristocrats to check out in thestock market today
Dividend Aristocrats To Watch Right Now
Abbott Laboratories (NYSE: ABT)
Archer-Daniels-Midland Company (NYSE: ADM)
Dover Corporation (NYSE: DOV)
Abbott Laboratories (ABT Stock)
Leading off, Abbott Laboratories (ABT) is a healthcare company that operates in a wide range of markets, including pharmaceuticals, medical devices, and consumer healthcare products.
This month, the company announced that its Board of Directors has declared an increase in ABT’s quarterly dividend on common stock. In detail, Abbott increased its quarterly dividend to $0.51 per share. This reflects an 8.5% jump. Also, this dividend is Abbott’s 51st consecutive year of increasing its dividend. Meanwhile, the company said the dividend is payable on February 15, 2023, to shareholders of record at the close of business on January 13, 2023.
In the last month of trading action, shares of ABT stock have started to recover by 2.40%, though shares are still down 23.50% year-to-date. Meanwhile, as of Tuesday afternoon’s trading session, ABT stock is trading at $106.46 a share.
Source: TD Ameritrade TOS
[Read More] 2 EV Stocks To Watch Right Now
Archer-Daniels-Midland (ADM Stock)
Next, Archer-Daniels-Midland Company (ADM) is a global agricultural processing company. For starters, the company operates in a wide range of markets, including feed, food, and industrial products. The company’s products include animal feed, plant-based protein, sweeteners, and food ingredients, among others. Today, ADM offers its shareholders a quarterly dividend of $0.20 per common stock. This results in an annual dividend yield of 1.72%.
Back in October, Archer-Daniels-Midland reported a beat for its third-quarter 2022 financial results. Getting straight into it, the company reported Q3 2022 earnings of $1.86 per share, along with revenue of $24.7 billion. This is versus Wall Street estimates for the quarter, which were earnings of $1.42 per share on revenue of $22.4 billion. Additionally, ADM notched in a 21.4% increase in revenue versus the same period, a year prior.
Moving along, year-to-date, Archer-Daniels-Midland stock is up 37.19%, outperforming the broader markets so far in 2022. Meanwhile, as of Tuesday’s afternoon trading action, shares of ADM stock are trading slightly higher on the day by 0.35% at $92.97 a share.
Source: TD Ameritrade TOS
[Read More] Cheap Stocks To Buy Now? 2 Tech Stocks To Watch In 2022
Dover Corp (DOV Stock)
Last but not least, Dover Corporation (DOV) is a diversified global manufacturer. The company operates in a broad range of industries, including energy, industrial, and aerospace. The company’s products include drilling and production equipment, engineered systems, and aerospace components, among others. Currently, Dover has a quarterly cash dividend of $0.51, which results in an annual dividend yield of 1.52%.
In late October, Dover Corp reported in-line results in its Q3 2022 financial results. In detail, the company posted 3rd quarter 2022 earnings of $2.26 per share and revenue of $2.2 billion. For context, analysts’ consensus estimates for the quarter were earnings of $1.20 per share and revenue of $2.2 billion.
Continuing on, over the past six months of trading, shares of DOV stock have rebounded by 11.77%. Meanwhile, as of Tuesday’s close, DOV stock closed the trading day modestly higher by 0.66% at $133.25 a share.
Source: TD Ameritrade TOS
If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel.
CLICK HERE RIGHT NOW!!
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With that being said, let’s take a look at three dividend aristocrats to check out in thestock market today Dividend Aristocrats To Watch Right Now Abbott Laboratories (NYSE: ABT) Archer-Daniels-Midland Company (NYSE: ADM) Dover Corporation (NYSE: DOV) Abbott Laboratories (ABT Stock) Leading off, Abbott Laboratories (ABT) is a healthcare company that operates in a wide range of markets, including pharmaceuticals, medical devices, and consumer healthcare products. This month, the company announced that its Board of Directors has declared an increase in ABT’s quarterly dividend on common stock. In the last month of trading action, shares of ABT stock have started to recover by 2.40%, though shares are still down 23.50% year-to-date. | With that being said, let’s take a look at three dividend aristocrats to check out in thestock market today Dividend Aristocrats To Watch Right Now Abbott Laboratories (NYSE: ABT) Archer-Daniels-Midland Company (NYSE: ADM) Dover Corporation (NYSE: DOV) Abbott Laboratories (ABT Stock) Leading off, Abbott Laboratories (ABT) is a healthcare company that operates in a wide range of markets, including pharmaceuticals, medical devices, and consumer healthcare products. This month, the company announced that its Board of Directors has declared an increase in ABT’s quarterly dividend on common stock. In the last month of trading action, shares of ABT stock have started to recover by 2.40%, though shares are still down 23.50% year-to-date. | With that being said, let’s take a look at three dividend aristocrats to check out in thestock market today Dividend Aristocrats To Watch Right Now Abbott Laboratories (NYSE: ABT) Archer-Daniels-Midland Company (NYSE: ADM) Dover Corporation (NYSE: DOV) Abbott Laboratories (ABT Stock) Leading off, Abbott Laboratories (ABT) is a healthcare company that operates in a wide range of markets, including pharmaceuticals, medical devices, and consumer healthcare products. This month, the company announced that its Board of Directors has declared an increase in ABT’s quarterly dividend on common stock. In the last month of trading action, shares of ABT stock have started to recover by 2.40%, though shares are still down 23.50% year-to-date. | With that being said, let’s take a look at three dividend aristocrats to check out in thestock market today Dividend Aristocrats To Watch Right Now Abbott Laboratories (NYSE: ABT) Archer-Daniels-Midland Company (NYSE: ADM) Dover Corporation (NYSE: DOV) Abbott Laboratories (ABT Stock) Leading off, Abbott Laboratories (ABT) is a healthcare company that operates in a wide range of markets, including pharmaceuticals, medical devices, and consumer healthcare products. This month, the company announced that its Board of Directors has declared an increase in ABT’s quarterly dividend on common stock. In the last month of trading action, shares of ABT stock have started to recover by 2.40%, though shares are still down 23.50% year-to-date. |
31279.0 | 2022-12-20 00:00:00 UTC | 2 Exceptional Dividend Growth Stocks to Buy Now | ABT | https://www.nasdaq.com/articles/2-exceptional-dividend-growth-stocks-to-buy-now | nan | nan | This is kind of a strange time to be a passive income investor. After more than a decade of ultra-low interest rates, you can suddenly receive a risk-free 3.5% interest rate on your totally liquid savings account deposits. That's a little more than twice as much as the yield you'd receive from the average dividend-paying stock in the S&P 500 index.
If you want a portfolio that generates enough dividend income to fuel your dream retirement, it's a good idea to fill it with companies that have the capacity to raise their payouts at a rapid pace. Both of these companies have histories of rapid dividend hikes and look well-positioned to continue boosting those payouts in the years to come.
Image source: Getty Images.
AbbVie
AbbVie (NYSE: ABBV) is a leading pharmaceutical company that offers investors a 3.7% yield at its current share price. It was the pharmaceutical segment of Abbott Laboratories until its parent spun it off as a separate company in 2013. Growing sales of its blockbuster drugs allowed AbbVie management to raise its payout by a whopping 270% over the past decade.
Abbott spun AbbVie out as a separate company in part to shield itself from the eventual loss of revenue from AbbVie's top product, Humira. That anti-inflammatory injection is approved for a host of conditions, and currently generates around $22 billion in annual sales.
In 2018, Humira lost its market exclusivity in Europe to lower-cost biosimilar versions, and international sales of the drug plummeted. Shares of AbbVie offer an above-average yield right now in part because U.S. Humira sales, which reached the level of $20 billion annualized in the third quarter, will begin shrinking in 2023 as biosimilars take off in the domestic market.
AbbVie looks like a great dividend growth stock to buy despite the impending loss of U.S. Humira sales. Over the years, it has acquired and developed multiple new blockbuster drugs, the sales of which can more than offset the looming declines from Humira and allow AbbVie to continue raising its dividend payout. For example, in 2019, the company launched a pair of drugs -- Skyrizi for psoriasis and Rinvoq for arthritis -- that between them are intended to provide better options for the indications that Humira treats. These two are already generating more than $8 billion in combined sales annually.
Over the past 12 months, AbbVie's finely tuned operation generated an astounding $21.9 billion in free cash flow. That was more than twice as much as was necessary to maintain the company's dividend payout. In the years ahead, raising its payout in line with its earnings growth should be a breeze.
CVS Health
At the current share price, CVS Health (NYSE: CVS) offers a 2.5% yield. This might not be as attractive as AbbVie's at the moment. However, given the reliable profits its collection of related healthcare businesses generate, the stock is a dividend growth investor's dream come true.
CVS may not have shown up on your dividend growth stock screen because it held its payout steady from 2018 through 2021. Despite that three-year pause in hikes, CVS Health has boosted its dividend by an impressive 169% over the past decade.
It froze the payout to help cover the costs of its transformational acquisition of Aetna, a leading health insurance company. And while CVS Health may be a bit infamous for the extraordinarily long receipts customers receive when shopping at its ubiquitous chain of retail pharmacies, it's the less-visible parts of the business that make it a great dividend growth stock to buy.
As an insurance benefits manager, CVS Health collects premiums from an estimated 35 million people. It also runs the country's leading pharmacy benefits manager, which has more than 110 million plan members. Providing the health benefits it also gets paid to manage is an extremely lucrative position to be in. The company has been able to repay $25.2 billion of debt since it closed its Aetna acquisition.
CVS Health's dual position as both a provider and manager of health benefits is about to get a lot larger. Its $8 billion acquisition of Signify Health is expected to close in the first half of 2023. Signify Health operates a network of more than 10,000 clinicians, and it expects to connect with nearly 2.5 million unique members in their homes this year. A much larger hand in the delivery of primary care services will help CVS Health push its dividend much higher in the years to come.
10 stocks we like better than AbbVie
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2022
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of AbbVie offer an above-average yield right now in part because U.S. Humira sales, which reached the level of $20 billion annualized in the third quarter, will begin shrinking in 2023 as biosimilars take off in the domestic market. Over the years, it has acquired and developed multiple new blockbuster drugs, the sales of which can more than offset the looming declines from Humira and allow AbbVie to continue raising its dividend payout. And while CVS Health may be a bit infamous for the extraordinarily long receipts customers receive when shopping at its ubiquitous chain of retail pharmacies, it's the less-visible parts of the business that make it a great dividend growth stock to buy. | AbbVie AbbVie (NYSE: ABBV) is a leading pharmaceutical company that offers investors a 3.7% yield at its current share price. CVS Health At the current share price, CVS Health (NYSE: CVS) offers a 2.5% yield. As an insurance benefits manager, CVS Health collects premiums from an estimated 35 million people. | AbbVie looks like a great dividend growth stock to buy despite the impending loss of U.S. Humira sales. CVS Health At the current share price, CVS Health (NYSE: CVS) offers a 2.5% yield. And while CVS Health may be a bit infamous for the extraordinarily long receipts customers receive when shopping at its ubiquitous chain of retail pharmacies, it's the less-visible parts of the business that make it a great dividend growth stock to buy. | Shares of AbbVie offer an above-average yield right now in part because U.S. Humira sales, which reached the level of $20 billion annualized in the third quarter, will begin shrinking in 2023 as biosimilars take off in the domestic market. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys. |
31280.0 | 2022-12-20 00:00:00 UTC | Here's Why You Should Retain Abbott (ABT) Stock for Now | ABT | https://www.nasdaq.com/articles/heres-why-you-should-retain-abbott-abt-stock-for-now-2 | nan | nan | Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of its solid Diabetes business. The optimism led by solid third-quarter 2022 performance and a few product launches are expected to contribute further. However, forex woes and Nutrition Product recall impeding growth are concerning.
Over the past year, this Zacks Rank #3 (Hold) stock has lost 21.2% compared with 44.2% decline of the industry and 19.5% fall of the S&P 500 composite.
This renowned provider of a diversified line of healthcare products has a market capitalization of $185.85 billion. The company projects 5.1% growth for the next five years and expects to maintain its strong performance. Abbott’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 21.8%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Progress With Diabetes Business: We are optimistic about Abbott’s diabetes business. This business achieved robust organic sales growth in the third quarter of 2022, led by strong growth in FreeStyle Libre. In the quarter, sales of FreeStyle Libre exceeded $1 billion. Abbott’s user base expanded to approximately 4.5 million users globally, while in the United States, sales grew more than 40%.
Product Launches: We are upbeat about the products launched by Abbott in recent months. At the time of third-quarter 2022 results announcement in October, the company confirmed the launch of its latest-generation FreeStyle Libre 3 system in the United States.
In September, Abbott announced the European launch of its Amplatzer Talisman patent foramen ovale (PFO) Occlusion System to treat people with a PFO who have experienced a stroke and are at risk of having another.
Strong Q3 Results: Abbott’s better-than-expected third-quarter 2022 results buoy optimism. Within the company’s Diagnostics business, excluding COVID testing revenues, sales growth of routine diagnostic tests in the third quarter went up globally. This was fueled by the continued global rollout of the Alinity instrument for immunoassay, clinical chemistry and molecular testing. In Medical Device, global sales growth was also strong. In the United States, sales growth was led by strong double-digit growth in Electrophysiology, Structural Heart and Diabetes Care.
Downsides
Forex Translation Impacts Sales: Foreign exchange is a major headwind for Abbott due to a considerable percentage of its revenues coming from outside the United States. The strengthening of the euro and some other developed market currencies has been constantly hampering the company’s performance in the international markets.
Nutrition Product Recall Impedes Growth: Within Abbott’s Nutrition business, in the third quarter, worldwide Nutrition sales were down on an organic basis, with a significant slump in Pediatric Nutrition sales. The downside in total worldwide Nutrition and Pediatric Nutrition sales can be attributed to a voluntary recall and manufacturing shutdown of certain infant formula products manufactured at one of Abbott's U.S. plants since last February.
Estimate Trend
Abbott has been witnessing a positive estimate revision trend for 2022. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 4.4% north to $5.21.
The Zacks Consensus Estimate for the company’s fourth-quarter 2022 revenues is pegged at $9.47 billion, suggesting a 17.4% decline from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Exact Sciences Corporation EXAS, ShockWave Medical, Inc. SWAV and Merit Medical Systems, Inc. MMSI.
Exact Sciences, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 27.5%. EXAS’ earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed the same in one, the average beat being 0.6%.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Exact Sciences has lost 39.3% compared with the industry’s 24.4% decline in the past year.
ShockWave Medical, carrying a Zacks Rank #2 at present, has an estimated growth rate of 21.2% for 2023. SWAV’s earnings surpassed estimates in all the trailing four quarters, the average beat being 146.1%.
ShockWave Medical has gained 21.5% against the industry’s 28.4% decline over the past year.
Merit Medical, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average beat being 25.4%.
Merit Medical has gained 15.7% against the industry’s 11.1% decline over the past year.
Zacks Top 10 Stocks for 2023
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2023? From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500’s +287.4%.
Now our Director of Research is combing through 4,000 companies covered by the Zacks Rank to handpick the best 10 tickers to buy and hold. Don’t miss your chance to get in on these stocks when they’re released on January 3.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
Exact Sciences Corporation (EXAS) : Free Stock Analysis Report
ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of its solid Diabetes business. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. At the time of third-quarter 2022 results announcement in October, the company confirmed the launch of its latest-generation FreeStyle Libre 3 system in the United States. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of its solid Diabetes business. Nutrition Product Recall Impedes Growth: Within Abbott’s Nutrition business, in the third quarter, worldwide Nutrition sales were down on an organic basis, with a significant slump in Pediatric Nutrition sales. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of its solid Diabetes business. This business achieved robust organic sales growth in the third quarter of 2022, led by strong growth in FreeStyle Libre. | Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of its solid Diabetes business. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. This business achieved robust organic sales growth in the third quarter of 2022, led by strong growth in FreeStyle Libre. |
31281.0 | 2022-12-20 00:00:00 UTC | Abbott's (ABT) Eterna SCS System Receives FDA's Approval | ABT | https://www.nasdaq.com/articles/abbotts-abt-eterna-scs-system-receives-fdas-approval | nan | nan | Abbott Laboratories ABT recently received FDA approval for its Eterna spinal cord stimulation (SCS) system for treating chronic pain. The Eterna SCS system is the smallest implantable, rechargeable system that is currently available on the market for this indication.
The recent development is likely to fortify Abbott’s Established Pharmaceuticals Division (EPD) segment.
More on Eterna SCS System
It also noted that the Eterna SCS system had been developed based on extensive studies conducted with patients, physicians and caregivers to understand the unmet requirements of chronic pain patients. Per the company, the SCS technology has shown 23% more pain reduction compared with traditional waveform technology approaches.
Eterna SCS leverages the company’s proprietary low-dose BurstDR stimulation, which mimics natural firing patterns in the brain to provide superior pain relief. Notably, Eterna enhances the patient charging experience, requiring as few as five recharges per year under standard use from a wireless charger.
Moreover, Eterna utilizes Abbott's TotalScan MRI technology, enabling full-body MRI scans — a vital need of chronic pain patients who require accessibility to enhanced diagnostics and healthcare.
Significance of the Approval
It is worth mentioning that in the United States, over 50 million people suffer from chronic pain. Per U.S. Pain Foundation, chronic pain is the leading cause of people going to the doctor and costs the nation about $635 billion each year in healthcare, disability and lost productivity costs. Abbott's low-dose BurstDR stimulation is clinically proven to lessen pain, enhance people's ability to perform day-to-day activities and lower emotional suffering associated with pain.
Image Source: Zacks Investment Research
Abbott is committed to simplifying healthcare, improving clinical outcomes and providing people suffering from chronic pain with the best experience possible. Eterna SCS System is the next major step forward. Per management, Eterna SCS System is the smallest rechargeable spinal cord stimulator available in the market, offering the longest therapy between charges and delivering an optimized recharging experience.
Industry Prospects
Per a report by Grand View Research, the global spinal cord stimulation devices market size was $1.83 billion in 2018 and is expected to expand at a CAGR of 8.7% by 2026. The rise in the number of patients suffering from failed back syndrome, chronic pain and Complex Regional Pain Syndrome (CRPS) is the key factor driving the market.
Recent Developments
In the third quarter of 2023, Established Pharmaceuticals sales improved 4.9% on a reported basis (up 12.2% on an organic basis) to $1.33 billion. Organic sales in key emerging markets improved 13% year over year. According to Abbott, organic sales improvement was backed by strong growth in several geographies, including India, China, Brazil and Vietnam and several therapeutic areas, including cardiometabolic, gastroenterology and central nervous system/pain management.
During the last quarter earnings update, Abbott also noted that EPD has achieved double-digit organic sales growth since the beginning of 2021, fueled by a steady cadence of new product launches and strong commercial execution.
Price Performance
Shares of the company have lost 21.2% in a year compared with the industry’s fall of 44%.
Zacks Rank and Key Picks
Currently, Abbott carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that investors can consider are ShockWave Medical, Inc. SWAV, Orthofix Medical Inc. OFIX and Merit Medical System MMSI.
ShockWave Medical, sporting a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 33.1% for 2023. The company’s earnings surpassed estimates in all the trailing four quarters, the average beat being 180.1%.
ShockWave Medical has outperformed its industry in the past year. SWAV has gained 35% against the industry’s 32.6% fall in the past year.
Orthofix Medical, currently carrying a Zacks Rank #1 (Strong Buy), reported third-quarter 2022 adjusted EPS of 13 cents, which beat the Zacks Consensus Estimate by a stupendous 550%. Revenues of $114 million outpaced the consensus mark by 2.7%.
Orthofix Medical has an estimated next-year growth rate of 58.97%. MMSI’s earnings surpassed estimates in the trailing three quarters and missed in one, the average being 129.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Merit Medical, currently carrying a Zacks Rank of 2, reported third-quarter 2022 adjusted EPS of 64 cents, which beat the Zacks Consensus Estimate by 20.8%. Revenues of $287.2 million outpaced the consensus mark by 5.2%.
Merit Medical has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average being 25.4%.
Zacks Top 10 Stocks for 2023
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2023? From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500’s +287.4%.
Now our Director of Research is combing through 4,000 companies covered by the Zacks Rank to handpick the best 10 tickers to buy and hold. Don’t miss your chance to get in on these stocks when they’re released on January 3.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT recently received FDA approval for its Eterna spinal cord stimulation (SCS) system for treating chronic pain. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Eterna SCS leverages the company’s proprietary low-dose BurstDR stimulation, which mimics natural firing patterns in the brain to provide superior pain relief. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT recently received FDA approval for its Eterna spinal cord stimulation (SCS) system for treating chronic pain. Orthofix Medical, currently carrying a Zacks Rank #1 (Strong Buy), reported third-quarter 2022 adjusted EPS of 13 cents, which beat the Zacks Consensus Estimate by a stupendous 550%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT recently received FDA approval for its Eterna spinal cord stimulation (SCS) system for treating chronic pain. Some better-ranked stocks in the broader medical space that investors can consider are ShockWave Medical, Inc. SWAV, Orthofix Medical Inc. OFIX and Merit Medical System MMSI. | Abbott Laboratories ABT recently received FDA approval for its Eterna spinal cord stimulation (SCS) system for treating chronic pain. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Organic sales in key emerging markets improved 13% year over year. |
31282.0 | 2022-12-19 00:00:00 UTC | Abbott (ABT) Stock Moves -0.3%: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-stock-moves-0.3%3A-what-you-should-know | nan | nan | Abbott (ABT) closed the most recent trading day at $106.59, moving -0.3% from the previous trading session. This move was narrower than the S&P 500's daily loss of 0.9%. Elsewhere, the Dow lost 0.5%, while the tech-heavy Nasdaq lost 0.27%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had gained 2.93% over the past month. This has traded in line with the Medical sector and outpaced the S&P 500's loss of 2.66% in that time.
Abbott will be looking to display strength as it nears its next earnings release. On that day, Abbott is projected to report earnings of $0.90 per share, which would represent a year-over-year decline of 31.82%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.47 billion, down 17.41% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $5.21 per share and revenue of $43.03 billion. These totals would mark changes of 0% and -0.1%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Abbott. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Abbott is currently a Zacks Rank #3 (Hold).
Digging into valuation, Abbott currently has a Forward P/E ratio of 20.53. Its industry sports an average Forward P/E of 19.7, so we one might conclude that Abbott is trading at a premium comparatively.
We can also see that ABT currently has a PEG ratio of 4.03. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ABT's industry had an average PEG ratio of 2.2 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 175, putting it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Special Report: The Top 5 IPOs for Your Portfolio
Today, you have a chance to get in on the ground floor of one of the best investment opportunities of the year. As the world continues to benefit from an ever-evolving internet, a handful of innovative tech companies are on the brink of reaping immense rewards - and you can put yourself in a position to cash in. One is set to disrupt the online communication industry. Brilliantly designed for creating online communities, this stock is poised to explode when made public. With the strength of our economy and record amounts of cash flooding into IPOs, you don’t want to miss this opportunity.
>>See Zacks’ Hottest IPOs Now
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed the most recent trading day at $106.59, moving -0.3% from the previous trading session. We can also see that ABT currently has a PEG ratio of 4.03. ABT's industry had an average PEG ratio of 2.2 as of yesterday's close. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) closed the most recent trading day at $106.59, moving -0.3% from the previous trading session. We can also see that ABT currently has a PEG ratio of 4.03. | Abbott (ABT) closed the most recent trading day at $106.59, moving -0.3% from the previous trading session. We can also see that ABT currently has a PEG ratio of 4.03. ABT's industry had an average PEG ratio of 2.2 as of yesterday's close. | Abbott (ABT) closed the most recent trading day at $106.59, moving -0.3% from the previous trading session. We can also see that ABT currently has a PEG ratio of 4.03. ABT's industry had an average PEG ratio of 2.2 as of yesterday's close. |
31283.0 | 2022-12-19 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On Peter Lynch - 12/19/2022 | ABT | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-peter-lynch-12-19-2022 | nan | nan | The following are the top rated Healthcare stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
EMERGENT BIOSOLUTIONS INC (EBS) is a small-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Emergent BioSolutions, Inc. is a life sciences company focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats (PHTs). The Company is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. It provides solutions for PHTs through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. It offers TEMBEXA (brincidofovir) an antiviral for the treatment of smallpox in all age groups, including adults, and for patients who have difficulty swallowing.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of EMERGENT BIOSOLUTIONS INC
Full Guru Analysis for EBS>
Full Factor Report for EBS>
LABORATORY CORP. OF AMERICA HOLDINGS (LH) is a large-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on Peter Lynch is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Laboratory Corporation of America Holdings is a global life sciences company. The Company provides information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make decisions. Its segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). The Dx segment is an independent clinical laboratory business. It offers a menu of frequently requested and specialty diagnostic tests through an integrated network of primary and specialty laboratories across the United States. In addition to diagnostic testing along with occupational and wellness testing for employers and forensic DNA analysis, Dx segment also offers a range of other testing services. The DD segment is a contract research organizations (CRO) business that provides end-to-end drug development services. The DD segment provides these services predominantly to pharmaceutical, biotechnology and medical device companies across the world. It serves clients in more than 100 countries.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of LABORATORY CORP. OF AMERICA HOLDINGS
Full Guru Analysis for LH>
Full Factor Report for LH>
NOVARTIS AG (ADR) (NVS) is a large-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of NOVARTIS AG (ADR)
Full Guru Analysis for NVS>
Full Factor Report for NVS>
REGENERON PHARMACEUTICALS INC (REGN) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of REGENERON PHARMACEUTICALS INC
Full Guru Analysis for REGN>
Full Factor Report for REGN>
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
Full Guru Analysis for ABT>
Full Factor Report for ABT>
More details on Validea's Peter Lynch strategy
Peter Lynch Stock Ideas
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of REGENERON PHARMACEUTICALS INC Full Guru Analysis for REGN> Full Factor Report for REGN> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> More details on Validea's Peter Lynch strategy Peter Lynch Stock Ideas About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. | Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> More details on Validea's Peter Lynch strategy Peter Lynch Stock Ideas About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Detailed Analysis of REGENERON PHARMACEUTICALS INC Full Guru Analysis for REGN> Full Factor Report for REGN> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of LABORATORY CORP. OF AMERICA HOLDINGS Full Guru Analysis for LH> Full Factor Report for LH> NOVARTIS AG (ADR) (NVS) is a large-cap value stock in the Biotechnology & Drugs industry. | Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> More details on Validea's Peter Lynch strategy Peter Lynch Stock Ideas About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Detailed Analysis of REGENERON PHARMACEUTICALS INC Full Guru Analysis for REGN> Full Factor Report for REGN> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. | Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> More details on Validea's Peter Lynch strategy Peter Lynch Stock Ideas About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Detailed Analysis of REGENERON PHARMACEUTICALS INC Full Guru Analysis for REGN> Full Factor Report for REGN> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Company Description: Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. |
31284.0 | 2022-12-19 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On John Neff - 12/19/2022 | ABT | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-john-neff-12-19-2022 | nan | nan | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
ENSIGN GROUP INC (ENSG) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: The Ensign Group, Inc. is a holding company, which provides skilled nursing, senior living, and rehabilitative services, as well as other ancillary businesses (including mobile diagnostics and medical transportation) through its subsidiaries. The Company operates through two segments: skilled services and real estate. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The real estate segment primarily comprised of properties owned by the Company and leased to skilled nursing and senior living operations, including its own operating subsidiaries and third-party operators, and are subject to triple-net long-term leases. It offers skilled nursing, senior living and rehabilitative care services through approximately 268 skilled nursing and senior living facilities. Its real estate portfolio includes approximately 107 owned real estate properties located in Arizona, California, Colorado, Idaho, and Nebraska, among others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of ENSIGN GROUP INC
Full Guru Analysis for ENSG>
Full Factor Report for ENSG>
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on John Neff is 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of ABBOTT LABORATORIES
Full Guru Analysis for ABT>
Full Factor Report for ABT>
AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Major Drugs industry. The rating according to our strategy based on John Neff is 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AmerisourceBergen Corporation is a global pharmaceutical sourcing and distribution services company. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes an offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. This segment consists of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of AMERISOURCEBERGEN CORP.
Full Guru Analysis for ABC>
Full Factor Report for ABC>
ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on John Neff is 42% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AbbVie Inc. is a research-based biopharmaceutical company, which is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta; aesthetics products that include Botox Cosmetic, Juvederm Collection and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products consists of Lumigan, Alphagan and Restasis; women's health products include Lo Loestrin, Orilissa and others; and other products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. Its products are sold to wholesalers, government agencies, health care facilities and independent retailers. It also discovers and develop antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: FAIL
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of ABBVIE INC
Full Guru Analysis for ABBV>
Full Factor Report for ABBV>
ABIOMED INC (ABMD) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on John Neff is 42% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: ABIOMED, Inc. is a medical technology provider, which provides circulatory support and oxygenation. The Company develops, manufactures and markets its products, which are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. Its products are used in the cardiac catheterization lab or cath lab, by interventional cardiologists and in the heart surgery suite by cardiac surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty, or heart surgery procedures. The Company's Impella device portfolio includes the Impella 2.5, Impella CP, Impella 5.0, Impella LD, Impella 5.5 and Impella RP devices. Its product pipeline includes Impella ECP, Impella XR Sheath, Impella BTR and precardiac. The Impella ECP device is designed for blood flow of greater than three and a half liters per minute. The Impella BTR device is designed to be a heart pump with integrated motors and sensors.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: FAIL
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of ABIOMED INC
Full Guru Analysis for ABMD>
Full Factor Report for ABMD>
More details on Validea's John Neff strategy
About John Neff: While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. He was mild-mannered and low-key, and the same might be said of the Windsor Fund that he managed for more than three decades. In fact, Neff himself described the fund as "relatively prosaic, dull, [and] conservative." There was nothing dull about his results, however. From 1964 to 1995, Neff guided Windsor to a 13.7 percent average annual return, easily outpacing the S&P 500's 10.6 percent return during that time. That 3.1 percentage point difference is huge over time -- a $10,000 investment in Windsor (with dividends reinvested) at the start of Neff's tenure would have ended up as more than $564,000 by the time he retired, more than twice what the same investment in the S&P would have yielded (about $233,000). Considering the length of his tenure, that track record may be the best ever for a manager of such a large fund.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of ENSIGN GROUP INC Full Guru Analysis for ENSG> Full Factor Report for ENSG> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Major Drugs industry. The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff. | Detailed Analysis of ENSIGN GROUP INC Full Guru Analysis for ENSG> Full Factor Report for ENSG> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Major Drugs industry. Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV> Full Factor Report for ABBV> ABIOMED INC (ABMD) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Detailed Analysis of ENSIGN GROUP INC Full Guru Analysis for ENSG> Full Factor Report for ENSG> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Major Drugs industry. The U.S. Healthcare Solutions segment distributes an offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. | Detailed Analysis of ENSIGN GROUP INC Full Guru Analysis for ENSG> Full Factor Report for ENSG> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Major Drugs industry. The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff. |
31285.0 | 2022-12-19 00:00:00 UTC | Abbott Says FDA Approves Eterna Spinal Cord Stimulation System To Treat Chronic Pain | ABT | https://www.nasdaq.com/articles/abbott-says-fda-approves-eterna-spinal-cord-stimulation-system-to-treat-chronic-pain | nan | nan | (RTTNews) - Abbott (ABT) announced Monday the U.S. Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system, which is the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain.
Eterna SCS utilizes Abbott's proprietary low-dose BurstDR stimulation, the only SCS waveform technology with the highest level of clinical evidence (1A evidence), proven to reduce pain 23% more than traditional waveform technology approaches.
Abbott developed Eterna based on extensive studies with patients, physicians and caregivers to understand the unmet needs of people living with chronic pain.
Abbott created Eterna to be recharged less than five times a year under normal use, making it the lowest recharge burden platform on the market.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) announced Monday the U.S. Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system, which is the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain. Eterna SCS utilizes Abbott's proprietary low-dose BurstDR stimulation, the only SCS waveform technology with the highest level of clinical evidence (1A evidence), proven to reduce pain 23% more than traditional waveform technology approaches. Abbott developed Eterna based on extensive studies with patients, physicians and caregivers to understand the unmet needs of people living with chronic pain. | (RTTNews) - Abbott (ABT) announced Monday the U.S. Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system, which is the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain. Eterna SCS utilizes Abbott's proprietary low-dose BurstDR stimulation, the only SCS waveform technology with the highest level of clinical evidence (1A evidence), proven to reduce pain 23% more than traditional waveform technology approaches. Abbott developed Eterna based on extensive studies with patients, physicians and caregivers to understand the unmet needs of people living with chronic pain. | (RTTNews) - Abbott (ABT) announced Monday the U.S. Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system, which is the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain. Eterna SCS utilizes Abbott's proprietary low-dose BurstDR stimulation, the only SCS waveform technology with the highest level of clinical evidence (1A evidence), proven to reduce pain 23% more than traditional waveform technology approaches. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) announced Monday the U.S. Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system, which is the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain. Eterna SCS utilizes Abbott's proprietary low-dose BurstDR stimulation, the only SCS waveform technology with the highest level of clinical evidence (1A evidence), proven to reduce pain 23% more than traditional waveform technology approaches. Abbott developed Eterna based on extensive studies with patients, physicians and caregivers to understand the unmet needs of people living with chronic pain. |
31286.0 | 2022-12-18 00:00:00 UTC | 1 Passive Income Stock to Buy Today, and 1 to Avoid for Now | ABT | https://www.nasdaq.com/articles/1-passive-income-stock-to-buy-today-and-1-to-avoid-for-now | nan | nan | When it comes to passive income, not all that glitters is gold. The temptation of a high dividend yield promises investors strong returns, but the reality is often that lower-yielding stocks can pay out far more sustainably.
With that in mind, let's examine two popular passive-income stocks. One can support your portfolio's value for years to come, and the other is more likely to leave you in the lurch than on the path to riches.
The gift that keeps on giving to investors
The healthcare giant Abbott Laboratories (NYSE: ABT) is forever a river of opportunity for passive income investors thanks to its stability and consistent growth over time. Its business model is to make and sell products like glucose monitors, surgical stents, generic drugs, and diagnostic tests around the globe.
And with $43.1 billion in revenue in 2021, business is booming; its trailing-12-month net income grew by 114% over the last three years, and more is on the way. In fact, this year, management had to issue an update to its earnings guidance because it was making even more money than anticipated.
Because Abbott's sales mix is so diversified, shareholders don't need to face nearly as much risk as they might with a focused operator competing in one of the company's segments. If, for example, a competitor like DexCom one-upped Abbott's glucose monitors by developing a better version of the technology, it wouldn't affect Abbott's base of revenue by that much as glucose monitors are merely one sub-segment within its medical devices division that brought in $3.6 billion in the third quarter alone. And since many of its products are crucial for hospitals and healthcare systems, the chances of multiple segments collapsing simultaneously are close to nil.
In terms of its passive income potential, given its forward dividend yield of around 1.8%, it would only take roughly $5,376 in Abbott stock to earn you $100 per year. That might not seem like much, because it isn't, at least not right away.
But that payout will almost certainly rise over time as the company hikes the dividend. For reference, over the last 10 years, its dividend rose by 264%. And since the company has a history of annual hikes that goes back more than 50 years, making it a Dividend King, you can have a good deal of confidence in future growth.
Avoid debt-driven business models
In contrast to Abbott Laboratories, Medical Properties Trust (NYSE: MPW) is a real estate investment trust (REIT) that invests in floor space for use by hospitals and clinics. Then, it collects rent or debt payments for years and years.
At the moment, it operates around 435 properties, which in total gave it more than $1.5 billion in revenue last year against its total adjusted gross assets of roughly $21.1 billion.
The REIT's forward dividend yield is above 9.8%, making it a high-yielder that's bound to tempt investors. But there's a reason its yield is so high, and it's also why it might be better to avoid this stock for now.
When Medical Properties Trust wants to expand, it needs to buy or invest in a new facility, then it needs to find a tenant that will reliably pay it back. Ideally, those property purchases would be made in cash, but the company only has a little over $299.1 million on hand, which isn't a huge amount given how expensive medical facilities can be.
So that means it needs to use debt to finance its expansion, and it already has a hefty debt load of nearly $9.5 billion. The implication is that it'll have a harder time finding loans with favorable terms than a business with less leverage.
What's more, because of the Federal Reserve's intent to control inflation by increasing the cost of borrowing money, Medical Properties is going to face more-restrictive borrowing conditions and higher interest rates -- at least, for the near term. That'll be exacerbated by the fact that it's already burdened by debt. And for whichever tenants it finds after an acquisition, they'll need to be willing to pay more for the privilege of renting to ensure that the REIT can still make a decent return.
These issues are unlikely to cause it to go bankrupt, and they're also unlikely to threaten its dividend in the short term. But given that the dividend has increased by only 45% in the last 10 years, there isn't much reason to buy it over Abbott Labs, and the borrowing headwinds it will continue to face make it a stock to avoid altogether for now.
10 stocks we like better than Abbott Laboratories
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2022
Alex Carchidi has positions in Abbott Laboratories. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The gift that keeps on giving to investors The healthcare giant Abbott Laboratories (NYSE: ABT) is forever a river of opportunity for passive income investors thanks to its stability and consistent growth over time. Its business model is to make and sell products like glucose monitors, surgical stents, generic drugs, and diagnostic tests around the globe. Ideally, those property purchases would be made in cash, but the company only has a little over $299.1 million on hand, which isn't a huge amount given how expensive medical facilities can be. | The gift that keeps on giving to investors The healthcare giant Abbott Laboratories (NYSE: ABT) is forever a river of opportunity for passive income investors thanks to its stability and consistent growth over time. Avoid debt-driven business models In contrast to Abbott Laboratories, Medical Properties Trust (NYSE: MPW) is a real estate investment trust (REIT) that invests in floor space for use by hospitals and clinics. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. | The gift that keeps on giving to investors The healthcare giant Abbott Laboratories (NYSE: ABT) is forever a river of opportunity for passive income investors thanks to its stability and consistent growth over time. If, for example, a competitor like DexCom one-upped Abbott's glucose monitors by developing a better version of the technology, it wouldn't affect Abbott's base of revenue by that much as glucose monitors are merely one sub-segment within its medical devices division that brought in $3.6 billion in the third quarter alone. In terms of its passive income potential, given its forward dividend yield of around 1.8%, it would only take roughly $5,376 in Abbott stock to earn you $100 per year. | The gift that keeps on giving to investors The healthcare giant Abbott Laboratories (NYSE: ABT) is forever a river of opportunity for passive income investors thanks to its stability and consistent growth over time. In terms of its passive income potential, given its forward dividend yield of around 1.8%, it would only take roughly $5,376 in Abbott stock to earn you $100 per year. But given that the dividend has increased by only 45% in the last 10 years, there isn't much reason to buy it over Abbott Labs, and the borrowing headwinds it will continue to face make it a stock to avoid altogether for now. |
31287.0 | 2022-12-18 00:00:00 UTC | 2022 Bargain Shopping: 2 Smart Stocks to Buy Before the New Year | ABT | https://www.nasdaq.com/articles/2022-bargain-shopping%3A-2-smart-stocks-to-buy-before-the-new-year | nan | nan | You may see a lot of bargains in the shops and online this season. But there's an even better place to find a good deal these days. I'm talking about the stock market. This year's long sell-off has weighed on the valuations of stocks across industries and left many at dirt-cheap levels. And this equals a buying opportunity for you.
"But what if these stocks fall even further?" you might wonder. Well, it's impossible to effectively time the market, and it's a bad idea to try. So the best thing you can do is buy strong stocks when their valuations are reasonable -- and then hold onto them for the long term. If your stocks gain, you'll still benefit even if you didn't buy them at their cyclical low points.
If you're ready to give this winning strategy a try, here are two smart stocks I'd recommend buying before the new year.
1. Teladoc Health
Teladoc Health (NYSE: TDOC) stock soared during the early part of the pandemic. Patients flocked to telemedicine providers -- and Teladoc's visits and revenue climbed by triple-digit percentages.
But the company has demonstrated it isn't a pandemic-only business. Teladoc's revenue already was on the rise before COVID-19 struck. And in this later stage of the health crisis, it continues to post double-digit percentage gains in revenue and visits. Teladoc also has built a solid client base, serving more than half of the companies in the Fortune 500.
Another positive point: Contracts are getting bigger. Its average deal size today is 50% bigger than a year ago.
So why is Teladoc stock heading for the end of 2022 with a mind-boggling 70% year-to-date decline? The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. This was disappointing news. But the Livongo purchase still gives Teladoc strengths in the chronic care space -- a key growth area. So this purchase could pay off over the long term.
The third quarter brought investors some good news. Teladoc's loss narrowed. And the company continued to grow its U.S. member numbers and its revenue per member metric. This is important because it should support revenue growth.
Another thing to keep in mind is that the telemedicine market is on the rise. In North America alone, it's expected to register a compound annual growth rate of about 19% through 2030, according to Grand View Research.
Today, Teladoc shares are trading at their cheapest level ever in relation to sales. This is a major bargain considering the company's long-term potential.
2. Abbott Laboratories
There are two reasons to like Abbott Laboratories (NYSE: ABT). First, let's talk about passive income. Abbott will pay you well just for owning the stock. Dividends are great any time. But it's particularly nice to have this guaranteed income during tough market times.
And Abbott isn't just a dividend stock -- it's a Dividend King. This means it has raised its payouts annually for at least the past 50 consecutive years. So you probably can count on your dividend payments progressively growing further.
Now for the second reason to like Abbott. The company is diversified across four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. This is positive because even when one of those businesses faces challenges, the others may still be gaining ground.
Abbott has grown its free cash flow and return on invested capital over time.
ABT Free Cash Flow data by YCharts.
And it recently increased its full-year earnings-per-share forecast.
All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. At today's valuation of 20 times forward earnings estimates, Abbott's a stock you won't want to miss.
10 stocks we like better than Teladoc Health
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Teladoc Health wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2022
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories and Teladoc Health. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories There are two reasons to like Abbott Laboratories (NYSE: ABT). ABT Free Cash Flow data by YCharts. The company reported billion-dollar non-cash goodwill impairment charges in the first two quarters linked to its acquisition of Livongo. | Abbott Laboratories There are two reasons to like Abbott Laboratories (NYSE: ABT). ABT Free Cash Flow data by YCharts. Teladoc Health Teladoc Health (NYSE: TDOC) stock soared during the early part of the pandemic. | Abbott Laboratories There are two reasons to like Abbott Laboratories (NYSE: ABT). ABT Free Cash Flow data by YCharts. Teladoc Health Teladoc Health (NYSE: TDOC) stock soared during the early part of the pandemic. | Abbott Laboratories There are two reasons to like Abbott Laboratories (NYSE: ABT). ABT Free Cash Flow data by YCharts. All of this means you can count on Abbott for passive income, earnings growth, and good use of its cash -- a great mix. |
31288.0 | 2022-12-16 00:00:00 UTC | XLV, ABBV, ABT, DHR: Large Inflows Detected at ETF | ABT | https://www.nasdaq.com/articles/xlv-abbv-abt-dhr%3A-large-inflows-detected-at-etf | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $302.6 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 306,620,000 to 308,820,000). Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 2.2%, and Danaher Corp (Symbol: DHR) is lower by about 2.6%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $143.42 as the 52 week high point — that compares with a last trade of $135.37. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
Also see:
Top 10 Hedge Funds Holding Centene
Institutional Holders of BLNK
MMR Historical Stock Prices
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 2.2%, and Danaher Corp (Symbol: DHR) is lower by about 2.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $302.6 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 306,620,000 to 308,820,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 2.2%, and Danaher Corp (Symbol: DHR) is lower by about 2.6%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $143.42 as the 52 week high point — that compares with a last trade of $135.37. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 2.2%, and Danaher Corp (Symbol: DHR) is lower by about 2.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $302.6 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 306,620,000 to 308,820,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $143.42 as the 52 week high point — that compares with a last trade of $135.37. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 2.2%, and Danaher Corp (Symbol: DHR) is lower by about 2.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $302.6 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 306,620,000 to 308,820,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $143.42 as the 52 week high point — that compares with a last trade of $135.37. |
31289.0 | 2022-12-16 00:00:00 UTC | Want $250 in Passive Income? Buy These 2 Dividend Kings and Wait | ABT | https://www.nasdaq.com/articles/want-%24250-in-passive-income-buy-these-2-dividend-kings-and-wait | nan | nan | It's no surprise why investors love Dividend Kings -- they're stocks that have grown their dividends for at least 50 years on end without fail. With such reliable track records, it's an easy affair to invest a relatively small amount of money up front and then watch the payout grow year after year -- and that's why they're excellent options for generating passive income from your portfolio.
Let's take a look at a pair of those Dividend Kings that shouldn't take too long to ramp up to providing you with an annual passive income of $250 after making an initial investment that's likely within your reach today.
1. Abbott Laboratories
Abbott Laboratories (NYSE: ABT) is a leading option for passive income investors, thanks to its perpetually rising dividend and its relatively low level of risk. Its forward dividend yield of around 1.8% isn't going to make you rich anytime soon, but the low yield is mitigated by the company's long-standing commitment to dividend growth spanning more than 50 years. Its payout rose by 82.1% in the last five years alone.
To accomplish that pace of dividend hikes, the company sells a massive mix of products, including ones you're probably familiar with, like the BinaxNow rapid antigen tests for COVID-19, not to mention more esoteric products, like specialized stents for heart surgery.
Such a diversified product base means that its dividend is more secure than other dividend stocks. In numbers, Abbott's net income in 2021 was more than $7 billion, though its free cash flow (FCF) was even higher, at above $8.6 billion -- and it only paid out around 42% of its net income as dividends, so there's plenty of room to keep hiking the payments. Plus, it means that the longer you're willing to wait, the more likely you are to accumulate a significant quarterly income stream from your shares.
If you're looking to make a relatively small sum of $250 per year from your shares, you'll "only" need to invest around $13,440 up front. Most of us don't have that much lying around, so a better approach to generate the same amount of income is to invest a smaller sum and then wait for the dividend hikes to add up over time. Over the last five years, Abbott's dividend rose at a compound annual growth rate (CAGR) of 10.9%.
That means if you were to invest around $8,064 today, it would yield you $150 in dividends per year, and if we (quite reasonably) assume that your payout will grow by at least the same CAGR moving forward, you'd only need to hold your shares for about five years before you'd be making just over $251 annually. Not too bad of a return for just waiting around.
2. Johnson & Johnson
Much like Abbott Labs, Johnson & Johnson (NYSE: JNJ) is a huge, diversified healthcare company that develops and sells medicines, medical devices, and consumer health products like Band-Aids and moisturizers. Many of its products are key for consumers to live happily and healthily, and the business is stable and predictable enough for Warren Buffett himself to have a position in it.
But with the planned spinoff of its consumer health goods division, it'll soon be devoted entirely to making new drugs and devices, which could drive additional growth. For reference, its trailing-12-month revenue expanded by only 43% in the past 10 years, reaching above $96 billion, so the next 10 years could be better for investors.
That should make it an even more lucrative investment for those seeking passive income. And with a payout ratio of 61% and 2021 net income of above $20.8 billion, there's plenty of overhead for more additions to its quarterly dividend.
Right now, its forward dividend yield is a hair over 2.5%, so an investment of just over $9,920 would get you $250 annually, but you can spend even less if you have some patience. Its five-year CAGR is a bit slower than Abbott's, at near 6.1%. So with the more manageable sum of $5,952 worth of its shares today, yielding $150 annually right off the bat, it'd take around nine years for your dividend to grow to become $250.
Of course, if you're willing to wait even longer, you could get the same amount of income with an even smaller investment up front.
10 stocks we like better than Abbott Laboratories
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2022
Alex Carchidi has positions in Abbott Laboratories. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a leading option for passive income investors, thanks to its perpetually rising dividend and its relatively low level of risk. Let's take a look at a pair of those Dividend Kings that shouldn't take too long to ramp up to providing you with an annual passive income of $250 after making an initial investment that's likely within your reach today. Most of us don't have that much lying around, so a better approach to generate the same amount of income is to invest a smaller sum and then wait for the dividend hikes to add up over time. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a leading option for passive income investors, thanks to its perpetually rising dividend and its relatively low level of risk. Over the last five years, Abbott's dividend rose at a compound annual growth rate (CAGR) of 10.9%. The Motley Fool recommends Johnson & Johnson. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a leading option for passive income investors, thanks to its perpetually rising dividend and its relatively low level of risk. Its forward dividend yield of around 1.8% isn't going to make you rich anytime soon, but the low yield is mitigated by the company's long-standing commitment to dividend growth spanning more than 50 years. That means if you were to invest around $8,064 today, it would yield you $150 in dividends per year, and if we (quite reasonably) assume that your payout will grow by at least the same CAGR moving forward, you'd only need to hold your shares for about five years before you'd be making just over $251 annually. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a leading option for passive income investors, thanks to its perpetually rising dividend and its relatively low level of risk. Such a diversified product base means that its dividend is more secure than other dividend stocks. That means if you were to invest around $8,064 today, it would yield you $150 in dividends per year, and if we (quite reasonably) assume that your payout will grow by at least the same CAGR moving forward, you'd only need to hold your shares for about five years before you'd be making just over $251 annually. |
31290.0 | 2022-12-16 00:00:00 UTC | 2 Top Dividend Stocks to Buy Hand Over Fist Before 2023 | ABT | https://www.nasdaq.com/articles/2-top-dividend-stocks-to-buy-hand-over-fist-before-2023 | nan | nan | Dividends are great all the time. But in a bear market, you'll welcome them even more. Your portfolio's performance may be down -- but you're still guaranteed annual income just for owning certain stocks, even if those stocks themselves have declined. A pretty good deal, right?
So, as you're doing your end-of-year stock shopping, put dividend stocks on your list. Whether the bear market continues next year or a bull market takes over, you'll be happy to collect this extra income.
Today, many dividend stocks are trading at bargain valuations. And we don't know how long that will last. Let's check out two top players to buy hand over fist before the new year.
1. Target
You may not automatically think of retail giant Target (NYSE: TGT) when you think of dividends. But Target is actually a terrific dividend stock.
It's also one of the elite. Target is a Dividend King. That means it's been increasing its dividend for at least the past 50 years, demonstrating that Target values the idea of rewarding shareholders. And that suggests it's likely to stick with its dividend policy.
If you own Target, you collect an annual dividend of $4.32 per share. And Target's dividend yield of 2.86% tops the average of the general retail sector.
When it comes to business, Target has had it rough this year. Higher inflation has increased the company's costs -- and weighed on margins. The inflation problem also is hurting consumers' buying power. So, they're favoring essentials and looking for deals.
Even in this context, though, Target managed to increase same-store sales, store traffic, and basket size in the most recent quarter. It represented Target's 222nd straight quarter of same-store sales growth. Target also gained market share in all of its five merchandising categories.
All of this tells me that once today's economic troubles ease, Target has what it takes to thrive. Today, Target is trading for 26.5 times forward earnings estimates. That's down from more than 40 earlier this year.
This looks like a great entry point for a stock that will offer you solid passive income -- and eventually earnings growth too.
2. Abbott Laboratories
Abbott Laboratories (NYSE: ABT) recently raised its quarterly dividend by 8.5%. It will be paid out in February. But to benefit, you must be a shareholder of record as of Jan. 13. So there's reason to get in on this stock as soon as possible.
The annual dividend totals $2.04 at a dividend yield of 1.83%. Like Target, Abbott is a Dividend King. That means you can count on dividend growth over time when you own this stock.
You'll also want to buy Abbott for its business model -- one that supports earnings no matter what the market is doing. Not only is Abbott a healthcare company -- and they generally hold up well during market downturns -- but it's also diversified. The company's four businesses include diagnostics, medical devices, established pharmaceuticals, and nutrition. The diversified model is great because, if one business faces challenges, the others can compensate.
Abbott has a solid track record of earnings growth. Generally, medical devices have powered revenue. But in recent times, Abbott's coronavirus tests have made the diagnostics business the strongest. Abbott reported more than $10 billion in total sales in the most recent quarter and lifted its full-year earnings-per-share forecast. So things are looking positive for Abbott as we head toward the new year.
But Abbott's shares haven't kept up with its earnings, forecasts, or dividends this year. The stock price has gone down 22%. That's left Abbott trading at about 25 times trailing-12-month earnings. That's at around its lowest level over the past three years.
All this means now is the time to scoop up shares of this healthcare player that you'll want to hold on to for the long term.
10 stocks we like better than Target
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Target wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2022
Adria Cimino has positions in Target. The Motley Fool has positions in and recommends Abbott Laboratories and Target. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) recently raised its quarterly dividend by 8.5%. That means it's been increasing its dividend for at least the past 50 years, demonstrating that Target values the idea of rewarding shareholders. Even in this context, though, Target managed to increase same-store sales, store traffic, and basket size in the most recent quarter. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) recently raised its quarterly dividend by 8.5%. It represented Target's 222nd straight quarter of same-store sales growth. The annual dividend totals $2.04 at a dividend yield of 1.83%. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) recently raised its quarterly dividend by 8.5%. But Target is actually a terrific dividend stock. Like Target, Abbott is a Dividend King. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) recently raised its quarterly dividend by 8.5%. But Target is actually a terrific dividend stock. But Abbott's shares haven't kept up with its earnings, forecasts, or dividends this year. |
31291.0 | 2022-12-15 00:00:00 UTC | Pick Either Intuitive Surgical Or Its Industry Peer – Both May Offer Similar Returns | ABT | https://www.nasdaq.com/articles/pick-either-intuitive-surgical-or-its-industry-peer-both-may-offer-similar-returns | nan | nan | We believe that Intuitive Surgical stock (NASDAQ: ISRG) and Edwards Lifesciences stock (NYSE: EW), in the medical devices industry, will likely give similar returns over the next three years. Intuitive Surgical is trading at a comparatively higher valuation of 15.8x trailing revenues, compared to 8.7x for Edwards Lifesciences. This gap in the valuation is justified, given Intuitive Surgical’s superior revenue growth, lower financial risk, and better growth prospects.
Looking at stock returns, ISRG, with -24% returns this year, has fared better than EW stock, down 42%, and both have underperformed the broader S&P500 index, down 16%. There is more to the comparison, and in the sections below, we discuss the possible returns from these stocks in the next three years. We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Intuitive Surgical vs. Edwards Lifesciences: Which Stock Is A Better Bet? Parts of the analysis are summarized below.
1. Intuitive Surgical’s Revenue Growth Is Better
Both companies managed to see sales growth over the last twelve months. Still, Intuitive Surgical has witnessed comparatively faster revenue growth of 11.3% vs. 5.3% for Edwards Lifesciences.
Even if we look at a longer time frame, Intuitive Surgical has fared better, with its sales rising at an average annual rate of 16.2% to $5.7 billion in 2021, compared to $3.7 billion in 2018, while Edwards Lifesciences’ sales grew at an average rate of 12.3% to $5.2 billion in 2021, compared to around $3.7 billion in 2018.
For Intuitive Surgical, revenue growth over the recent past has been driven by a rebound in procedure volume, which was adversely impacted in the initial phases of the pandemic due to the shelter-in-place restrictions. The company continues to expand its installed base, which results in the growth of recurring revenues, such as consumables.
Edwards Lifesciences’ revenue growth was also impacted during the pandemic due to lower procedure volume. This trend reversed later, and the company saw revenue growth led by its Transcatheter Aortic Valve Replacement (TAVR) products, primarily the Edwards SAPIEN platform. However, of late, U.S. hospital staffing shortages and Covid headwinds in Japan have weighed on TAVR sales growth as well.
EW stock has been under pressure this year after a Q2 and Q3 miss and guidance cut due to forex headwinds and labor shortage.
Our Intuitive Surgical Revenue Comparison and Edwards Lifesciences Revenue Comparison dashboards provide more insight into the companies’ sales.
Looking forward, Intuitive Surgical’s revenue is expected to grow faster than Edwards Lifesciences’ over the next three years. The table below summarizes our revenue expectations for the two companies over the next three years. It points to a CAGR of 13.7% for Intuitive Surgical, compared to a 10.3% CAGR for Edwards Lifesciences, based on Trefis Machine Learning analysis.
Note that we have different methodologies for companies negatively impacted by Covid and those not impacted or positively impacted by Covid while forecasting future revenues. For companies negatively affected by Covid, we consider the quarterly revenue recovery trajectory to forecast recovery to the pre-Covid revenue run rate. Beyond the recovery point, we apply the average annual growth observed three years before Covid to simulate a return to normal conditions. For companies registering positive revenue growth during Covid, we consider yearly average growth before Covid with a certain weight to growth during Covid and the last twelve months.
2. Edwards Lifesciences Is More Profitable, But It Comes With Higher Risk
Intuitive Surgical’s operating margin of 20.5% over the last twelve months is lower than 31.6% for Edwards Lifesciences.
This compares with 30.7% and 26.9% figures seen in 2019, before the pandemic, respectively.
Our Intuitive Surgical Operating Income Comparison and Edwards Lifesciences Operating Income Comparison dashboards have more details.
Intuitive Surgical’s free cash flow margin of 31.4% is higher than 24.4% for Edwards Lifesciences.
Looking at financial risk, Intuitive Surgical is much better placed than Edwards Lifesciences. Its 0.5% debt as a percentage of equity is lower than 1.3% for the latter, while its 61.7% cash as a percentage of assets is much higher than 20.1% for the latter, implying that Intuitive Surgical has a better debt position, and has more cash cushion.
3. The Net of It All
Intuitive Surgical has demonstrated better revenue growth and offers lower financial risk. On the other hand, Edwards Lifesciences is more profitable and is available at a relatively lower valuation.
Now, looking at prospects, using P/S as a base, due to high fluctuations in P/E and P/EBIT, we believe both stocks are likely to offer similar returns.
The table below summarizes our revenue and return expectations for Intuitive Surgical and Edwards Lifesciences over the next three years and points to an expected return of 44% for ISRG over this period vs. a 41% expected return for EW stock, implying that both stocks offer good buying opportunity at current levels, based on Trefis Machine Learning analysis – Intuitive Surgical vs. Edwards Lifesciences – which also provides more details on how we arrive at these numbers.
While ISRG and EW stocks may offer similar returns, it is helpful to see how Intuitive Surgical’s Peers fare on metrics that matter. You will find other valuable comparisons for companies across industries at Peer Comparisons. Furthermore, the Covid-19 crisis has created many pricing discontinuities, which can offer attractive trading opportunities. For example, you’ll be surprised at how counter-intuitive the stock valuation is for Syneos Health vs. Amerco.
With inflation rising and the Fed raising interest rates, among other factors, ISRG stock has plunged 24% this year. Can it drop more? See how low Intuitive Surgical stock can go by comparing its decline in previous market crashes. Here is a performance summary of all stocks in previous market crashes.
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
Returns Dec 2022
MTD [1] 2022
YTD [1] 2017-22
Total [2]
ISRG Return 1% -24% 289%
EW Return -2% -42% 141%
S&P 500 Return -2% -16% 78%
Trefis Multi-Strategy Portfolio -2% -19% 221%
[1] Month-to-date and year-to-date as of 12/13/2022
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Intuitive Surgical vs. Edwards Lifesciences: Which Stock Is A Better Bet? For Intuitive Surgical, revenue growth over the recent past has been driven by a rebound in procedure volume, which was adversely impacted in the initial phases of the pandemic due to the shelter-in-place restrictions. This trend reversed later, and the company saw revenue growth led by its Transcatheter Aortic Valve Replacement (TAVR) products, primarily the Edwards SAPIEN platform. | Even if we look at a longer time frame, Intuitive Surgical has fared better, with its sales rising at an average annual rate of 16.2% to $5.7 billion in 2021, compared to $3.7 billion in 2018, while Edwards Lifesciences’ sales grew at an average rate of 12.3% to $5.2 billion in 2021, compared to around $3.7 billion in 2018. Our Intuitive Surgical Operating Income Comparison and Edwards Lifesciences Operating Income Comparison dashboards have more details. The table below summarizes our revenue and return expectations for Intuitive Surgical and Edwards Lifesciences over the next three years and points to an expected return of 44% for ISRG over this period vs. a 41% expected return for EW stock, implying that both stocks offer good buying opportunity at current levels, based on Trefis Machine Learning analysis – Intuitive Surgical vs. Edwards Lifesciences – which also provides more details on how we arrive at these numbers. | We believe that Intuitive Surgical stock (NASDAQ: ISRG) and Edwards Lifesciences stock (NYSE: EW), in the medical devices industry, will likely give similar returns over the next three years. We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Intuitive Surgical vs. Edwards Lifesciences: Which Stock Is A Better Bet? The table below summarizes our revenue and return expectations for Intuitive Surgical and Edwards Lifesciences over the next three years and points to an expected return of 44% for ISRG over this period vs. a 41% expected return for EW stock, implying that both stocks offer good buying opportunity at current levels, based on Trefis Machine Learning analysis – Intuitive Surgical vs. Edwards Lifesciences – which also provides more details on how we arrive at these numbers. | Intuitive Surgical is trading at a comparatively higher valuation of 15.8x trailing revenues, compared to 8.7x for Edwards Lifesciences. Still, Intuitive Surgical has witnessed comparatively faster revenue growth of 11.3% vs. 5.3% for Edwards Lifesciences. For companies registering positive revenue growth during Covid, we consider yearly average growth before Covid with a certain weight to growth during Covid and the last twelve months. |
31292.0 | 2022-12-15 00:00:00 UTC | What's Next For Boston Scientific Stock After An 11% Rise In A Month? | ABT | https://www.nasdaq.com/articles/whats-next-for-boston-scientific-stock-after-an-11-rise-in-a-month | nan | nan | Boston Scientific stock (NYSE: BSX) has seen an 11% rise in a month and year-to-date. This compares with 1% and -16% returns for the broader S&P500 index over the same periods, respectively. This recent outperformance of Boston Scientific can partly be attributed to its announcement to acquire Apollo Endosurgery in a $615 million deal. This move is largely seen as positive for the company enabling it to expand its endoscopy offerings. Boston Scientific has also announced its plans to acquire a majority stake in Acotec Scientific Holdings – a Chinese medical technology company focused on solutions for interventional procedures. Acotec will strengthen Boston Scientific’s MedSurg segment.
But now that BSX stock has seen a rise of 11% in a month, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is a higher chance of a rise for Boston Scientific stock over the next month. Of 247 instances in the last ten years that BSX stock saw a twenty-one-day rise of 11% or more, 145 resulted in BSX stock rising over the subsequent one-month period (twenty-one trading days). This historical pattern reflects 145 out of 247, or about a 59% chance of a rise in BSX stock over the next month. See our analysis of Boston Scientific Stock Chance of Rise for more details.
Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using the last ten years’ data
After moving 4.5% or more over five days, the stock rose on 52% of the occasions in the next five days.
After moving 6.1% or more over ten days, the stock rose on 56% of the occasions in the next ten days.
After moving 11.0% or more over a twenty-one-day period, the stock rose on 59% of the occasions in the next twenty-one days.
This historical pattern suggests a higher chance of a rise in BSX stock over the next five, ten, and twenty-one days.
Boston Scientific (BSX) Stock Return (Recent) Comparison With Peers
Five-Day Return: SYK highest at 7.8%; ILMN lowest at 2.3%
Ten-Day Return: SYK highest at 11.8%; ILMN lowest at 1.1%
Twenty-One Day Return: SYK highest at 13.2%; ILMN lowest at -13.2%
may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you'll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck. \n\nBased on article theme, variations to \"While may have moved\" can be (a) While may be overvalued (or undervalued) (b) While can move (c) Although may not be attractive (d) While is worth considering"}" data-sheets-userformat="{"2":1049345,"3":{"1":0},"11":4,"12":0,"23":1}" data-sheets-textstyleruns="{"1":0}{"1":210,"2":{"2":{"1":2,"2":1136076},"5":1,"9":1}}{"1":225}{"1":229,"2":{"4":8}}{"1":267,"2":{"4":8,"6":1}}{"1":299,"2":{"4":8}}" data-sheets-hyperlinkruns="{"1":210,"2":"https://dashboards.trefis.com/data/companies/PFE/no-login-required/HMIwIvym/Pfizer-vs-Merck-PFE-stock-s-similar-valuation-vs-MRK-stock-is-counter-intuitive"}{"1":225}">While BSX stock may see higher levels, the Covid-19 crisis has created many pricing discontinuities, which can offer attractive trading opportunities. For example, you’ll be surprised at how counter-intuitive the stock valuation is for Boston Scientific vs. West Pharmaceutical Services.
Despite higher inflation and rising interest rates, BSX stock has risen 11% this year. But can it drop from here? See how low Boston Scientific stock can go by comparing its decline in previous market crashes. Here is a performance summary of all stocks in previous market crashes.
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
Returns Dec 2022
MTD [1] 2022
YTD [1] 2017-22
Total [2]
BSX Return 4% 11% 118%
S&P 500 Return -1% -16% 80%
Trefis Multi-Strategy Portfolio 0% -18% 231%
[1] Month-to-date and year-to-date as of 12/14/2022
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This recent outperformance of Boston Scientific can partly be attributed to its announcement to acquire Apollo Endosurgery in a $615 million deal. This historical pattern suggests a higher chance of a rise in BSX stock over the next five, ten, and twenty-one days. For example, you’ll be surprised at how counter-intuitive the stock valuation is for Boston Scientific vs. West Pharmaceutical Services. | Boston Scientific (BSX) Stock Return (Recent) Comparison With Peers Five-Day Return: SYK highest at 7.8%; ILMN lowest at 2.3% Ten-Day Return: SYK highest at 11.8%; ILMN lowest at 1.1% Twenty-One Day Return: SYK highest at 13.2%; ILMN lowest at -13.2% may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. \n\nBased on article theme, variations to \"While may have moved\" can be (a) While may be overvalued (or undervalued) (b) While can move (c) Although may not be attractive (d) While is worth considering"}" data-sheets-userformat="{"2":1049345,"3":{"1":0},"11":4,"12":0,"23":1}" data-sheets-textstyleruns="{"1":0}{"1":210,"2":{"2":{"1":2,"2":1136076},"5":1,"9":1}}{"1":225}{"1":229,"2":{"4":8}}{"1":267,"2":{"4":8,"6":1}}{"1":299,"2":{"4":8}}" data-sheets-hyperlinkruns="{"1":210,"2":"https://dashboards.trefis.com/data/companies/PFE/no-login-required/HMIwIvym/Pfizer-vs-Merck-PFE-stock-s-similar-valuation-vs-MRK-stock-is-counter-intuitive"}{"1":225}">While BSX stock may see higher levels, the Covid-19 crisis has created many pricing discontinuities, which can offer attractive trading opportunities. Total [2] BSX Return 4% 11% 118% S&P 500 Return -1% -16% 80% Trefis Multi-Strategy Portfolio 0% -18% 231% [1] Month-to-date and year-to-date as of 12/14/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of 247 instances in the last ten years that BSX stock saw a twenty-one-day rise of 11% or more, 145 resulted in BSX stock rising over the subsequent one-month period (twenty-one trading days). Boston Scientific (BSX) Stock Return (Recent) Comparison With Peers Five-Day Return: SYK highest at 7.8%; ILMN lowest at 2.3% Ten-Day Return: SYK highest at 11.8%; ILMN lowest at 1.1% Twenty-One Day Return: SYK highest at 13.2%; ILMN lowest at -13.2% may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. Total [2] BSX Return 4% 11% 118% S&P 500 Return -1% -16% 80% Trefis Multi-Strategy Portfolio 0% -18% 231% [1] Month-to-date and year-to-date as of 12/14/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Boston Scientific has also announced its plans to acquire a majority stake in Acotec Scientific Holdings – a Chinese medical technology company focused on solutions for interventional procedures. Going by historical performance, there is a higher chance of a rise for Boston Scientific stock over the next month. Total [2] BSX Return 4% 11% 118% S&P 500 Return -1% -16% 80% Trefis Multi-Strategy Portfolio 0% -18% 231% [1] Month-to-date and year-to-date as of 12/14/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
31293.0 | 2022-12-15 00:00:00 UTC | ABT Makes Notable Cross Below Critical Moving Average | ABT | https://www.nasdaq.com/articles/abt-makes-notable-cross-below-critical-moving-average-0 | nan | nan | In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $109.08, changing hands as low as $109.04 per share. Abbott Laboratories shares are currently trading down about 1.9% on the day. The chart below shows the one year performance of ABT shares, versus its 200 day moving average:
Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $142.60 as the 52 week high point — that compares with a last trade of $109.45. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com
Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average »
Also see:
TRST Dividend Growth Rate
M Average Annual Return
TLT Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $109.08, changing hands as low as $109.04 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $142.60 as the 52 week high point — that compares with a last trade of $109.45. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » Also see: TRST Dividend Growth Rate M Average Annual Return TLT Videos The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $109.08, changing hands as low as $109.04 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $142.60 as the 52 week high point — that compares with a last trade of $109.45. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » Also see: TRST Dividend Growth Rate M Average Annual Return TLT Videos The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $109.08, changing hands as low as $109.04 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $142.60 as the 52 week high point — that compares with a last trade of $109.45. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » Also see: TRST Dividend Growth Rate M Average Annual Return TLT Videos The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $109.08, changing hands as low as $109.04 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $142.60 as the 52 week high point — that compares with a last trade of $109.45. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » Also see: TRST Dividend Growth Rate M Average Annual Return TLT Videos The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
31294.0 | 2022-12-13 00:00:00 UTC | Why Abbott Laboratories Topped the Market on Tuesday | ABT | https://www.nasdaq.com/articles/why-abbott-laboratories-topped-the-market-on-tuesday | nan | nan | What happened
Abbott Laboratories (NYSE: ABT) concocted a stock market win on Tuesday, with its shares rising nearly 2% on the day against the S&P 500's 0.7% gain. That followed an analyst's inclusion of the company on a top-shelf list of stock picks for next year.
So what
Before market open, Cowen prognosticator Joshua Jennings tapped Abbott as a Best Idea for 2023. In doing so, he reiterated his outperform (buy, in other words) recommendation on the stock and $130 per share price target.
Jennings' rosy view on Abbott is based on the consensus estimates for 2023.
He pointed out in his latest research note that the average analyst estimate for that year's profitability has dropped 15% across 2022 (to the current $4.41). According to him, this is due to "above average" macroeconomic difficulties and challenges arising from foreign exchange for the global company. Jennings added that a steep decline in sales of COVID-19 testing kits has contributed to the lowered expectations.
"We view $4.41 as a beatable number, and we expect ABT to be rewarded as it enters a post-pandemic era of solid growth with far less exposure to COVID test sales," the analyst concluded.
Now what
Abbott has been on a bullish upward trajectory over the past few days, not least because it declared a dividend raise on Friday. While this was entirely in character for the company -- it's a Dividend King, after all -- the lift was quite generous, at nearly 9% over the current payout. This indicates that its underlying business is robust, and it is confident it can continue to perform well going forward.
10 stocks we like better than Abbott Laboratories
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2022
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Abbott Laboratories (NYSE: ABT) concocted a stock market win on Tuesday, with its shares rising nearly 2% on the day against the S&P 500's 0.7% gain. "We view $4.41 as a beatable number, and we expect ABT to be rewarded as it enters a post-pandemic era of solid growth with far less exposure to COVID test sales," the analyst concluded. He pointed out in his latest research note that the average analyst estimate for that year's profitability has dropped 15% across 2022 (to the current $4.41). | What happened Abbott Laboratories (NYSE: ABT) concocted a stock market win on Tuesday, with its shares rising nearly 2% on the day against the S&P 500's 0.7% gain. "We view $4.41 as a beatable number, and we expect ABT to be rewarded as it enters a post-pandemic era of solid growth with far less exposure to COVID test sales," the analyst concluded. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. | What happened Abbott Laboratories (NYSE: ABT) concocted a stock market win on Tuesday, with its shares rising nearly 2% on the day against the S&P 500's 0.7% gain. "We view $4.41 as a beatable number, and we expect ABT to be rewarded as it enters a post-pandemic era of solid growth with far less exposure to COVID test sales," the analyst concluded. 10 stocks we like better than Abbott Laboratories When our award-winning analyst team has a stock tip, it can pay to listen. | What happened Abbott Laboratories (NYSE: ABT) concocted a stock market win on Tuesday, with its shares rising nearly 2% on the day against the S&P 500's 0.7% gain. "We view $4.41 as a beatable number, and we expect ABT to be rewarded as it enters a post-pandemic era of solid growth with far less exposure to COVID test sales," the analyst concluded. Jennings' rosy view on Abbott is based on the consensus estimates for 2023. |
31295.0 | 2022-12-13 00:00:00 UTC | Abbott (ABT) Outpaces Stock Market Gains: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-outpaces-stock-market-gains%3A-what-you-should-know-3 | nan | nan | In the latest trading session, Abbott (ABT) closed at $111.53, marking a +1.86% move from the previous day. This move outpaced the S&P 500's daily gain of 0.73%. Elsewhere, the Dow gained 0.31%, while the tech-heavy Nasdaq added 0.16%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had gained 7.33% over the past month. This has outpaced the Medical sector's gain of 4.79% and the S&P 500's gain of 0.09% in that time.
Abbott will be looking to display strength as it nears its next earnings release. On that day, Abbott is projected to report earnings of $0.90 per share, which would represent a year-over-year decline of 31.82%. Meanwhile, our latest consensus estimate is calling for revenue of $9.47 billion, down 17.41% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $5.21 per share and revenue of $43.03 billion. These totals would mark changes of 0% and -0.1%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Abbott. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Abbott is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that Abbott has a Forward P/E ratio of 21.02 right now. This represents a premium compared to its industry's average Forward P/E of 19.97.
Investors should also note that ABT has a PEG ratio of 4.13 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Products stocks are, on average, holding a PEG ratio of 2.22 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the latest trading session, Abbott (ABT) closed at $111.53, marking a +1.86% move from the previous day. Investors should also note that ABT has a PEG ratio of 4.13 right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | In the latest trading session, Abbott (ABT) closed at $111.53, marking a +1.86% move from the previous day. Investors should also note that ABT has a PEG ratio of 4.13 right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | In the latest trading session, Abbott (ABT) closed at $111.53, marking a +1.86% move from the previous day. Investors should also note that ABT has a PEG ratio of 4.13 right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | In the latest trading session, Abbott (ABT) closed at $111.53, marking a +1.86% move from the previous day. Investors should also note that ABT has a PEG ratio of 4.13 right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. |
31296.0 | 2022-12-13 00:00:00 UTC | Noteworthy Tuesday Option Activity: XRX, PAR, ABT | ABT | https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-xrx-par-abt | nan | nan | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Xerox Holdings Corp (Symbol: XRX), where a total volume of 5,770 contracts has been traded thus far today, a contract volume which is representative of approximately 577,000 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 45.9% of XRX's average daily trading volume over the past month, of 1.3 million shares. Particularly high volume was seen for the $14 strike put option expiring April 21, 2023, with 4,404 contracts trading so far today, representing approximately 440,400 underlying shares of XRX. Below is a chart showing XRX's trailing twelve month trading history, with the $14 strike highlighted in orange:
Par Technology Corp. (Symbol: PAR) options are showing a volume of 1,260 contracts thus far today. That number of contracts represents approximately 126,000 underlying shares, working out to a sizeable 45.1% of PAR's average daily trading volume over the past month, of 279,555 shares. Particularly high volume was seen for the $25 strike call option expiring January 20, 2023, with 503 contracts trading so far today, representing approximately 50,300 underlying shares of PAR. Below is a chart showing PAR's trailing twelve month trading history, with the $25 strike highlighted in orange:
And Abbott Laboratories (Symbol: ABT) options are showing a volume of 21,321 contracts thus far today. That number of contracts represents approximately 2.1 million underlying shares, working out to a sizeable 44.3% of ABT's average daily trading volume over the past month, of 4.8 million shares. Particularly high volume was seen for the $110 strike put option expiring June 16, 2023, with 2,706 contracts trading so far today, representing approximately 270,600 underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $110 strike highlighted in orange:
For the various different available expirations for XRX options, PAR options, or ABT options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
Also see:
Funds Holding HTBI
HAL Split History
WPO Historical Stock Prices
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $110 strike put option expiring June 16, 2023, with 2,706 contracts trading so far today, representing approximately 270,600 underlying shares of ABT. Below is a chart showing PAR's trailing twelve month trading history, with the $25 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) options are showing a volume of 21,321 contracts thus far today. That number of contracts represents approximately 2.1 million underlying shares, working out to a sizeable 44.3% of ABT's average daily trading volume over the past month, of 4.8 million shares. | Below is a chart showing PAR's trailing twelve month trading history, with the $25 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) options are showing a volume of 21,321 contracts thus far today. That number of contracts represents approximately 2.1 million underlying shares, working out to a sizeable 44.3% of ABT's average daily trading volume over the past month, of 4.8 million shares. Particularly high volume was seen for the $110 strike put option expiring June 16, 2023, with 2,706 contracts trading so far today, representing approximately 270,600 underlying shares of ABT. | That number of contracts represents approximately 2.1 million underlying shares, working out to a sizeable 44.3% of ABT's average daily trading volume over the past month, of 4.8 million shares. Below is a chart showing PAR's trailing twelve month trading history, with the $25 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) options are showing a volume of 21,321 contracts thus far today. Particularly high volume was seen for the $110 strike put option expiring June 16, 2023, with 2,706 contracts trading so far today, representing approximately 270,600 underlying shares of ABT. | Particularly high volume was seen for the $110 strike put option expiring June 16, 2023, with 2,706 contracts trading so far today, representing approximately 270,600 underlying shares of ABT. Below is a chart showing PAR's trailing twelve month trading history, with the $25 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) options are showing a volume of 21,321 contracts thus far today. That number of contracts represents approximately 2.1 million underlying shares, working out to a sizeable 44.3% of ABT's average daily trading volume over the past month, of 4.8 million shares. |
31297.0 | 2022-12-12 00:00:00 UTC | Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock | ABT | https://www.nasdaq.com/articles/here-is-what-to-know-beyond-why-abbott-laboratories-abt-is-a-trending-stock | nan | nan | Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this maker of infant formula, medical devices and drugs have returned +3.3% over the past month versus the Zacks S&P 500 composite's +5.1% change. The Zacks Medical - Products industry, to which Abbott belongs, has gained 7.7% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Abbott is expected to post earnings of $0.90 per share, indicating a change of -31.8% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
The consensus earnings estimate of $5.21 for the current fiscal year indicates no change from the prior year. This estimate has remained unchanged over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $4.39 indicates a change of -15.6% from what Abbott is expected to report a year ago. Over the past month, the estimate has changed -0.2%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Abbott is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Abbott, the consensus sales estimate for the current quarter of $9.47 billion indicates a year-over-year change of -17.4%. For the current and next fiscal years, $43.03 billion and $39.3 billion estimates indicate -0.1% and -8.7% changes, respectively.
Last Reported Results and Surprise History
Abbott reported revenues of $10.41 billion in the last reported quarter, representing a year-over-year change of -4.7%. EPS of $1.15 for the same period compares with $1.40 a year ago.
Compared to the Zacks Consensus Estimate of $9.58 billion, the reported revenues represent a surprise of +8.67%. The EPS surprise was +26.37%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Abbott is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom Line
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Abbott. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Zacks Top 10 Stocks for 2023
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2023? From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500’s +287.4%.
Now our Director of Research is combing through 4,000 companies covered by the Zacks Rank to handpick the best 10 tickers to buy and hold. Don’t miss your chance to get in on these stocks when they’re released on January 3.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Shares of this maker of infant formula, medical devices and drugs have returned +3.3% over the past month versus the Zacks S&P 500 composite's +5.1% change. | Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Abbott is rated Zacks Rank #3 (Hold). | Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. | Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Abbott is rated Zacks Rank #3 (Hold). |
31298.0 | 2022-12-10 00:00:00 UTC | 2 Ultra-Reliable Dividend Stocks You Can Buy Now and Hold Forever | ABT | https://www.nasdaq.com/articles/2-ultra-reliable-dividend-stocks-you-can-buy-now-and-hold-forever | nan | nan | Investors who want to put their money to work for them in the stock market are justifiably nervous about buying shares of anything lately. The benchmark S&P 500 index that tracks the largest publicly traded businesses is down a frightening 17% from the peak it reached in January. The Nasdaq Composite index, which tracks a lot more growth stocks than the S&P 500, is down a stunning 30% from the peak it set less than a year ago.
Rather than completely staying on the sidelines, cautious investors are increasingly attracted to dividend-paying stocks. With inflation on the rise, it's easy to understand why. According to Fidelity, dividend stocks in the S&P 500 contributed 54% of the index's total return during periods when inflation averaged 5% or higher.
Image source: Getty Images.
We know that dividend-paying stocks generally outperform companies that haven't committed to distributing profits. We also know that not all dividend payers have what it takes to maintain and raise their quarterly payouts.
Investors who want a positive long-term return that they can rely on should consider these dividend-paying stocks. Both have a long history of raising their dividend payouts. There's also a good chance they can continue the tradition for many years to come.
AbbVie
AbbVie (NYSE: ABBV) was the biopharmaceutical segment of Abbott Laboratories until it spun off as a separate company nearly a decade ago. Abbott Laboratories recently declared its 394th consecutive quarterly dividend payment, and it's increased that payment every year for 50 consecutive years.
AbbVie has continued Abbott's commitment to steadily increasing its dividend year after year but at a much faster pace. The drugmaker's payout has soared a whopping 270% since 2013.
At recent prices, shares of AbbVie offer an above-average 3.6% yield. This is well above the average yield paid by dividend stocks in the S&P 500, which is a paltry 1.7% right now.
AbbVie offers an above-average dividend yield right now because U.S. sales of its lead drug, Humira, will fall in response to competition from lower-priced biosimilar versions that will enter the market in 2023.
Humira's an anti-inflammation injection mainly used to treat arthritis and psoriasis. In 2018, AbbVie launched Rinvoq to treat arthritis and Skyrizi to treat psoriasis, and they're already on pace to offset impending Humira losses. The pair are already on pace to generate $8.4 billion annually and AbbVie expects more than $15 billion in 2025.
Johnson & Johnson
If you're impressed by AbbVie's and Abbott's commitment to dividend growth, just wait until you hear about Johnson & Johnson (NYSE: JNJ). This April the company increased its quarterly payout for the 60th year in a row.
You're no doubt familiar with J&J's consumer health brands because it practically invented the industry over a century ago. For several years, though, the company's pharmaceutical segment has been responsible for a majority of total revenue and an even larger share of total profits. For this reason, the company will spin off its consumer health business into a separate entity to be named Kenvue in the second half of 2023.
At recent prices, shares of J&J offer a 2.6% yield that investors can depend on to continue growing. The company used three-fifths of its earnings over the past year to meet its dividend obligation. This is a reasonable payout ratio that should give J&J enough flexibility to adjust its dividend in line with earnings growth over the next several years.
Investors can look forward to J&J's drug development pipeline driving growth for the business that remains. Management expects annual pharmaceutical sales to rise from $52 billion in 2021 to $60 billion in 2025. Buying J&J stock now, then holding it through the Kenvue spin-off and over the long run gives you a great chance to come out way ahead.
10 stocks we like better than AbbVie
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2022
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Nasdaq Composite index, which tracks a lot more growth stocks than the S&P 500, is down a stunning 30% from the peak it set less than a year ago. AbbVie offers an above-average dividend yield right now because U.S. sales of its lead drug, Humira, will fall in response to competition from lower-priced biosimilar versions that will enter the market in 2023. Buying J&J stock now, then holding it through the Kenvue spin-off and over the long run gives you a great chance to come out way ahead. | Abbott Laboratories recently declared its 394th consecutive quarterly dividend payment, and it's increased that payment every year for 50 consecutive years. At recent prices, shares of AbbVie offer an above-average 3.6% yield. The Motley Fool recommends Johnson & Johnson. | AbbVie has continued Abbott's commitment to steadily increasing its dividend year after year but at a much faster pace. Johnson & Johnson If you're impressed by AbbVie's and Abbott's commitment to dividend growth, just wait until you hear about Johnson & Johnson (NYSE: JNJ). See the 10 stocks *Stock Advisor returns as of December 1, 2022 Cory Renauer has no position in any of the stocks mentioned. | AbbVie has continued Abbott's commitment to steadily increasing its dividend year after year but at a much faster pace. This April the company increased its quarterly payout for the 60th year in a row. The Motley Fool has positions in and recommends Abbott Laboratories. |
31299.0 | 2022-12-09 00:00:00 UTC | Have $1,000? 2 Top Dividend Stocks to Buy Right Now | ABT | https://www.nasdaq.com/articles/have-%241000-2-top-dividend-stocks-to-buy-right-now | nan | nan | Even in the current inflationary environment, where stocks across a wide variety of sectors are trading down, companies with a favorable history of growing investor returns in a range of markets are still ripe for the taking.
If you're looking to add more dividend stocks to your portfolio this month, it's important to focus on companies that not only regularly increase their payout to investors but have a long track record of maintaining their dividends even in difficult environments.
Here are two such top dividend stocks to consider adding to your portfolio ASAP.
1. AbbVie
AbbVie (NYSE: ABBV) originated as a spin-off of Abbott Laboratories nearly a decade ago, and in doing so, inherited its predecessor's dividend history. AbbVie holds a coveted spot on the list of Dividend Kings. The stock, which currently yields 3.6% for investors, has seen its dividend rise by approximately 270% in the decade since it became an independent company. In turn, the stock has delivered a total return of 606% for investors in that same period.
AbbVie is known by many investors for its blockbuster product, Humira. Patent exclusivity for the world's top-selling drug, which brought in about $21 billion in revenue in 2021 alone, is set to expire in the U.S. in 2023. It already expired in Europe in 2018.
Some investors have been concerned about AbbVie's long-term growth story once generic competition ramps up, and as sales from Humira inevitably wane. However, Humira is far from the only product upon which AbbVie can rely to drive forward long-term growth.
AbbVie boasts an incredibly diversified portfolio of products that span areas ranging from women's health to immunology to oncology. Among a variety of products, its 2020 acquisition of Allergan also added Botox Therapeutic and Botox Cosmetic to its portfolio, which are proving to be key sources of growth for AbbVie.
In the first nine months of 2022, AbbVie's net revenue grew 4% year over year to $43 billion, while its net earnings for the same period jumped 25% year over year to $9.4 billion. And over the past decade, AbbVie's annual revenue and net income has grown by 206% and 119%, respectively.
If it's a diversified healthcare business you're looking for, with a strong dividend history and a track record of delivering enviable balance sheet and shareholder returns, AbbVie fits the bill on all counts.
2. Kimberly-Clark
In a challenging macro environment where consumers are regulating their spending, you're not alone if you find yourself shying away from stocks that might be directly impacted by these trends. However, a household name and consumer staples giant like Kimberly-Clark (NYSE: KMB) has the staying power to ride out the current environment and beyond.
In terms of its dividend, Kimberly-Clark currently yields a robust 3.4% for investors. It has not only paid but raised its dividend for 50 consecutive years and counting. And over the past decade, the company has grown its dividend by more than 40%. Shareholders who held on to the stock through the entire trailing-10-year period would have benefited from its total return of about 130%.
From feminine care to baby products, most of the items that Kimberly-Clark sells are considered daily essentials that people will need no matter what's happening with the market or the economy at large. In fact, the company estimates that roughly one-quarter of the entire global population relies on its products as a part of daily life. Kimberly-Clark counts well-known names like Kleenex, Cottonelle, Huggies, and Pull-Ups among its family of brands.
Supply chain disruptions and inflation have weighed on Kimberly-Clark's margins and bottom line in recent financial reports, but it has nonetheless continued to generate consistent revenue growth and profitability. In the most recent quarter, the company reported total revenue of $5.1 billion, up 1% year over year, while it generated net income to the tune of $470 million for the three-month period.
Kimberly-Clark's resilient business can drive growth even in a changing macro environment, which makes the consumer staples stock a worthwhile addition to the long-term income investor's portfolio.
10 stocks we like better than AbbVie
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2022
Rachel Warren has positions in AbbVie. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If it's a diversified healthcare business you're looking for, with a strong dividend history and a track record of delivering enviable balance sheet and shareholder returns, AbbVie fits the bill on all counts. Supply chain disruptions and inflation have weighed on Kimberly-Clark's margins and bottom line in recent financial reports, but it has nonetheless continued to generate consistent revenue growth and profitability. Kimberly-Clark's resilient business can drive growth even in a changing macro environment, which makes the consumer staples stock a worthwhile addition to the long-term income investor's portfolio. | In the first nine months of 2022, AbbVie's net revenue grew 4% year over year to $43 billion, while its net earnings for the same period jumped 25% year over year to $9.4 billion. And over the past decade, AbbVie's annual revenue and net income has grown by 206% and 119%, respectively. In the most recent quarter, the company reported total revenue of $5.1 billion, up 1% year over year, while it generated net income to the tune of $470 million for the three-month period. | If you're looking to add more dividend stocks to your portfolio this month, it's important to focus on companies that not only regularly increase their payout to investors but have a long track record of maintaining their dividends even in difficult environments. In the first nine months of 2022, AbbVie's net revenue grew 4% year over year to $43 billion, while its net earnings for the same period jumped 25% year over year to $9.4 billion. Kimberly-Clark's resilient business can drive growth even in a changing macro environment, which makes the consumer staples stock a worthwhile addition to the long-term income investor's portfolio. | However, Humira is far from the only product upon which AbbVie can rely to drive forward long-term growth. And over the past decade, the company has grown its dividend by more than 40%. In the most recent quarter, the company reported total revenue of $5.1 billion, up 1% year over year, while it generated net income to the tune of $470 million for the three-month period. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.